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Introduction 
This systematic review addressed 10 Questions (middle column of Table 1) pertaining to solid organ 
transplantation and three bloodborne pathogens (HIV, HBV, and HCV). These questions were carefully 
developed by the Centers for Disease Control and Prevention in consultation with the Center for 
Evidence-based Practice at the University of Pennsylvania and ECRI Institute. These questions are not 
intended to encompass all important issues related to infectious diseases and organ transplantation. 
Instead, they were specifically focused to support the development of an evidence-based guideline. 
The leftmost column of the table shows which section of the guideline pertains to the questions, and the 
rightmost column provides explanatory comments. 
Table 1. Questions for Systematic Review 
Major topic area of the 
guideline 
Question for Systematic 
Review Comments 
I. Probability of 
transmission of HIV, 
HBV, or HCV through 
solid organ 
transplantation (SOT) 
1. What are the prevalence 
and incidence rates of HIV, 
HBV, and HCV among 
potential solid organ 
donors? 
This question addresses the extent of the 
possible problem. The focus is on the 
epidemiology rates for each of the three 
pathogens among people who are being 
considered for solid organ donation. 
2. What are the rates of 
transmission to recipients 
from donors infected with 
HIV, HBV, or HCV? Do the 
rates vary by the organ 
transplanted or when the 
donor was infected? 
A key concern is that a solid organ donor 
will transmit infection to a recipient. This 
question concerns the specific situation 
when the donor is positive for a pathogen 
but the recipient is not, and what 
percentage of such recipients become 
infected after transplantation. 
II. Methodology to better 
estimate donor 
infection with HIV, 
HBV, or HCV 
3. What behavioral risk factors 
are associated with an 
increased probability of 
infection with HIV, HBV, or 
HCV? What is the 
prevalence of these 
characteristics among 
potential solid organ 
donors?  
Some behaviors may be associated with 
infection of HIV, HBV or HCV, and the 
first half of the question attempts to 
identify these behaviors. This is 
accomplished by comparing the rate of 
infection among those who do engage in 
a behavior to the rate of infection among 
those who do not. The second half 
addresses the frequency of those 
behaviors among potential solid organ 
donors. 
4. What nonbehavioral factors 
are associated with an 
increased probability of 
infection with HIV, HBV, or 
HCV? What is the 
prevalence of these factors 
among potential solid organ 
donors?  
This is similar to the previous question, 
except here the focus is on 
nonbehavioral factors. Our primary intent 
was to identify signs and symptoms of 
incident infections (i.e., recently 
acquired), but we also included data on 
signs and symptoms of chronic infection, 
medical comorbidities, socioeconomic 
information, and demographic factors. 
5. What are the test 
characteristics of the 
screening methods 
Numerous tests exist to detect HIV, HBV 
and/or HCV in potential donors, and this 
question concerns the diagnostic 
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Major topic area of the 
guideline 
Question for Systematic 
Review Comments 
available to detect HIV, 
HBV, and HCV in potential 
solid organ donors? Do test 
characteristics differ in 
particular populations and 
with donor clinical status 
(i.e., heart beating vs. non-
heart beating donors OR 
adult vs. pediatric donors)? 
accuracy of those tests, as well as the 
length of the window period and the 
turnaround time. The window period is 
particularly important in this context, 
because an infected individual in the 
window period would not be detectable 
prior to donation of solid organs. 
III. Donor interventions to 
decrease transmission 
of HIV, HBV,or HCV 
from infected donors 
6. Which donor interventions 
reduce the probability of 
pathogen transmission from 
an organ donor infected 
with HIV, HBV, or HCV to a 
previously uninfected 
recipient? 
Given an infected organ donor, it may be 
possible to inactivate the virus prior to 
transplantation into a recipient. This 
question seeks to identify effective 
methods for inactivation of viruses in 
solid organs donors. 
IV. Potential risks and 
benefits of 
transplanting, or not 
transplanting, solid 
organs from donors 
positive for HIV, HBV, 
or HCV 
7. How do the clinical 
outcomes of recipients of 
organs from donors infected 
with HIV, HBV, or HCV 
compare to those who 
remain on the transplant 
list? 
This question concerns whether a patient 
will live longer after 1) receiving a known 
infected organ or 2) remaining on the 
transplant list. Other clinical outcomes of 
interest include graft survival and quality 
of life. 
V. Potential risks and 
benefits of 
transplanting, or not 
transplanting, organs 
from donors with risk 




8. How do the clinical 
outcomes of transplant 
recipients who receive 
organs from donors with 
behavioral or nonbehavioral 
risk factors compare to 
those who remain on the 
transplant list? 
This question is conceptually similar to 
question 7. Here, however, the donor is 
not known to be infected, but the donor is 
at risk for infection based on a behavioral 
or clinical factor. As in question 7, the 
comparison is between implanting or not 
implanting organs from such donors, with 
a focus on clinical outcomes 
(e.g., recipient survival). 
9. What is the impact of 
excluding potential solid 
organ donors with 
behavioral or nonbehavioral 
risk factors on the organ 
donor pool? 
If at-risk donors are excluded, one 
negative consequence is a reduction in 
the organ donor pool. This question 
attempts to quantify the size of the 
reduction. 
10. What is the impact of false 
positive tests on the organ 
donor pool? 
If donors testing positive are excluded 
from the donor pool, then false positives 
will result in an inappropriate reduction of 
the donor pool; this question attempts to 
quantify the size of the reduction. 
 
The questions are depicted in an analytic framework (Figure 1) on the next page. The patient population 
of interest is candidates for solid organ transplantation. The availability of such organs can be influenced 
by numerous factors depicted in the lower half of the figure, notably the infection status of the donor, and 
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donor behavioral and nonbehavioral risk factors. In this framework, each candidate either 1) receives an 
organ or 2) remains on the waitlist. The clinical outcomes of interest include patient survival, graft 
survival, quality of life and recipient infection status. 
The rest of this document is divided into numerous sections, as follows: 
 Methodology, wherein we describe the methods used for conducting the systematic review 
 Overview of the evidence, which paints a broad portrait of the included evidence 
 Evidence for each question, which is divided into 10 sections. All text and evidence tables for a 
given question are collated together with that question. Thus, there are no appendices of evidence 
tables. 
 Gaps in the current literature, which discussed the primary areas where further research is 
necessary 
 References, which provides the full bibliography of included evidence 
 Details of literature search, which provides the search strategies we employed 
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Figure 1. Analytic Framework 
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We searched six bibliographic databases including MEDLINE, EMBASE, and the Cochrane 
Library to identify clinical trials and other relevant publications. (All searched databases are 
listed in Table 77 of Appendix A.) Separate date limits were used for some questions, although 
most spanned 1990 through 2009. Mechanisms used to retrieve additional relevant information 
included review of bibliographies/reference lists from peer reviewed and gray literature. 
(Gray literature consists of reports, studies, articles, and monographs produced by federal and 
local government agencies, private organizations, educational facilities, consulting firms, and 
corporations. These documents do not appear in the peer-reviewed journal literature.) 
Alphabetical lists of the concepts searched and detailed search strategies are provided in 
Appendix A (Details of Literature Search). 
Inclusion Criteria 
The following universal criteria were applied to all Questions for Systematic Review 
 English language 
 Peer-reviewed, full-length publication with original data 
 Multiple publications of the same study were treated as a single study rather than as multiple 
studies to avoid double-counting patients. 
 The study included at least one of the following bloodborne pathogens: HIV, HBV, and HCV. 
 The determination of the presence or absence of HIV/HBV/HCV must have been based on 
laboratory test(s), rather than subjective estimates, physician interviews, or patient interviews. 
Additional criteria were applied on a per-question basis, as depicted in Table 2 on the next page. 
For many questions, an insufficient number of studies was identified to support the development of the 
guideline. Consequently, in an effort to provide a sufficient amount of relevant information to support the 
development of the guideline, committee members expanded the inclusion criteria in multiple iterations 
over several months. The final question-specific inclusion criteria are shown in Table 3. The specific 
diagnostics tests of interest for Question 5 are listed in Table 4. 
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Table 2. Original Question-Specific Inclusion Criteria 
Inclusion Criteria* 
Questions for Systematic Review 
1 2 3 4 5 6 7 8 9 10 
Pertinent data on at least five people           
Data collected in U.S.A.           
Potential organ donors           
Rates not restricted to actual donors           
Not voluntary reporting           
Regardless of symptoms           
Data collected in year 2000 or later           
Donor seropositive pre-transplant           
Recipient seronegative pre-transplant           
Single type of organ, or separated data on different types of organs           
Waitlist control group           
Systematic review           
Addressed test sensitivity and specificity           
Experimental group with inactivation procedure           
Control group without an inactivation procedure           
Donor+ for behavioral or clinical factor pre-transplant           
* For each Question for Systematic Review, five universal criteria were also applied (see text). A checkmark in a given column means that a study must have met 
that criterion in order to be included for the numbered Question for Systematic Review. 
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Table 3. Modified Question-Specific Inclusion Criteria 
Inclusion Criteria* 
Questions for Systematic Review 
1 2 3 4 5 6 7 8 9 10 
Pertinent data on at least five people           
Data collected in U.S.A.           
Rates not restricted to actual donors           
At least one of four populations: 1) Potential organ donors; 2) organ donors with samples taken 
prior to 1992 that were retrospectively tested for HCV; 3) potential tissue donors; or 4) the 
general population (for this last population, we included only the most up-to-date 
epidemiological estimates) 
          
Regardless of symptoms           
Donor seropositive pre-transplant           
Recipient seronegative pre-transplant           
Single type of organ, or separated data on different types of organs           
Waitlist control OR Control is recipients of organs from uninfected donors           
If pre-transplant infected recipients and pre-transplant uninfected recipients were included, the 
study must have reported separate outcome data on these two types of recipients. 
          
Reported patient survival, graft survival, or quality of life.           
At least one of four populations, enrolling individuals of any age: 1) Potential organ donors; 
2) potential tissue donors; 3) potential blood donors; or 4) a sample representative of the 
general population (i.e., population unselected for any particular demographic, occupational, or 
behavioral characteristics, or health status other than HCV, HBV, or HIV infection status) 
          
A study of a specific demographic or socioeconomic subpopulation was included for HBV, but 
excluded for HIV and HCV. 
          
A study of a specific subpopulation of patients who were all selected for having the same 
behavioral risk factor was excluded for all three pathogens. 
          
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Inclusion Criteria* 
Questions for Systematic Review 
1 2 3 4 5 6 7 8 9 10 
Article must have been published in 1990 or later if pertinent to HIV or HCV, or 1966 or later 
if pertinent to HBV. 
          
In order to identify risk factors for the pathogen, study must have enrolled people with the risk 
factor as well as people without the risk factor; similarly, the study must have enrolled people 
positive for the pathogen as well as people negative for the pathogen. 
          
For identification of clinical signs and symptoms that may indicate infection, data may be from 
any country. For identification of co-morbidities or demographic factors that may be associated 
with infection, data must be from U.S only. 
          
Reported at least one of the diagnostic tests listed in Table 4.           
Reported at least one of the following: 
• Sensitivity and specificity  
• Positive and negative predictive values (clinical populations only) 
• Positive and negative likelihood ratios (clinical populations only) 
• Sufficient data to calculate the above  
• Window period 
• Turnaround time 
          
Reported data on an individual test basis rather than multiple tests or algorithms.           
Inactivation procedure performed before transplant on organs obtained from infected 
individuals. 
          
Donor positive pre-transplant for behavioral risk factor or signs/symptoms risk factor or 
comorbidity risk factor. 
          
Waitlist control OR Control is recipients of organs from donors without that risk factor.           
Reported the number of organs that would not be included in the organ pool if donors with 
behavioral or nonbehavioral risk factors identified in questions 3 and 4 were excluded. 
          
Reported the number of organs that would not be included in the organ pool if false positives 
were excluded. 
          
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* For each Question for Systematic Review, five universal criteria were also applied (see text). A checkmark in a given column means that a study must have met 
that criterion in order to be included for the numbered Question for Systematic Review. 
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Table 4. Diagnostic Tests of Interest for Question 5 
Virus Test Name Manufacturer 
Tests Currently in Use by U.S. Organ Procurement Organizations 
HIV Genetics System (GS) HIV-1/HIV-2 Plus 0 EIA Bio-Rad Laboratories 
HIVAB HIV-1/HIV-2 (rDNA) EIA Abbott Laboratories 
HBV (HBsAg; the 
surface antigen) 
Abbott PRISM HbsAg Assay Abbott Laboratories 
ADVIA Centaur HbsAg Assay Siemens Healthcare Diagnostics 
AxSYM HBsAg Abbott Laboratories 
Genetic Systems (GS) HBsAg EIA 3.0 Bio-Rad Laboratories 
HBV (anti-HBs; 
antibodies to the 
surface antigen) 
Ortho Antibody to HbsAg ELISA Test System 3 Ortho Clinical Diagnostics 
HBV (anti-HBc; 
antibodies to the core 
antigen) 
Abbott PRISM HBcore Abbott Laboratories 
ADVIA Centaur HBc Total Assay Siemens Healthcare Diagnostics 
AxSYM Core 2.0 Abbott Laboratories 
CORZYME Abbott Laboratories 
Ortho HBc ELISA Test System  Ortho Clinical Diagnostics 
HCV Abbott HCV EIA 2.0 Abbott Laboratories 
ADVIA Centaur Anti-HCV  Siemens Healthcare Diagnostics 
AxSYM Anti-HCV Abbott Laboratories 
Ortho HCV Version 3.0 ELISA Test System Ortho Clinical Diagnostics 
HIV NAT COBAS AmpliScreen HIV-1 Test v. 1.5 Roche Diagnostics 
HCV NAT COBAS AmpliScreen HCV Test v. 2.0 Roche Diagnostics 
HBV NAT COBAS AmpliScreen HBV Test Roche Diagnostics 
HCV and HIV-1 NAT ProCleix HIV-1/HCV Assay Gen-Probe Incorporated 
Fourth Generation Tests 
HIV ARCHITECT HIV Combo Abbott Laboratories 
AxSYM HIV Ag/Ab Combo Abbott Laboratories 
COBAS Core HIV Combo Roche Diagnostics 
Coulter HIV-1 p24 Antigen Assay Coulter Corporation 
Enzygnost HIV Integral II Siemens Healthcare Diagnostics 
Genscreen Plus HIV Ag/Ab Combo Bio-Rad Laboratories 
Genscreen HIV Ultra Ag-Ab Assay Bio-Rad Laboratories 
Murex HIV Ag/Ab Combo Abbott Laboratories 
Modular HIV Combo Roche Diagnostics 
VIDAS DUO ULTRA bioMerieux Clinical Diagnostics 
VIDAS DUO QUICK bioMerieux Clinical Diagnostics 
Vironostika HIV Uni-Form II Ag/Ab bioMerieux Clinical Diagnostics 
11 
Virus Test Name Manufacturer 
HCV INNOTEST HCV Ab IV Innogenetics NV 
Monolisa HCV Ag/Ab Ultra  Bio-Rad Laboratories 
Murex 4.0 Abbott Laboratories 
EIA or ELISA– Enzyme-linked immunosorbent assay 
NAT – Nucleic acid test 
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Quality Assessment 
In order to assess the quality of the data for each Question for Systematic Review, we applied the criteria 
listed in Table 5. Due to substantial differences among the questions, we generally used different criteria 
for each question. These criteria were determined after examining existing instruments for quality 
assessment and selecting the most appropriate items. 
Table 5. Quality Assessment Criteria 
Question Quality Criteria 
1. What are the prevalence and incidence rates 
of HIV, HBV, and HCV among potential solid 
organ donors? 
1a. Was the population potential solid organ 
donors? 
1b. For other populations, was the population 
unselected (i.e., not based on demographic or 
behavioral characteristics)? (studies of 
potential solid organ donors were scored as 
Yes, because they enrolled the population of 
interest)) 
1c. Was infection status determined accurately? 
(i.e., accuracy of diagnostic test method used 
to determine infection status) 
2. What are the rates of transmission to 
recipients from donors infected with HIV, 
HBV, or HCV? Do the rates vary by the organ 
transplanted or when the donor was infected? 
2a. Was the study planned prospectively 
(i.e., before any data were collected) 
2b. Were all consecutive patients enrolled 
(or a random sample of eligible patients)? 
2c. Were laboratory tests performed on recipients 
regularly in order to monitor 
antigens/antibodies? (greater frequency 
means greater accuracy at estimating the 
rate)  
2d. Did all patients receive the same prophylaxis 
strategy (or none received any prophylaxis)? 
(a mix of prophylaxis strategies means a less 
interpretable rate) 
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Question Quality Criteria 
3. What behavioral risk factors are associated 
with an increased probability of infection with 
HIV, HBV, or HCV? What is the prevalence of 
these characteristics among potential solid 
organ donors?  
3a. Was the population potential solid organ 
donors? 
3b. For other populations, was the population 
unselected (i.e., not based on demographic or 
behavioral characteristics)? Were infected 
and uninfected participants similar on other 
risk factors? 
3c. Were infected and uninfected participants 
similar on other risk factors? 
3d. If not, were statistical adjustments performed 
to control for other risk factors? 
3e. Was risk factor data collected in a valid 
manner (e.g., confidential or anonymous 
collection of sensitive risk factor data, 
collection of personal information from the 
person directly instead of someone else) 
3f. Was infection status determined accurately? 
(i.e., accuracy of diagnostic test method used 
to determine infection status) 
4. What nonbehavioral factors are associated 
with an increased probability of infection with 
HIV, HBV, or HCV? What is the prevalence of 
these factors among potential solid organ 
donors?  
Same as Question 3 
5. What are the test characteristics of the 
screening methods available to detect HIV, 
HBV, and HCV in potential solid organ 
donors? Do test characteristics differ in 
particular populations and with donor clinical 
status (i.e., heart beating vs. non-heart 
beating donors OR adult vs. pediatric 
donors)? 
5a. For measures of diagnostic performance other 
than window period detection and turnaround 
time, were the sample sets representative of 
real-world use in terms of infection 
prevalence, infection genotypes, and 
proportion of samples in window period?  
5b. For measures of diagnostic performance other 
than window period detection and turnaround 
time, was a reference standard with excellent 
accuracy used? If not, was a reference 
standard with very good accuracy used?  
5c. Were all consecutive patients enrolled (or a 
random sample of eligible patients)? 
5d. Were readers of the diagnostic test of interest 
blinded to the results of the reference 
standard? 
5e. Were readers of the reference standard 
blinded to the results of the diagnostic test of 
interest? 
5f. Was the funding for this study derived from a 
source that would not benefit financially from 
either data favorable to the test or data 
unfavorable to the test? 
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Question Quality Criteria 
6. Which donor interventions reduce the 
probability of pathogen transmission from an 
organ donor infected with HIV, HBV, or HCV 
to a previously uninfected recipient? 
6a. Were the patients randomly assigned to 
treatments? 
6b. Was the study planned prospectively 
(i.e., before any data were collected) 
6c. Were all consecutive patients enrolled (or a 
random sample of eligible patients)? 
6d. Were the two groups comparable at baseline? 
(age, sex, comorbidities, indication for 
transplant, previous duration on waitlist) 
6e. If not, were statistical adjustments performed 
to control for baseline differences?  
6f. Were the two groups treated concurrently? 
6g. Did at least 85% of the study enrollees 
provide data? 
6h. Was the between-group difference in study 
completion rates less than 15%? 
7. How do the clinical outcomes of recipients of 
organs from donors infected with HIV, HBV, or 
HCV compare to those who remain on the 
transplant list? 
Same as Question 6 
8. How do the clinical outcomes of transplant 
recipients who receive organs from donors 
with behavioral or nonbehavioral risk factors 
compare to those who remain on the 
transplant list? 
Same as Question 6 
9. What is the impact of excluding potential solid 
organ donors with behavioral or 
nonbehavioral risk factors on the organ donor 
pool? 
Same as Question 6 
10. What is the impact of false positive tests on 
the organ donor pool? 




We used the GRADE evidence rating methodology, which has been developed for treatment comparisons 
(Questions 6, 7 and 8)
1
 and diagnostics (Question 5).
2
 The GRADE system determines the quality of the 
evidence for a single outcome of a single comparison based on nine factors. “Quality” here encompasses 
not only quality in terms how well the study was designed, but also eight additional factors including 
inconsistency, indirectness, and imprecision of the evidence base (evidence base being all studies 
included for that outcome). The first factor (study design) sets the starting GRADE, in which randomized 
studies start at High, observational studies start at Low, and all other study designs start at Very Low. 
The next four factors can only be used to downgrade from this starting level (study quality limitations, 
inconsistency, indirectness, imprecision). The other four factors are grouped under “Other 
considerations”, and they are reporting bias (which can only be used to downgrade), large magnitude of 
effect, all plausible confounders would have reduced the effect, and dose-response association (these 
latter three factors can only be used to upgrade, if applicable). Ultimately, the GRADE system yields an 
overall rating for each outcome, which ranges from “very low” to “high”. The interpretation of these 
ratings is summarized in Table 6.
3
 The details of the application of the GRADE system for each question 
are described in those sections. 
Table 6. Interpretation of GRADE Ratings 
Quality Rating Interpretation 
High Further research is very unlikely to change our confidence in
 




is likely to have an important impact on our confidence in the
 
estimate of effect and may change the estimate 
Low  Further research is very likely to have an important impact
 
on our confidence 
in the estimate of effect and is likely to
 
change the estimate 
Very Low Any estimate of
 
effect is very uncertain 
Note: These interpretations are from Box 2 of Guyatt et al. (2008).
3
 
GRADE methodology has not been developed for the questions on epidemiology (Question 1), 
transmission (Question 2), risk factors (Questions 3 and 4), and the impact of exclusions on the donor 
pool (Questions 9 and 10). For these, we created GRADE methodology as follows. For Questions 1 and 2, 
no randomized trials are necessary to address the questions, therefore the starting evidence grade was 
High, and we applied the other components of the GRADE system as appropriate. For Questions 3 and 4, 
we used a starting evidence grade of Low because risk factor studies are by nature observational. Portions 
of Questions 3 and 4 involve the prevalence of risk factors; these were graded similarly as Question 1 
(epidemiology). For Questions 9 and 10, it was not necessary to develop new GRADE methodology, 
because for Question 9 there was only one study and it had already been graded in Question 8, and for 
Question 10 there were no included studies. 
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Statistical Analysis 
To compute the 95% confidence interval around a single percentage, we used the Wilson score method.
4,5
 
For comparing pre-transplant characteristics, we computed the size of the between-group difference using 
Hedges’ g for continuous data and the difference in percentages for dichotomous data. We defined a large 
difference at baseline as a Hedges’ g of 0.4 or more for continuous data, or a difference in percentage of 
15 percentage points or more for dichotomous data. Where appropriate, we combined the results of 
multiple studies using DerSimonian and Laird random-effects meta-analysis
6
 using specialized software 





 For risk factors, we computed the odds ratio and/or relative risk (and 95% confidence 
intervals) using standard methods with a 0.5 continuity correction applied to studies with a 0% rate in 
either group. For diagnostics, we computed sensitivity and specificity (and 95% confidence intervals) 
using MetaDisc 1.4. Additional statistical methods are described for each question in the text for that 
question. 
Evidence Tables 
For each question, we constructed evidence tables displaying numerous details about each study. 
These varied by question, and included: 
 Question 1 (epidemiology): Years of data collection, donor population, data sources, relevant viruses, 
diagnostic methods, whether diagnoses were confirmed, quality assessment criteria, and relevant data 
 Question 2 (transmission): Country, specific transplantation centers, which organ(s), number of 
transplantation centers, study funding source, the use of pre-transplant prophylaxis, the frequency of 
post-transplant testing for infection, duration of follow-up, timing of post-transplant infections, 
diagnostic methods, pre-transplant patient characteristics, quality assessment criteria, which 
antigen/antibody was used for defining donor positivity, which antigen/antibody was used for defining 
recipient positivity after transplant, and the relevant data. 
 Question 3 (behavioral risk factors): Virus(es), data source(s), country, selection methods, how risk 
factor data were collected, relevant blood tests used, study funding source, years of data collection, 
participant characteristics, specific risk factor(s) under investigation, specific population(s) included, 
how enrollees were selected, which confounders were adjusted for (if applicable), quality assessment 
criteria, reported statistical test results, and the relevant data 
 Question 4 (nonbehavioral risk factors): Generally the same as in Question 3 
 Question 5 (diagnostics): the index test and its category, data source(s), country, whether the 
infection status of samples was known before the study was conducted, whether the sample was 
unselected, the reference standard, other tests performed, test manufacturer, FDA approval date 
(if applicable), test format, whether specimens can be obtained from living donors or deceased donors 
or both, whether tests are applied to serum of plasma or both, quality assessment criteria, GRADE 
tables, reported data on diagnostic performance, window period, and turnaround time 
 Question 6 (inactivation): all steps in the inactivation procedure, when the viral load was measured, 
quality assessment criteria, GRADE tables, the total viral burden before and after inactivation, the 
percentage of viral copies that had been removed  
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 Question 7 (clinical outcomes of known positive organs vs. waitlist or known negative organs): 
Country, specific transplantation centers, which organ(s), number of transplantation centers, study 
funding source, pre-transplant patient characteristics, which antigen/antibody was used for defining 
donor positivity, diagnostic methods, quality assessment criteria, GRADE tables, whether “survival” 
meant graft survival or patient survival, duration of follow-up for each data point, any adjustments for 
confounding, reported statistical test results, and the relevant data 
 Question 8 (clinical outcomes of at-risk organs vs. waitlist or not-at-risk organs): for models, 
key assumptions about donors/recipients/death rates/costs/QALYS, assumed incidence and prevalence 
in specific subpopulations, quality assessment criteria, GRADE tables, and relevant data 
 Question 9 (impact of excluding donors with risk factors on the donor pool): Same as in Question 8 
 Question 10 (impact of false positives on the donor pool): Same as in Question 8 
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Overview of the Evidence 
A graphical depiction of the process of article identification appears in Figure 2. The three most common 
reasons for exclusion were: Not an empirical study (review, letter, commentary, etc.), did not address any 
questions for systematic review, and data on participants outside the U.S., and did not meet inclusion 
criteria for any of the questions that included non-U.S. data. Of the 167 included articles, the largest 
evidence bases were for Question 2 on transmission (60 articles) and Question 5 on diagnostic tests (45 
articles). The counts for other questions are shown in the figure. 
For Question 5 (diagnostics), 99 items from the gray literature were reviewed for potentially useful data. 
These included literature from manufacturers’ Web sites (40), the internet (6), the Food and Drug 
Administration (FDA) (23), agencies in the United Kingdom (14), agencies from Australia (13), and 
items from the World Health Organization (3). We included data on window period or turnaround time 
from 26 of the 99 items. 
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Figure 2. Study Attrition Diagram 
3,532 articles identified




1008 - Not an empirical study (review, letter, 
commentary, etc.)
667 - Did not address any questions for 
systematic review
494 - Data on participants outside the U.S., and 
did not meet inclusion criteria for any of the 
questions that included non-U.S. data
299 - Not a diagnostic test of interest
233 - Special population
113 - Did not report any outcomes of interest
84 - Used inactivation, but the target was not 
solid organs
80 - Fewer than five people enrolled
71 - Study of a pathogen or condition other 
than HIV/HBV/HCV
316 - Other
NOTE: The counts add to more than 166 because some articles were included for multiple questions.
Question 1 (epidemiology): 22 articles
Question 2 (transmission rate): 60 articles
Question 3 (behavioral risk factors): 22 articles
Question 4 (nonbehavioral risk factors): 29 articles
Question 5 (diagnostic tests): 45 articles
Question 6 (inactivation): 2 articles
Question 7 (clinical outcomes of organs from infected donors vs. waitlist or uninfected
                   donors): 25 articles
Question 8 (clinical outcomes of organs from at-risk donors vs. waitlist or not-at-risk 
                   donors): 2 articles
Question 9 (impact on pool of exclusion of those with risk factors): 1 article
Question 10 (impact on pool of exclusion of false positives): 0 articles
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Evidence Reviews: I. Probability of transmission of HIV, HBV, or 
HCV through solid organ transplantation (SOT) 
Question 1. What are the prevalence and incidence rates of HIV, HBV, 
and HCV among potential solid organ donors? 
This question involves the frequency of HIV, HBV, and HCV among individuals whose organ(s) are 
being considered for donation. These rates may differ from rates in the general population or from the 
rates in individuals who actually did donate organ(s). We considered both the prevalence (the percentage 
of potential organ donors at a given time who test positive for the pathogen) as well as incidence (the 
percentage of potential organ donors who newly acquire the pathogen in a one-year period).  
Due to the small amount of evidence on potential solid organ donors, we expanded the scope to include 
other possibly relevant populations. Thus, the evidence for this question is described in separate sections: 
1) Potential solid organ donors (three studies) 
2) Actual solid organ donors who had donated prior to 1991 and their lab samples were 
retrospectively tested for HCV (four studies). Hepatitis C virus (HCV) was discovered in April of 
1989, and serological screening for it was not widely performed until 1991. Therefore, another 
possible source of epidemiological data is studies of stored blood or plasma samples from actual 
organ donors before 1991. Because of the early donation date, the samples had not been screened 
for HCV prior to donation. 
3) Potential tissue donors (two studies). This population may be a reasonable approximation of 
potential solid organ donors.  
4) The general population (six studies). This population may also approximate potential solid organ 
donors. 
Potential Organ Donors 
Three studies reported prevalence estimates of HIV, HCV, and/or HBV among potential organ donors. 
The definition of “potential organ donor” involved liver donor referrals in two studies (relatives wishing 
to donate to children,
8,9
  and deceased donors in the other studies.
10,11
 Testing methods and diagnostic 
criteria were not consistently reported and may have varied among the studies. Differences in donor 
populations and methods used to diagnose and report infection probably contributed to the range in 
reported prevalence. It is not clear that the antibody tests were confirmed by a more specific method such 
as Western blot, recombinant immunoblot assay (RIBA), or nucleic acid-amplification tests (NAT) in 
most of these studies; lack of confirmation may have contributed to overestimation of prevalence due to 
antibody reaction false-positives. Lack of confirmation could also lead to an underestimation of 
prevalence if less sensitive antibody are used and if recent infections are missed. One study
10
 tested for 
HBV DNA among those whose serological tests was equivocal or positive for antibodies for the core 
antigen (anti-HBc) or the surface antigen (HBsAg).  
In the study that reported it, the prevalence of HCV was 3.6% among potential living donor relatives.
8
 
The prevalence of active hepatitis, type unspecified, among deceased potential donors rejected from 
21 
donation was reported as 5.3% (95% CI: 2.2% to 12.2%) in a study of potential deceased donors.
11
 The 
remaining study reported the prevalence of unspecified hepatitis at 18.2% (95% CI: 7.0% to 39.6%) 
among potential living donor relatives excluded at the second stage of evaluation.
9
 
HIV prevalence was also reported by two of those studies. A study of living adult potential donors did not 
detect any cases of HIV out of the 45 individuals screened
9,9
, and the study on potential deceased donors 




The quality assessment items are listed in Table 13. Meta-analysis was not performed because there were 
no instances where at least two studies reported the prevalence of the same virus. These data and 
additional information regarding the studies they were extracted from are shown in Table 7, below. 
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HCV Not reported Not reported  3.6% 













also tested in 
16 of 22, and it 
was positive in 
1/16. 
4.9%* 

















Not reported 18.2% 























Not reported Not reported Of the 94 potential 
donors excluded from 
donation for medical 
reasons, 5.3%; 
95% CI: 2.2% to 
12.2%)¶ were excluded 



























Method Confirmed? Prevalence 
Richards
11



















Not reported Not reported Of the 94 potential 
donors excluded from 
donation for medical 
reasons, 2.1%; 
95% CI: 0.5% to 8.1%)¶ 
were excluded due to 
HIV or syphilis. 
* Domen et al.
10
 included those with equivocal tests as well as those with positive tests, but did not report the corresponding counts. 
95% confidence interval (CI) calculated by ECRI Institute. 
¶  **The denominator of 22 is the number of candidates who  underwent phase 2 of evaluation for donation, out of 75 total considered for evaluation. 
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Pre-1991 Organ Donors Retrospectively Tested for HCV 
We included four such studies, the methods and results are shown in Table 8. All four studies met two of the three quality criteria (not selecting 
patients on the basis of behavioral or demographic factors, and using a standardized diagnostic test for determining infection status). Two studies 
only included deceased donors, and the other two did not report whether donors were living. The studies found a wide range of prevalence from 
2.4% to 6.8%. Because the studies’ methods were sufficiently similar, we combined the results in a random-effects meta-analysis, and this 
revealed substantial heterogeneity (I
2
 = 85%); the combined estimate of HCV prevalence was 4.0% (95% CI: 2.2% to 7.3%). 
 
These rates may be influenced by geography as well as the specific anti-HCV tests used by investigators. Shah et al. (1993)
12
 collected data from 
those who had received transplants in Pittsburgh, and they used a second generation ELISA assay (no further specifics reported). Vincenti et al. 
(1993)
13
 assessed organ donors from California and tested samples for anti-HCV using an ELISA but did not report the generation, and also tested 
for HCV RNA. Pereira et al. (1992)
14
 assessed organ donors from New England using a second generation ELISA assay (the HCV Elisa 2.0 Test 
System from Ortho Diagnostics) that "detects antibody to four recombinant HCV antigens (5-1-1, c100, c33, and c22)", the RIBA HCV Test 
system from Chiron, and test for HCV RNA using PCR.
14
 Roth et al. (1992)
15
 assessed organ donors from Miami "using a commercial ELISA 
(Ortho Diagnostic Systems)" (unreported generation), "a second generation RIBA" (Chiron Corporation)", and test for HCV RNA via PCR.
15
 
Table 8. Prevalence of HCV among Pre-1991 Organ Donors 
Citation 
Dates of 
Organ Donation Donor Population Data Collection Diagnostic Method Confirmed? Prevalence 




Mar-86 to Mar-90 Liver donors 
(unreported whether 




Anti-HCV by ELISA2 Not reported 5.8% 
(95% CI: 4.1% to 8.2%) 
(30/516) ¶ 









Anti-HCV by ELISA 
(unreported version) 
Yes, all four positives 
were confirmed as 
HCV RNA+ 
2.8% 













Anti-HCV by ELISA1 
and ELISA2 
Of those positive by 


















version) and RIBA 









Organ Donation Donor Population Data Collection Diagnostic Method Confirmed? Prevalence 
Combined prevalence (random-effects meta-analysis; I
2
 = 85%) 
4.2% 
(2.2% to 7.7%) 
¶ 95% confidence interval (CI) calculated by ECRI Institute. 
a
 The prevalence in the Pereira et al. study was based on the largest publication, which included 3078 tested donors.
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 The number in the table is the study’s 
estimated prevalence of positivity for HCV RNA, based on the two findings that 5.1% of the 3078 donors were ELISA1 positive, and 47% of those were HCV 
RNA positive (i.e., 47% of 5.1% is 2.4%) 
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Potential Tissue Donors 
We included one retrospective study on this population.  Zou et al. assessed the frequency of HBV, HCV, 
and/or HIV among tissue donors and estimated both incidence and prevalence.
21
 Four of the 5 tissue 
centers in Zou et al. reported confirmed positive results whereas one center reported screening results 
only. Zou et al. estimated confirmed positive results for the fourth center using data from the other sites.   
Table 9 shows the pertinent data. The prevalence of confirmed HIV was 0.093% (95% CI 0.036% to 
0.150%) of donors.. The prevalence of confirmed HBV was 0.229% (95% CI 0.139% to 0.319%) among 
donors in Zou et al. Zou et al. also used the tissue donor data as well as blood donor data to estimate the 
incidence of early viral infection undetected during the serologic window period. Their estimated 
incidence rates per 100,000 person years were 30.11 for anti-HIV, 18.325 for HbsAg, and 12.380 for anti-
HCV.
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Table 9. Prevalence of Hepatitis and HIV Among Potential Tissue Donors 
Citation Year 

























5 tissue banks; 
Incidence 
estimated 
HBV HbsAg  Yes  0.229% 
(95% CI: 0.139% to 0.319%)¶ 
HCV Anti-HCV Yes 1.091% 


















5 tissue banks; 
Incidence 
estimated 
HIV Anti-HIV Yes 0.093% 
(95% CI: 0.036% to 0.150%)¶ 
* Denominator represents all potential donors who were tested for HIV, HBV and HCV. 




The six included general population studies are listed in Table 10. All six studies met two of the three 
quality criteria (not selecting patients on the basis of behavioral or demographic factors, and using a 
standardized diagnostic test for determining infection status). 
For HIV in the general population, the CDC has estimated that the annual U.S. incidence in 2006 was 
56,300
22,23
 and the prevalence was 1,106,400.
24
 The U.S. population was approximately 299,000,000 in 
that year,
25
 thus the incidence was approximately 0.019% (1 in 5,308) and the prevalence was 
approximately 0.37% (1 in 270). 
For HBV and HCV in the general population, Table 11 provides the most recently available estimates. 
The U.S. population was approximately 302,000,000 in 2007,
25
, which means the incidence rates for 
HBV and HCV were 0.014% (1 in 7,023) and 0.0056% (1 in 17,765), respectively. These data are based 
on estimates from multiple sources including the National Health and Nutrition Examination Survey 
(NHANES), the National Notifiable Diseases Surveillance System (NNDSS), the Emerging Infection 
Program, and the American Community Survey. 
Table 10. Methods of Studies Included on Incidence and Prevalence in the 




















2006 NHANES, ACS HBV Not reported NR 




1988-1994 NHANES HBV Not reported NR 
















2006 A new national 
case reporting 
system  






2006 A new national 
case reporting 
system 
HIV STARHS NR 
* ACS – American Community Survey 
ELISA – Enzyme-linked immunosorbent assay 
NHANES – National Health and Nutrition Examination Survey 
NNDSS – National Notifiable Disease Surveillance System 
STARHS – Serological testing algorithm for recent HIV seroconversion 
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Table 11. Incidence and Prevalence of HBV and HCV in the U.S. General Population 
 HBV HCV 
Incidence 43,000 (in 2007)
26,27
 17,000 (in 2007)
26,27
 
Number of acute clinical cases
a 
 13,000 (in 2007)
26,27
 2,800 (in 2007)
26,27
 




Between 0.8 million and 
1.4 million (in 2006)
28
 
Between 2.7 million and 
3.9 million (in 1999-2002)
30
 
Percentage of people ever infected
c









 For hepatitis B, the incidence estimates and the estimated number of acute clinical cases are “derived from catalytic 
modeling of seroprevalence data from the Third National Health and Nutrition Examination Survey (NHANES III) 
applied to cases reported to the National Notifiable Diseases Surveillance System (NNDSS).”
27
 For hepatitis C in 
2007, these estimates were based on data from the Emerging Infection Program.
27 The number of acute clinical 
cases is different from incidence, because most new infections are asymptomatic (and thus not diagnosed or 
reported).. 
b
 For hepatitis B, the number of people with chronic infection was based on the 2006 American Community Survey 
and a U.S. Department of Justice study of prison and jail inmates.
28
 For hepatitis C, the numbers were based on 




 For hepatitis B, the percentage of people ever infected was based on NHANES data from 1988-1994.
29
 
For hepatitis C, the numbers were based on NHANES data from 1999-2002.
30
 
GRADE Assessment of Epidemiology 
The GRADE table for this question appears in Table 12. We graded the evidence as Low for all three 
pathogens. This was due to two concerns: varying estimates of epidemiological statistics, and the use of 
populations other than potential organ donors. The variation in estimates between the different studies 
was not simply due to their enrollment of different populations. For example, even within the four studies 
of pre-1991 actual organ donors who were retrospectively tested for HCV, prevalence estimates ranged 
widely (by a factor of more than three: from 1 in 15 to 1 in 55). 
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HIV Incidence 1 study of potential 
tissue donors21 
1 study of the U.S. 
general population22,23 
In the study of potential tissue 
donors, incidence of 30.11 per 
100,000 person-years 
In the general population 
study, incidence of 56,300 in 
2006, which corresponds to 
18.8 per 100,000 person years 
High 0 -1 -1 0 0 0 0 0 Low 
 
 Prevalence 2 studies of potential 
organ donors9,11 
1 study of potential 
tissue donors21 
1 study of the U.S. 
general population24 
In the studies of tested 
potential organ donors, 
prevalence of HIV was 
0/22 (0%), and prevalence of 
HIV or syphilis was and 
2/94 (2.1% or 1 in 48). 
In the study of potential tissue 
donors, prevalence was 
10/10,910 (0.093% or 
1 in 1,090). 
In the general population 
study, prevalence was 
1,106,400 in 2006 (0.37%, or 
1 in 270) 
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HBV Incidence 1 study of potential 
tissue donors21 
1 study of the U.S. 
general population26,27 
In the study of potential tissue 
donors, incidence of 18.325 
per 100,000 person-years 
In the general population 
study, 43,000 incidence in 
2007, which corresponds to 
14.4 per 100,000 person-years 
High 0 0 -1 0 0 0 0 0 Moderate 
 
 Prevalence 1 study of HBV in 
potential organ donors10 
2 studies of 
hepatitis(including HBV 
and HCV) in tested 
potential organ 
donors9,11 
1 study of potential 
tissue donors21 
1 study of the U.S. 
general population28 
In the study of HBV in potential 
organ donors, prevalence was 
22/446 (4.9%, or 1 in 20). 
In the two studies of hepatitis 
in potential organ donors, 
prevalence of 5/94 (5.3%, or 1 
in 19) and4/22 (18.2%, or 1 in 
6). 
The study of potential tissue 
donors reported a prevalence 
of 25/10901 (0.229%, or 1 in 
436).. 
In the general population 
study, prevalence of chronic 
infection was 1.1 million in 
2006 (0.36% or 1 in 274) 
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HCV Incidence 1 study of potential 
tissue donors21 
1 study of the U.S. 
general population26,27 
In the study of potential tissue 
donors, incidence of 12.38 per 
100,000 person-years 
In the general population 
study, 17,000 incidence in 
2007, which corresponds to 5.7 
per 100,000 person-years 
High 0 -1 -1 0 0 0 0 0 Low 
 
 Prevalence 1 study of HCV in 
potential organ donors8 
1 study of “hepatitis” in 
potential organ donors9 
4 studies of prevalence 
among pre-1991 organ 
donors12-18,20 
1 study of potential 
tissue donors21 
1 study of the U.S. 
general population30 
In the study of HCV in potential 
organ donors, prevalence was 
2/55 (3.6%, or 1 in 28). 
In the study of HBV and HCV 
in potential organ donors, 
prevalence was  5/430 (1.2%, 
or 1 in 86) 
In the studies of pre-1991 
organ donors, combined 
estimate of prevalence of 4.0% 
or 1 in 25. 
In the study of potential tissue 
donors, prevalence of 
119/10915 (1.091%, or 1 in 
92). 
In the general population 
study, prevalence of infection 
was 4.1 million (1.6% of the 
U.S. population) in 1999-2002. 
High 0 -1 -1 0 0 0 0 0 Low Low 
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Additional Evidence Tables for Question 1 
Table 13. Question 1: Quality Assessment 
Study 1a 1b 1c 
Potential Solid Organ Donors 
Hidalgo et al.(2001)
8
    
Domen et al.(2000)
10
    
Renz et al. (1995)
9
    
Richards (1993)
11
    
Actual Solid Organ Donors Pre-1991 Retrospectively Tested for HCV 
Shah et al. (1993)
12,16
    
Vincenti et al. (1993)
13
    
Pereira et al. (1992)
14,17-19
    
Roth et al. (1992)
15,20
    
Potential Tissue Donors 
Zou et al. (2004)
21
    
General Population 
Daniels et al. (2009)
26,27
    
Weinbaum et al. (2008)
28
    
McQuillan et al. (1999)
29
    
Armstrong et al. (2006)
30
    
Prejean et al. (2009)
22,23
    
Centers for Disease Control (2008)
24
    
A checkmark () means that the study met the quality criterion for this Question; the lack of a checkmark means that 
the study either did not meet the criterion, or it was unclear whether the study met the criterion. The criteria specific to 
this Question were:  
1a. Was the population potential solid organ donors? 
1b. For other populations, was the population unselected (i.e., not based on demographic or behavioral 
characteristics)? (Studies of potential solid organ donors were scored as Yes, because they enrolled the 
population of interest.) 
1c. Was infection status determined accurately? (i.e., accuracy of diagnostic test method used to determine 
infection status) 
34 
Question 2. What are the rates of transmission to recipients from donors 
infected with HIV, HBV, or HCV? Do the rates vary by the organ 
transplanted or when the donor was infected? 
For this question, the rate of transmission is the chance that an infected organ donor transmits the 
infection to a previously uninfected recipient. The observed rate of transmission likely depends on 
numerous factors, including the bloodborne pathogen (HIV, HBV, or HCV), the organ transplanted, the 
specific antigens or antibodies for which the donor was positive, whether HBV prophylaxis was used, and 
the type of serologic testing used for detection. Thus, as we tabulated information from the large evidence 
base for this question, we carefully delineated those facets that could potentially influence the results. 
Sixty articles met the inclusion criteria. These contained some duplication of patients, and after careful 
perusal, the evidence comprised 44 unique studies (a single “study” can involve multiple publications 
from the same center on the same kinds of patients who were enrolled in overlapping timeframes). All 
studies addressed either HBV or HCV, and we extracted data on those recipients who were negative 
before transplant and who had received organs from donors who had tested positive. The lack of evidence 
on HIV is probably a result of federal regulations that prohibit transplantation of organs from individuals 
known to be HIV-positive.  
The evidence for this question is considered in seven separate sections, according to different pathogens 
and organs: 
- 16 studies of HBV transmission from liver transplantation 
- 9 studies of HBV transmission from kidney transplantation 
- 6 studies of HBV transmission from heart transplantation 
- 1 study of HBV transmission from lung transplantation 
- 2 studies of HCV transmission from liver transplantation 
- 10 studies of HCV transmission from kidney transplantation 
- 4 studies of HCV transmission from heart transplantation 
Reported results on transmission can vary greatly based on numerous factors. Obviously, the specific 
pathogen and the specific organ are critical factors. Also, the type of serological testing will matter, 
specifically 1) For which antigen/antibody was the donor positive? and 2) For which antigen/antibody 
was the recipient tested? One study might include organ donors who were anti-HBc+ and HBsAg-, and 
report the rate of HBsAg positivity among recipients. Another study might include the same types of 
donors, but report the rate of positive HBV DNA in serum among recipients. These studies are detecting 
infection in different ways, therefore it would not make sense to consider their results together. Still other 
important factors include the use of prophylaxis (e.g., lamivudine), specific diagnostic tests used, the 
frequency and timing of these tests, and the length of follow-up after transplantation. In our presentation 
of the evidence, we provide information about these factors to aid interpretation of results. 
General characteristics of the 44 included studies are listed in Table 22 and Table 23. Twenty-six studies 
were conducted in the U.S., with the remaining 17 studies conducted in Spain (four studies), Japan (three 
35 
studies), Italy (three studies), France (two studies), Latvia, Belgium, Germany, Taiwan, Canada, and the 
U.K. (one study each). Thirty-five studies were conducted at only a single center. Data were collected 
retrospectively in 35 studies, prospectively in seven studies, and not reported in the other two studies. 
Consecutive enrollment was performed in 26 studies. The pre-transplant patient characteristics are listed 
in Table 24, quality assessments appear in Table 25, and the reported results are listed in Table 26. 
A plot of the transplantation dates appears in Figure 3 below. The start dates of organ transplantations 
ranged from January 1979 to April 2001, with the median at June 1994. The end dates ranged from 
December 1988 to June 2004, with the median at July 1999. The median length of the transplantation 
period (the period of time when data were collected) was 4.4 years, with a range from 1.7 to 15.7. 
Only 13 studies reported information about study funding. These generally involved national funding 
sources, not corporations with conflicts of interest. The mean or median length of follow-up was reported 
by 26 studies, and it ranged from five months to 5.25 years, with a median of two years. 
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Figure 3. Question 2: Plot of Transplantation Dates 
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Thus, the “typical” study for Question 2 was a single-center U.S. study of unknown funding source that 
collected data retrospectively on consecutive patients who received an organ transplant in a four-year 
period in the mid-late 1990’s, and were followed for an average of two years. 
Pre-transplant characteristics of donors and recipients are listed in Table 24. Most studies (30 of 44, or 
68%) did not report any characteristics specifically for those donor-recipient pairs in which the donor was 
positive and the recipient was negative before transplant. For the 13 studies that did report these 
characteristics, the following characteristics were reported by three or more studies: 
 The mean donor age ranged from 39 to 43 (in the three studies reporting donor age) 
 The mean recipient age ranged from 33 to 57 (nine studies) 
 The percentage of males among donors ranged from 42% to 74% (three studies) 
 The percentage of males among recipients ranged from 33% to 90% (ten studies) 
 The percentage or recipients who were UNOS Status 1 ranged from 56% to 100% (three studies; 
these were studies of HCV transmission after heart transplantation) 
Regarding quality assessment (Table 25), 37 of 44 studies (84%) were retrospective, and 26 of 44 studies 
(59%) enrolled patients consecutively. Twelve of 44 studies (27%) used some form of prophylaxis 
(e.g., HBIg, lamivudine) for all recipients, six used it for some but not all recipients, two used it for no 
recipients, and the other 23 studies did not report whether prophylaxis had been used. The frequency of 
post-transplant serology testing was reported by 21 studies, and the methods varied widely: 
 Seven studies performed relatively intensive monitoring for hepatitis (e.g., “at weeks 1, 2, 3, 4, 
then monthly for one year, then every three months.”)
31
 
 Four studies performed relatively moderate monitoring (e.g., “At months 1, 3, and 6, then yearly”)32 
 Six studies used only sporadic monitoring. (e.g., “When possible, samples were obtained at 
4 months, one year, and two years after transplant”)
33
 
 Three studies reported regular monitoring without stating a frequency (e.g., each patient was 
“tested on one or more occasions during routine clinical visits”)
34
 
 One study reported the use of liver biopsy “when clinically indicated”35 
The next seven subsections describe the study results for this question. 
HBV Transmission from Liver Transplantation 
Studies measured virus transmission in 14 different ways for the transmission of HBV from liver 
transplantation (Table 14). As shown in the next to rightmost column, the range of rates was very wide. 
The results are shown graphically in Figure 4 and Figure 5. One possible explanation for the differences 
among studies is the use of prophylaxis, which may result in negative recipient testing despite potential 
transmission. Studies that used HBV prophylaxis for all patients are depicted with open circles; studies 
that used HBV prophylaxis for some but not all patients are depicted with gray circles; studies that used 
HBV prophylaxis for no patients are depicted with black circles; studies that did not report whether 
38 
patients received prophylaxis are depicted with X’s. The graphs suggest that rates were lower when 
prophylaxis was used. 
Table 14. LIVER Transplantation: Ranges of HBV Results 
Donor was: 







Anti-HBc+ HBsAg 5 0% to 94% Roque-Afonso et al. (2002)
36
, 
Yu et al. (2001)
35
, 
Dodson et al. (1999)
37
, 
Uemoto et al. (1998)
38-41
, 
Kadian et al. (1994)
42
 
Anti-HBc+ HBeAg 2 40% to 94% Uemoto et al. (1998)
38-41
, 
Kadian et al. (1994)
42
 
Anti-HBc+ anti-HBs 2 0% to 44% Roque-Afonso et al. (2002)
36
, 
Yu et al. (2001)
35
 
Anti-HBc+ anti-HBc 2 0% to 78% Roque-Afonso et al. (2002)
36
, 
Yu et al. (2001)
35
 
Anti-HBc+ serum HBV-DNA 2 40% to 94% Uemoto et al. (1998)
38-41
, 
Kadian et al. (1994)
42
 
Anti-HBc+ “Developed de novo 
infection” 





HBsAg 9 0% to 78% De Feo et al. (2005)
44,45
, 
Holt et al. (2002)
46
, 
Donataccio et al. (2006)
47
, 
Suehiro et al. (2005)
48
, 
Fabrega et al. (2003)
49
, 
Nery et al. (2003)
50
, 
Preito et al. (2001)
32
, 
Dickson et al. (1997)
33
, 





HBeAg 2 13% to 67% Nery et al. (2003)
50
, 





anti-HBs 2 0% to 5% Castells et al. (2002)
52
, 





anti-HBc 3 0% to 37% Holt et al. (2002)
46
, 
Donataccio et al. (2006)
47
, 





liver HBV-DNA 2 0% to 13% Holt et al. (2002)
46






serum HBV-DNA 7 0% to 71% Holt et al. (2002)
46
, Suehiro et 
al. (2005)
48
, Fabrega et al. 
(2003)
49




Nery et al. (2003)
50
, 
Castells et al. (2002)
52
, 



















Figure 4. LIVER Transplantation: HBV Positivity in Recipients After the Use of 
Anti-HBc+ Donors 

















Note: This figure displays the reported rates of positivity among pre-transplant negative recipients after receiving 
organs from positive donors.. The title of the figure indicates the relevant pathogen(s) and organ(s). These 
data also appear in Table 26. The definitions of donor positivity appear on the left side of the figure, and the 
definitions of recipient post-transplant positivity appear on the right side of the figure. White circles indicate 
studies where all recipients received prophylaxis; gray circles indicate studies where some but not all 
recipients received prophylaxis; black circles indicate studies where none of the recipients received 
prophylaxis; an X indicates studies that did not report whether prophylaxis was used. 
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Figure 5. LIVER Transplantation: HBV Positivity in Recipients After the Use of Organs 
from Anti-HBc+ HbsAg- Donors 


















Note: This figure displays the reported rates of positivity among pre-transplant negative recipients after receiving 
organs from positive donors. The title of the figure indicates the relevant pathogen(s) and organ(s). These data 
also appear in Table 26. The definitions of donor positivity appear on the left side of the figure, and the 
definitions of recipient post-transplant positivity appear on the right side of the figure. White circles indicate 
studies where all recipients received prophylaxis; gray circles indicate studies where some but not all 
recipients received prophylaxis; black circles indicate studies where none of the recipients received 
prophylaxis; an X indicates studies that did not report whether prophylaxis was used. 
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HBV Transmission from Kidney Transplantation 
Studies measured virus transmission in 13 different ways for the transmission of HBV from kidney 
transplantation (Table 15). These rates were very low. The reported resultsare shown graphically in 
Figure 6 and the top section of Figure 7. 
Table 15. KIDNEY Transplantation: Ranges of HBV Results 
Donor was: 







anti-HBc+ HBsAg 1 0% Kadian et al. (1994)
42
 
anti-HBc+ HBeAg 1 0% Kadian et al. (1994)
42
 
anti-HBc+ anti-HBs 1 0% Kadian et al. (1994)
42
 
anti-HBc+ anti-HBc 1 0% Kadian et al. (1994)
42
 





HBsAg 6 0% De Feo et al. (2005)
44,45
, 
Veroux et al. (2005)
54
, 
Fong et al. (2002)
55
, 
Madayag et al. (1997)
56
, 
Satterthwaite et al. (1997)
57
, 





anti-HBs 4 0% to 55% Akalin et al. (2005)
58
, 
Madayag et al. (1997)
56
, 
Satterthwaite et al. (1997)
57
, 





anti-HBc 7 0% to 13% De Feo et al. (2005)
44,45
, 
Akalin et al. (2005)
58
, 
Veroux et al. (2005)
54
, 
Fong et al. (2002)
55
, 
Madayag et al. (1997)
56
, 
Satterthwaite et al. (1997)
57
, 

































Figure 6. KIDNEY Transplantation: HBV Positivity in Recipients After the Use of 
Organs from Anti-HBc+ Donors or Anti-HBc+ HbsAg- Donors 




















Note: This figure displays the reported rates of positivity among pre-transplant negative recipients after receiving 
organs from positive donors. The title of the figure indicates the relevant pathogen(s) and organ(s). These data 
also appear in Table 26. The definitions of donor positivity appear on the left side of the figure, and the 
definitions of recipient post-transplant positivity appear on the right side of the figure. White circles indicate 
studies where all recipients received prophylaxis; gray circles indicate studies where some but not all 
recipients received prophylaxis; black circles indicate studies where none of the recipients received 
prophylaxis; an X indicates studies that did not report whether prophylaxis was used. 
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Figure 7. Other Results for HBV 









































Note: This figure displays the reported rates of positivity among pre-transplant negative recipients after receiving 
organs from positive donors. The title of the figure indicates the relevant pathogen(s) and organ(s). These data 
also appear in Table 26. The definitions of donor positivity appear on the left side of the figure, and the 
definitions of recipient post-transplant positivity appear on the right side of the figure. White circles indicate 
studies where all recipients received prophylaxis; gray circles indicate studies where some but not all 
recipients received prophylaxis; black circles indicate studies where none of the recipients received 
prophylaxis; an X indicates studies that did not report whether prophylaxis was used. 
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HBV Transmission from Heart Transplantation 
Studies measured virus transmission in nine different ways for the transmission of HBV from heart 
transplantation (Table 16). The reported results are shown graphically in the middle section of Figure 7 
above. 
Table 16. HEART Transplantation: Ranges of HBV Results 
Donor was: 







anti-HBc+ HBsAg 2 0% to 4% Pinney et al. (2005)
60
, 
Kadian et al. (1994)
42
 
anti-HBc+  anti-HBs 3 8% to 48% Pinney et al. (2005)
60
, 
Tenderich et al. (2005)
61
, 
Kadian et al. (1994)
42
 
anti-HBc+ anti-HBc 2 18% to 65% Tenderich et al. (2005)
61
, 








































HBV Transmission from Lung Transplantation 
Studies measured virus transmission in two different waysfor the transmission of HBV from lung 
transplantation (Table 17). Both rates were 0%. The reported resultsare shown graphically in the lower 
section of Figure 7 (above). 
Table 17. LUNG Transplantation: Ranges of HBV Results 
Donor was: 







HBsAg-, anti-HBc+ HBsAg 1 0% Hartwig et al. (2005)
65
 




HCV Transmission from Liver Transplantation 
Studies measured virus transmission in three different waysfor the transmission of HCV from liver 
transplantation (Table 18). The reported resultsare shown graphically in Figure 8. 
Table 18. LIVER Transplantation: Ranges of HCV Results 
Donor was: 






















Figure 8. LIVER transplantation: HCV Positivity in Recipients After the Use of 
Organs Donors Positive for HCV 

















Note: This figure displays the reported rates of positivity among pre-transplant negative recipients after receiving 
organs from positive donors. The title of the figure indicates the relevant pathogen(s) and organ(s). These data 
also appear in Table 26. The definitions of donor positivity appear on the left side of the figure, and the 
definitions of recipient post-transplant positivity appear on the right side of the figure. Prophylaxis was not 
generally applicable to the HCV studies, therefore all studies are represented by X’s. 
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HCV Transmission from Kidney Transplantation 
Studies measured virus transmission in eight different ways for the transmission of HCV from kidney 
transplantation (Table 19). The reported resultsare shown graphically in Figure 9 below. 
Table 19. KIDNEY Transplantation: Ranges of HCV Results 
Donor was: 







anti-HCV+ anti-HCV 8 6% to 91% Abbott et al. (2004)
67,68
, 
Rozental et al. (2002)
69
, 
Tokumoto et al. (1996)
70
, 
Tokumoto et al. (1996)
70
, 
Wreghitt et al. (1994)
71
, 
Mendez et al. (1993)
72,73
, 
Pereira et al. (1992)
14,17-19
, 
Roth et al. (1992)
15,20
 
anti-HCV+ HCV-RNA 2 50% to 100% Tokumoto et al. (1996)
70
, 





anti-HCV 2 0% to 19% Tesi et al. (1994)
74,75
, 












HCV-RNA 2 0% to 57% Tesi et al. (1994)
74,75
, 





RIA 1 0% Vincenti et al. (1993)
13
 
anti HCV+ and 
RIBA+ 
anti-HCV 1 62% Preiksaitis et al. (1997)
76
 
anti HCV+ and 
RIBA+ 






Figure 9. KIDNEY Transplantation: HCV Positivity in Recipients After the Use of 
Organs from Donors Positive For HCV 






















Note: This figure displays the reported rates of positivity among pre-transplant negative recipients after receiving 
organs from positive donors. The title of the figure indicates the relevant pathogen(s) and organ(s). These data 
also appear in Table 26. The definitions of donor positivity appear on the left side of the figure, and the 
definitions of recipient post-transplant positivity appear on the right side of the figure. Prophylaxis was not 
generally applicable to the HCV studies, therefore all studies are represented by X’s. 
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HCV Transmission from Heart Transplantation 
Studies measured virus transmission in six different waysfor the transmission of HCV from heart 
transplantation (Table 20). The reported results are shown graphically in Figure 10. 
Table 20. HEART Transplantation: Ranges of HCV Results 
Donor was: 







anti-HCV+ “detectable” anti-HCV 3 11% to 24% Haji et al. (2004)
77-79
, 
Gudmundsson et al. (2003)
80
, 
Marelli et al. (2002)
81
 
anti-HCV+ HCV-RNA 3 12% to 75% Haji et al. (2004)
77-79
, 
Gudmundsson et al. (2003)
80
, 
Marelli et al. (2002)
81
 
anti-HCV+ liver HCV 1 29% Gudmundsson et al. (2003)
80
 















Figure 10. HEART Transplantation: HCV Positivity in Recipients After the Use of 
Organs from Donors Positive for HCV 



















Note: This figure displays the reported rates of positivity among pre-transplant negative recipients after receiving 
organs from positive donors. The title of the figure indicates the relevant pathogen(s) and organ(s). These data 
also appear in Table 26. The definitions of donor positivity appear on the left side of the figure, and the 
definitions of recipient post-transplant positivity appear on the right side of the figure. Prophylaxis was not 
generally applicable to the HCV studies, therefore all studies are represented by X’s. 
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GRADE Assessment of Transmission  
The GRADE table for this question appears in Table 21; the seven categories of evidence were graded 
separately. There are numerous permutations of antigens/antibodies, and the committee decided that of 
these, the most critical HBV results were when the donor was positive for anti-HBc and may or may not 
have been HBsAg+  (e.g., studies where donor HBsAg status was not reported).The only exception to this 
was when the recipient was being tested for anti-HBs, which was not considered critical. For HCV, we 
considered it a critical result whenever the donor was positive for HCV RNA. To acknowledge these 
priorities, we shaded the rows summarizing and grading the corresponding evidence. The unshaded rows 
represent less critical results. For the seven categories of evidence, the primary reasons for the Low or 
Very Low grades involve study quality and consistency. Results were often widely different, even within 
the specific antigens and antibodies being tested. 
53 




































































































































HBV and Liver Transplantation 
Anti-HBc+ HBsAg 5 OBS
35-42
 0% to 94% High -1 -1 0 0 0 0 0 0 Low 
Low 
Anti-HBc+ HBeAg 2 OBS
38-42
 40% to 94% High -2 -1 0 0 0 0 0 0 Very Low 
Anti-HBc+ anti-HBc 2 OBS
35,36











 6% High -2 -1 0 0 0 0 0 0 Very Low 
Anti-HBc+ anti-HBs 2 OBS
35,36
 0% to 44% High -1 -1 0 0 0 0 0 0 Low 
Anti-HBc+ 
and HBsAg- 
HBsAg 9 OBS 
32,33,44-51
 










































































































































































 0% High 0 -1 0 0 0 0 0 0 Moderate 
HBV and Kidney Transplantation 
anti-HBc+ HBsAg 1OBS
42
 0% High -2 0 0 0 0 0 0 0 Low 
Low 
anti-HBc+ HBeAg 1 OBS
42
 0% High -2 -1 0 0 0 0 0 0 Very Low 
anti-HBc+ anti-HBc 1OBS
42





 0% High -2 -1 0 0 0 0 0 0 Very Low 
anti-HBc+ anti-HBs 1 OBS
42
 0% High -2 -1 0 0 0 0 0 0 Very Low 
HBsAg-, 
anti-HBc+ 
HBsAg 6 OBS 
44,45,51,54-57
 





 0% to 11% High -1 0 0 0 0 0 0 0 Moderate 
HBsAg-, 
anti-HBc+ 
anti-HBc 7 OBS 
44,45,51,54-58
 















































































































































“HBV viremia” 1 OBS
58























 0% High -2 -1 0 0 0 0 0 0 Very Low 
HBV and Heart Transplantation 
anti-HBc+ HBsAg 2 OBS
42,60
 0% to 4% High -2 0 0 0 0 0 0 0 Low 
Very Low 
anti-HBc+ anti-HBc 2 OBS
42,61
 18% to 65% High -2 -1 0 0 0 0 0 0 Very Low 
anti-HBc+ anti-HBs 3 OBS
42,60,61
















































































































































































 20% High -2 -1 0 0 0 0 0 0 Very Low 
















































































































































HCV and Liver Transplantation 
anti-HCV+ anti-HCV 1 OBS
12,16













 100% High -1 -1 0 0 0 0 0 0 Low 
HCV and Kidney Transplantation 




6% to 91% High -2 -1 0 0 0 0 0 0 Very Low 
Very Low 
anti-HCV+ HCV-RNA 2 OBS
70,71








































































































































































 67% High -2 -1 0 0 0 0 0 0 Very Low  
HCV and Heart Transplantation 
anti-HCV+ anti-HCV 3 OBS
77-81
 11% to 24% High -2 0 0 0 0 0 0 0 Low 
Very Low 
anti-HCV+ HCV-RNA 3 OBS
77-81
 12% to 75% High -2 -1 0 0 0 0 0 0 Very Low 
anti-HCV+ liver HCV 1 OBS
80
 29% High -2 -1 0 0 0 0 0 0 Very Low 
















 100% High -2 -1 0 0 0 0 0 0 Very Low 
Note: The shaded rows denote evidence on rates where the donor was positive for anti-HBc but it was not reported whether the donor was positive for HBsAg; 
these were considered “critical” outcomes. The only expectation to this was when the recipient was being tested for anti-HBs, which was not considered 
critical. For HCV, we considered the result critical whenever the donor was positive for HCV RNA (thus the row was shaded). 
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Additional Evidence Tables for Question 2 















































Studies of HBV Transmission 
De Feo et al. (2005)
44,45
 Italy North Italy 
Transplant program 
    39 Jan-97 to 
Dec-99 
Supported in part by a grant 
from the Italian Institute of 
Health 
Kadian et al. (1994)
42
 USA Mount Sinai Medical 
Center (NY) 
    1 Sep-90 to 
Jun-92 
Not reported (NR) 
Akalin et al. (2005)
58
 USA Mt. Sinai School of 
Medicine, 
New York, NY 
    1 NR NR 
Veroux et al. (2005)
54
 Italy University Hospital of 
Catania 
    1 Jan-01 to 
Jun-04 
NR 
Miedouge et al. (2003)
59
 France Toulouse University 
Hospital 
    1 Jan-99 to 
Nov-01 
NR 
Fong et al. (2002)
55
 USA UNOS Scientific 
Renal Transplant 
Registry 
    >1 1994 to 
1999 
NR 
Madayag et al. (1997)
56
 USA University of 
Maryland, 
Baltimore, MD 
    1 Jan-92 to 
Jul-96 
NR 
Satterthwaite et al. (1997)
57
 USA St. Vincent Medical 
Center, 
Los Angeles, CA 


















































Wachs et al. (1995)
51
 USA University of 
California 
(San Francisco, CA) 
    1 Jun-85 to 
Dec-93 
NR 
Donataccio et al. (2006)
47
 Belgium Universite catholique 
de Louvain 
    1 Feb-92 to 
Mar-04 
One author was the 
recipient of a grant from 
Associzaone Italiana 
Trapiantati di Fegato 
(AITF), First Department of 
General Surgery, Verona 
University, Verona Italy 
Suehiro et al. (2005)
48




    2 Oct-96 to 
Mar-03 
Supported in part by a 
Grant-in-Aid for Scientific 
Research and the 21st 
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 Italy University of Bologna     1 Apr-86 to 
Jan-02 
NR 
Fabrega et al. (2003)
49
 Spain University Hospital 
Marques de 
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    1 Nov-99 to 
Mar-02 
Fundacion Marques del 
Valdecilla 
Loss et al. (2003)
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 USA Ochsner Clinic 
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    1 Mar-96 to 
Mar-02 
NR 
Castells et al. (2002)
52
 Spain Hospital General Vall 
d’Hebron 
    1 Jun-94 to 
Jun-00 
NR 
Holt et al. (2002)
46
 USA Loyola University 
Medical Center, 
Chicago, IL 
    1 Feb-98 to 
Mar-01 
NR 
Roque-Afonso et al. (2002)
36
 France Hospital Paul 
Brousse 
    1 Jan-97 to 
Sep-00 
NR 
Preito et al. (2001)
32
 Spain University Hospital la 
Fe 
    1 Mar-95 to 
Dec-98 
NR 
Yu et al. (2001)
35
 USA Cedars-Sinai 
Medical Center, 
Los Angeles, CA 
    1 Mar-96 to 
Mar-00 
NR 
Dodson et al. (1999)
37




    1 Aug-96 to 
Jun-98 
NR 
Uemoto et al. (1998)
38-41
 Japan Kyoto University     1 Jun-90 to 
Jun-95 
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(Omaha, NE), and 
University of 
California 
(San Francisco, CA) 
    4 Aug-89 to 
Jun-94 
NR 
Pinney et al. (2005)
60
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Presbyterian Medical 
Center, New York, 
NY 
    1 Jan-97 to 
Dec-02 
NR 
Tenderich et al. (2005)
61
 Germany Herz und 
Diabeteszentrum 
NRW 
    1 Feb-99 to 
May-04 
NR 
Blanes et al. (2002)
64
 Spain University Hospital la 
Fe 
    1 Jan-95 to 
Jun-99 
NR 
Ko et al. (2001)
62,63
 Taiwan National Taiwan 
University Hospital 
    1 Jan-92 to 
Aug-99 
NR 
Hartwig et al. (2005)
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 USA Duke University 
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    1 Apr-01 to 
Aug-03 
“The authors have no 
conflict of interest with 
















































Studies of HCV Transmission 
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University Hospital 
    1 1997 to 
Jul-01 
NR 
Preiksaitis et al. (1997)
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Hospitals, Alberta 
    1 1984 to 
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NR 
Tokumoto et al. (1996)
70
 Japan Nigata University     1 Nov-89 to 
Nov-92 
NR 
Tesi et al. (1994)
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 USA Ohio State 
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Columbus, OH 
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Papworth 
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(Omaha, NE), and 
University of 
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(San Francisco, CA) 
    3 Apr-90 to 
Jun-94 
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12,16
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Haji et al. (2004)
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New Orleans, LA 
    1 1991 to 
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NR 
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    1 Jan-95 to 
Jul-97 
Robert D. Van Kampen 
Research Fund 
Marelli et al. (2002)
81
 USA University of 
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 January 1993 is an approximate estimate of the latest transplant date (based on the publication date of the primary publication of March 1994), so that the study 
could be included in the plot of transplant dates. 
NR – Not reported. 
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occur? Diagnostic Tests 
Studies of HBV Transmission 
De Feo et al. (2005)
44,45
 No No NR NR NR NR Microparticle Enzyme 
Immunoassay for HBV, and 
ImxCORE and ImxAVSAB 
Kadian et al. (1994)
42










Akalin et al. (2005)
58
 NR NR Lamivudine NR Median: 
36 months 
(Range: 6-60) 
NA Tests NR; PCR for 
HBV-DNA 
Veroux et al. (2005)
54




Miedouge et al. (2003)
59
 No Yes NR NR Mean: 
11 months 
(Range: 6-29) 
NA Abbott Diagnostics and 
AxSYM for HBV, and 







































occur? Diagnostic Tests 
Fong et al. (2002)
55
 No Yes NR “The majority 
of centers 




NR NR NR 
Madayag et al. (1997)
56









Abbott Diagnostics for HBV  
Satterthwaite et al. (1997)
57
 No Yes No HBIg, NR 
others 
NR NR NR NR 
Wachs et al. (1995)
51
 No No NR NR NR NR NR 
Donataccio et al. (2006)
47
 No Yes Of 11 patients, 
4 had none, 
6 had HBIg, and 
one had both 
HBIg and 
lamivudine 
At weeks 1, 2, 
3, 4, then at 
months 2, 3, 6 
and 12, and 
then yearly. 
Liver biopsy 
at days 0, 7, 
and also 6 mo. 
And 12 mo. 
Infections 





NR AxSYM or Abbott 







































occur? Diagnostic Tests 
Suehiro et al. (2005)
48
 NR No HBIg and 
lamivudine 
At weeks 1, 2, 








NA Abbott Diagnostics for 
HBV, and Amplicor PCR for 
HBV-DNA 
Montalti et al. (2004)
43
 No Yes NR for the 
18 negative 
recipients; of 44 
total recipients, 









NR NR NR NR 
Fabrega et al. (2003)
49
 Yes Yes HBIg At weeks 1, 2, 














































occur? Diagnostic Tests 
Loss et al. (2003)
31,53
 Yes Yes Recombivax HB, 
HBIg, and 
lamivudine 
At weeks 1, 2, 







NA Qiagen for HBV,  
PCR for HBsAg 
Nery et al. (2003)
50
 No No Of 8 patients, 
1 had none, 6 
had lamivudine 
only, and 1 had 
both HBIg and 
lamivudine 
Every 
1-6 months or 




NR Abbott Diagnostics for 
HBV, and Qiagen for 
HBV-DNA, also in-house 
PCR 
Castells et al. (2002)
52





At months 1, 







HBV using Abbott AxSYM; 
HBeAg and anti-Hbe using 
Diasorin; HBV-DNA using 
PCR 
Holt et al. (2002)
46










at 6 mo., 












































occur? Diagnostic Tests 




No Yes Of 9 patients, 
4 had none, and 
5 had HBIg 







At months 8, 9, 
11, 15, and 17 
anti-HBs using Dade 
Behring; anti-HBc using 
Merux Biotech; HBeAg 
using BioMerieux; 
HBV-DNA using Quantiplex 
Preito et al. (2001)
32
 No No Some had 
lamivudine, but 
did not report 
how many 
At months 1, 3, 









HBsAg using Abbott 
product; antiHBs and 
anti-HBc and anti-Hbe 
using Diasiron; HBV-DNA 
using PCR via Diogene 
Yu et al. (2001)
35















NA HBV-DNA with Qiogen and 
nested PCR 
Dodson et al. (1999)
37
 Yes Yes Of 8 patients, 
1 had HBIg only, 
and the other 7 
had both HBIg 
and lamivudine 
















































occur? Diagnostic Tests 
Uemoto et al. (1998)
38-41
 No Yes None NR NR The 15 new 
infections were 





Dinabot for HBV, and 
nested PCR for HBV-DNA 
Dickson et al. (1997)
33














HBV using Abbott product; 
HBV-DAN by PCR via 
National Genetics Institute 
Pinney et al. (2005)
60
 No Yes Some had 
lamivudine, but 
















































occur? Diagnostic Tests 
Tenderich et al. (2005)
61





six hours and 
one year after 
transplant; 













at 5 weeks and 
4 months 
after transplant 
HBV using Abbott AxSYM; 
also analyzed two samples 
of Flebogamma 
Blanes et al. (2002)
64
 No No NR NR Mean: 37.7 NR HBcAg using AxSYM; 
anti-HBc and anti-HBs 
using Diasorin; HBV-DNA 
by nested PCR 
Ko et al. (2001)
62,63







NA Well-cozyme or Chatillon 
for HBV, and Qiagen for 
HBV-DNA 
Hartwig et al. (2005)
65









































occur? Diagnostic Tests 
Studies of HCV Transmission 
Abbott et al. (2004)
67,68
 No Yes NR NR Range: 
6-36 months 
NR ELISA2 or ELISA3 
Rozental et al. (2002)
69
 No Yes NR NR 18 months 
(did not report 
whether this 
was a mean or 
median) 







































occur? Diagnostic Tests 
Preiksaitis et al. (1997)
76
 No Yes NR One year after 
transplant, 











occurred in 8 
kidney 
recipients at an 





2 to 60.5). 
Positive HCV 
RNA tests 
occurred in 7 
kidney 
recipients at an 




years, range 2 
to 60.5). 
Anti-HCV using Ortho HCV 
3.0 ELISA, RIBA using 
Chiron RIBA HCV 3.0 strip 
immunoblot assay, and 
HCV RNA by PCR using 
the Amplicor HCV virus 
test. 
Tokumoto et al. (1996)
70
 Yes Yes Interferon Weeks 2, 4, 6, 
8, 10, 12, 16, 




NR RIBA1; HCV-RNA using 
PCR 
Tesi et al. (1994)
74,75
 Yes No NR NR Mean: 
20 months 
(Range: 2-38) 
NR ELISA1, ELISA 2, 







































occur? Diagnostic Tests 
Wreghitt et al. (1994)
71







7 months and 
9 months after 
transplantation; 





Mendez et al. (1993)
72,73
 No Yes NR NR Range: 
12-23 months 




Vincenti et al. (1993)
13
 No Yes NR NR Range: 
36-40 months 
NA HCV using Chiron-Orth; 
if reactive, then tested for 
HCV-RNA 
Pereira et al. (1992)
14,17-19







NR ELISA2 and RIBA2; 
HCV-RNA using PCR 
Roth et al. (1992)
15,20
 No No NR NR Median: 
55 months 
(Range: 3-73) 
At 10 weeks 
after transplant 
ELISA1, and if reactive, 
RIBA2 
Everhart et al. (1999)
66
 Yes No NR At 4 months, 
one year, 
two years and 
at study end 
(which was 
2-5 years after 
transplant) 
NR NR ELISA2, and if that was 
reactive, then RIBA2; 







































occur? Diagnostic Tests 
Shah et al. (1993)
12,16
 No No NR At six months, 




(plus or minus 
16; did not 
report whether 
the plus or 
minus meant 
SD, or SE, or 
CI, or IQR, or 
SIQR, or range) 
ELISA2 
Haji et al. (2004)
77-79
 No No NR NR Mean: 
50 months 
(SD: 23) 
NR ELISA2; HCV-RNA using 
PCR 
File et al. (2003)
34
 No Yes NR Each patient 
was “tested on 








NR NR ELISA2; HCV-RNA using 
PCR (Amplicor) 




No Yes NR NR Mean: 
63 months 
(Range: 28-86) 
At 19, 39, and 
55 months 
after transplant 








































occur? Diagnostic Tests 
Marelli et al. (2002)
81
 No Yes NR NR Median: 
22 months 
(Range: 7-112) 
NR ELISA2; HCV-RNA using 
PCR (Amplicor) 
NA – Not applicable 
NR – Not reported 
78 
Table 24. Question 2: Pre-transplant Patient Characteristics 
Study Patient Characteristics Pre-transplant Mean (SD) or % (N/N) Comments 
Studies of HBV Transmission 
De Feo et al. (2005)
44,45
, 
Kadian et al. (1994)
42
, 
Akalin et al. (2005)
58
, 
Veroux et al. (2005)
54
, 
Miedouge et al. (2003)
59
, 
Madayag et al. (1997)
56
, 
Wachs et al. (1995)
51
, 
Donataccio et al. (2006)
47
, 
Montalti et al. (2004)
43
, 
Fabrega et al. (2003)
49
, 
Loss et al. (2003)
31,53
, 
Nery et al. (2003)
50
, 
Castells et al. (2002)
52
, 
Preito et al. (2001)
32
, 
Dodson et al. (1999)
37
, 
Uemoto et al. (1998)
38-41
, 
Dickson et al. (1997)
33
, 
Pinney et al. (2005)
60
, 
Blanes et al. (2002)
64
, 
Ko et al. (2001)
62,63
, 
Hartwig et al. (2005)
65
 
These studies did not report pre-transplant characteristics for pre-transplant negative patients who received 
organs from positive patients 
Fong et al. (2002)
55
 Cold ischemia time (hours) 22.1 (SD: 8.5)   
 Donor % African-American 17% (130/763)   
 Donor % death due to stroke 51% (389/763)   
 Donor % HCV+ 11% (84/763)   
 Donor % male 42% (320/763)   
 Donor mean age 40.5 (SD: 16)   
 Num. of HLA mismatches 3.7 (SD: 1.6)   
79 
Study Patient Characteristics Pre-transplant Mean (SD) or % (N/N) Comments 
 Recipient % African-American 34% (259/763)   
 Recipient % Asian-American 5% (38/763)   
 Recipient % being retransplanted 12% (92/763)   
 Recipient % HCV+ 11% (84/763)   
 Recipient % male 63% (481/763)   
 Recipient mean age 47.8 (SD: 13.1)   
 Recipient duration of dialysis (months) 38.1 (SD: 34.6)   
 Recipient Peak Panel Reactive Antibody 13.2 (SD: 24.3)   
Satterthwaite et al. (1997)
57
 “Avermean age match” (not defined) 1.6 (SD: NR)   
 % with Cold ischemia time >36 hours 41% (11/27)   
 Recipient % age <12 7% (2/27)   
 Recipient % being retransplanted 11% (3/27)   
 Recipient % African-American 15% (4/27)  
 Recipient % Caucasian-American 44% (12/27)   
 Recipient % Hispanic-American 30% (8/27)   
 Recipient % Other race 4% (1/27)  
 Recipient % male 63% (17/27)   
 Recipient % with diabetes 15% (4/27)   
 Recipient panel reactive antibody <40 0% (0/27)   
Suehiro et al. (2005)
48
 Donor % male 53% (8/15)   
 Donor mean age 43.3 (SD: 10.2)   
 Recipient % male 33% (5/15)   
 Recipient mean age 35.3 (SD: 14.4)   
80 
Study Patient Characteristics Pre-transplant Mean (SD) or % (N/N) Comments 
Holt et al. (2002)
46
 Recipient % indication for transplant was 
active hepatitis, IgA deficiency 
13% (1/8)   
 Recipient % indication for transplant was 
acute Budd-Chiari syndrome 
13% (1/8)   
 Recipient % indication for transplant was 
alcoholic cirrhosis 
13% (1/8)   
 Recipient % indication for transplant was 
chronic active HCV 
13% (1/8)   
 Recipient % indication for transplant was 
fulminant liver failure 
13% (1/8)   
 Recipient % indication for transplant was 
liver failure secondary to amyloidosis 
13% (1/8)   
 Recipient % indication for transplant was 
primary biliary cirrhosis 
13% (1/8)   
 Recipient % indication for transplant was 
primary biliary cirrhosis and scleroderma 
13% (1/8)   
 Recipient % male 50% (4/8)   
 Recipient mean age 48.9 (SD: 13.5)   
Roque-Afonso et al. (2002)
36
 Recipient % blood type A+ 56% (5/9)   
 Recipient % blood type B+ 11% (1/9)   
 Recipient % blood type O+ 33% (3/9)   
 Recipient % indication for transplant was 
alcoholic cirrhosis 
44% (4/9)   
 Recipient % indication for transplant was 
Budd-Chiari syndrome 
11% (1/9)   
 Recipient % indication for transplant was 
HCV+ alcoholic cirrhosis 
11% (1/9)   
81 
Study Patient Characteristics Pre-transplant Mean (SD) or % (N/N) Comments 
 Recipient % indication for transplant was 
primary biliary cirrhosis 
11% (1/9)   
 Recipient % indication for transplant was 
symptomatic amyloidosis 
22% (2/9)   
Yu et al. (2001)
35
 Recipient % indication for transplant was 
HCC (NR what this meant) 
60% (3/5)   
 Recipient % indication for transplant was 
HCV cirrhosis 
100% (5/5)   
Tenderich et al. (2005)
61
 Recipient % indication for transplant was 
coronary heart disease 
43% (10/23)   
 Recipient % indication for transplant was 
dilated cardiomyopathy 
48% (11/23)   
 Recipient % male 83% (19/23)   
 Recipient % other indication for transplant 9% (2/23)   
 Recipient mean age 53.5 (“+/- 5.4”; NR 
what this meant) 
  
 Serum creatinine 1.25 (“+/- 0.49”; NR 
what this meant) 
  
 Recipient height (cm) 171 (“+/- 21”; NR what 
this meant) 
  
 Recipient left ventricular ejection fraction 
(%) 
29.6 (“+/- 12.9”; NR 
what this meant) 
  
 Recipient serum creatinine 72.4 (“+/- 20.6”; NR 
what this meant) 
  
82 
Study Patient Characteristics Pre-transplant Mean (SD) or % (N/N) Comments 
Studies of HCV transmission    
Abbott et al. (2004)
67,68
, 
Rozental et al. (2002)
69
, 
Preiksaitis et al. (1997)
76
, 
Tesi et al. (1994)
74,75
, 
Wreghitt et al. (1994)
71
, 
Vincenti et al. (1993)
13
, 
Pereira et al. (1992)
14,17-19
, 
Everhart et al. (1999)
66
, 
Shah et al. (1993)
12,16
 
These studies did not report pre-transplant characteristics for pre-transplant negative patients who received 
organs from positive patients 
Tokumoto et al. (1996)
70
 Recipient HLA AB mismatch 1.3 (SD: 0.8)   
 Recipient HLA DR mismatch 0.7 (SD: 0.8)   
 Recipient % male 50% (3/6)   
 Recipient % received organs from 
deceased donors 
50% (3/6)   
 Recipient mean age 36.7 (SD: 13.3)   
Mendez et al. (1993)
72,73
 Donor % CMV+ 85% (28/33)   
 Recipient % CMV+ 76% (25/33)   
 Recipient % etiology diabetes 27% (9/33)   
 Recipient % etiology hypertension 18% (6/33)   
 Recipient % male 45% (15/33)   
 Recipient mean age 33 (SD: 11)   
 Recipient pre-transplant dialysis tie 
(months) 
25 (SD: 6)   
 Recipient prior number of blood 
transfusions 
9 (SD: 4)   
83 
Study Patient Characteristics Pre-transplant Mean (SD) or % (N/N) Comments 
Roth et al. (1992)
15,20
 Donor % chronic active hepatitis 45% (5/11) 3 of the 14 donors’ pre-transplant 
CMV status was not reported 
 Donor % chronic persistent hepatitis 9% (1/11) 3 of the 14 donors’ pre-transplant 
CMV status was not reported 
 Donor % CMV+ 50% (7/14)   
 Donor % normal liver histology 45% (5/11) 3 of the 14 donors’ pre-transplant 
CMV status was not reported 
 Recipient % CMV+ 69% (9/13) 1 of the 14 recipients’ pre-transplant 
CMV status was not reported 
Haji et al. (2004)
77-79
 % “Cause” was dilated cardiomyopathy 32% (11/34)   
 % “Cause” was ischemic cardiomyopathy 62% (21/34)   
 % “Cause” was something else 5% (2/34)   
 Donor % male 74% (25/34)   
 Donor mean age 39 (SD: 9)   
 Recipient % male 76% (26/34)   
 Recipient mean age 57 (SD: 10)   
 Recipient mean age biopsy score 1.31 (SD: 0.65)   
 Recipient episodes of acute rejection 
before this transplant 
1.7 (SD: 1.5)   
File et al. (2003)
34
 Recipient % history of alcohol abuse 10% (1/10)   
 Recipient % ischemic cardiomyopathy 100% (10/10)   
 Recipient % male 90% (9/10)   
 Recipient % UNOS status I 100% (10/10)   
 Recipient mean age 52 (SD: 7.1) SD calculated by ECRI Institute 
based on Table 1 of the article 
84 
Study Patient Characteristics Pre-transplant Mean (SD) or % (N/N) Comments 
Gudmundsson et al. (2003)
80
 Recipient % anti-HBs+ 13% (1/8)   
 Recipient % indication for transplant was 
idiopathic dilation 
25% (2/8)   
 Recipient % indication for transplant was 
ischemia 
50% (4/8)   
 Recipient % indication for transplant was 
restrictive cardiomyopathy 
13% (1/8)   
 Recipient % indication for transplant was 
valvular 
13% (1/8)   
 Recipient % male 88% (7/8)   
 Recipient % UNOS status I 88% (7/8)   
 Recipient % with HCV+ serology 0% (0/8)   
 Recipient % with other positive HBV 
serology 
0% (0/8)   
 Recipient mean age 55 (SD: NR)   
Marelli et al. (2002)
81
 Recipient % UNOS status 1 56% (10/18)   
SD – Standard deviation 
 
85 
Table 25. Question 2: Quality Assessment 
Study 2a 2b 2c 2d 
Studies of HBV Transmission     
De Feo et al. (2005)
44,45
     
Kadian et al. (1994)
42
     
Akalin et al. (2005)
58
     
Veroux et al. (2005)
54
     
Miedouge et al. (2003)
59
     
Fong et al. (2002)
55
     
Madayag et al. (1997)
56
     
Satterthwaite et al. (1997)
57
     
Wachs et al. (1995)
51
     
Donataccio et al. (2006)
47
     
Suehiro et al. (2005)
48
     
Montalti et al. (2004)
43
     
Fabrega et al. (2003)
49
     
Loss et al. (2003)
31,53
     
Nery et al. (2003)
50
     
Castells et al. (2002)
52
     
Holt et al. (2002)
46
     
Roque-Afonso et al. (2002)
36
     
Preito et al. (2001)
32
     
Yu et al. (2001)
35
     
Dodson et al. (1999)
37
     
Uemoto et al. (1998)
38-41
     
Dickson et al. (1997)
33
     
Pinney et al. (2005)
60
     
Tenderich et al. (2005)
61
     
Blanes et al. (2002)
64
     
Ko et al. (2001)
62,63
     
Hartwig et al. (2005)
65
     
86 
Study 2a 2b 2c 2d 
Studies of HCV Transmission     
Abbott et al. (2004)
67,68
     
Rozental et al. (2002)
69
     
Preiksaitis et al. (1997)
76
     
Tokumoto et al. (1996)
70
     
Tesi et al. (1994)
74,75
     
Wreghitt et al. (1994)
71
     
Mendez et al. (1993)
72,73
     
Vincenti et al. (1993)
13
     
Pereira et al. (1992)
14,17-19
     
Roth et al. (1992)
15,20
     
Everhart et al. (1999)
66
     
Shah et al. (1993)
12,16
     
Haji et al. (2004)
77-79
     
File et al. (2003)
34
     
Gudmundsson et al. (2003)
80
     
Marelli et al. (2002)
81
     
A checkmark () means that the study met the quality criterion for this Question; the lack of a checkmark means that 
the study either did not meet the criterion, or it was unclear whether the study met the criterion. The criteria specific to 
this Question were:  
2a. Was the study planned prospectively (i.e., before any data were collected)? 
2b. Were all consecutive patients enrolled (or a random sample of eligible patients)? 
2c. Were laboratory tests performed on recipients regularly in order to monitor antigens/antibodies? (Greater 
frequency means greater accuracy at estimating the rate.)  
2d. Did all patients receive the same prophylaxis strategy (or none received any prophylaxis)? (A mix of 
prophylaxis strategies means a less interpretable rate.) 
87 
Table 26. Question 2: Data Table of Results 
Study 
Specific Test 
Results in these 
Donors 
The rate applies to 
recipient positivity 
for what specific 
antigen/antibody? 
Percentage of recipients 
who tested positive 
(95% CI) ¶ 
(Number of Recipients 
Positive Post-transplant/ 
Number of Recipients 
Negative Pre-transplant) 
HBV Transmission from LIVER Transplantation 
Roque-Afonso et al. (2002)
36
 anti-HBc+ HBsAg 56% 
(95% CI: 27% to 81%) 
(5/9) 
Yu et al. (2001)
35
 anti-HBc+ HBsAg 0% 
(95% CI: 0% to 43%) 
(0/5) 
Dodson et al. (1999)
37
 anti-HBc+ HBsAg 13% 
(95% CI: 2% to 47%) 
(1/8) 
Uemoto et al. (1998)
38-41
 anti-HBc+ HBsAg 94% 
(95% CI: 72% to 99%) 
(15/16) 
Kadian et al. (1994)
42
 anti-HBc+ HBsAg 40% 
(95% CI: 17% to 69%) 
(4/10) 
Uemoto et al. (1998)
38-41
 anti-HBc+ HBeAg 94% 
(95% CI: 72% to 99%) 
(15/16) 
Kadian et al. (1994)
42
 anti-HBc+ HBeAg 40% 
(95% CI: 17% to 69%) 
(4/10) 
Roque-Afonso et al. (2002)
36
 anti-HBc+ anti-HBs 44% 
(95% CI: 19% to 73%) 
(4/9) 
Yu et al. (2001)
35
 anti-HBc+ anti-HBs 0% 
(95% CI: 0% to 43%) 
(0/5) 
Roque-Afonso et al. (2002)
36
 anti-HBc+ anti-HBc 78% 
(95% CI: 45% to 94%) 
(7/9) 
Yu et al. (2001)
35
 anti-HBc+ anti-HBc 0% 
(95% CI: 0% to 43%) 
(0/5) 
Uemoto et al. (1998)
38-41
 anti-HBc+ serum HBV-DNA 94% 





Results in these 
Donors 
The rate applies to 
recipient positivity 
for what specific 
antigen/antibody? 
Percentage of recipients 
who tested positive 
(95% CI) ¶ 
(Number of Recipients 
Positive Post-transplant/ 
Number of Recipients 
Negative Pre-transplant) 
Kadian et al. (1994)
42
 anti-HBc+ serum HBV-DNA 40% 




 anti-HBc+ “Developed de novo 
infection” 
6% 
(95% CI: 1% to 26%) 
(1/18) 





(95% CI: 21% to 67%) 
(6/14) 





(95% CI: 0% to 32%) 
(0/8) 





(95% CI: 35% to 85%) 
(7/11) 





(95% CI: 0% to 20%) 
(0/15) 





(95% CI: 0% to 39%) 
(0/6) 





(95% CI: 2% to 47%) 
(1/8) 





(95% CI: 50% to 86%) 
(15/21) 





(95% CI: 58% to 90%) 
(18/23) 





(95% CI: 23% to 88%) 
(3/5) 





(95% CI: 2% to 47%) 
(1/8) 










Results in these 
Donors 
The rate applies to 
recipient positivity 
for what specific 
antigen/antibody? 
Percentage of recipients 
who tested positive 
(95% CI) ¶ 
(Number of Recipients 
Positive Post-transplant/ 
Number of Recipients 
Negative Pre-transplant) 





(95% CI: 1% to 25%) 
(1/19) 





(95% CI: 0% to 43%) 
(0/5) 





(95% CI: 0% to 32%) 
(0/8) 





(95% CI: 4% to 62%) 
(1/5) 





(95% CI: 19% to 59%) 
(7/19) 




liver HBV-DNA 0% 
(95% CI: 0% to 32%) 
(0/8) 




liver HBV-DNA 13% 
(95% CI: 2% to 47%) 
(1/8) 




serum HBV-DNA 0% 
(95% CI: 0% to 32%) 
(0/8) 




serum HBV-DNA 0% 
(95% CI: 0% to 20%) 
(0/15) 




serum HBV-DNA 0% 
(95% CI: 0% to 39%) 
(0/6) 




serum HBV-DNA 0% 
(95% CI: 0% to 43%) 
(0/5) 




serum HBV-DNA 13% 
(95% CI: 2% to 47%) 
(1/8) 




serum HBV-DNA 0% 





Results in these 
Donors 
The rate applies to 
recipient positivity 
for what specific 
antigen/antibody? 
Percentage of recipients 
who tested positive 
(95% CI) ¶ 
(Number of Recipients 
Positive Post-transplant/ 
Number of Recipients 
Negative Pre-transplant) 




serum HBV-DNA 71% 
(95% CI: 50% to 86%) 
(15/21) 







(95% CI: 0% to 39%) 
(0/6) 
HBV Transmission from KIDNEY Transplantation 
Kadian et al. (1994)
42
 anti-HBc+ HBsAg 0% 
(95% CI: 0% to 22%) 
(0/14) 
Kadian et al. (1994)
42
 anti-HBc+ HBeAg 0% 
(95% CI: 0% to 22%) 
(0/14) 
Kadian et al. (1994)
42
 anti-HBc+ anti-HBs 0% 
(95% CI: 0% to 22%) 
(0/14) 
Kadian et al. (1994)
42
 anti-HBc+ anti-HBc 0% 
(95% CI: 0% to 22%) 
(0/14) 
Kadian et al. (1994)
42
 anti-HBc+ serum HBV-DNA 0% 
(95% CI: 0% to 22%) 
(0/14) 





(95% CI: 0% to 6%) 
(0/62) 





(95% CI: 0% to 32%) 
(0/8) 





(95% CI: 0% to 1%) 
(2/763) 





(95% CI: 0% to 26%) 
(0/11) 





(95% CI: 0% to 12%) 
(0/27) 










Results in these 
Donors 
The rate applies to 
recipient positivity 
for what specific 
antigen/antibody? 
Percentage of recipients 
who tested positive 
(95% CI) ¶ 
(Number of Recipients 
Positive Post-transplant/ 
Number of Recipients 
Negative Pre-transplant) 





(95% CI: 0% to 23%) 
(0/13) 





(95% CI: 28% to 79%) 
(6/11) 





(95% CI: 4% to 28%) 
(3/27) 





(95% CI: 0% to 10%) 
(0/34) 





(95% CI: 0% to 32%) 
(0/8) 





(95% CI: 0% to 23%) 
(0/13) 





(95% CI: 2% to 47%) 
(1/8) 





(95% CI: 1% to 4%) 
(17/763) 





(95% CI: 2% to 38%) 
(1/11) 





(95% CI: 2% to 23%) 
(2/27) 





(95% CI: 0% to 10%) 
(0/34) 







(95% CI: 0% to 12%) 
(0/27) 




“HBV viremia” 0% 





Results in these 
Donors 
The rate applies to 
recipient positivity 
for what specific 
antigen/antibody? 
Percentage of recipients 
who tested positive 
(95% CI) ¶ 
(Number of Recipients 
Positive Post-transplant/ 
Number of Recipients 
Negative Pre-transplant) 






(95% CI: 0% to 39%) 
(0/6) 






(95% CI: 0% to 39%) 
(0/6) 





serum HBV-DNA 0% 
(95% CI: 0% to 39%) 
(0/6) 
HBV Transmission from HEART Transplantation 
Pinney et al. (2005)
60
 anti-HBc+ HBsAg 4% 
(95% CI: 1% to 19%) 
(1/26) 
Kadian et al. (1994)
42
 anti-HBc+ HBsAg 0% 
(95% CI: 0% to 26%) 
(0/11) 
Pinney et al. (2005)
60
 anti-HBc+ anti-HBs 8% 
(95% CI: 2% to 24%) 
(2/26) 
Tenderich et al. (2005)
61
 anti-HBc+ anti-HBs 48% 
(95% CI: 29% to 67%) 
(11/23) 
Kadian et al. (1994)
42
 anti-HBc+ anti-HBs 18% 
(95% CI: 5% to 48%) 
(2/11) 
Tenderich et al. (2005)
61
 anti-HBc+ anti-HBc 65% 
(95% CI: 45% to 81%) 
(15/23) 
Kadian et al. (1994)
42
 anti-HBc+ anti-HBc 18% 
(95% CI: 5% to 48%) 
(2/11) 





(95% CI: 0% to 18%) 
(0/18) 






(95% CI: 0% to 28%) 
(0/10) 











Results in these 
Donors 
The rate applies to 
recipient positivity 
for what specific 
antigen/antibody? 
Percentage of recipients 
who tested positive 
(95% CI) ¶ 
(Number of Recipients 
Positive Post-transplant/ 
Number of Recipients 
Negative Pre-transplant) 






(95% CI: 0% to 43%) 
(0/5) 





serum HBV-DNA 0% 
(95% CI: 0% to 43%) 
(0/5) 








(95% CI: 4% to 62%) 
(1/5) 
HBV Transmission from LUNG Transplantation 





(95% CI: 0% to 13%) 
(0/26) 





(95% CI: 0% to 13%) 
(0/26) 
HCV Transmission from KIDNEY Transplantation 
Abbott et al. (2004)
67,68
 anti-HCV+ anti-HCV 9% 
(95% CI: 6% to 14%) 
(17/187) 
Rozental et al. (2002)
69
 anti-HCV+ anti-HCV 25% 
(95% CI: 7% to 59%) 
(2/8) 
Tokumoto et al. (1996)
70
 anti-HCV+ anti-HCV-1 33% 
(95% CI: 10% to 70%) 
(2/6) 
Tokumoto et al. (1996)
70
 anti-HCV+ anti-HCV-2 60% 
(95% CI: 23% to 88%) 
(3/5) 
Wreghitt et al. (1994)
71
 anti-HCV+ anti-HCV 25% 
(95% CI: 7% to 59%) 
(2/8) 
Mendez et al. (1993)
72,73
 anti-HCV+ anti-HCV 6% 
(95% CI: 2% to 20%) 
(2/33) 
Pereira et al. (1992)
14,17-19
 anti-HCV+ anti-HCV 91% 
(95% CI: 62% to 98%) 
(10/11) 
Roth et al. (1992)
15,20
 anti-HCV+ anti-HCV 7% 





Results in these 
Donors 
The rate applies to 
recipient positivity 
for what specific 
antigen/antibody? 
Percentage of recipients 
who tested positive 
(95% CI) ¶ 
(Number of Recipients 
Positive Post-transplant/ 
Number of Recipients 
Negative Pre-transplant) 
Tokumoto et al. (1996)
70
 anti-HCV+ HCV-RNA 50% 
(95% CI: 19% to 81%) 
(3/6) 
Wreghitt et al. (1994)
71
 anti-HCV+ HCV-RNA 100% 
(95% CI: 65% to 100%) 
(7/7) 





(95% CI: 10% to 33%) 
(8/43) 





(95% CI: 0% to 39%) 
(0/6) 







(95% CI: 22% to 50%) 
(15/43) 





(95% CI: 41% to 71%) 
(21/37) 





(95% CI: 0% to 39%) 
(0/6) 





(95% CI: 0% to 39%) 
(0/6) 
Preiksaitis et al. (1997)
76
 anti HCV+ and 
RIBA+ 
anti-HCV 62% 
(95%CI 36% to 82%) 
(8/13) 
Preiksaitis et al. (1997)
76
 anti HCV+ and 
RIBA+ 
HCV-RNA 67% 
(95% CI: 35% to 88%) 
(6/9) 
HCV Transmission from LIVER Transplantation 
Shah et al. (1993)
12,16
 anti-HCV+ anti-HCV 24% 
(95% CI: 11% to 43%) 
(6/25) 





(95% CI: 30% to 90%) 
(4/6) 





(95% CI: 61% to 100%) 
(6/6) 




Results in these 
Donors 
The rate applies to 
recipient positivity 
for what specific 
antigen/antibody? 
Percentage of recipients 
who tested positive 
(95% CI) ¶ 
(Number of Recipients 
Positive Post-transplant/ 
Number of Recipients 
Negative Pre-transplant) 
Haji et al. (2004)
77-79
 anti-HCV+ “detectable” anti-
HCV 
11% 
(95% CI: 4% to 27%) 
(3/28) 
Gudmundsson et al. (2003)
80
 anti-HCV+ anti-HCV 14% 
(95% CI: 3% to 51%) 
(1/7) 
Marelli et al. (2002)
81
 anti-HCV+ anti-HCV 24% 
(95% CI: 10% to 47%) 
(4/17) 
Haji et al. (2004)
77-79
 anti-HCV+ HCV-RNA 75% 
(95% CI: 57% to 87%) 
(21/28) 
Gudmundsson et al. (2003)
80
 anti-HCV+ HCV-RNA 43% 
(95% CI: 16% to 75%) 
(3/7) 
Marelli et al. (2002)
81
 anti-HCV+ HCV-RNA 12% 
(95% CI: 3% to 34%) 
(2/17) 
Gudmundsson et al. (2003)
80
 anti-HCV+ liver HCV 29% 
(95% CI: 8% to 64%) 
(2/7) 
Gudmundsson et al. (2003)
80
 anti-HCV+ “Any HCV infection” 43% 
(95% CI: 16% to 75%) 
(3/7) 





(95% CI: 19% to 73%) 
(4/9) 





(95% CI: 72% to 100%) 
(10/10) 
¶ The 95% confidence interval (CI) around each rate was calculated by ECRI Institute. 
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Evidence Reviews: II. Methodology to better estimate donor 
infection with HIV, HBV, or HCV 
Question 3. What behavioral risk factors are associated with an 
increased probability of infection with HIV, HBV, or HCV? What is the 
prevalence of these characteristics among potential solid organ donors? 
And 
Question 4. What nonbehavioral risk factors are associated with an 
increased probability of infection with HIV, HBV, or HCV? What is the 
prevalence of these factors among potential solid organ donors? 
As most of the included studies address both Questions 3 and 4, information regarding study populations 
and protocols, study risk of bias, and our methods of analysis are reported together for both questions in 
this section. Findings regarding behavioral risk factors are reported in Question 3: Results, and findings 
regarding nonbehavioral risk factors (e.g., signs and symptoms suggestive of infection, co-morbidity, 
socioeconomic factors, demographic factors) are reported in Question 4: Results.  
The CDC document Guidelines for Preventing Transmission of Human Immunodeficiency Virus Through 
Transplantation of Human Tissue and Organs (1994),
100
 listed seven “Behavior/History Exclusionary 
Criteria.” According to the guideline, any potential donor with any of these characteristics should not 
donate organs regardless of HIV test results: 
1. “Men who have had sex with another man in the preceding 5 years.” 
2. “Persons who report nonmedical intravenous, intramuscular, or subcutaneous injection of drugs 
in the preceding 5 years.” 
3. “Persons with hemophilia or related clotting disorders who have received human-derived clotting 
factor concentrates.” 
4. “Men and women who have engaged in sex in exchange for money or drugs in the preceding 
5 years.” 
5. “Persons who have had sex in the preceding 12 months with any person described in items 1-4 
above or with a person known or suspected to have HIV infection.” 
6. “Persons who have been exposed in the preceding 12 months to known or suspected HIV-infected 
blood through percutaneous inoculation or through contact with an open wound, nonintact skin, 
or mucous membrane.” 
7. “Inmates of correctional systems. (This exclusion is to address issues such as difficulties with 
informed consent and increased prevalence of HIV in this population.)” 
The 1994 guideline also excludes children with certain risk factors from donating, regardless of HIV test 
result status. The guideline states: 
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1. “Children meeting any of the exclusionary criteria listed above for adults should not be accepted 
as donors. 
2. Children born to mothers with HIV infection or mothers who meet the behavioral or laboratory 
exclusionary criteria for adult donors (regardless of their HIV status) should not be accepted as 
donors unless HIV infection can be definitely excluded in the child as follows: 
Children >18 months of age who are born to mothers with or at risk for HIV infection, 
who have not been breast fed within the last 12 months, and whose HIV antibody tests, 
physical examination, and review of medical records do not indicate evidence of HIV 
infection can be accepted as donors. 
3. Children 18 months of age who are born to mothers with or at risk for HIV infection or who 
have been breast fed within the past 12 months should not be accepted as donors regardless of 
their HIV test results.”  
The purpose of Questions 3 and 4 is to search and summarize evidence regarding potential risk factors for 
the transmission of HIV, and also HBV and HCV. Behavioral factors are presented in Question 3, and 
nonbehavioral factors are presented in Question 4. Nonbehavioral factors include signs and symptoms 
suggestive of acute or chronic infection, co-morbidity, socioeconomic factors, and demographic factors. 
To be included in these questions, studies had to meet inclusion criteria, as discussed in the Introduction. 
Although data restricted to potential solid organ donors were initially sought to identify risk factors, the 
paucity of evidence motivated the inclusion of data from three additional populations: potential tissue 
donors, blood donors, and the general population. Because there was still little data on the identification 
of risk factors for HBV infection, for HBV only the criteria were expanded to include demographic and 
socioeconomic subpopulations. Such subpopulation studies may have limited enrollment to people with a 
particular ethnic heritage or occupation. Risk factors identified in these populations may not be 
generalizable to other populations, including potential solid organ donors. In addition, they cannot be 
used to determine whether the characteristic all participants were selected for is a risk factor, unless there 
is a control or comparison group in the study.  
Inclusion criteria for prevalence and incidence of identified risk factors were stricter. We did not include 
prevalence estimates from populations with pre-screened blood donors (which would underestimate 
prevalence), special demographic or socioeconomic subpopulations (which could overestimate or 
underestimate prevalence, depending on the population), or populations that over-selected for infected 
individuals in case-control study designs (which would overestimate prevalence). We also did not extract 
demographic prevalence (e.g., race or sex) or infection incidence or prevalence data (e.g., proportion co-
infected) because there are other, more accurate, sources of this type of information available than the 
studies included for this question provide (such as in Question 1). Some data on the prevalence of risk 
factors appeared to overlap between Armstrong et al.
30
 and McQuillan et al.
101
, as both used NHANES IV 
(1992 to 2002) data. In these instances we used the prevalence data from Armstrong et al. because the 
data set they used was larger. No studies that assessed risk factors associated with incident infection were 
identified. 
Thirty studies comprise the evidence base for Questions 3 and 4, with 22 addressing Question 3 and 
29 addressing Question 4. Of the 29 studies that associated behavioral and/or nonbehavioral risk factors 
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with infection, 12 addressed HBV, 12 addressed HCV, and 6 addressed HIV (one study addressed both 
HBV and HCV). Twenty one studies reported identification of behavioral factors (such as drug use or 
sexual activities) and are included in Question 3. Only eight studies reported the prevalence of identified 
behavioral risk factors in potential donors or the general population, including one study that did not 
provide data for the identification of risk factors.
8
 (One additional study reported information on 
prevalence of risk factors from the National Health and Nutrition Examination Surveys (NHANES)-III 
(1988-1994)
29
 but this information was superseded by NHANES-IV (1992-2002) data from other 
studies.
30,101
 Twenty-nine studies reported on the identification of nonbehavioral risk factors. Of those, 
only four reported prevalence of identified factors. Although we sought information on signs and 
symptoms that may be associated with infection, extremely little information on this was identified. 
Included studies and the Questions they address are listed below in Table 27. 
Table 27. Included Studies, Questions 3 and 4 
Citation Year Virus(es) 
Question 3 Question 4 
Identification Prevalence Identification Prevalence 
Potential and Actual Organ Donors 
Gasink et al.102 2006 HCV     
Hidalgo et al.8 2001 Not Applicable*     
Potential Tissue Donors 
Sanchez et al.103 2006 HBV     
Blood Donors 
Orton et al.104 2004 HCV     
Murphy et al.105 2000 HCV     
Conry-Cantilena et al.106 1996 HCV     
Murphy et al.107 1996 HCV     
General Population 
McGinn et al.108 2008 HCV     
McQuillan et al.29 1999 HBV     
Mehta et al.109 2008 HIV     
Nguyen et al.110 2008 HIV     
Zetola et al.111 2008 HIV     
Armstrong et al.30 2006 HCV     
McQuillan et al.101 2006 HIV     
Hand and Vasquez112 2005 HCV     
Nguyen et al.113 2005 HCV     
Fischer et al.114 2000 HCV     
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Citation Year Virus(es) 
Question 3 Question 4 
Identification Prevalence Identification Prevalence 
Alpert et al.115 1996 HIV     
Kaur et al.116 1996 HBV, HCV     
Alter et al.117 1989 HBV     
Children and Adolescents 
Luban et al.118 2007 HCV     
D’Angelo et al.119 1991 HIV     
Demographic and Socioeconomic Subpopulation (HBV Only) 
Lee et al.120 2008 HBV     
Tabibian et al.121 2008 HBV     
Hann et al.122 2007 HBV     
Lin et al.123 2007 HBV     
Hwang et al.124 2006 HBV     
Butterfield et al.125 2004 HBV     
Butterfield et al.126 1990 HBV     
Turner et al.127 1989 HBV     
* Hidalgo et al. assessed the prevalence of a general risk factor only (unspecified substance abuse), and did not attempt associate the factor 
with any particular infection. 
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Studied Populations and Study Methods 
This section provides a brief description of the enrollees and methods in the included studies. The studies 
are organized by population type (as divided in Table 27). Additional information regarding study 
protocols, including setting and location of study, method of data collection, relevant blood test used to 
determine infection status, funding source, and year(s) of data collection, are shown in Table 28. Details 
regarding participant characteristics, including methods of participant selection and selection criteria, 
demographic descriptors (e.g., percent male, race, age), are shown in Table 29. 
Data on potential or actual solid organ donors were very limited. Two retrospective studies, each with few 
factors reported, were identified. Only one of those studies focused on potential solid organ donors, 
Hidalgo et al.
8
 This study provides reasons for donor ineligibility among a cohort of 55 potential living 
who were able to provide data regarding their health status. A second study, Gasink et al.
102
, statistically 
assessed the association between donor characteristics and HCV infection to indentify risk factors for 
HCV in a cohort of 10,915 actual heart donors, including 261 with HCV, using data from the Scientific 
Registry of Transplant Recipients (SRTR). Prevalence of some factors was also reported. 
Potential Tissue Donors 
One study on risk factors for HCV among potential cornea donors, Sanchez et al., was also included.
103
 
Eighty three potential donors with positive serological result(s) and 56 randomly selected controls were 
included. In this study, infection status was retrospectively tested for association with behavioral and 
clinical factors in a questionnaire completed by next of kin. This study is unique in that the identification 
of risk factors relied upon next-of-kin interviews rather than medical record review or self-report.  
Actual Blood Donors 
Also included were four studies that examined risk factors for HCV among actual blood donors, Conry-
Cantilena et al.,
106
 Murphy et al. (2000),
105
 Murphy et al. (1996),
107
 and Orton et al.
104
 We included these 
studies with the intent of examining factors other than those that potential donors are screened for 
(e.g., other than men having sex with men or injection drug use). However, in all four studies, some 
donors who were followed-up with questionnaires or interviews admitted to exclusionary behaviors. 
Therefore, it was possible to investigate these factors for association with HCV. However, because 
potential donors who were not deceptive about these factors were screened out and not permitted to 
donate, we did not consider the prevalence of these factors among actual donors because the prevalence 
would be underestimated. We did not identify any studies on potential (i.e., pre-screened) blood donors, 
or potential donors who were eliminated from the donor pool as a result of the screening process. 
The four studies used different approaches to identifying risk factors. Conry-Cantilena et al. and 
Murphy et al. (2000) were case-control studies that enrolled samples of infected and uninfected donors 
and compared the factors among them.
105,106
 Conry-Cantilena et al. enrolled 248 individuals with HCV 
and 131 without. Murphy et al. (2000) enrolled 758 infected individuals and 1,039 uninfected individuals. 
Both of these studies identified participants by retrospective assessment of their HCV status and 
prospectively collected data on risk factors using questionnaires. Orton et al. recalled blood donors who 
initially tested anti-HCV positive for further testing and collection of risk factor data and prospectively 
re-tested them using nucleic acid tests, and administered in-person questionnaires. Of those who 
completed follow-up at the time of donation, the factors of 65 participants who were confirmed as 
positive by nucleic acid tests were compared to the factors among the 225 participants who were 
101 
ultimately deemed uninfected (initial false-positives). Murphy et al. (1996) was a much larger 
(n = 862,398) study that examined consecutive blood donors and retrospectively evaluated infection 




Thirteen additional studies enrolled participants representative of a general population. By “general 
population,” we mean a population unselected for any particular demographic, occupational, or 
behavioral characteristics, or health status other than HCV, HBV, or HIV infection status. These studies 
recruited participants from various settings including emergency departments,
111,115





 health plan enrollees,
114





 (When extracting data we were careful to ensure that duplicate NHANES data 
were not included. Where data from probably overlapping pools of participants were reported, we used 
the statistic from the study with the larger sample size. We only collected prevalence information from 
the most recent NHANES data.)  
The general design of these studies was to collect blood samples to test for infection and administer 
questionnaires or interviews regarding potential risk factors. Most of these studies were prospective. 
The studies were generally large, with only four enrolling under 1,000 participants. Five of these studies 
addressed HIV, five addressed HCV, and one addressed both HCV and HBV. 
Children 
Two included studies specifically assessed children. Luban et al. performed a record review of 2,758 
children who had received a blood transfusion and targeted factors for HCV.
118
 D’Angelo et al. reviewed 




Demographic and Socioeconomic Subpopulations 
A total of eight subpopulation studies that evaluated risk factors and HBV were included. Populations 
assessed in these studies include mentally ill veterans in inpatient Veterans Administration (VA) Hospital 
psychiatric care,
121,125









 and Korean-American church-goers.
120,122
 Most of the Asian 
Americans and Korean American church-goers were foreign-born. All of these studies were prospective. 
On the whole, these studies were smaller than the general population studies: Half enrolled fewer than 
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Assay v. 3.0 
(Chiron Corp). 
RIBA positive or 
indeterminate 
tested for RNA 
with COBAS 
Amplicor HCV 











Fischer et al.114 2000   HCV HMO 
enrollees 
Twin Cities 
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with Western blot 
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Remnants tested 
for HIV-1 RNA 
by PCR. 
No Prospective CDC 2004 
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Demographic and Socioeconomic Subpopulations (HBV only) 
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Hwang et al.124 2006   HBV College 
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Turner et al.127 1989   HBV Embalm-


































Table 29. Participant Characteristics for KQ 4 and 5 
Citation Year KQ4 KQ5 Virus(es) 
Participant 





Race (as reported 
in study) Age 
Potential and Actual Organ Donors 








All heart donors of 
transplant recipients 





























donors of all children 
<21 years with end-
stage renal disease 
and surviving 
transplant between 















Potential Tissue Donors 

























Citation Year KQ4 KQ5 Virus(es) 
Participant 





Race (as reported 
















blood donors who 
donated between 
1991 and 1994 and 













57% Black: 12.7% Mean: 
40 years 
Murphy et al.105 2000   HCV All HCV positive 






cases and controls 
matched by age, sex, 
race/ethnicity, 
first time vs. 














Most aged 30 
to 49 years 
Murphy et al.107 1996   HCV All blood donors Consecutive blood 
donors 
862,398 53% White: 81%, 
Black: 7%, 
Hispanic: 6%, 
Asian: 3%,  




and 49 years, 
Range:  
11 to 93 years 
118 
Citation Year KQ4 KQ5 Virus(es) 
Participant 





Race (as reported 
in study) Age 
Orton et al.104 2004   HCV Blood donors 
anti-HCV- but 
unconfirmed 






NAT results who 
donated blood in time 




of whom 116 
confirmed 
positive. 

































Citation Year KQ4 KQ5 Virus(es) 
Participant 





Race (as reported 
in study) Age 





Cases had acute 
HBV infection and 
none of the following 
factors within last 
six months: 
blood transfusion, 
IV drug use, 
male homosexual 
activity, health care 
employment requiring 
frequent contact with 
blood, hemodialysis, 
sexual or household 
contact with HBV 
carrier. Controls were 
HBV-uninfected and 
were matched by 
age within 5 years, 







Not reported Not reported 



























Citation Year KQ4 KQ5 Virus(es) 
Participant 





Race (as reported 
in study) Age 
Fischer et al.114 2000   HCV Health plan 
patients identified 




(or health care 
workers, not 
















454 at higher 
risk and 
926 controls.  
34%  NR NR, 26% less 
than 50 years 
Hand and 
Vasquez112 
2005   HCV Clinic or hospital 
patients selected 
by HCV test 
result 
For cases, positive 
HCV test, for 
controls, negative 
HCV test. Patients 




hepatitis risk factors 
People who 
participated in 
interview could be 
included. 





Range: 14 to 
99 













error [SE] 15) 
years 
121 
Citation Year KQ4 KQ5 Virus(es) 
Participant 





Race (as reported 
in study) Age 
McGinn et al.108 2008   HCV A stochastically 
randomized 
sample of all 
patients attended 
primary care 
were invited to 
participate  
Age 18 or older, 










50.1 (SD: 14.7) 
years 
McQuillan et al.101 2006   HIV “Stratified multi-
staged probability 
cluster design 
that selected a 
sample 
representative of 




Participants aged 18 
to 59 who were 
anonymously tested 
















to exam and 
had HIV test 
NR NR NR 
McQuillan et al.29 1999   HBV Stratified, 
multistage, 
probability cluster 
design of U.S. 
households 









NR NR NR 
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Citation Year KQ4 KQ5 Virus(es) 
Participant 





Race (as reported 
in study) Age 




for participation  








229 new HIV 
diagnoses 


































Mean age NR; 
57.3% at least 
40 years old 
Nguyen et al.113 2005   HCV Patients with 
known HCV 









Aged 18 to 60 years 
English proficient 
















Citation Year KQ4 KQ5 Virus(es) 
Participant 





Race (as reported 
in study) Age 




who had blood 
drawn and were 
not known to be 
infected with HIV 
Consecutive patients 1,820 had 
blood drawn, 













18-30 years,  
29.1% 
31-45 years,  
44.1% 
>45 years 
Children and Adolescents 
Luban et al.118 2007   HCV Children who had 
blood or blood 
product 
transfusions 
Under 15 years at 






disease, HIV, or 





















one year on 
average 






Appears to be all 
children with leftover 
serum  
3,520 33% NR Mean NR, 
all patients 
20 years and 
younger 
124 
Citation Year KQ4 KQ5 Virus(es) 
Participant 





Race (as reported 
in study) Age 
Demographic and Socioeconomic Subpopulations (HBV only) 







with severe mental 
illness who were 
either African 
American or 
Caucasian and had 









Butterfield et al.126 1990   HBV Consecutive 
women seeking 
prenatal care 
All patients included 1,466 0% NR NR 





6,130 48% Korean-American: 
100% 
NR 
Hwang et al.124 2006   HBV College students For HBV risk 
assessment, U.S. or 
Canada born and 




were U.S. or 
Canada born 












Lee et al.120 2008   HBV Korean-
Americans 
attending church  
Adult, literate Korean-
Americans (18 to 70 
years old) willing to 
sign informed 
consent 
609 46% Korean-American: 
100%,  




Lin et al.123 2007   HBV Asian Americans Adults (at least 
18 years old) willing 





39.7% Asian Americans: 
100%,  




Citation Year KQ4 KQ5 Virus(es) 
Participant 





Race (as reported 
in study) Age 





















(SD: 8.9 years) 
Turner et al.127 1989   HBV Have embalmed 
more than 
20 bodies 





We extracted all data on the identification of risk factors from the included literature, including factors 
that were investigated but not found to be associated with infection. For Question 3 these data are 
presented in Table 33 (HBV), Table 34 (HCV), and Table 35 (HIV). For Question 4 these data are shown 
in Table 39 (HBV), Table 40 (HCV), and Table 41 (HIV). We grouped the extracted data by category as 
listed in the 1994 CDC document Guidelines for Preventing Transmission of Human Immunodeficiency 
Virus Through Transplantation of Human Tissue and Organs
100
, and qualitatively summarized the 
evidence for each of the risk factors listed in the guideline by describing which studies identified 
associations for which infection in which population type. Following that, in the same manner we 
summarized the evidence for additional risk factors not listed in the 1994 guideline. Information on 
behavioral risk factors is presented first (Question 3), followed by information on nonbehavioral factors 
(Question 4).  
We performed the analysis qualitatively (i.e., using narrative descriptive analysis) because the 
methodologic and reporting differences among the studies made combining them in quantitative analysis 
(i.e., meta-analysis) inappropriate. These fundamental between-study differences fell into four main 
categories: 
1. Population: We included data from organ, tissue and blood donors, as well as from general 
populations drawn from various settings, and, for HBV, various special subpopulations 
2. Outcomes: Potential risk factors were often reported in different ways. For instance, studies used 
different numbers to define “multiple” sex partners or gathered data regarding different time 
spans (i.e., lifetime drug use, drug use within past 6 months). 
3. Comparators: Some studies used different bases of comparison. For instance, in assessing 
whether MSM is a risk factor, one study compared the prevalence of infection in MSM to 
heterosexual men, and another compared it to the prevalence of infection among men who have 
never had sex. 
4. Analysis type: Although use of various metrics can be dealt with in secondary quantitative 
analysis, most of these studies differed with respect to whether univariate or multivariate analyses 
were used. Some reported one but not the other. Data reporting methods did not provide sufficient 
information to make standardization possible. Not having information on both clouds the 
independence of the relationship between the factor of interest and the infection in question, 
especially since data from various populations were considered. For more information on this, 
please see the following text. 
We considered data calculated in two main ways, through univariate analyses and multivariate analysis. 
Univariate analyses look at the association between the factor of interest and infection. These may be the 
only type of analysis performed in a study, or it may be the first step in identifying which potentially 
important factors should be included in the multivariate model. Multivariate models look at the 
association between the factor of interest and infection while taking into consideration additional 
confounding factors. This is the type of analysis required to determine if the risk factor is an independent 
risk factor. This is important because many of the behavioral risk factors are found together in 
individuals. For instance, among individuals who have been incarcerated, is exposure during incarceration 
itself or the illicit activity that led to incarceration (e.g., sex work, drug use) that is the true risk factor? 
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Demographic and socioeconomic factors are not risk factors in and of themselves but proxies for other 
risk factors. On the other hand, dependent factors identified by univariate analyses may be useful for 
identifying at-risk potential donors. To provide as much information as possible about these factors, we 
extracted information on both univariate and multivariate analyses where both were provided. Where 
ECRI Institute calculated effect sizes and p-values, unadjusted univariate analyses were performed by 
necessity because that is what the reported data permits.  
Assessment of Risk of Bias (Quality of Study Design): Identification of Risk Factors 
To assess the risk of bias of the included studies, we asked the questions listed in Table 30. (Itemized 
quality assessment for each study for both questions is provided in Table 31.) Following Table 30 
we provide a discussion of each of the quality domains assessed. 











Were infected and uninfected participants similar on other risk 
factors? 
I-B If not, were statistical adjustments performed to control for other 
risk factors? 
Validity of risk 
factor data 
collection 
I-C Was risk factor data collected in a valid manner (e.g., confidential 
or anonymous collection of sensitive risk factor data, collection of 
personal information from the person directly instead of someone 
else)? 
Validity of method 
used to determine 
infection status 
I-D Was infection status determined accurately? (i.e., accuracy of 
diagnostic test method used to determine infection status) 
 
Comparability of Uninfected and Infected Participants (Quality Items I-A and I-B) 
Regarding item A, none of the studies were uninfected and infected groups of participants similar on all 
risk factors besides the one being investigated at the time (most studies investigated multiple factors). 
That is, infected and uninfected participants differed in many ways. Therefore, none of the studies can be 
considered to satisfy these items. However, many of the studies did perform statistical adjustments to 
control for confounding factors. Whether controlled or adjusted analyses were performed for each study is 
reported in the table of study protocols (Table 28), in the data extraction tables, and in the text of the 
results section. 
Although not all studies met items A or B, all of these studies drew all of their participants from a single 
pool, either selecting them from the pool based upon their infection status or including all participants in 
the pool and subdividing them by infection status. 
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Validity of Risk Factor Data Collection (Quality Item I-C) 
Much of the data collected for Question 3, regarding behavioral risk factors, is very private and highly 
sensitive. Much of these data also pertain to illicit activity. Therefore, to promote reliable reporting of risk 
factor data, confidentiality and anonymity are preferable. Although not all studies went to great pains to 
ensure privacy (e.g., anonymous questionnaires, interview given through computer interface only), all of 
the included studies for Question 4 offered confidentiality, at the very least within the context of medical 
care. In addition, because behavioral risk factors are nearly always personal matters, the most reliable 
information will come from the individual about him or herself.  
Although objective record and database reviews are generally regarded as being more reliable than patient 
interview, most types of information of interest, especially behavioral risk factors, are unlikely to be 
catalogued in such records. The applicability of these interview and questionnaire self-report data to 
potential solid organ donors is unclear, since most solid organ donors are deceased.  
Data on deceased actual organ donors in Gasink et al. were collected from a registry and record review, 
but most of the items inquired about were not highly sensitive, and this is unlikely to compromise the 
integrity of their findings. However, sensitive data for Sanchez et al. was collected from next of kin of 
deceased potential tissue donors. Findings from Sanchez et al. suggest that next-of-kin may be unaware of 
(or unwilling to report) important factors including high-risk sexual activities, or history of sexually 
transmitted infection (STI). Although the data in Sanchez et al. were not verified against objective 
records, it is unlikely that the prevalence of these items was actually zero, as the next-of-kin reported. 
The next-of-kin data in Sanchez et al. may be inaccurate. This was the only study that did not satisfy 
quality item c. 
Although not all studies that only addressed Question 4 appear to have explicitly offered confidentiality, 
most of these studies investigated factors that are less sensitive (e.g., country of birth, race, age) and so it 
is unlikely that the validity of the findings will be affected, and this should not be considered a threat to 
the validity of Question 4. 
Validity of Infection Status Determination (Quality Item I-D) 
In accord with the general inclusion criteria for this review, the infection status of all participants had to 
be determined using objective laboratory testing methods. The validity of infection status determination 
therefore is based upon the accuracy of diagnostic test used (see Table 28 for which test(s) were used in 
each study; nearly all studies reported it). Most studies confirmed antibody or antigen tests with more 
specific methods such as Western blot, nucleic acid tests, or immunoblots. These studies should have 
fewer false positives than studies that did not confirm positives. On the whole, the validity of infection 
status determination is good. Studies nearly universally used reputable commercially-available diagnostic 
tests. No studies relied upon rapid or oral tests or home brew (i.e., noncommercial, unregulated) tests 
alone. Only one study, Nguyen et al., used a test with potentially compromised accuracy. In this study, 
participants were given a kit to take home and test themselves with. Although the test may be accurate 
with appropriate use, because the test was not administered under supervision and were not verified with 
follow-up testing, it is not possible to be as confident in the results. 
Itemized quality assessment for each of the studies is shown in Table 31, below. 
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Table 31. Quality Assessment for Questions 3 and 4: Identification of Risk Factors 
Study Year 
Question 3 Question 4 
I-A I-B I-C I-D I-A I-B I-C I-D 
Potential and Actual Organ Donors 
Gasink et al.
102
 2006         
Hidalgo et al.
8
 2001     Not applicable 
Potential Tissue Donors 
Sanchez et al.
103




 1996         
Murphy et al.
105
 2000         
Murphy et al.
107
 2000 Not applicable     
Orton et al.
104




 1996         
Alter et al.
117
 1989         
Armstrong et al.
30
 2006         
Fischer et al.
114
 2000         
Hand and Vasquez
112
 2005         
Kaur et al.
116
 1996         
McGinn et al.
108
 2008 Not applicable     
McQuillan et al.
101
 2006         
McQuillan et al.
29
 1999         
Mehta et al.
109
 2008         
Nguyen et al.
110
 2008         
Nguyen et al.
113
 2005         
Zetola et al.
111
 2008 Not applicable     
Children and Adolescents 
Luban et al.
118
 2007 Not applicable     
D’Angelo et al.
119
 1991 Not applicable     
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Study Year 
Question 3 Question 4 
I-A I-B I-C I-D I-A I-B I-C I-D 
Demographic and Socioeconomic Subpopulations (HBV only) 
Butterfield et al.
125
 2004         
Butterfield et al.
126
 1990         
Hann et al.
122
 2007 Not applicable     
Hwang et al.
124
 2006         
Lee et al.
120
 2008 Not applicable     
Lin et al.
123
 2007 Not applicable     
Tabibian et al.
121
 2008         
Turner et al.
127
 1989         
A checkmark () means that the study met the quality criterion for this Question; the lack of a checkmark means that 
the study either did not meet the criterion, or it was unclear whether the study met the criterion. The criteria specific to 
this Question were: 
3/4 I-A. Was the population potential solid organ donors? 
3/4 I-B. For other populations, was the population unselected (i.e., not based on demographic or behavioral 
characteristics)? Were infected and uninfected participants similar on other risk factors? 
3/4 I-C. If not, were statistical adjustments performed to control for other risk factors? 
3/4 I-D. Was risk factor data collected in a valid manner (e.g., confidential or anonymous collection of sensitive 
risk factor data, collection of personal information from the person directly instead of someone else) 
3/4 I-E. Was infection status determined accurately? (i.e., accuracy of diagnostic test method used to determine 
infection status) 
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Assessment of Risk of Bias (Quality of Study Design): Prevalence of Risk Factors 
To assess the risk of bias of the included studies, we used the same quality assessment instrument as was 
used in Question 1. One modification was made for the third item. Rather than ask about the accuracy of 
determining infection status, we ask about the accuracy of determining the prevalence of the risk factor. 
Specifically, highly personal information should be reported by the person in question. Ideally, medical 
history (e.g., history of STD) would be collected using objective data, but we considered subject self-
report acceptable as well. Studies meeting 2 or 3 criteria were not penalized for quality in the GRADE 
system. Studies meeting only 0 or 1 criterion were penalized one level. 
Table 32. Quality Assessment for Questions 3 and 4: Prevalence of Risk Factors 
Study Year 
Question 3 Question 4 
P*-A P-B P-C P-A P-B P-C 
Potential Organ Donors 
Hidalgo et al.
8
 2001    Not applicable 
Actual Organ Donors 
Gasink et al.
102




 2006 -   -   
Kaur et al.
116
 1996 -   -   
McQuillan et al.
101
 2006 -   Not Applicable 
Mehta et al.
109
 2008 -   -   
Nguyen et al.
110
 2008 -   -   
*P: Prevalence 
A checkmark () means that the study met the quality criterion for this Question; the lack of a checkmark means that 
the study either did not meet the criterion, or it was unclear whether the study met the criterion. The criteria specific to 
this Question were: 
3/4 P-A. Was the population potential solid organ donors? 
3/4 P-B. For other populations, was the population unselected (i.e., not based on demographic or behavioral 
characteristics)? (studies of potential solid organ donors were scored as Yes, because they enrolled 
the population of interest) 
3/4 P-C. Was risk factor prevalence determined accurately? (i.e., were personal factors reported by subject 
themselves?) 
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GRADE Assessment of Identification of Risk Factors 
To assess the strength of the evidence regarding the identification of risk factors, we applied a GRADE 
system modified for this purpose. We assigned GRADE ratings for evidence bases comprised of at least 
two studies addressing a certain factor, divided by virus. The steps used to assign a rating are described in 
this section. The GRADE table for Question 4 is Table 36, and the table for Question 5 is Table 42, which 
appear following the results sections. 
Because all of these studies are observational, they were all assigned a starting grade of “Low,” per 
convention. The following factors could be used to decrease this grade: Overall quality, consistency, 
directness, and precision. Large magnitude of effect could be used to increase one grade. Criteria for these 
are provided in the following text. If a direct relationship between infection and the factor was suggested 
(e.g., higher number of sex partners associated with higher odds of infection), the GRADE was increased 
by one. Explanation of all plausible confounders could also increase the GRADE. These steps are 
described in the following subsections. We did not assess publication bias. 
Overall Risk of Bias 
Overall quality was determined in two steps. First, each study was assessed for risk of bias, as shown in 
Table 31. Then, the overall risk of bias of the evidence base was determined using the median number of 
quality items. Evidence bases with a median of 3 or 4 criteria were considered “moderate,” those with a 
median of 2 criteria were considered “low,” and those with only 1 criterion were considered “very low.” 
Evidence bases with a “very low” quality rating were decreased by one grade. 
Consistency 
Consistency was determined based upon how well the qualitative findings of the studies agreed with each 
other. If studies were consistent with the exception of a special population study or a very low-quality 
study; or if all studies (two or more) had large magnitudes of effect (OR>5) with the exception of one 
study, the evidence base was still considered consistent because these studies are least reliable. Other 
inconsistency that was easily explained for a single reason (with no other possible explanation) would not 
be downgraded. Evidence bases with only one study were downgraded due to lack of demonstrated 




 examined potential organ donors, and this was a very small study of living relative 
donors, who comprise the minority of potential donors. One study on actual heart donors that did not 
exclude donors with HCV was included.
102
 Although a large number of donors were examined in this 
study, it is not possible to determine how highly selected they were (i.e., how many potential donors were 
excluded and for what reasons) because these data are not reported. 
Most of the remaining studies studied potential tissue donors, actual blood donors, or members of the 
general population. These studies were not downgraded due to indirectness, despite the fact that they 
did not enroll potential organ donors. This is because the identification of a risk factor in these 
populations may be generalizable to potential organ donors. By contrast, studies of demographic and 
socioeconomic subpopulations are probably not very representative of potential organ donors. Some of 
the populations have high prevalence of multiple high-risk behaviors and a relatively high prevalence of 
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HBV (e.g., psychiatric inpatient veterans with co-morbid substance abuse problems), while others had 
few high-risk behaviors and a relatively low prevalence of HBV (e.g., women receiving prenatal care). 
We therefore downgraded evidence bases that predominately had this type of study (i.e., -1). 
Precision 
We considered all evidence bases with three or more studies to be precise (and therefore did not 
downgrade for imprecision). When there were only two studies, we considered the factor precise if one of 
two criteria were met. We considered the evidence base precise if both effects were statistically 
significant. If this criterion was not met, we evaluated the evidence base for precision by combining the 
two studies’ data in a summary effect size and evaluating the confidence intervals around the point 
estimate. We considered the evidence base precise if the confidence intervals were sufficiently narrow, 
defined as a maximum difference of 0.4 between the estimated log odds ratio and the upper bound of its 
95% confidence interval. For example, if the summary effect size was 1.1 with a 95% CI from 0.86 to 1.4, 
this was deemed sufficiently precise (because ln(1.4)-ln(1.1) is less than 0.4), whereas if the summary 
effect size was 1.1 with a 95% CI from 0.6 to 2.0, this was considered imprecise (because ln(2)-ln(1.1) is 
greater than 0.4, and the evidence is consistent with important effects in either direction). When there was 
only a single study, we considered the evidence base precise if either the effect was statistically 
significant, or if the confidence interval around the effect size was sufficiently narrow (defined in the 
same way as with two studies).  
Large Magnitude of Effect 
We upgraded the rating for any evidence base in which the studies consistently showed a large magnitude 
of effect. We defined this as any statistically significant odds ratio with a point estimate of 2.0 or higher. 
We did not require that the confidence intervals around the effect size point estimate be fully above 2.0. 
Dose-Response Association 
Evidence of a dose-response association is suggested if increasing levels of the factor corresponded to 
increasing risk of infection. Although studies could have measured such outcomes using continuous 
reporting (e.g., total number of lifetime sex partners), in this evidence base studies measured a risk factor 
on a categorical basis. For example, Nguyen et al. (2005)
113
 examined the risk factor of number of 
lifetime sex partners by placing each respondent into one of five categories: 0, 1, 2-9, 10-49, or 50+. 
If the risk of infection increased along with the number of sex partners, we considered this a dose-
response association. We upgraded some evidence bases +1 where the dose-response association was 
clear multiple studies. 
Significant Association Found Despite Confounders 
If the studies in an evidence base found a factor to have a statistically significant relationship with 
infection despite the fact that the evidence base was clearly biased against finding such a relationship, 
we upgraded +1 GRADE Assessment of Prevalence of Risk Factors 
GRADE Assessment of Prevalence of Risk Factors 
To assess the prevalence of behavioral and nonbehavioral risk factors, we used the system described in 
Question 1.  
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Question 3: Results 
The results on identification of risk factors are presented in this section. Information pertinent to the 
exclusionary factors listed in the 1994 guideline is presented first, and then information regarding 
additional factors is presented. Text was prepared for all factors that were reported by at least two studies. 
All of the data used to produce this section is provided in Table 33 (HBV), Table 34 (HCV), Table 35 
(HIV), and Table 37 (prevalence of factors), which follow the text. 
Exclusionary Behavioral Criteria from 1994 Guideline 
The following sections present all data identified as relevant to the exclusion criteria from the 1994 
guideline. Specifically, we did not restrict the information provided to original timeframes (e.g., engaged 
in a particular behavior “within 5 preceding years,” “currently” incarcerated.). We also included 
additional very relevant information in these sections, such as sex partners not identified in the original 
guideline. 
Men Who Have Sex with Men 
The 1994 guideline excludes from donating “Men who have had sex with another man in the preceding 
5 years.” We identified zero studies that inquired whether men engaged in sex with other men (MSM) in 
this particular time frame. However, several studies addressed lifetime history of having sex with other 
men. Briefly, two studies found associations with HBV, two did not find associations with HCV, and two 
studies found an association with HIV. 
HBV: In a sample of men aged 17 to 59 years drawn from the general population, McQuillan et al. 
compared the prevalence of HBV among men who reported having sex with other men to those who did 
not and found a significantly increased prevalence of HBV among MSM.
29
 Hwang et al. compared HBV 
infection rates among MSM compared to men who have never had sex in a population of college students 
and found that the rate of HBV was higher among MSM in both univariate and multivariate analyses.
124
 
HCV: Murphy et al. (2000) compared HCV prevalence between homosexual or bisexual men to men who 
had never had sex among blood donors and did not find an increased prevalence when the comparison 
was controlled for intravenous drug use (IDU). However, the unadjusted risk was elevated.
105
 Hand and 
Vasquez compared the rates of HCV among MSM and non-MSM among adults tested for HCV because 
of clinical suspicion and did not find a significant difference in a univariate analysis.
112
  
HIV: McQuillan et al. reported the prevalence of HIV among MSM to non-MSM in a sample drawn from 
the general population (using NHANES data), and the unadjusted rate shows MSM have a significantly 
higher prevalence of HIV.
101
Using New York City (NYC) HANES data from a later year, Nguyen et al.
110
 
also found a significantly higher rate of HIV among MSM in a univariate analysis. 
GRADE Summary: The evidence associating MSM with HBV and HIV was moderate. For both the 
evidence bases consistently found an association, and the magnitude of the effect was large. However, the 
strength of evidence associating MSM with HCV infection in blood donor and general populations 
studies was very low due to inconsistent findings. Neither pertinent study found MSM to be an 
independent risk factor for HCV (although MSM may be an important proxy factor; the evidence is 
insufficient to tell).  
135 





GRADE Summary of Prevalence: The evidence for the prevalence data was rated as low due to 
indirectness and inconsistency. 
Injection Drug Users 
The 1994 guideline excludes from donating “Persons who report nonmedical intravenous, intramuscular, 
or subcutaneous injection of drugs in the preceding 5 years.” We identified zero studies that investigated 
the risk of injection drug use (IDU) within this time frame. Most identified studies associated lifetime 
IDU with infection, and one considered the association with IDU greater or less than 6 months before the 
blood draw. Some studies reported IDU, and others reported intravenous drug use (IVU). In general, 
studies did not report both or distinguish between the two. Briefly, IDU/IVU was associated with HBV by 
three studies but not in a fourth (the fourth study being a smaller study of a special obstetric population), 
HCV in seven studies, and HIV in two of three studies. 
HBV: Kaur et al. associated IDU with HBV in a multivariate analysis of volunteers from the general 
population.
116
 Tabibian et al.
121
 and Butterfield et al. (2004)
125
 identified an increased risk of HBV among 
IVU veterans in inpatient psychiatric hospitals, and Hwang et al. identified an increased risk of HBV 
among IDU college students.
124
 Butterfield et al. (1990)
126
 did not find an elevated risk in an obstetric 
population. However, it appears that this is probably due to the low prevalence of HBV and IDU in this 
population. Only one individual in the population reported IDU, and she was HBV negative. Rather than 
contradict the association between IDU and HBV, the study was probably underpowered to detect an 
association given the low prevalence of both in this special low-risk subpopulation. 
HCV: Among blood donors, Orton et al.
104
 and Murphy et al.
105
 detected an association between IDU and 
HCV, and Conry-Cantilena et al.
106
 detected an association between IVU and HCV. Orton et al., use 
within the last six months only was associated with infection.
104
 Among people in a study group drawn 
from the general population, an increased prevalence of HCV was associated with IDU in Armstrong et 
al.,
30
 Fischer et al.,
114
 and Hand and Vasquez,
112
 and with IVU in Kaur et al.
116
  
HIV: McQuillan et al.
101
 studied IDU and the national general population, and Nguyen et al.
110
 assessed 
ever having used a needle for drugs, and in univariate analyses both found an increased rate of HIV. 
Mehta et al.
109
 did not find an association between IDU and HIV among hospital patients; the reason for 
this is unclear. 
Two studies specifically investigated the association between infection and injection steroid use, and 
neither found any association. Hwang et al. did not detect an increased risk of HBV among college 
students who injected steroids,
124
 and Orton et al. did not find an increased risk of HCV among blood 
donors.
104
 However, the Orton study did find a trend toward higher infection rate among blood donors 
who had injected steroids longer than six months ago (P = 0.07), and a larger study might detect an 
association.  
GRADE Summary: The strength of the evidence associating IDU with HCV was “moderate” due to the 
consistently large effect sizes found in all studies that associated this factor (with the exception of one 
small study on steroid use only that did not find an association with infection). For HBV, the evidence 
was “low.” All but one special population study found an association, but not all of the studies found a 
136 
large magnitude of effect (not including the findings of one study that injection steroid use was not 
associated with HBV). For HIV, the evidence was “low.” 













GRADE Summary of Prevalence: The prevalence data for injection drug abuse was rated as low due to 
inconsistency and indirectness. 
Related Factors: In addition, reporting living with an IDU was associated with HCV among blood 
donors, even when IDU was controlled for,
105
 as was living with an IDU in the last six months.
104
 
Alter et al. grouped household and sexual contact with an IDU during the last six months and found it was 
associated with recent HBV infection in a univariate, but not multivariate, analysis.
117
 Among the general 
population, both being at a social gathering with injection drugs and witnessing the use of injection drugs 
were associated with HCV.
113
 See the section High Risk Sex Partners for information on infection risk 
among people who have sex with IDUs. 
We also identified information on other types of substance abuse. For information, under Risk Factors 
Identified in the Literature as of 2009 see “Non-injection substance use and abuse.” 
Sex Work 
The 1994 guideline excludes from donating “Men and women who have engaged in sex in exchange for 
money or drugs in the preceding 5 years.” We did not find any literature that studied the association 
between this factor and the given time frame, but we did find literature that studied lifetime sex work and 
infection risk. Briefly, sex work was not associated with HBV in three studies (one was the next-of-kin 
tissue donor interview study, the other two enrolled special subpopulations of psychiatric inpatient 
veterans) or with HIV in one study (the next-of-kin interview study) but was associated with HCV in 
three studies. 
HBV: In their study of tissues donors, Sanchez et al. did not find any association between sex work and 
infection with HBV upon univariate analysis. However, their data came from next-of-kin interviews, and 
none of the relatives of infected potential donors reported sex work.
103
 Among psychiatric inpatient 
veterans, Tabibian et al.
121
 did not detect an association between “sex bartering” in a multivariate 
analysis. In that population rates of sex bartering were high among both HBV negative (30%) and HBV 
positive (37%) participants. Unprotected sex for drugs was not associated with HBV infection upon 




HCV: Sanchez et al. did not find any association between sex work and infection with HBV among tissue 
donors, with sex work as reported by next of kin.
103
 Sex work was associated with HCV among blood 
donors in Murphy et al. in a multivariate analysis
105
 and in general populations studies by Hand and 
Vasquez
112
 and Nguyen et al. in univariate analyses.
113
 (In Hand and Vasquez, all women who reported 
sex work also reported IDU.) 
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GRADE Summary: The evidence relating sex work and HBV and HIV infection was rated as very low. 
For HBV this was due to indirectness; the data were from primarily special populations. For HIV, this 
was due to having only one study of very low quality. In the HBV and HIV studies, no relationship was 
detected. For HCV, the evidence was rated as low. Three studies found associations. A fourth study 
did not, but we did not downgrade the evidence due to inconsistency because it was of very poor quality. 
Prevalence: One study reported the prevalence of exchanging sex for drugs or money among patients in 
an urban medical care center at 2.3%.
109
 
GRADE Summary of Prevalence: The prevalence of sex work was rated as low due to indirectness and 
lack of proof of consistency. 
High-Risk Sex Partners 
The 1994 guideline excludes from donating “Persons who have had sex in the preceding 12 months with 
any person described in items 1–4 above [refers to MSM, IDU, sex workers, and people with clotting 
disorders, who are covered in Question 4] or with a person known or suspected to have HIV infection.” 
We did not identify any literature on infection risk in people with high-risk sex partners during this time 
frame, but we did identify literature on infection risk associated with having high-risk sex partners at 
some point in life. As the scope of this evidence report encompasses HBV and HCV in addition to HIV, 
we have also included data on infection risk among people having sex with a person with known or 
suspected hepatitis. Briefly, having a high-risk or infected sex partner was associated with HBV in six of 
seven studies (the seventh being a special subpopulation study of psychiatric inpatient veterans), with 
HCV in ten studies, and with HIV in one study.  
Sex with IDU 
HBV: Sex with an IDU was associated with HBV in general population groups (including when use of 
IDU was controlled for) by Kaur et al.
116
 and in univariate analyses among college students by Hwang et 
al.,
124
 but not among psychiatric inpatient veterans in Tabibian et al.
121
 Sex or household contact with an 
IDU was associated with HBV infection in Alter et al.
117
 upon univariate investigation, but not when use 
of IDU was controlled for.  
HCV: Sex with an IDU or IVU was found to be associated with HCV in blood donors by Murphy et al. 
(2000)
105
 in univariate analysis and Orton et al.,
104
 in multivariate analysis, and in the general population 
by Nguyen et al.
113
 in univariate analysis and Kaur et al.
116
 in multivariate analysis. In Orton et al. the 
time frame was limited to the six months prior to donation. 
GRADE Summary: The evidence associating HBV infection with having a sex partner who uses injection 
drugs was rated as very low due to inconsistent findings. For HCV, the evidence was moderate due to the 
consistent findings of association with large magnitude of effect. 




GRADE Summary of Prevalence: The evidence of prevalence of having an IDU sex partner was low due 
to indirectness and lack of proof of consistency.  
Sex with a Sex Worker 
HBV: Sex with a sex worker was not associated with HBV among psychiatric inpatient veterans in a 
univariate analysis in Tabibian et al.
121
  
HCV: Sex with a sex worker was associated with HCV among blood donors in a multivariate analysis in 
Murphy et al.
105
 and in univariate analyses of general population studies by Ngyuen et al.
113
 and Hand and 
Vasquez.
112
 However, in Hand and Vasquez the relationship was no longer significant in the multivariate 
analysis. 
GRADE Summary: A single special population study did not associate HBV with sex with a sex worker, 
but this evidence is rated as “very low” due to indirectness and lack of proof of consistency of evidence. 
Three studies associated having sex with a sex worker with HCV in univariate analyses. This evidence 
was rated as “very low.”  
Prevalence: In one study, 7.4% of respondents indicated they had had sex with a sex worker.
109
 
GRADE Summary of Prevalence: The estimate of prevalence of having sex with a sex worker was graded 
as low due to indirectness and lack of proof of consistency. 
Sex with People Known to Have Infection 
HBV: Sex with a partner with hepatitis was found to be a risk factor for HBV in college students in 
Hwang et al.,
124
 but not in an obstetric population in Butterfield et al. (1990).
126
 Both of these analyses 
were univariate. 
HCV: Among blood donors, sex with someone with hepatitis at any point in life in Murphy et al. (2000)
105
 
in a multivariate analysis, or during the last six months in Orton et al.
104
in a univariate analysis, was 
associated with HCV.  
HIV: Having sex with someone known to have HIV was associated with having HIV by Mehta et al. in a 
group of patients from a general population using univariate analysis.
109
 
GRADE Summary: The evidence associating HBV and having a sex partner with a known infection was 
rated as very low due to low quality, inconsistency, and indirectness. The evidence associating the factor 
with HIV was also rated as low, for having no proof of consistency but a large effect size magnitude. For 
HCV the evidence was rated as low for consistently identifying sex with people known to have infection 
as a risk factor for HCV.  




GRADE Summary of Prevalence: The estimate of prevalence of having sex with someone known to be 
HIV-positive was graded as low due to indirectness and lack of proof of consistency. 
Other High-Risk Sex Partners 
139 
Some miscellaneous types of high-risk sex partners pertinent to high-risk sex partners not mentioned in 
the original guideline were also reported. Sexual promiscuity (defined as history of STD, sex with a sex 
worker, or at least five sex partners per year) was associated with HCV infection in blood donors in 
Conry-Cantilena et al.
106
 Alter et al. did not associate HBV infection with sex with a blood transfusion 
recipient, with a health care worker, or a person with a foreign birth in an endemic area.
117
 Sex with a 
transfusion recipient was associated with HCV in blood donors in Murphy et al.
105
 We report these other 
high-risk sex partners here because they are germane to the larger issue of having high-risk sex partners. 
However, we did not grade this evidence because these factors were reported by one study only. 
Inmates 
The 1994 guideline excludes from donating “Inmates of correctional systems. (This exclusion is to 
address issues such as difficulties with informed consent and increased prevalence of HIV in this 
population.)” No studies that examined the association between present incarceration and infection were 
identified. However, the searches did identify studies that examined the association between recent or 
lifetime history of incarceration. In brief, a history of incarceration was associated with HBV in three of 
four studies, with HCV in four of five studies, and was not associated with HIV in one study. The study 
that did not detect an association of incarceration and HBV, HCV, or HIV infection was Sanchez et al., 
the tissue donor study based upon information provided by next of kin. 
HBV: A history of incarceration as reported by next-of-kin was not associated with HBV in potential 
tissue donors in Sanchez et al.
103
 In general population studies, imprisonment within the last six months 
was associated with recent HBV infection in a univariate analysis, but not a multivariate analysis in Alter 
et al.
117
 Incarceration was also associated with HBV upon univariate analysis among psychiatric inpatient 
veterans in Tabibian et al.
121




HCV: A history of incarceration as reported by next-of-kin was not associated with HCV infection in 
potential tissue donors in Sanchez et al.
103
 Incarceration was associated with HCV in three studies of 
blood donors, Orton et al.,
104
 Murphy et al. (2000),
105
, and Conry-Cantilena et al.
106
 Two of those studies 
also tested whether incarceration was an independent risk factor; in both of those studies incarceration 
was associated with IDU. Murphy et al. (2000) found that incarceration for more than three days was an 
independent risk factor (although, compared with the unadjusted odds, odds were not as large once IDU 
was controlled for in the multivariate model),
105
 while Conry-Cantilena et al. found that, once adjusted for 
IDU, it was not.
106
 In addition, having been arrested was associated with HCV infection in a general 
population sample by Nguyen et al.
113
 
HIV: A history of incarceration as reported by next-of-kin was not associated with HIV infection in 
potential tissue donors in Sanchez et al.
103
  
GRADE Summary: Aside from one very low-quality study, a history of incarceration was consistently 
associated with HCV, and rated as low in strength overall. The association with HBV was inconsistent 
due to conflicting findings, and the association with HIV is unclear because only one very low-quality 
study addressed this outcome. The ratings for HBV and HIV were therefore both very low. 
Risk Factors in Children 
140 
We identified no literature on any behavioral risk factors in children, or on the risk of infection from 
mothers who engage in those risk behaviors. While vertical transmission is generally recognized as a 
mode of hepatitis or HIV transmission, this body of literature lacks the evidence to assess the 1994 
criteria as risk factors. This may be because of the relative infrequency of this mode of transmission, and 
because of the lack of data on children. For instance, although they used NHANES data from the general 
nationwide population, Armstrong et al. reported identifying only three people under the age of 20 years 
that were infected with HCV, which precluded the investigation of risk factors in children and adolescents 
in their study.
30
 In the literature base analyzed in this report, only one individual, a 17-year-old first-time 
blood donor with HCV RNA but not anti-HCV, had perinatal exposure as a possible mode of 
transmission.
104
 Her mother had an HCV infection during her pregnancy, and no other likely causes 
exposure were identified. 
Additional Potential Risk Factors Identified in the 2009 Literature Search 
In addition to the factors identified in the 1994 guideline, we extracted data on all other reported 
behavioral risk factors identified in the literature and describe the findings regarding factors reported by 
at least two studies. 
Other Sex Practices 
Multiple Partners 
Having multiple partners, including heterosexual partners, was associated with increased risk of infection 
across different populations. In brief, various measures of having multiple partners were associated with 
HBV in five studies, with HCV in six studies, and with HIV in one of three studies. 
HBV: HBV infection was associated with sex with multiple partners in general populations in Kaur et al.
116
 
in multivariate analysis. In multivariate analyses, multiple partners within the last six months was 
associated with recent HBV infection in a general population in Alter et al.
117
 and among psychiatric 
inpatient veterans in Butterfield et at. (2004).
125
 In a sample of people representative of the general 
population, compared to individuals with zero or one lifetime sex partners, having at least two lifetime sex 
partners was associated with HBV in McQuillan et al. in a multivariate analysis, and the odds of infection 
increased with greater numbers of partners.
29
 Among college students in the study by Hwang et al., both 
having at least 50 lifetime heterosexual partners and having at least 5 heterosexual partners in the preceding 
four months were associated with HBV infection in univariate analyses.
124
 
HCV: HCV infection in women blood donors was associated with having at least 11 male sexual partners 
(compared to having zero sexual partners) in Murphy et al. (2000)
105
 in multivariate analysis. Having the 
same number of lifetime female partners among men was not associated with HCV in the same study. 
Having two or more sexual partners, whether same sex or not, in the last six months was associated with 
an increased rate of HCV infection overall in Orton et al.
104
 in a univariate analysis. In general population 
univariate analyses, HCV was also associated with having “frequent” sex partners in Fischer et al.,
114
 
“multiple” sex partners in Kaur et al.,
116
 and at least 20 sexual partners in Armstrong et al.
30
 Greater 
numbers of sex partners was also associated with HCV infection in Nguyen et al.
113
 Hand and Vasquez 
noted the strong association between greater numbers of sex partners and IDU in their study. Of the 





HIV: In the general population, having multiple sex partners in the past year was not associated with HIV 
in Nguyen et al.,
110
 nor was having at least 10 lifetime sex partners in Mehta et al.
109
, but having 50 or 
more lifetime sex partners was associated with HIV in McQuillan et al.
101
 All of these analyses were 
univariate. 
GRADE Summary: Studies used different thresholds to define “multiple sex partners,” (ranging from as 
few as 2 to as many as 50 or more) so identifying the minimum number of partners associated with an 
increased risk of infection is not possible based upon this evidence base. However, using their various 
definition, HBV and HCV studies did (with the exception of heterosexual men in one HCV study) 
consistently associate infection with having multiple sex partners. For HBV and HCV, the strength of this 
association was moderate due to a positive “dose” response association. For HIV there was also a dose-
response relationship in two studies (one study found a relationship with having at least 50 partners, the 
other did not find a relationship with having at least 10 partners). The third study did not find a 
relationship with having “multiple” sex partners in the past year. The evidence was rated as low for 
having a dose-response relationship but inconsistent findings. 
Prevalence: In a national general population, 29% of survey respondents indicated having had at least 10 
sex partners,
30
 and 3.5% reported having at least 50 sex partners.
101
 Among New Yorkers, 6.6% reported 
at least 50 sex partners.
110
 22% of New Yorkers reported having sex with multiple partners during the 
previous year,
110
 and 26% of volunteers from an urban area reported sex with multiple partners.
116
 
GRADE Summary of Prevalence: Prevalence estimates of having “multiple” sex partners (number 
undefined) and having at least 2 sex partners (but not more than 49 in one study) were both rated as 
moderate due to indirectness. The prevalence of having at least 50 partners was rated as low due to 
indirectness and lack of consistency. 
Same-Sex Partners, Not Restricted to Men 
Three studies investigated having same sex partners but did not restrict the analysis to MSM. Two 
associated this factor with HCV, and the other associated it with HIV. 
HCV: Having same-sex partners among women was associated with an increased risk of HCV among 
women blood donors in Murphy et al. (2000)
105
 in multivariate analysis. For women who had had only 
one same-sex partner, this risk was no longer significant when adjusted for IDU, but it remained 
significant if there were two or more same-sex partners. Among outpatients, Nguyen did not find any 
association between having sex with a person of the same sex and HCV infection.
113
 
HIV: Mehta et al. detected a univariate association between having a same-sex partner and HIV, including 
both men and women in the sample.
109
 
GRADE Summary: The evidence for HCV was rated as very low due to inconsistency and imprecision. 
The evidence for HIV was rated as low because the single study had large magnitude of effect but could 
provide no proof of consistency for the evidence base. 





GRADE Summary of Prevalence: This evidence was rated as low due to indirectness and lack of proof of 
consistency. 
Age at First Sexual Intercourse 
Younger age at the time of first sexual experience was also associated with infection among adults in 
univariate analyses. One study associated it with HBV, two associated it with HCV, and one associated it 
with HIV. 
HBV: Age of 18 years or younger was not associated with HBV in McQuillan et al. (1990) in a 
multivariate analysis.
29
 Age at first intercourse of 15 years or younger was associated with HBV infection 
among college students in Hwang et al. in a univariate analysis.
124
  
HCV: In the general population, age of 17 years or younger was associated with HCV in Armstrong et al. 
in a univariate analysis. The study stratified age at first intercourse by age younger than 11, age 12-15, 
and age 16-17 years. The groups of people who were younger at the time of their first sexual intercourse 
had the highest risk of HCV.
30
  
HIV: Age of 18 years or younger was associated with HIV in McQuillan et al. (2006) in a univariate 
analysis. The size of this effect was large.
101
 
GRADE Summary: For HBV, one study associated HBV with age at first intercourse 15 or younger, and 
another did not find a relationship with age at first intercourse 18 or younger. This evidence was rated as 
low because, although the findings were not necessarily consistent, they do suggest a ‘dose-dependent’ 
relationship between younger age at first intercourse and increased risk of HBV. For HCV, one study 
found that younger age was associated with infection in a dose-dependent relationship, and the evidence 
rating for it was ‘low.’ For HIV, age younger than 18 was associated with increased risk of infection, and 
the evidence for this was rated as ‘low’ for having a large magnitude of effect despite no proof of 
consistency. 





 in two studies. 
GRADE Summary of Prevalence: This estimate was rated as moderate due to lack of directness to 
potential organ donors. 
Additional Various Associations 
We report additional reported associations between sexual practices and infection below because they are 
relevant to this overall section. However, we did not assign Grade ratings because these factors were 
reported by so few studies. 
 Unprotected sex was associated with HCV infection in a general population by Fischer et al.114, 
although not using condoms consistently was not associated with HIV infection in a general 
population by Mehta et al.
109
 or Nguyen et al.
110
 
 Anal-insertive sex that occurred at least six weeks ago was associated with HIV infection among men 
in a general population, and anal-receptive sex at least six weeks ago among women and men in a 




 Having vaginal sex was associated with a reduced risk in HIV compared with people who did not have 




Other Illicit Drugs 
Of the studies that inquired about the association between non-injection illicit drug use (mostly inhaled 
drugs, predominantly intranasal cocaine), two of five found an association with HBV and seven of eight 
found an association with HCV. Two of the studies that did not find an association with HBV both enrolled 
a special subpopulation (psychiatric inpatient veterans). The other study that did not find an association 
with either HBV or HCV was the next-of-kin interview study of tissue donors, Sanchez et al.
103
 
HBV: Illicit drug use was not associated with HBV in the tissue donor study by Sanchez et al.
103
 Ever 
having used cocaine was associated with HBV in the general population by McQuillan et al.
29
 in a 
multivariate analysis. HBV infection was associated with intranasal drug use among the college students 
in Hwang et al.
124
 However, in Tabibian et al.
121
 and Butterfield et al.
125
, who enrolled psychiatric 
inpatient veterans, HBV infection was not associated with inhaled or ‘snorted’ drugs.  
HCV: Any illicit drug use was not associated with HCV in the tissue donor study by Sanchez et al.
103
 





 and Murphy et al.
105
, including when adjusted for IDU or other factors in two of those studies 
(the third study did not perform adjusted analyses.
104





 using intranasal cocaine,
112
 and use of non-injection drugs 
other than marijuana
30
 were all associated with increased prevalence of HCV. Two of the studies 
investigated whether this factor was independently associated with HCV, and Armstrong et al. found it 
was using NHANES data
30
 while Hand and Vasquez found it was not based upon a smaller set of data on 
adults tested for HCV because of clinical suspicion.
112
 However, Hand and Vasquez note that cocaine use 
in the absence of IDU or tattoos was unusual in their sample. Although 39% of patients admitted to 
intranasal cocaine, only 2% of whom did not have tattoos or IDU used cocaine.  
Being at a social gathering with cocaine was associated with HCV in Nguyen et al.
113
 Having friends who 
use “street drugs” was associated with an increased risk of HCV among blood donors Orton et al.
104
 
HIV: HIV was associated with ever using cocaine or street drugs in a univariate analysis by McQuillan et 
al. (2006)
101
 and in a multivariate analysis by Alpert et al.
115
 among members of the general population. 
GRADE Summary: The evidence associating non-injection illicit drug use and HBV was inconsistent and 
graded as “very low” due to this inconsistency. Aside from one very low-quality study, studies 
consistently associated non-injection drug use with HCV. The evidence associating HCV with non-
injection drugs was rated as low. Two studies associated HIV with non-injection drug use, and this 
evidence was rated also rated as low. 
Prevalence: Among potential living organ donors in one smaller study, 5.5% reported having ongoing 
drug abuse problems.
8
 In the general population, 17% reported lifetime use of drugs other than 
marijuana,
30
 18% reported ever having used street drugs,
110





GRADE Summary of Prevalence: The estimate of ongoing drug use prevalence in living potential organ 
donors was rated as low due to imprecision and lack of proof of consistency. The estimates of drug use in 
the general population were rated as moderate due to indirectness. 
Alcohol 
The association between alcohol intake and infection was less consistent.  
HBV: Alcohol use, as reported by next-of-kin, was not associated with HBV infection among potential 
tissue donors in a univariate analysis in Sanchez et al.
103
 HBV was not associated with alcohol use 
disorder among psychiatric inpatient veterans in Butterfield et al. in a multivariate analysis (2004).
125
  
HCV: HCV was associated with “heavy” alcohol use in heart donors in Gasink et al.
102
, and with having 
at least two units of alcohol per day among adults tested for HCV because of clinical suspicion in Hand 
and Vasquez.
112
 However, HCV was not associated with alcohol use among tissue donors in Sanchez et 
al.,
103
 having at least 5 alcoholic drinks weekly in patients in Nguyen et al.
113
 or alcoholism in HMO 
enrollees in Fischer et al.
114
 All of these analyses were univariate. 
HIV: HIV was associated with having an alcohol and/or (unspecified) drug problem among HMO 
enrollees in Fischer et al.
114
 (as identified in a claims database), but not with alcohol use among potential 
tissue donors in Sanchez et al.
103
 Both of these analyses were univariate. 
GRADE Summary: Alcohol use was not associated with HBV and was inconsistently associated with 
HCV and HIV. These evidence bases were all rated as “very low” due to inconsistency and/or 
imprecision. 
Prevalence: In a database study of actual organ donors, 20% reportedly drank heavily.
102
 
GRADE Summary of Prevalence: The estimate of heavy alcohol abuse was rated as low due to low study 
quality and lack of proof of consistency. The directness to potential donors is also unclear. 
Tobacco 




HCV: A history of tobacco use was associated with HCV in heart donors in Gasink et al.,
102
 and cigarette 
smoking was associated with HCV (but not HBV or HIV) in tissue donors in Sanchez et al.
103
 Both of 
these associations were made using univariate analyses.  
HIV: The same tissue donor study that did not find an association between cigarette smoking and HBV or 
HCV also did not find one between cigarette smoking and HIV.
103
 
GRADE Summary: One organ donor study associated tobacco with HCV, but the tissue donor study did 
not; the strength of the evidence base as very low. For HBV and HIV the evidence was rated as very low 
because only one study that did not find a relationship was identified. 




GRADE Summary of Prevalence: The estimate of tobacco use was rated as low due to low study quality 
and lack of proof of consistency. The directness to potential donors is also unclear. 
Tattoos and Piercing 
Tattoos and piercings were not associated with HBV in any of five studies or with HIV in one study, but 
tattoos were associated with HCV in six studies and piercings were associated with HCV in three of six 
studies. We report on tattoos and piercing because the tissue donor study, Sanchez et al.
103
 reported on 
them together. 
HBV: Tattoos, piercing, and acupuncture (as collectively analyzed as one outcome and reported by next-
of-kin) were not associated with HBV in tissue donors in Sanchez et al.
103
  
Tattoos were not associated with HBV infection among psychiatric inpatient veterans in Tabibian et al.,
121
 
women receiving prenatal care in Butterfield et al. (1990),
126
 or among college students in Hwang et al.,
124
 
unless the college students were tattooed with reused non-autoclaved needles. Having a tattoo in the last 
six months was not associated with acute HBV infection by Alter et al.
117
  
Piercings were not associated with HBV among psychiatric inpatient veterans in Tabibian et al.
121
, and 
body piercings (other than ears) were not associated with HBV among college students in Hwang et al.
124
 
Piercings within the last six months were not associated with acute HBV in the general population either 
in Alter et al.
117
 
HCV: Tattoos, piercing, and acupuncture (as collectively analyzed as one outcome and reported by next-
of-kin) were not associated with HCV in potential tissue donors in Sanchez et al.
103
  





 and Murphy et al. (2000)
105
 Orton et al. focused on having had a tattoo within the last 
six months and the appearance of acute HCV. Two of these studies also performed multivariate analyses. 
Conry-Cantilena found that tattoos were not significantly associated with infection once other factors are 
controlled for.
106
 Murphy et al. found that, although the odds of infection were reduced once IDU was 
controlled for, tattoos were an independent predictor of HCV.
105
 Three general populations studies, 
Nguyen et al.,
113
 Fischer et al.,
114
 and Hand and Vasquez et al.,
112
 also detected significant associations 
between tattoos and HCV. Only Hand and Vasquez investigated further and found that tattoos were an 
independent predictor. In that study, adults were enrolled based upon clinical suspicion of hepatitis. Most 
patients enrolled in the Hand and Vasquez study reported that their tattoos had been applied by friends, 
fellow gang members, or fellow inmates (as opposed to professional tattooists working from commercial 
parlors). 
Among blood donors, HCV was not associated with body piercing in the last 6 months by Orton et al.,
104
 
but was associated with ear piercing among men in Conry-Cantilena et al.,
106
 and with pierced ears or 
body parts in Murphy et al. (2000).
105
 Fischer et al.
114
 and Hand and Vasquez
112
 considered the 
association between body piercing and HCV in general population patients and did not find an 
association. Nguyen et al.
113
 and Hand and Vasquez
112
 investigated ear piercing in adult patients, and 
while Nguyen et al. detected an association Hand and Vasquez did not. 
146 
HIV: Tattoos, piercing, and acupuncture (as collectively analyzed as one outcome and reported by next-
of-kin) were not associated with HIV in potential tissue donors in Sanchez et al.
103
 
GRADE Summary: Tattoos and piercings were consistently not assocated with HBV. The rating of this 
evidence is low. Aside from one very low-quality study, tattoos were consistently associated with HCV, 
and piercings were inconsistently associated with HCV. The rating of this evidence is also low. Only one 
very low study considered piercing and tattoos and HIV, and did not find an association. This evidence 
was rated as very low due to low quality, lack of proof of consistency, and imprecision. 
International Travel 
Several studies inquired whether participants had traveled outside the U.S. but none detected an 
association with infection. Among potential tissue donors in Sanchez et al., international travel was not 
associated with HBV, HCV, or HIV.
103
 International travel within the last six months was not associated 
with acute HBV in a general population by Alter et al.
117
 Among blood donors, traveling outside the U.S. 
during the last six months was not found to be significantly associated with HCV in Orton et al.,
104
 and 




GRADE Summary: International travel was not associated with any of the viruses. For HBV and HIV the 
evidence was rated as very low due to imprecision and, for HIV, low quality. For HCV the evidence was 
rated as low. 
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Evidence Tables for Question 3 















































































































history of  










No Potential tissue donors, 









Sanchez et al.103 2006 NR 47 NR 56 NR NS † Proportion in 
HBV+ vs. 
HBV- 
No Potential tissue donors, 










Illicit drug use 
(any) 
Sanchez et al.103 2006 NR 47 NR 56 NR NS † Proportion in 
HBV+ vs. 
HBV- 
No Potential tissue donors, 
as reported by next of kin 
Alcohol use Sanchez et al.103 2006 NR 47 NR 56 NR NS † Proportion in 
HBV+ vs. 
HBV- 
No Potential tissue donors, 
as reported by next of kin 
Smoking 
history 
Sanchez et al.103 2006 NR 47 NR 56 NR NS † Proportion in 
HBV+ vs. 
HBV- 
No Potential tissue donors, 











 Tattoos, body 
piercing, or 
acupuncture 
Sanchez et al.103 2006 NR 47 NR 56 NR NS † Proportion in 
HBV+ vs. 
HBV- 
No Potential tissue donors, 













































































































 Foreign travel Sanchez et al.103 2006 NR 47 NR 56 NR NS† Proportion in 
HBV+ vs. 
HBV- 
No Potential tissue donors, 





 Men who 




1999 6.5% 323 1.2% 5,058 5.7 
(3.4 to 9.5)†¶ 
<0.001† Proportion in 
HBV+ vs. 
HBV- 
Yes General population aged 17 





Kaur et al.116 1996 62.6% 6,121 17.2% 1,417 8.11 
(5.47 to 12.03)‡ 
SS Proportion in 
HBV+ vs. 
HBV- 

















Kaur et al.116 1996 44.7% 1,189 16.7% 5,373 2.57 
(1.78 to 3.17)‡ 
SS Proportion in 
HBV+ vs. 
HBV- 






history of IV 
drug use, 
last 6 months 









General population adults 
with no obvious cause of 







Alter et al.117 1989 3% 76 5% 152 NR NS† Proportion in 
HBV+ vs. 
HBV- 
No General population adults 
with no obvious cause of 

















































































































Alter et al.117 1989 0% 76 5% 152 NR NS† Proportion in 
HBV+ vs. 
HBV- 
No General population adults 
with no obvious cause of 





foreign birth in 
area with high 
endemic HBV 
rate 
Alter et al.117 1989 3% 76 0% 152 NR NS† Proportion in 
HBV+ vs. 
HBV- 
No General population adults 
with no obvious cause of 









last 6 months 









General population adults 
with no obvious cause of 












 Sex with 
multiple 
partners 
Kaur et al.116 1996 22.6% 1,402 17.9% 5,923 1.33 
(1.08 to 1.64)‡ 
NR  Proportion in 
HBV+ vs. 
HBV- 










<0.01 Proportion in 
HBV+ vs. 
HBV- 
Yes General population adults 
with no obvious cause of 














































































































2 to 9 
McQuillan et 
al.29 
1999 47% 505 50% 10,613 2.1 
(1.4 to 3.2)‡ 
SS Prevalence 
HBV+ vs. 
HBV- vs. 0 to 
1 
Yes General population aged 17 
to 59 years 
Lifetime sex 
partners 
10 to 49 
McQuillan et 
al.29 
1999 26% 505 20% 10,613 2.9 
(1.9 to 4.3)‡ 
SS Prevalence 
HBV+ vs. 
HBV- vs. 0 to 
1 
Yes General population aged 17 





1999 4% 505 11% 10,613 6.5 
(3.5 to 12.2)‡ 
SS Prevalence 
HBV+ vs. 
HBV- vs. 0 to 
1 
Yes General population aged 17 
to 59 years 





1999 69% 496 60% 9,978 1.2 





No General population aged 17 















1999 22% 541 11% 10,773 1.8 
(1.2 to 2.7)‡ 
SS Proportion in 
HBV+ vs. 
HBV- 
Yes General population aged 17 







Alter et al.117 1989 1% 76 1% 152 NR NS† Proportion in 
HBV+ vs. 
HBV- 
No General population adults 
with no obvious cause of 
















































































































 Ear piercing, 
last six 
months 
Alter et al.117 1989 3% 76 3% 152 NR NS† Proportion in 
HBV+ vs. 
HBV- 
No General population adults 
with no obvious cause of 








Alter et al.117 1989 1% 76 <1% 152 NR NS† Proportion in 
HBV+ vs. 
HBV- 
No General population adults 
with no obvious cause of 









Alter et al.117 1989 15% 76 8% 152 NR NS† Proportion in 
HBV+ vs. 
HBV- 
No General population adults 
with no obvious cause of 





Alter et al.117 1989 4% 76 3% 152 NR NS† Proportion in 
HBV+ vs. 
HBV- 
No General population adults 
with no obvious cause of 







Alter et al.117 1989 22% 76 27% 152 NR NS† Proportion in 
HBV+ vs. 
HBV- 
No General population adults 
with no obvious cause of 

















































































































have sex with 
men 
Hwang et al.124 2006 6% 245 3% 3,824 Relative risk 
(RR): 
2.06 
(1.17 to 3.61)† 
OR: 
3.54 














Tabibian et al.121 2008 62.5% 40 27% 89 4.51 
(2.04 to 9.96)†¶ 
<0.001 Prevalence in 
HBV+ vs. 
HCV- 






2004 NR 80 NR 276 4.54 
















No Obstetric population 
Injected illegal 
drugs 
Hwang et al.124 2006 6% 266 2% 3,968 RR:  
3.02 
(1.91 to 4.77)† 
<0.05  Prevalence 
HBV+ vs. 
HBV- 
Yes College students 
Injected 
steroids 
Hwang et al.124 2006 1% 268 1% 4,013 RR: 
0.98 










k Sex bartering Tabibian et al.121 2008 30% 40 37% 89 NR  NS† Prevalence in 
HBV+ vs. 
HBV- 













































































































sex for drugs 
Butterfield et 
al.125 
2004 NR 80 NR 276 1.25 






















Tabibian et al.121 2008 17.5% 40 11% 89 NR  NS† Prevalence in 
HBV+ vs. 
HBV- 





Hwang et al.124 2006 8% 267 4% 4,006 RR: 
2.05 




Yes College students 
Sex with 
prostitute 
Tabibian et al.121 2008 32.5% 40 18% 89 NR  NS† Prevalence in 
HBV+ vs. 
HBV- 





Hwang et al.124 2006 4% 268 2% 4,010 RR: 
2.28 
(1.30 to 3.99)† 
p <0.05 Prevalence 
HBV+ vs. 
HBV- 







1990 0% 12 0.1% 1,454 0.36 














Tabibian et al.121 2008 85.0% 40 67% 89 NR  <0.05† Prevalence in 
HBV+ vs. 
HBV- 




Hwang et al.124 2006 13% 268 8% 4,026 RR: 
1.71 





























































































































Hwang et al.124 2006 67% 243 74% 3,824 RR 0.89 











Hwang et al.124 2006 4% 243 1% 3,824 RR 3.08 







Yes College students 
Heterosexual 
partners 
last 4 months 
≥5 
Hwang et al.124 2006 3% 240 1% 3,790 RR: 
2.02 
(1.00 to 4.10)†; 
OR: 
2.61 





HBV- vs. <5 
Yes College students 
Multiple sex 
partners 
last 6 months 
Butterfield et 
al.125 
2004 NR 80 NR 276 2.01 




Yes Psychiatric inpatient 
veterans 
Age at first 
intercourse 
≤15 years 
Hwang et al.124 2006 20% 249 13% 3,810 RR: 
1.52 

















































































































Age at first 
intercourse 
≥15 years 
Hwang et al.124 2006 65% 249 70% 3,810 RR: 
0.97 






















Tabibian et al.121 2008 80% 40 66% 89 NR  NS† Prevalence in 
HBV+ vs. 
HBV- 




Hwang et al.124 2006 19% 262 14% 3,921 RR: 
1.39 









2004 NR 80 NR 276 1.06 










2004 NR 80 NR 276 1.18 










2004 NR 80 NR 276  0.93 










Tattoo Tabibian et al.121 2008 40% 40 30% 89 NR  NS† Prevalence 
HBV+ vs. 
HBV- 
No Psychiatric inpatient 
veterans 
Tattoo  Hwang et al.124 2006 25% 274 26% 4,047 RR: 
0.96 
(0.73 to 1.25)† 
NS  Prevalence 
HBV+ vs. 
HBV-  











































































































Tattoo Butterfield et 
al.126 










Hwang et al.124 2006 20% 274 20% 4,039 RR: 
0.99 





No College students 
Tattoo, 
number of ≥3 
Hwang et al.124 2006 5% 274 5% 4,039 RR: 
0.87 









Hwang et al.124 2006 21% 274 22% 4,035 RR: 
0.93 










Hwang et al.124 2006 4% 274 3% 4,035 RR: 
1.24 










Hwang et al.124 2006 18% 267 21% 3,920 RR: 
0.87 










Hwang et al.124 2006 4% 267 2% 3,920 RR: 
1.91 

















































































































ink in single 
wells only 
Hwang et al.124 2006 12% 242 15% 3,646 RR: 
0.79 









Hwang et al.124 2006 2% 242 2% 3,646 RR: 
1.10 












Piercing Tabibian et al.121 2008 37.5% 40 30% 89 NR  NS† Prevalence in 
HBV+ vs. 
HBV- 





Hwang et al.124 2006 16% 268 21% 4,008 RR: 
0.74 
(0.54 to 1.02)† 
NS  Prevalence 
HBV+ vs. 
HBV- 




Hwang et al.124 2006 14% 266 17% 3,975 RR: 
0.77 









Hwang et al.124 2006 2% 266 3% 3,975 RR: 
0.55 





















































































































Hwang et al.124 2006 56% 272 54% 4,033 RR: 
1.08 





No College students 




Turner et al.127 1989 NR 14 NR 94 RR: 
9.8 





Yes Embalmers in high-
prevalence urban area 











No Embalmers in high-
prevalence urban area 
Eat or drink 
while 
embalming 
Turner et al.127 1989 NR 14 NR 94 RR: 
1.8 





No Embalmers in high-
prevalence urban area 
Smoke while 
embalming 
Turner et al.127 1989 NR 14 NR 94 RR: 
1.6 





No Embalmers in high-
prevalence urban area 
* Odds ratios as reported in publication, unless otherwise specified 
** As reported in publication, unless otherwise specified 
† Univariate, unadjusted 
‡ Multivariate, adjusted for other factors 
¶ Calculated by ECRI Institute 
NR – Not reported 
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2006 49.2% 261 19.9% 10,654 Not reported 
(NR) 
<0.001†  Proportion in 
HCV+ vs. 
HCV- 





2006 69.0% 261 35.4% 10,654 NR <0.001† Proportion in 
HCV+ vs. 
HCV- 
Yes Heart donors 










2006 NR 18 NR 56 NR NS  Proportion in 
HCV+ vs. 
HCV- 
No Potential tissue 
donors, as reported 











2006 NR 18 NR 56 NR NS  Proportion in 
HCV+ vs. 
HCV- 
No Potential tissue 
donors, as reported 





















































































































Illicit drug use Sanchez et 
al.103 
2006 NR 18 NR 56 4.65 
(1.21 to 17.91) 
X2 = 0.016  Proportion in 
HCV+ vs. 
HCV- 
Yes Potential tissue 
donors, as reported 
by next of kin 
Alcohol use Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS  Proportion in 
HCV+ vs. 
HCV- 
No Potential tissue 
donors, as reported 





2006 NR 18 NR 56 4.01 
(1.11 to 14.65)  
X2 = 0.024  Proportion in 
HCV+ vs. 
HCV- 
Yes Potential tissue 
donors, as reported 



















2006 NR 18 NR 56 NR NS  Proportion in 
HCV+ vs. 
HCV- 
No Potential tissue 
donors, as reported 





Foreign travel Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS  Proportion in 
HCV+ vs. 
HCV- 
No Potential tissue 
donors, as reported 





















































































































2000 3% 400 1% 568 0.9 
(0.2 to 4.4)‡ 














2000 6% 400 1% 568 1.1 
(0.2 to 5.4)‡ 













2000 8% 758 2% 1,039 1.0 
(0.3 to 3.0)‡ 






















































































































last 6 months 











<0.001† Proportion in 
HCV+ vs. 
HCV- 






1996 42% 248 2% 131 12.5 
(2.7 to 57.1)‡ 
0.001  Proportion in 
HCV+ vs. 
HCV- 
Yes Blood donors initially 




Injected drugs  Murphy et 
al.105  














Yes Blood donors 
Injection drug 
use longer 
than 6 months 
ago only 
Orton et al.104 2004 4.9% 46 0.5%% 225 10.9 
(0.6 to 647)† 
0.07  Proportion in 
HCV+ vs. 
HCV- 














































































































6 months ago 
only 
Orton et al.104 2004 3.5% 65 0.5% 225 7.6 
(0.4 to 448)† 






2000 38% 758 1% 1,039 5.1 
(2.9 to 8.8)‡ 





Yes Blood donors 
Reside with 
an injection 
drug user in 
last 6 months 





<0.001† Proportion in 
HCV+ vs. 
HCV- 







money for sex 
Murphy et 
al.105 
2000 7% 758 1% 1,039 3.0 
(0.9 to 9.7)‡ 


















s Sex with 
injection drug 
user in 
last 6 months 
Orton et al.104 2004 18.5% 65 1.8% 225 12.5 
(3.6 to 54)† 
<0.001  Proportion in 
HCV+ vs. 
HCV- 
















































































































2000 41% 758 3% 1,039 6.3 
(3.3 to 12.0)‡ 











2000 15% 758 6% 1,039 1.5 
(0.9 to 2.5)‡ 










2000 7% 758 3% 1,039 2.2 
(1.1 to 4.5)‡ 










Orton et al.104 2004 7.7% 65 1.8% 225 4.6 
(1.0 to 24)† 
0.03 Proportion in 
HCV+ vs. 
HCV- 






2000 5% 758 3% 1,039 2.5 
(1.3 to 5.0)‡ 






















































































































Been in jail 
within 
6 months of 
donation 
Orton et al.104 2004 30.9% 65 12.0% 225 3.3 
(1.6 to 6.6)† 
<0.001  Proportion in 
HCV+ vs. 
HCV- 
Yes Blood donors 





Orton et al.104 2004 30.9% 65 12.0% 225 3.3 
(1.6 to 6.6)† 
<0.001  Proportion in 
HCV+ vs. 
HCV- 
Yes Blood donors 
In jail more 
than 3 days 
Murphy et 
al.105 
2000 22% 758 2% 1,039 5.0 
(2.6 to 9.8)‡ 



















Blood donors initially 






















1996 53% 248 24% 131 3.0 
(1.5 to 5.9)‡ 
0.002 Proportion in 
HCV+ vs. 
HCV- 
Yes Blood donors initially 

















































































































2000 8% 400 24%% 568 0.8 
(0.3 to 2.6)‡ 





reference to 0 








2000 38% 400 44% 568 1.5 
(0.6 to 4.0)‡ 
















2000 51% 400 24% 568 1.7 
(0.6 to 4.8)‡ 













2000 3% 400 6% 568 0.7 
(0.2 to 2.0)‡ 





















































































































2000 13% 351 32% 463 1.2 
(0.5 to 3.3)‡ 














2000 46% 351 50% 463 1.9 
(0.7 to 5.0)‡ 
















2000 28% 351 11% 463 3.2 
(1.1 to 9.1)‡ 














2000 8% 351 1% 463 8.8 
(2.0 to 39.4)‡ 
SS Proportion in 



















































































































2000 3% 351 4% 463 0.9 
(0.3 to 2.4)‡ 
NS Proportion 
with HCV+ vs. 
HCV- adjusted 
for IDU and 
compared to 
hetero-sexual 
No Blood donors 
Two or more 
sexual 
partners in 
last 6 months 
Orton et al.104 2004 21.5% 65 4.9% 225 5.3 
(2.3 to 13)† 
<0.001  Proportion in 
HCV+ vs. 
HCV- 








2000 6% 351 2% 463 1.3 





with HCV+ vs. 
HCV- adjusted 


















2000 9% 351 2% 463 3.7 
(1.2 to 11.1)‡ 
SS Proportion 
with HCV+ vs. 
HCV- adjusted 






















































































































2000 16% 351 4% 463 2.3 
(1.0 to 5.2)‡ 
NS Proportion 
with HCV+ vs. 
HCV- adjusted 



















Snort drugs in 
last 6 months 





<0.001†  Proportion in 
HCV+ vs. 
HCV- 
Yes Blood donors 
Intranasal 
drugs longer 
than 6 months 
ago 
Orton et al.104 2004 17.4% 52 6.6% 225 3.0 
(1.0 to 8.2)† 
0.04† Proportion in 
HCV+ vs. 
HCV- 






1996 68% 248 11% 131 8.0 
(3.9 to 16.5)‡ 
<0.001 Proportion in 
HCV+ vs. 
HCV- 
Yes Blood donors initially 
positive on EIA 
Inhaled drugs Murphy et 
al.105 
2000 63% 758 21% 1,039 2.2 
(1.6 to 3.1)‡ 





Yes Blood donors 
Friends use 
street drugs in 
last 6 months 
Orton et al.104 2004 38.5% 65 6.7% 225 8.8 
(4.2 to 18)† 
<0.001 Proportion in 
HCV+ vs. 
HCV- 















































































































last 6 months 
Orton et al.104 2004 4.6% 65 0.5% 225 11 
(0.8 to 566)† 
0.04  Proportion in 
HCV+ vs. 
HCV- 












Blood donors initially 
positive on EIA 
Tattoo Murphy et 
al.105 
2000 27% 758 5% 1,039 3.9 
(2.5 to 6.1)‡ 













last 6 months 
Orton et al.104 2004 4.6% 65 2.2% 225 2.1 
(0.3 to 11)† 
0.38  Proportion in 
HCV+ vs. 
HCV- 






1996 30% 139 0% 83 NR <0.05‡ Proportion in 
HCV+ vs. 
HCV- 
Yes Blood donors initially 
positive on EIA 







2000 56% 758 40% 1,039 2.0 
(1.1 to 3.7)‡ 























































































































last 6 months 
Orton et al.104 2004 1.5% 65 6.7% 225 0.2 
(0.01 to 1.5)† 
0.13 Proportion in 
HCV+ vs. 
HCV- 





2000 17% 758 15% 1,039 1.0 
(0.7 to 1.5)‡ 













2000 8% 758 2% 1,039 2.8 
(1.2 to 7.0)‡ 













2000 16% 758 7% 1,039 1.6 
(1.0 to 2.5)‡ 



















































































































2000 3% 758 3% 1,039 1.2 
(0.6 to 2.6)‡ 









 Men who 




2005 5% 320 6% 307 NR 0.658† Proportion 
HCV+ vs. 
HCV- 
No Adults tested for 
HCV in health 










2006 45% 114 0.7% 5,254 148.9 
(44.9 to 49.4)‡ 
SS No use (or 
marijuana 
only) HCV+ 
Yes General population 
aged 20 to 59 years 
Injected drugs Fischer et 
al.114 
2000 27% 11 2% 1,369 26.47 
(8.39 to 
83.55)‡¶ 
<0.001† Proportion in 
HCV+ vs. 
HCV- 






2005 53% 320 5% 307 20.1 
(10.3 to 39.4)‡ 
<0.0001 Proportion in 
HCV+ vs. 
HCV- 
Yes Adults tested for 
HCV in health 




Kaur et al.116 1996 66.6% 6,121 5.2% 528 23.34 
(15.21 to 
35.81)‡ 
SS Proportion in 
HCV+ vs. 
HCV- 



















































































































2005 45.0% 225 7.4% 204 NR <0.001 Proportion 
HCV+ vs. 
HCV- 
Yes Adults at general 
internal medicine 
clinic (controls) and 
hepatology clinic 
(cases) 





2005 55.0% 225 10.8% 204 NR <0.001 Proportion 
HCV+ vs. 
HCV- 
Yes Adults at general 
internal medicine 












2005 2% 320 0% 307 NR 0.028†  Proportion 
HCV+ vs. 
HCV- 
Yes Adults tested for 
HCV in health 
system because of 
clinical suspicion 
Exchanging 
sex for money 
Nguyen et 
al.113 
2005 17.1% 225 2.0% 204 NR <0.001†  Proportion 
HCV+ vs. 
HCV- 
Yes Adults at general 
internal medicine 



















2005 37.8% 225 3.4% 204 5.39 
(2.01 to 
14.42)†  
<0.001  Proportion 
HCV+ vs. 
HCV- 
Yes Adults at general 
internal medicine 






Kaur et al.116 1996 45.7% 408 4.7% 5,373 7.29 
(4.74 to 
11.21)‡ 
NR Proportion in 
HCV+ vs. 
HCV- 
















































































































2005 20.7% 225 1.5% 204 9.76 
(2.50 to 
38.13)†  
<0.01†  Proportion 
HCV+ vs. 
HCV- 
Yes Adults at general 
internal medicine 







2005 3% 320 0.7% 307 NR†;  
3.4 









Adults tested for 
HCV in health 












2005 33.3% 225 6.9% 204 NR <0.001†  Prevalence in 
HCV+ vs. 
HCV- 
Yes Adults at general 
internal medicine 




















2000 45% 11 12% 1,369 NR <0.001† Proportion in 
HCV+ vs. 
HCV- 
Yes Adults enrolled in 
HMO 
Number of 




2005 11.7% 225 8.8% 204 NR <0.01†  Proportion with 
factor HCV+ 
vs. HCV- 
Yes Adults at general 
internal medicine 
clinic (controls) and 
hepatology clinic 
(cases) Number of 




2005 7.2% 225 17.2% 204 
Number of 




















































































































2005 37.8% 225 25.0% 204 
Number of 
sex partners – 
At least 50 
Nguyen et 
al.113 






2006 27% 179 63% 5,178 1.4 
(0.3 to 6.0)‡ 
NR 0-1 partners 
prevalence of 
HCV+ 
No General population 






2006 39% 179 14% 5,178 5.2 
(1.5 to 18.2)‡ 
NR 0-1 partners 
prevalence of 
HCV+ 
Yes General population 





2000 36% 11 7% 1,369 NR <0.001† Proportion in 
HCV+ vs. 
HCV- 





Kaur et al.116 1996 13.5% 542 6.5% 5,923 2.24 
(1.87 to 2.69)† 
NR Proportion in 
HCV+ vs. 
HCV- 









2005 8.6% 225 8.8% 204 NR >0.99†  Proportion 
HCV+ vs. 
HCV- 
No Adults at general 
internal medicine 


























































































































Yes General population 














Yes General population 














Yes General population 


















2006 29% 114 2.2% 5,254 3.7 
(1.7 to 7.9)‡ 
NR No drug use or 
only marijuana, 
HCV+ 
Yes General population 

















































































































2005 55.4% 225 18.1% 204 NR <0.00†  Proportion 
HCV+ vs. 
HCV- 
Yes Adults at general 
internal medicine 







2000 18% 11 2% 1,369 NR <0.05† Proportion in 
HCV+ vs. 
HCV- 






2005 39% 320 14% 307 NR†,  
1.4 









Adults tested for 
HCV in health 
system because of 
clinical suspicion 






2005 66.2% 225 28.4% 204 NR <0.001†  Proportion 
HCV+ vs. 
HCV- 
Yes Adults at general 
internal medicine 
clinic (controls) and 
hepatology clinic 
(cases) 





2005 15.3% 225 11.8% 204 NR 0.12†  Prevalence of 
factor in HCV+ 
vs. HCV- 
No Adults at general 
internal medicine 
clinic (controls) and 
hepatology clinic 





2005 59.0% 225 52.5% 204 






















































































































2005 10.4% 225 7.8% 204 
Alcoholism Fischer et 
al.114 
2000 18% 11 9% 1,369 NR NS † Proportion in 
HCV+ vs. 
HCV- 




use (at least 




2005 58% 320 49% 307 NR 0.034†  Proportion in 
HCV+ vs. 
HCV- 
Yes Adults tested for 
HCV in health 






Tattoo Nguyen et 
al.113 
2005 28.4% 225 16.2% 204 NR 0.003†  Proportion 
HCV+ vs. 
HCV- 
Yes Adults at general 
internal medicine 
clinic (controls) and 
hepatology clinic 
(cases) 
Tattoo Fischer et 
al.114 
2000 36% 11 6% 1,369 NR <0.001† Proportion in 
HCV+ vs. 
HCV- 
Yes Adults enrolled in 
HMO 
Tattoo Hand and 
Vasquez112 
2005 57% 320 22% 307 NR†; 
2.9 






Yes Adults tested for 
HCV in health 

















































































































Pierced ears Nguyen et 
al.113 
2005 59.0% 225 73.5% 204 NR 0.002†  Proportion 
HCV+ vs. 
HCV- 
Yes Adults at general 
internal medicine 
clinic (controls) and 
hepatology clinic 
(cases) 
Pierced ears Hand and 
Vasquez112 
2005 38% 320 38% 307 NR 0.998† Proportion 
HCV+ vs. 
HCV- 
No Adults tested for 
HCV in health 
system because of 
clinical suspicion 
Body piercing Fischer et 
al.114 
2000 45% 11 33% 1,369 NR NS† Proportion 
HCV+ vs. 
HCV- 
No Adults enrolled in 
HMO 
Body piercing Hand and 
Vasquez112 
2005 2% 320 3% 307 NR 0.737† Proportion in 
HCV+ vs. 
HCV- 
No Adults tested for 
HCV in health 









2000 0% 11 32% 1,369 NR <0.05† Proportion in 
HCV+ vs. 
HCV- 
Yes Adults enrolled in 
HMO 
* Odds ratios as reported in publication, unless otherwise specified 
** As reported in publication, unless otherwise specified 
† Univariate, unadjusted 
‡ Multivariate, adjusted for other factors 
¶ Calculated by ECRI Institute 
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Table 35. HIV Identification of Behavioral Risk Factors Data 












































































in Study? Population 


















HIV+ vs. HIV 
No Potential tissue 
donors, as reported 











2006 NR 10 NR 56 NR NS  Proportion in 
HIV+ vs. HIV 
No Potential tissue 
donors, as reported 







Illicit drug use Sanchez et 
al.103 
2006 NR 10 NR 56 NR NS  Proportion in 
HIV+ vs. 
HIV- 
No Potential tissue 
donors, as reported 





2006 NR 10 NR 56 NR NS  Proportion in 
HIV+ vs. HIV 
No Potential tissue 
donors, as reported 
by next of kin 
Alcohol use Sanchez et 
al.103 
2006 NR 10 NR 56 NR NS  Proportion in 
HIV+ vs. HIV 
No Potential tissue 
donors, as reported 



















2006 NR 10 NR 56 NR NS  Proportion in 
HIV+ vs. HIV 
No Potential tissue 
donors, as reported 




l Foreign travel Sanchez et 
al.103 
2006 NR 10 NR 56 NR NS  Proportion in 
HIV+ vs. HIV 
No Potential tissue 
donors, as reported 
by next of kin 
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2006 52% 21 4% 2,418 26.0 
(10.8 to 62.7)†¶ 
<0.001 Proportion in 
HIV+ vs. 
HIV- 





2008 53.8% 13 8.3% 577 15.11 
(4.11 to 55.91)† 





Yes General population of 
adults in New York 









2008 9% 229 NR 16,467 1.17 
(0.75 to 1.85)† 
NR Percent 
HIV+ vs. no 
injection 
drug use 






2006 13% 30 2% 4,938 7.3 
(2.5 to 21.6)†¶ 
0.001  Proportion in 
HIV+ vs. 
HIV- 
Yes General population 





2008 14.3% 21 1.2% 1,482 21.01 
(3.99 to 110.64)† 
SS Never used 
needle 
Yes General population of 



















2008 10% 229 NR 16,467 3.25 
(2.11 to 5.01)† 
NR No sex with 
HIV+ person 
in HIV+ 
Yes Hospital inpatients 
and outpatients 
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2008 22% 229 NR 16,467 0.79 
(0.41 to 1.53)† 
NR 0 partners, 
HIV+ 
No Hospital inpatients 
and outpatients 




2008 34% 229 NR 16,467 1.03 
(0.55 to 1.95)† 
NR 0 partners, 
HIV+ 
No Hospital inpatients 
and outpatients 




2008 12% 229 NR 16,467 1.09 
(0.54 to 2.20)† 
NR 0 partners, 
HIV+ 
No Hospital inpatients 
and outpatients 




2008 10% 229 NR 16,467 1.14 
(0.55 to 2.36)† 
NR 0 partners, 
HIV+ 
No Hospital inpatients 
and outpatients 





2008 17% 229 NR 16,467 0.92 
(0.47 to 1.80)† 
NR 0 partners, 
HIV+ 






2006 13% 31 26% 5,360 0.43 









2006 55% 31 71% 5,360 0.50 
(0.25 to 1.02)†¶ 
0.55 Proportion 
HIV+ vs. HIV 





2006 32% 31 4% 5,360 11.3 
(5.5 to 24.3)†¶ 
<0.001 Proportion 
HIV+ vs. HIV 






2008 30.0% 20 22.1% 1,346 1.41 
(0.59 to 3.37)† 
NS Single sex 
partner past 
year 
No General population of 
adults in New York 
City who have ever 
had sex 
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2008 16% 229 NR 16,467 2.17 
(1.49 to 3.15)† 
NR Prevalence 




Yes Hospital inpatients 
and outpatients 





2006 77% 31 58% 5,342 2.4 
(1.0 to 5.6)†¶ 
0.038 Proportion in 
HIV+ vs. 
HIV- 





2008 33.3 3 59.2 238 0.32 





No General population of 
adults in New York 
City who reported 
multiple sex partners 
during the past year 
and sexual activity 







2008 52% 229 NR 16,467 1.14 













2008 20% 229 NR 16,467 0.75 













2008 14% 229 NR 16,467 1.54 





No Hospital inpatients 
and outpatients 
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<6 weeks ago 
Mehta et 
al.109 





NR 9,589 1.83 
(0.94 to 3.57)† 
NR Did not 
have, HIV+ 





≥6 weeks ago 
Mehta et 
al.109 





NR 9,589 3.32 
(2.01 to 5.48)† 
NR Did not 
have, HIV+ 













NR 9,589 1.43 
(0.97 to 2.11)† 
NR Did not 
have, HIV+ 
No Hospital inpatients 
and outpatients 
Anal-receptive 




2008 2% 229 NR 16,467 2.29 
(0.93 to 5.65)† 
NR Did not 
have, HIV+ 
No Hospital inpatients 
and outpatients 
Anal-receptive 




2008 6% 229 NR 16,467 6.56 
(3.73 to 11.5)† 
NR Did not 
have, HIV+ 







2008 21% 229 NR 16,467 1.70 
(1.23 to 2.34)† 
NR Did not 
have, HIV+ 
Yes Hospital inpatients 
and outpatients 
Vaginal sex 
<6 weeks ago 
Mehta et 
al.109 
2008 43% 229 NR 16,467 0.33 
(0.22 to 0.50)† 



















































































in Study? Population 
 
Vaginal sex 
≥6 weeks ago 
Mehta et 
al.109 
2008 32% 229 NR 16,467 0.49 
(0.32 to 0.74)† 










2008 21% 229 NR 16,467 0.56 
(0.33 to 0.95)† 






















2006 47% 30 21% 4,938 3.3 
(1.6 to 6.9)†¶ 
<0.001  Proportion in 
HIV+ vs. 
HIV- 





1996 NR 35 NR 840 NR‡ SS Proportion in 
HCV+ vs. 
HCV- 









2000 36% 11 12% 1,369 12.5 
(2.3 to 69.0)† 
0.004 Proportion in 
HCV+ vs. 
HCV- 
Yes Adults enrolled in 
HMO 
* Odds ratios as reported in publication, unless otherwise specified 
** As reported in publication, unless otherwise specified 
† Univariate, unadjusted 
‡ Multivariate, adjusted for other factors 
¶ Calculated by ECRI Institute 
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Table 36. GRADE Table for Question 3 (Behavioral Risk Factors) 
Factor Virus 
Quantity and 
Type of Evidence Findings 
Starting 
Grade 










































































































HBV 2 OBS29,124 HBV was significantly associated with MSM in 
univariate analyses in two studies, one on the 
general population and one on college students. 
The college students study also performed an 
multivariate analysis and the association 
remained significant.124 
Low 0 0 0 0 0 1 0 0 Moderate 
HCV 2 OBS105,112 One blood donor study found a significant 
association between HCV and MSM upon 
univariate but not multivariate analysis.105 
A general population study found no association 
at all in univariate analysis.112 
Low 0 -1 0 0 0 0 0 0 Very Low 
HIV 2 OBS101,110 HIV infection was significantly associated with 
MSM in the general population in two univariate 
analyses. 




Type of Evidence Findings 
Starting 
Grade 






































































































HBV 5 OBS116,121,124-126 HBV was significantly associated with IDU in 
four studies, one of the general population116 and 
three of special populations.121,124,125 Three of 
these studies had large effect sizes, and the 
fourth came close.124 The fifth study, another 
special population study, did not find any 
association. This may be a statistical anomaly 
due to the very low prevalence of HBV and IDU 
in this obstetric population.126 The general 
population study and one of the special population 
studies125 performed multivariate analyses, the 
rest were univariate. 
One of the special population studies also 
considered steroid injection but did not find a 
significant relationship.124 
Low 0 0 0 0 0 0 0 0 Low 
HCV 7 OBS30,104-
106,112,114,116 
Three blood donor studies104-106 and four general 
population studies30,112,114,116 detected 
associations between IDU and HCV. All of these 
studies found large effect sizes. Two of the blood 
donor studies and three of general population 
studies30,112,116 performed multivariate analyses 
and determined IDU is an independent risk factor 
(the other studies performed univariate 
assessments only). 
One of the blood donor studies also considered 
past steroid injection use and did not find a 
significant association with HCV.104 




Type of Evidence Findings 
Starting 
Grade 
























































































HIV 3 OBS101,109,110 All three studies assessed IDU in the general 
population in univariate analyses. Two found a 
significant association with large effect sizes,101,110 
and the third did not find any association.109 






HBV 3 OBS103,121,125 None of the studies found an association between 
sex work (including sex bartering or sex for drugs) 
and HBV; however, one was a very low-quality 
tissue donor study based upon next-of-kin 
interviews,103 and the other two studied special 
populations.121,125 
Low 0 0 -1 0 0 0 0 0 Very Low 
HCV 4 OBS103,105,112,113 The very low-quality tissue donor study based 
upon next-of-kin data did not detect any 
association between HCV and sex work. The 
remaining three studies did. One multivariate-
analysis blood donor study105 and two univariate-
analysis general populations studies112,113 did 
detect significant associations. 
Low 0 0 0 0 0 0 0 0 Low 
HIV 1 OBS103 The very low-quality tissue donor study based 
upon next-of-kin data did not detect any 
association between HCV and sex work. 




Type of Evidence Findings 
Starting 
Grade 






































































































HBV 4 OBS116,117,121,124 In a multivariate analysis in the general 
population, having a sex partner IDU was 
significantly associated with HBV.116 In another 
general population study, recent sex or household 
contact with an IDU was associated with recent 
HBV infection.117 In univariate analysis it was 
significantly associated with HBV in one special 
population study124 but in not another.121  
Low 0 -1 0 0 0 0 0 0 Very Low 
HCV 4 OBS104,105,113,116 A univariate investigation of blood donors,105 
a multivariate investigation of blood donors,104 
a univariate investigation of people in the general 
population,113 and a multivariate investigation in a 
general population116 all found a significant 
relationship between HCV and having sex with an 
IDU. In all four studies the effect size was large. 
Low 0 0 0 0 0 1 0 0 Moderate 
HIV No Studies 
Identified 




















HBV 1 OBS121 Sex with a sex worker was not associated with 
HBV in a special population study.121 
Low 0 -1 -1 -1 0 0 0 0 Very Low 
HCV 3 OBS105,112,113 Sex with a sex worker was associated with HCV 
in a multivariate analysis of blood donors105 and 
in two univariate analyses of general 
populations.112,113 However, one of those general 
population studies also performed a multivariate 
analyses and did not detect a relationship.112 




Type of Evidence Findings 
Starting 
Grade 























































































HIV No Studies 
Identified 




























HBV 2 OBS124,126 Of the two univariate analyses of special 
population studies, one study found a significant 
relationship between having a sexual partner with 
hepatitis and having HBV,124 while the other 
did not.126 
Low -1 -1 -1 -1 0 0 0 0 Very Low 
HCV 2 OBS104,105 Two studies of blood donors, one with a 
multivariate analysis105 and one with a univariate 
analysis,104 found significant associations 
between having a sex partner with hepatitis and 
having HCV. 
Low 0 0 0 0 0 0 0 0 Low 
HIV 1 OBS109 On general population study performed a 
univariate analysis and found that the relationship 
between having a sex partner with HIV and 
having HIV was significant and large.109 








HBV 4 OBS103,117,121,124 The tissue donor study based upon next-of-kin 
interview did not associate HBV with a history of 
incarceration.103 Upon univariate analyses, 
one general population study117 and two special 
population studies did find a significant 
association.121,124 However, the general 
population study also performed a multivariate 
analysis and did not find an association.117 




Type of Evidence Findings 
Starting 
Grade 























































































HCV 4 OBS103-106,113 The tissue donor study based upon next-of-kin 
interview did not associate HCV with a history of 
incarceration.103 Three blood donor studies104-106 
found an association between HCV and history of 
incarceration, and of the two that performed 
multivariate analysis,105,106 one found it was an 
independent risk factor.105 Having ever been 
arrested was associated with HCV in the general 
population study.113 
Low 0 0 0 0 0 0 0 0 Low 
HIV 1 OBS103 The tissue donor study based upon next-of-kin 
interview did not associate HIV with a history of 
incarceration.103 
Low -1 -1 0 -1 0 0 0 0 Very Low 
















HBV 5 OBS 
29,116,117,124,125 
Various definitions of having multiple partners 
were associated with HBV in three general 
population studies29,116,117 and two special 
population studies.124,125 In all but one of these 
studies124 multivariate analyses were performed. 




Type of Evidence Findings 
Starting 
Grade 























































































HCV 6 OBS 
30,104,105,113,114,116 
As was the case for HBV, the studies testing the 
association of this factor with  HCV defined 
“multiple” using different thresholds. A blood donor 
study found that having multiple partners was a 
risk factor for HCV among women but not men in a 
multivariate analysis.105 The remaining 5 studies 
are all general population studies that performed 
univariate analyses and found associations 
between having multiple sex partners and having 
HCV.30,104,113,114,116 
Low 0 0 0 0 0 0 1 0 Moderate 
 
HIV 3 OBS101,109,110 All 3 studies performed univariate analyses on 
general populations using different definitions for 
“multiple” partners. The study with the highest 
threshold for defining “multiple” (>50) found an 
association with HIV,101 while the other two studies 
(one investigating having at least 10 lifetime109 
partners and other investigating having “multiple” 
partners in the past year) did not.110  

























HBV No studies - - - - - - - - - - NA 
HCV 2 OBS105,113 One blood donor study found a significant 
association between women who have sex with 
women and HCV infection, but in multivariate 
analysis this was only significant if the woman had 
had 2 or more same-sex partners. One general 
population study did not find an association 
between same-sex partners, not limited to MSM, 
in a univariate analysis.113 




Type of Evidence Findings 
Starting 
Grade 























































































HIV 1 OBS109 One general population study did detect an 
association between HIV and having a same-sex 
sex partner in a univariate analysis.109 
















HBV 2 OBS29,124 Age of 18 years or younger was not associated 
with HBV in general population multivariate 
analysis.29 Age at first intercourse of 15 years or 
younger was associated with HBV infection in a 
special population univariate analysis.124  
Low 0 -1 0 0 0 0 1 0 Low 
HCV 1 OBS30 In the general population, age of 17 years or 
younger was associated with HCV in a univariate 
analysis.30 In that study, the size of effect was 
larger for people who were younger than 11 or 12-
15 than for those 16-17 years old. 
Low 0 -1 0 0 0 0 1 0 Low 
HIV 1 OBS101 Age of 18 years or younger was associated with 
HIV in a univariate analysis of a general 
population.101 














 HBV 5 OBS 
29,103,121,124,125 
HBV was not associated with illicit non-injection 
drugs in the tissue donor study103 or two special 
population studies.121,125 A multivariate general 
population analysis29 and univariate special 
population analysis124 did find associations.  




Type of Evidence Findings 
Starting 
Grade 

























































































The tissue donor study did not find an association 
between HCV and drug use as reported by next of 
kin.103 Three blood donor studies did associate 
HCV with noninjection drug use,104-106 including in 
multivariate analyses in two of them.105,106 In a 
general population univariate analyses, use of 
snorting or inhaling nonprescription drugs,113 
inhaling cocaine,114 using intranasal cocaine,112 
and use of non-injection drugs other than 
marijuana30 were all associated with HCV. 
Two of these studies performed multivariate 
analyses,30,112 and one did not find the factor to 
be an independent predictor of HCV.112 
Low 0 0 0 0 0 0 0 0 Low 
HIV 2 OBS101,115 HIV was associated with ever using cocaine or 
street drugs in a univariate analysis101 and in a 
multivariate analysis115 among members of the 
general population. 






HBV 2 OBS103,125 HBV was not associated with alcohol use in a 
univariate analysis of tissue donors103 or alcohol 
use disorder in a multivariate analysis of a special 
population.125 
Low 0 0 0 -1 0 0 0 0 Very Low 
HCV 5 OBS102,103,112-114 HCV was associated with “heavy” alcohol use in 
heart donors102 and with having at least two units 
of alcohol per day in a general population.112 
HCV was not associated with alcohol use among 
tissue donors103 or having at least 5 alcoholic 
drinks weekly113 or alcoholism114 in general 
populations. All of these analyses were univariate. 




Type of Evidence Findings 
Starting 
Grade 























































































HIV 2 OBS103,114 HIV was associated with having an alcohol and/or 
(unspecified) drug problem in a general 
population114, but not with alcohol use among 
potential tissue donors.103 Both of these analyses 
were univariate. 






HBV 1 OBS103 No association was found between cigarette 
smoking and HBV among tissue donors.103 
Low -1 -1 0 -1 0 0 0 0 Very Low 
HCV 2 OBS102,103 A history of tobacco use was associated with HCV 
in heart donors,102 and cigarette smoking was 
associated with HCV in tissue donors.103 Both of 
these associations were made using univariate 
analyses.  
Low -1 0 0 0 0 0 0 0 Very Low 
 HIV 1 OBS103 No association was found between cigarette 
smoking and HIV among tissue donors.103 













HBV 5 OBS 
103,117,121,124,126 
Tattoos, piercing, and acupuncture (as collectively 
analyzed as one outcome and reported by next-of-
kin) were not associated with HBV in tissue 
donors.103 
Tattoos were not associated with HBV in one 
general population study117 or three special 
population studies.121,124,126 
Piercings were not associated with HBV in one 
general population study117 or two special 
population studies.121,124 
All analyses were univariate. 




Type of Evidence Findings 
Starting 
Grade 
























































































HCV 7 OBS103-106,112-114 Tattoos, piercing, and acupuncture (as collectively 
analyzed as one outcome and reported by next-of-
kin) were not associated with HBV in tissue 
donors.103 
3 blood donor studies104-106 and three general 
population studies112-114 detected significant 
associations between tattoos and HCV. Three 
performed multivariate analyses, and one found 
that tattoos were not an independent predictor106 
while the other two did.105,112 
Of 3 blood donor studies, HCV was associated 
with ear piercing among men in one study106 and 
pierced ears or body parts in another105in 
multivariate analyses, but not recent body piercing 
in a third with univariate analysis.104  
In univariate analyses of general populations, HCV 
was not associated with body piercing in two 
studies112,114 but was associated with ear piercing 
in a third study.113 
Low 0 0 0 0 0 0 0 0 Low 
 HIV 1 OBS103 Tattoos, piercing, and acupuncture (as collectively 
analyzed as one outcome and reported by next-of-
kin) were not associated with HBV in tissue 
donors.103 




Type of Evidence Findings 
Starting 
Grade 

































































































HBV 2 OBS103,117 International travel was not associated with HBV 
among tissue donors103 or with recent HBV 
infection in a general population.117 
Low 0 0 0 -1 0 0 0 0 Very Low 
HCV 3 OBS103-105 International travel was not associated with HCV 
among tissue donors.103 In blood donors neither 
recent travel outside the U.S.104 nor ever having 
lived outside the U.S.105 was associated with HCV. 
Low 0 0 0 0 0 0 0 0 Low 
HIV 1 OBS103 International travel was not associated with HIV 
among tissue donors.103 
Low -1 -1 0 -1 0 0 0 0 Very Low 
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Table 37. Prevalence of Behavioral Risk Factors 
Category Risk Factor Citation Year Prevalence N = in population Population 






































Male-to-male sex McQuillan et al.101 2006 3.7% 2,439 men General population 
Men who have sex with men, 
history of 












Ever used a needle for drugs Nguyen et al.110 2008 1.4% 1,505 General population in N.Y.C. 
Lifetime injection drug use 
(participants aged 20-59) 
Armstrong et al.30 2006 1.7% 5,368 General population, nationwide 
Injection drug use Mehta et al.109 2008 7.9% 16,696 Patients in urban medical care center 
Injection drug use Kaur et al.116 1996 3.5% 7,538 Volunteers from general population, 
mainly urban 
No use of needle exchange 
program among injection drug 
users 





k Exchanged sex for money or 
drugs 
Mehta et al.109 2008 2.3% 16,696 Patients in an urban medical care center 
199 














Sexual partner with HIV Mehta et al.109 2008 3.6% 16,696 Patients in urban medical care center 
Sex with IV drug user Kaur et al.116 1996 5% 6,562 Volunteers from general population, mainly 
urban 
Sex with a commercial sex 
worker 














Sex with same or both 
genders (asked both men and 
women) 
Mehta et al.109 2008 8.2% 15,586 Patients in urban medical care center 
Lifetime number of sexual 
partners 10+ 
(participants aged 18-59) 
Armstrong et al.30 2006 29% 5,357 General population, nationwide 
Lifetime number of sexual 
partners 2+ 
McQuillan et al.101 2006 74% 5,391 General population, nationwide 
Lifetime number of sexual 
partners 2-49 
Nguyen et al.110 2008 74% 1,469 General population in N.Y.C. 
Lifetime number of sexual 
partners 50+ 
McQuillan et al.101 2006 3.5% 5,391 General population, nationwide 
Lifetime number of sexual 
partners 50+ 
Nguyen et al.110 2008 6.6% 1,469 General population in N.Y.C. 
Sex with multiple partners Kaur et al.116 1996 26% 7,325 Volunteers from general population, mainly 
urban 
Sex with multiple partners 
during previous year 
Nguyen et al.110 2008 22% 1,368 General population in N.Y.C. 
Age at first intercourse 
younger than 18 years 
(participants aged 18-59) 
Armstrong et al.30 2006 58% 5,054 General population, nationwide 
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Category Risk Factor Citation Year Prevalence N = in population Population 
 
Age at first intercourse 
younger than 18 years 
















 Lifetime drug use 
other than marijuana 
(participants aged 20-59) 
Armstrong et al.30 2006 17% 5,683 General population, nationwide 
Ever used cocaine/ 
street drugs 
McQuillan et al.101 2006 21% 4,969 General population, nationwide 




Table 38. GRADE Table for Question 3: Prevalence of Behavioral Risk Factors 
Factor 
































































































Men who have 
sex with men 
2 OBS*101,110 In two general population studies, one 
reported that 3.7% of men have sex with 
another man,101 while the other reported 
that 9.3% have a history of having sex 
with another man.128 
High 0 -1 -1 0 0 0 0 0 Low 
Injection drug 
abuse 
4 OBS30,109,110,116 All four studies assessed general 
populations. Reported prevalences of 
injection drug use were 1.4%,110 1.7%,30 
3.5%,116 and 7.9%.109 The lower two 
estimates were derived from NHANES 
data, and the higher two were drawn 
from patients and volunteers in urban 
areas. 
(Of the injection drug users in one study, 
63.2% reported they did not use needle 
exchange programs.109 ) 
High 0 -1 -1 0 0 0 0 0 Low 
Sex Work 1 OBS109 One general population study reported 
2.3% of participants reported 
exchanging sex for money or drugs.109 





1 OBS116  Among general population volunteers 
from a mainly urban area, 5% reported 
having sex with an injection drug use.116  
High 0 -1 -1 0 0 0 0 0 Low 
202 
Factor 



































































































1 OBS109 In the same population, 7.4% reported 
sex with a commercial sex worker.109 





2 OBS110,116  26% of volunteers in one study reported 
having sex with multiple partners,116 
while 22% of NHANES participants 
reported having multiple sex partners 
during the previous year.110 
High 0 0 -1 0 0 0 0 0 Moderate 
Multiple Sex 
Partners: At 
least 2 partners 
2 OBS101,129 74% reported having sex with at least 
two partners,101 74% reported having 
sex with 2-49 partners.110 
High 0 0 -1 0 0 0 0 0 Moderate 
Multiple Sex 
Partners: At 
least 50 partners 
2 OBS101,110 In one study, 3.5% reported having at 
least 50 sex partners,101 while in another 
6.6% did.110 
High 0 -1 -1 0 0 0 0 0 Low 
Age at first 
intercourse (<18 
years) 
2 OBS30,101 The proportion of adults who reported 
having sex at age 18 or younger were 
58%30 and 59%101 in two general 
population studies. 





1 OBS109 8.2% of men and women reported 
having sex with same or both 
genders.109 




1 OBS8 Among potential living donors, 5.5% had 
unspecified ongoing drug abuse.8 
High 0 -1 0 -1 0 0 0 0 Low 
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Factor 



































































































3 OBS30,101,110 In the general population, 17% reported 
lifetime use of drugs other than 
marijuana,30 18% reported ever having 
used any drugs,110 and 21% reported 
ever using street drugs/cocaine.101 
High 0 0 -1 0 0 0 0 0 Moderate 
Alcohol 1 OBS102 Among heart donors, 20% reportedly 
drank alcohol heavily.102 
High -1 -1 0 0 0 0 0 0 Low 
Tobacco 1 OBS102 Among heart donors, 36% reportedly 
used tobacco.102 




Question 4: Results 
In this section, data on nonbehavioral potential risk factors including signs and symptoms indicative of 
infection, potential exposure, co-morbidities, and demographic factors are presented. Information 
regarding exclusionary factors listed in the 1994 guideline is presented first, and then information 
regarding additional factors for which at least two studies provided evidence regarding the same factor is 
presented. All of the data related to the identification of risk factors is provided in Table 39 (HBV), 
Table 40 (HCV), Table 41 (HIV), and Table 42 (GRADE tables). Prevalence information is provided in 
Table 43. 
Exclusionary Criteria from 1994 Guideline 
People with Hemophilia or Related Clotting Disorder who Received Clotting Factor Blood Products 
The 1994 guideline excludes from donating “Persons with hemophilia or related clotting disorders who 
have received human-derived clotting factor concentrates.” We identified zero studies that studied 
whether this factor was associated with an increased prevalence of infection. This may be due to the 
relative rarity of having hemophilia or a related blood clotting disorder in the populations included in the 
evidence base for these questions. However, we did identify a large number of studies that considered the 
association between blood transfusions and infection regardless of any underlying disease. For more 
information, see Receipt of Blood Transfusion under Risk Factors Identified in the 2009 Literature 
Search. 
Exposure to Infected or Suspected Blood 
The 1994 guideline excludes from donating “Persons who have been exposed in the preceding 12 months 
to known or suspected HIV-infected blood through percutaneous inoculation or through contact with an 
open wound, nonintact skin, or mucous membrane.” 
Only one of the studies specifically inquired as to whether patients had been exposed to blood known or 
suspected to be infected. Among embalmers, Turner et al. did not find an association between needlestick 
injury with exposure to recognized HBV infection during embalming and HBV infection.
127
 
GRADE Summary: This evidence is rated as “very low” because of indirectness, imprecision, and lack of 
consistency. 
Many of the studies did, however, ask about exposure to blood in general, including by needlestick 
injuries and in other accidents. See Nonspecific exposure below for information on these factors.  
Children 
The nonbehavioral exclusion criteria for children are the same as listed in Question 3. We did not identify 
any information regarding the two (above) nonbehavioral exclusion criteria in children or in children of 
mothers with such factors, or any other clinical factors. 
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Additional Potential Risk Factors Identified in the 2009 Literature Search 
In addition to the factors identified in the 1994 guideline, we extracted data on all other reported risk 
factors identified in the literature. The following sections describe the evidence regarding the various 
factors and infection reported by at least two studies. 
Signs and Symptoms 
An objective of this section was to identify nonbehavioral factors that could be predictive of infection, 
especially acute infection during the window period before diagnostic tests could recognize the infection. 
However, extremely little data on such signs and symptoms were identified.  
The only signs identified were associated with HCV infection. In blood donors, alanine aminotransferase 
(ALT)  reactivity was associated with infection by Orton et al.
104
 In a general young adult population 
(aged 18 to 49), serum ALT of >40 U/L was associated with HCV by Armstrong et al.
30
 “Elevated liver 
enzyme” was associated with HCV in adults comprising individuals at risk for HCV, and healthcare 
workers enrolled in a health maintenance organization (HMO) in Fischer et al.
114
 In addition, jaundice 
was associated with HCV in adults in a general medical clinic by Nguyen et al.
113
 
GRADE Summary: Although several signs were reported, they are all different and therefore must be 
considered in isolation. The association of HCV with jaundice, ALT reactivity, and elevated ALA were 
large effect sizes and therefore rated as low. The effect size for “elevated liver enzyme” was not large, 
and therefore rated as very low.  
Prevalence: In a general population, 9% of survey respondents had ALT >40 U/L.
30
  
GRADE Summary of Prevalence: The prevalence estimate was rated as low due to indirectness and lack 
of proof of consistency. 
Receipt of Blood Transfusion 
Although no studies reported on risk in people with clotting disorders or who have received clotting factor 
blood products, many did investigate risk of infection associated with blood transfusion. Two of three 
studies associated blood transfusion with HBV, and all eight studies associated it with HCV.  
HBV: Blood transfusion was associated with HBV infection in a general population in Kaur et al.,
116
 
as was blood transfusion before 1991 among college students in Hwang et al.
124
 Blood transfusion was 
not associated with HBV in the low prevalence obstetric patients study by Butterfield et al. (1990).
126
 
HCV: All 8 studies that looked at this factor did find some association with transfusion and HCV 
infection. Receiving a blood transfusion was independently associated with HCV in three studies of blood 
donors, Conry-Cantilena et al.,
106
 Murphy et al. (2000),
105
  and Murphy et al. (1996).
107
 In Murphy et al. 
(2000), the association was only significant among donors who had never injected drugs.
105
  





 and Kaur et al.,
116
, and in the two studies that calculated multivariable models,
112,116
 
the association was independent. In the general population, Armstrong et al. found that the relationship 
between HCV and blood transfusion before 1992 was independent,
30
 and Fischer et al. detected an 
association but did not test whether the risk factor was independent.
114
 Sex with a blood transfusion 




Some studies combined having received a blood transfusion with other outcomes. Being a blood 
transfusion recipient or donor (data not reported separately) as reported by next-of-kin was not associated 
with an increased risk of HBV, HCV, or HIV among potential tissue donors by Sanchez et al.
103
 Either 
receiving a blood transfusion or having a household contact with a person who had was not associated 
with acute HBV by Alter et al.
117
 We did not consider these outcomes sufficiently similar to group with 
receipt of blood transfusion only. 
GRADE Summary: The evidence for HBV was mostly indirect, and downgraded to very low rating 
accordingly. For HCV, the evidence consistently pointed to an association with transfusion with large 
magnitude, and was rated as moderate. 
Prevalence: Among general population survey respondents, 6% of those aged 20 to 59 years (in 2006) 
reported having a blood transfusion before 1992, and 16% of those aged at least 60 years did.
30
 Among 
volunteers from an urban area, 20% reported having ever had a blood transfusion.
116
 
GRADE Summary of Prevalence: The evidence of these prevalence estimates were rated as low due to 
indirectness and lack of proof of consistency. 
Nonspecific Exposure 
Although only one study asked participants whether they had ever been exposed to infected or potentially 
infected blood, many studies asked about exposure to blood without regard to any knowledge about the 
infection status of the blood. Besides hemodialysis, most of these factors were not found to be 
consistently associated with infection. 
Accidental Needle Stick 
According to data collected from next-of-kin, accidental needle sticks were not associated with HBV, 
HCV, or HIV among potential tissue donors in Sanchez et al.
103
 
In a general population study by Kaur et al., needlestick injuries were actually associated with lower 
prevalence of HBV and HCV infection.
116
 This may be because a substantial proportion of the enrollees 
were healthcare workers, and in that study healthcare workers had a lower prevalence of HBV than the 
group as a whole. Needlestick injuries among healthcare worker blood donors in Conry-Cantilena et al. 
were not associated with HCV either.
106
 However, “bloody” needlestick injuries in a medical setting was 
associated with an increased prevalence of HCV in Murphy et al. (2000).
105
 
GRADE Summary: For all three viruses this evidence was rated as “very low.” For HBV this was due to 
lack of precision, for HCV it was due to inconsistency, and for HIV it was due to low quality, 
imprecision, and lack of consistency.  
Hemodialysis 
Most studies found an association between hemodialysis and HBV or HCV. Hemodialysis was associated 
with HBV among volunteers from the general population by Kaur et al.
116
 and among college students by 
Hwang et al.
124
 In studies that enrolled people from the general population, HCV infection was associated 
with hemodialysis  in Kaur et al.,
116
 and with “kidney dialysis” in Nguyen et al,
113
 but not with 
hemodialysis in Hand and Vasquez.
112
 The duration of administration of dialysis was not specified. 
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GRADE Summary: The evidence associating HBV with hemodialysis was rated as “moderate” because 
the size of the association in the special population was large. For HCV, strength of evidence was low. 
Surgery 
The relationship between surgery and infection was inconsistent. Based upon next-of-kin data for 
potential tissue donors, Sanchez et al. did not find any associations between HBV, HCV, or HIV and 
surgeries.
103
 In the general population, surgery was associated with a lower HBV prevalence by 
Kaur et al.,
116
 and surgery during the last six months was not associated with acute HBV in Alter et al.
117
 
Having surgery or a medical procedure in the six months before blood donation was not associated with 
HCV in Orton et al.,
104
 and having a history of surgery was not associated with HCV in general 
population studies by Fischer et al.
114
 or Kaur et al.
116
 However, lifetime history of surgery or sutures was 
associated with elevated HCV prevalence in blood donors in Murphy et al. (2000).
105
  
GRADE Summary: For all three viruses, the evidence was inconsistent and rated as “very low.” For HIV 
the evidence base was also of very low quality and imprecise. 
Organ and Corneal Transplantation Recipients 
No organ transplantation studies were identified that met the inclusion critiera. Receipt of corneal 
transplantation was not associated with a greater risk of HBV, HCV, or HIV in the tissue donor study by 
Sanchez et al.
103
, or with HBV among psychiatric inpatient veterans in the study by Tabibian et al.
121
  
GRADE Summary: For all three viruses, the evidence was rated as very low due to imprecision. For HCV 
and HIV the evidence was also of very low quality with no proof of consistency.  
Acupuncture 
Acupuncture during the last six months was not associated with an increased incidence of acute HBV in 
Alter et al.
117
 or increased prevalence of HBV among psychiatric inpatient veterans in Tabibian et al.,
121
 
or with HCV among blood donors in Conry-Cantilena et al.
106
 or Murphy et al.,
107
 or people in a general 
population in Hand and Vasquez et al.
112
  
GRADE Summary: For both HBV and HCV, the GRADE was not decreased and the evidence was rated 
as low. 
Dental Work 
Dental work within the last six months was not associated with acute HBV in Alter et al.
117
 Dental work 
was not associated with HCV among blood donors in Murphy et al.
105
; nor was having dental work in the 
six months before donation in Orton et al.
104
  
GRADE Summary: For HBV, the evidence was downgraded due to imprecision and rated as very low. For 
HCV, the evidence was not downgraded and was rated as low. 
Blood Draws 
Blood draws should not expose patients to blood (and is probably a proxy for other risk factors). 
Sanchez et al. did not find an association between HIV testing and HIV, HBV, or HCV among tissue 
donors, based upon next-of-kin interviews.
103
 However, Nguyen et al. (2005) did find an association 
between having had a blood test for HBV and having an HCV infection in a univariate analysis of adults 
in the general population.
113
 Similarly, being a blood donor should not pose a direct infectious risk. In the 
208 
same study, Nguyen et al. found that being a blood donor was associated with reduced risk of HCV, and 
that having been rejected as a blood donor was associated with an increased risk of HCV.
113
  
GRADE Summary: Because evidence was imprecise for each of the viruses and also inconsistent for HBV 
and HIV, the evidence regarding blood draws was rated as “very low.” 
Other Blood Exposure 
Neither bloody object contact in Tabibian et al.
121
 nor combat exposure in Butterfield et al. (2004)
125
 were 
associated HBV among psychiatric inpatient veterans. Having been “stuck” or “cut” with a blood object 
was independently associated with HCV among blood donors in Murphy et al. (2000)
107
 Among blood 
donors in Orton et al.
104
 blood exposure during fighting, by biting, at an accident site, or during a 
manicure in the last six months was associated with HCV, but not during a haircut in the last six months. 




We report these factors here because of their relevance but did not rate the GRADE for these “other” 
outcomes due to lack of replication of the various factors. 
Household Exposure 
Whether hepatitis infection among other household members was a risk factor for exposure was 
investigated in several studies, with inconsistent findings. Having household contact with someone with 
hepatitis was associated with HBV among college students in Hwang et al.
124
, as was a family history of 
HBV among Asian Americans in Lin et al.
123
 Having a household member with hepatitis was not 
associated with HBV in an obstetric population in Butterfield et al.;
126
 nor was being the wife of a man 
with HBV among Korean American church goers in Hann et al.
122
 Among blood donors in Murphy et al., 
living with someone with hepatitis or having a relative with hepatitis was not associated with HCV 
infection, but living with a transfusion recipient was.
105
 In general population studies, having at least 
one family member treated for viral hepatitis was not associated with an increased risk of HCV in 
Fischer et al.,
114
 but having at least one family member with HCV was in Nguyen et al.
113
  
Sharing a razor or toothbrush with another household member was not associated with HBV members of 
the general population in Alter et al.
117
 However, sharing a toothbrush or razor with person(s) unspecified 
was associated with HCV among blood donors in Murphy et al.
105
  
GRADE Summary: All of the evidence pertaining to household exposure and HBV and HCV infection 
was inconsistent, and therefore rated as very low. For HBV the evidence was also indirect: all of it came 
from special population studies. 
Other Infections 
Sexually transmitted infections were nearly universally associated with increased risk of HBV, HCV, or 
HIV. HBV surface antigen positivity was associated with HCV infection among heart donors in Gasink et 
al.
102
 Among college students, HBV infection was associated with having had a sexually transmitted 
disease (STD) in Hwang et al.
124
 Among blood donors, HCV was significantly associated with history of 
STD in Conry-Cantilena et al.
106
 and Murphy et al. (2000),
105
  and with having a STD within six months 
of donating in Orton et al.,
104
 and with seropositivity for other reactive infectious diseases in Orton et 
al.
104
 and Murphy et al. (1992).
107
 Among people from general populations, having past treatment for 
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STDs was not associated with HCV in Nguyen et al.,
113
 but having herpes simplex virus (HSV) infection 
was in Armstrong et al.
30
 HIV infection was not associated with HCV infection upon univariate analysis 
of a general population in Hand and Vasquez.
112
 Diagnosis of STD in Mehta et al.,
109
 HSV-2 in 
McQuillan et al. (2006),
101
 HSV-2 in Nguyen et al.,
110
 and syphilis or other infection not apparently 
related to HIV in Alpert et al.,
115
 were all associated with HIV in general populations. Rabies exposure 
was not associated with any of the viruses in the tissue donor study by Sanchez et al.
103
 
GRADE Summary: For HBV and HIV, the evidence associating them with another infection was rated as 
low. For HCV the evidence was rated as very low due to inconsistency. 
Prevalence: Antibodies to HSV-2 were detected in 19% of general nationwide population aged 18 to 
49 years,
30
 and 28% of New Yorkers.
110




GRADE Summary of Prevalence: The estimate of HSV-2 infection was rated as moderate due to 
indirectness. For unspecified STD it was rated as low due to indirectness and lack of proof of consistency. 
Demographic Factors 
Sex 
Male sex was not consistently associated with an increased risk of infection. Males had higher rates of 
HBV than women in studies that considered the general population,
116
 psychiatric inpatient veterans 
(of whom nearly all were male),
121
 and Asian Americans,
123





 females had higher rates of HBV, and among children who had received a 
blood transfusion, in Luban et al., rates were not significantly different.
118
 Among heart transplant donors, 
being male was associated with an increased risk of HCV.
102
 In one study of blood donors, being male 
was associated with an increased risk of HCV,
107
 but among two others it was not.
104,106
 In four general 
population studies, significantly higher proportions of males had HCV infection in four
30,108,113,116
 out of 
five studies.
114
 Male sex was not associated with HIV in three general population studies.
109-111
 
GRADE Summary: For HBV and HCV, the evidence was rated as very low due to inconsistent findings. 
For HBV, the evidence was also indirect because it was drawn primarily from special population studies. 
For HIV, the evidence was rated as low because lack of association was consistently found. 
Age 
Studies assessed the relationship between age and infection in a variety of different ways. While some 
used mean age, others used various cutoffs (such as older or younger than 30 years) or categorization 
(such as age by decade). Older age was associated with a greater rate of HCV among heart transplant 
donors in Gasink et al.,
102
 but inconsistently associated with HCV among blood donors, HCV or HIV in 
the general population, or HBV in special subpopulations. 
GRADE Summary: Evidence on age was collected using inconsistent methods among studies, clouding 
any potential relationship between age and infection. For HBV the evidence was inconsistent and came 
primarily from special population studies, and was therefore rated as “very low.” The evidence for HCV 
and HIV was also inconsistent and rated as very low.  
210 
Race or Ethnicity, and National Origin 
HBV: Higher HBV prevalence in the general population was associated with non-Hispanic Black 
ethnicity compared with non-Hispanic White ethnicity in McQuillan et al.
29
 In the same study, being 
Mexican-American was associated with no increase in prevalence compared with being non-Hispanic 
white. In another general population study, the prevalence of HBV was lower among white and Hispanic 
individuals than other races.
116
 The rest of the studies examined subpopulations. Prevalence was higher 
for African Americans compared to white people among psychiatric inpatient veterans in Butterfield et 
al.
125 
and among college students
 
in Hwang et al.,
124
 but not among inpatient veterans in Tabibian et al.
121
 
Hispanic or Latino ethnicity was not associated with HBV among psychiatric inpatient veterans in 
Tabibian et al.
121
 or college students in Hwang et al.
124
Among college students in Hwang et al., Asian 
students had higher rates of HBV.
124
 
HBV was associated with birth in a Southeast Asian or African country in a general population study by 
Kaur et al.
116
  but not in a study of Asian Americans by Lin et al.
123
  Acute HBV was not associated with 
birth in an area with a high endemic rate of HBV or having a household contact with someone who was 
born in an endemic area in Alter et al.
117
  Among Asian Americans, being born in the U.S. was found to 
be protective in children in Hann et al.
122
  and in Asian Americans of any age in Lin et al.
123
 Any 
international birth was associated with increased prevalence of HBV in McQuillan et al.
29
 
HCV: Among heart donors in Gasink et al., ethnicity was not associated with HCV.
102
 Among blood 
donors, two studies associated increased prevalence with “black” race
106,107
, and two studies found 
inconsistent relationships between Hispanic ethnicity and HCV.
104,107
 However, black or Hispanic 
ethnicity was not associated with infection in general population studies,
30,108,113
 Orton et al.
104
 found that 
being born in a country other than the U.S. was associated with HCV among blood donors, but Murphy et 
al.
107




HIV: HIV was not associated with Asian
109,110
 or Hispanic ethnicity
110,111





 studies. Being a Spanish speaker was not  associated with prevalence of 
HIV among public emergency room patients in Zetola et al.
111
 
GRADE Summary: All of the evidence regarding race or ethnicity was rated as very low. For HBV this 
was because most of the data came from special subpopulation studies and because some information was 
inconsistent. For HCV and HIV, most studies found no relationship between race or ethnicity and 
infection, but there were some inconsistencies. Very low evidence ratings for national origin/birthplace 
and preferred language were assigned for the same reasons. 
Occupation 
Unemployment was significantly associated with recent HBV infection in the general population in a 
multivariate analysis, in Alter et al.
117
 Some of the studies investigated whether occupational exposure to 
blood was associated with hepatitis; however, findings were inconsistent. Being a healthcare worker with 
frequent blood exposure was associated with an increased prevalence of HBV in college students in 
Hwang et al.
124
, but being a healthcare worker was not associated with HBV in a general population 
studies by Kaur et al.
116
 or McQuillan et al.
29
 or having been a healthcare worker in psychiatric inpatient 
veterans in Tabibian et al.
121
 or a low-prevalence obstetric population in Butterfield et al.
126
 Among blood 
donors, occupational blood exposure was associated with HCV infection in Murphy et al.,
105
 but medical 
211 
or dental job or public safety job with frequent blood contact were not in Orton et al.
104
 In the general 
population, work contact with blood was not associated with increased HCV in Fischer et al.
114
, and being 
a healthcare worker was actually associated with a lower rate of HCV in Kaur et al.
116
 Services in the 
armed forces was not associated with HBV in McQuillan et al.
29





 Having a job at a prison was associated with HCV in Nguyen et al.
113
 
GRADE Summary: Most of the occupational information pertained to healthcare workers. Most evidence 
did not associate employment in healthcare with infection. For HBV this finding was consistent and rated 
as low. An additional study considered the association between HBV and military service and did not find 
a relationship and was rated very low for imprecision. For HCV associations with health care job or job 
with blood exposure was inconsistently related with HCV and was rated as very low due to inconsistency 
and imprecision. A lack of association between HCV and serving in the armed forces was found; this 
evidence was rated as very low due to imprecision. Findings associating HCV and working in public 
safety were inconsistent and therefore rated as very low. 
Education 
Inconsistent evidence suggests lower educational level attainment may be associated with infection. Less 
than a high school education was associated with a higher prevalence of HBV in the general population 
by McQuillan et al.
29
, but total years of education was not associated with HBV among psychiatric 
inpatient veterans in Tabibian et al.
121
 College students enrolled in 4-year colleges had lower rates of 
HBV than students enrolled in 2-year colleges in Hwang et al.
124
 Lower educational attainment was 
associated with HCV in blood donors in Orton et al.
104
 and Conry-Cantilena et al.
106
 and in the general 
population in Armstrong et al.
30
 However, this association was not found in the general population by 
McGinn et al.
108
 or Nguyen et al.
113
 An association between HIV and education was not detected in 
general population studies McQuillan et al.
101
 or Mehta et al.
109
 
GRADE Summary: The association between lower educational level and infection was inconsistent for 
HBV and HCV. For HBV the evidence was also indirect, and so it was rated as very low. For HCV, the 
evidence was rated as very low because there was a dose-response association. For HIV, information was 
consistent but imprecise and therefore rated as very low. 
Economic Factors 
Being homeless was not associated with an increased risk of HBV among psychiatric inpatient veterans in 
Tabibian et al.
121
 Ever having been homeless was associated with an increased risk of HCV in adults 
attending general medicine or hepatology clinics in Nguyen et al.
113
 and being homeless was associated 
with an increased prevalence of HIV in public hospital emergency room patients in Zetola et al.
111
 Neither 
income or nor living in poverty was associated with HCV in Nguyen et al.
113
 or Armstrong et al.
30
 or with 
HIV in McQuillan et al.
101
  
GRADE Summary: Economic factors were inconsistently associated with HCV and HIV, and imprecisely 
associated with HBV and HCV. For all three viruses, the evidence was rated as very low. 
Health Insurance 
Type of health insurance (Medicaid, Medicare, private, or self-pay) was significantly associated with 




 Patients with no health insurance had higher prevalence of HIV in one study of hospital patients, 
Mehta et al.,
109
 but not in another such study, Zetola et al.
111
 
GRADE Summary: The evidence relating health insurance and infection was inconsistent for HCV and 
HIV and imprecise for HIV and therefore rated as very low for both. 
Marital Status 
Being married may be associated with a lower risk of infection. Being divorced or separated was 
associated with a higher prevalence of HBV in McQuillan et al., a general population study, than any 
other status.
29
 Being married was associated with a lower rate of HCV among blood donors in Murphy et 
al.
105
 and a lower prevalence of HIV in the general population in McQuillan et al.
101
 Marital status was 
not associated with HBV infection among psychiatric inpatient veterans in Butterfield et al.
125
 
GRADE Summary: One study for each HCV and HIV found a relationship between being married and 
having a lower risk of infection and were rated as low. For HBV, infection was higher among divorced or 
single persons in a general population study. A special population study did not find any association 
between marital status and infection, but since it was a special population study we did not detract from 
the GRADE and rated it as low. 
213 
Evidence Tables for Question 4 
































































































































No Potential tissue donors, 

















2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 





2006 NR 47 NR 56 NR NS Proportion 
in HBV+ 
vs. HBV- 
No Potential tissue donors, 
as reported by next of kin 
Surgeries Sanchez et 
al.103 
2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 
as reported by next of kin 
HIV testing Sanchez et 
al.103 
2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 














































































































Liver disease Sanchez et 
al.103 
2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 
as reported by next of kin 
Treatment by 
physician in 
last 2 years 
Sanchez et 
al.103 
2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 





2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 





2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 





2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 
as reported by next of kin 
Medications Sanchez et 
al.103 
2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 
as reported by next of kin 
Toxic exposure Sanchez et 
al.103 
2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 






2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 

















































































































2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 





2006 NR 47 NR 56 NR NS Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 
as reported by next of kin 
Heart disease Sanchez et 
al.103 
2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 
as reported by next of kin 
Hypertension Sanchez et 
al.103 
2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 
as reported by next of kin 
Kidney disease Sanchez et 
al.103 
2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 






2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 
as reported by next of kin 
Cancer history Sanchez et 
al.103 
2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 





2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 















































































































2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 





2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 





2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 





2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 





2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 
as reported by next of kin 
Ocular disease Sanchez et 
al.103 
2006 NR 47 NR 56 NR NS  Proportion 
in HBV+ 
vs. HBV 
No Potential tissue donors, 




















































































































Kaur et al.116 1996 23% 1,432 18.2% 6,107 1.27 
(1.04 to 1.57)‡ 
NR  Proportion 
in HBV+ 
vs. HBV- 







Alter et al.117 1989 5% 76 12% 152 NR NS† Proportion 
in HBV+ 
vs. HBV- 
No General population adults 
with no obvious cause of 
















Kaur et al.116 1996 15.7% 1,406 19.9% 5,982 0.75 
(0.64 to 0.87)† 






Volunteers from general 
population (Note that a 
larger proportion of 
participants than would be 
expected in the general 
population were health 
care workers, and that in 
this population health 
care workers had 
significantly lower HBV 
prevalence) 
Hemodialysis Kaur et al.116 1996 37.5% 1,396 18.7% 6,033 2.60 
(1.14 to 5.96)† 
NR  Proportion 
in HBV+ 
vs. HBV- 
Yes Volunteers from general 
population 
Surgery Kaur et al.116 1996 17.9% 1,446 21.6% 6,147 0.79 
(0.70 to 0.89)† 



















































































































last six months 
Alter et al.117 1989 4% 76 3% 152 NR NS† Proportion 
in HBV+ 
vs. HBV- 
No General population adults 
with no obvious cause of 
acute HBV and matched 
controls 
Hospitalization, 
last six months 
Alter et al.117 1989 13% 76 8% 152 NR NS† Proportion 
in HBV+ 
vs. HBV- 
No General population adults 
with no obvious cause of 
acute HBV and matched 
controls 
Acupuncture, 
last six months 
Alter et al.117 1989 1% 76 0% 152 NR NS† Proportion 
in HBV+ 
vs. HBV- 
No General population adults 
with no obvious cause of 





last six months 
Alter et al.117 1989 16% 76 17% 152 NR NS† Proportion 
in HBV+ 
vs. HBV- 
No General population adults 
with no obvious cause of 




last six months 
Alter et al.117 1989 13% 76 22% 152 NR NS† Proportion 
in HBV+ 
vs. HBV- 
No General population adults 
with no obvious cause of 




last six months 
Alter et al.117 1989 5% 76 6% 152 NR NS† Proportion 
in HBV+ 
vs. HBV- 
No General population adults 
with no obvious cause of 





 Vaccinated for 
hepatitis B 
Kaur et al.116 1996 7.8% 1,356 22% 8,509 0.40 
(0.31 to 0.52)‡ 






































































































































1989 NR 14 NR 94 NR NR† Prevalence 
HBV+ vs. 
no injury 
No Embalmers in high-













2006 4% 269 2.4% 3,999 RR: 
1.80 
(1.04 to 3.11)†  
<0.05  Prevalence 
HBV+ vs. 
HBV- 





1990 0% 12 2.5% 1,454 1.54 





















2008 0% 40 1% 89 NR NS†  Prevalence 
in HBV+ vs. 
HBV- 
No Psychiatric inpatient 
veterans 
Hemodialysis Hwang et 
al.124 
2006 0.7% 270 0.05% 4,045 RR: 
7.96 
(2.97 to 21.35)† 
<0.05  Prevalence 
HBV+ vs. 
HBV- 
Yes College students 
Acupuncture Tabibian et 
al.121 
2008 15% 40 17% 89 NR NS† Prevalence 
in HBV+ vs. 
HBV- 






2008 35% 40 20% 89 NR NS† Prevalence 
in HBV+ vs. 
HBV- 






2004 NR 80 NR 276 1.30 





















































































































2006 12% 268 7% 3,987 RR: 
1.70 
















No Obstetric population 
Wives of men 
surface antigen 
positive 




NR NR NR NR 0.23† Married 
equivalent 






Lin et al.123 2007 NR 283 NR 2,880 RR:  
1.9 


















2006 29% 256 13% 3,924 RR: 
2.48 
(1.92 to 3.58)†; 
OR: 
1.61 
(1.10 to 2.37)‡ 
<0.05  Prevalence 
HBV+ vs. 
HBV- 







Lee et al.120 2008 NR NR NR NR 0.12 
(0.05 to 0.29)† 
SS Prevalence 










Lin et al.123 2007 NR 283 NR 2,880 RR: 
0.5 





















































































































 Male Kaur et al.116 1996 58% 1,416 35% 6,275 2.14 









Age >60 Kaur et al.116 1996 35% 1,356 19% 5,853 1.22 














Kaur et al.116 1996 65% 1,302 84% 5,764 0.32 













1999 NR 1,085 NR 20,180 3.9 













1999 NR 1,085 NR 20,180 0.7 
























































































































S.E. Asia or 
Africa 
Kaur et al.116 1996 52% 1,421 17.6% 6,069 3.87 




Yes Volunteers from general 
population 
Birth in an area 
with high 





Alter et al.117 1989 3% 76 <1% 152 NR NS† Proportion 
in HBV+ 
vs. HBV- 
No General population adults 
with no obvious cause of 






1999 50% 1,236 16.5% 19,971 3.4 















Kaur et al.116 1996 11.6% 1,453 21.5% 6,185 0.48 













1999 5% 955 4.7% 15,451 1.07 




No General population 





Alter et al.117 1989 0% 76 11% 152 NR NS† Proportion 
in HBV+ 
vs. HBV- 
No General population adults 
with no obvious cause of 






1999 13.2% 961 14.6% 15,568 0.89 




No General population aged 










































































































Unemployed Alter et al.117 1989 20% 76 6% 152 NR 0.01‡ Proportion 
in HBV+ 
vs. HBV- 
Yes General population adults 
with no obvious cause of 













1999 56.4% 1,081 40.9% 15,431 1.5 











1999 24.3% 1,081 31.0% 15,431 1.1 


















1999 10.6% 1,301 10.7% 15,284 1.6 







Yes General population aged 































































































































Male Tabibian et 
al.121 




No Psychiatric inpatient 
veterans 
Male Hwang et 
al.124 
2006 32% 274 39% 4,047 RR: 
0.77 
(0.61 to 0.99)†; 
OR: 
0.69 











Male Lin et al.123 2007 NR NR NR NR RR: 
2.1 





Yes Asian Americans 
Male Lee et al.120 2008 NR 24 NR 609 1.69 


















































































































Age, mean Tabibian et 
al.121 
2008 48.9 mean 40 48.9 
mean 
89 NR NS†  Mean age 
HBV+ vs. 
HBV- 






2006 NR 269 NR 4,054 1.04 
(1.03 to 1.06)‡ 
<0.05  Mean age 
in HBV+ 
vs. HBV- 
Yes College students 
Age ≤20 years Hann et al.122 2007 NR 377 NR 5,753 NR 0.0051† >20 years Yes Korean-American church-
goers 
Age ≤30 years Lee et al.120 2008 NR NR NR NR 0.072 
(0.02 to 0.21) 









Age 30 to 
49 years 
Lee et al.120 2008 NR NR NR NR 0.287 
(0.15 to 0.55)† 













1989 NR 14 NR 94 RR: 
3.6 
(1.2 to 11.2)† 
NR HBV+ in 
<35 years 
Yes Embalmers in high-





2004 NR 80 NR 276 1.27 





No Psychiatric inpatient 
veterans 
Age 30-39 Lin et al.123 2007 NR 283 NR 2,880 RR: 
1.4 
















































































































Age 40-49 Lin et al.123 2007 NR 283 NR 2,880 RR: 
1.5 





No Asian Americans 
Age 50-59 Lin et al.123 2007 NR 283 NR 2,880 RR: 
1.0 





No Asian Americans 
Age 60-69 Lin et al.123 2007 NR 283 NR 2,880 RR: 
0.9 





No Asian Americans 
Age ≥70 Lin et al.123 2007 NR 283 NR 2,880 RR: 
0.6 


















































































































































2004 NR 80 NR 276 2.79 












2006 36% 269 26% 4,001 RR: 
1.92 
(1.44 to 2.56)†; 
OR: 
1.95 

























2006 12% 269 23% 4,001 RR: 
0.72 
(0.48 to 1.08)†; 
OR: 
0.81 



















































































































Asian  Hwang et 
al.124 
2006 20% 269 5% 4,001 RR: 
4.49 
(3.26 to 6.19)†; 
OR: 
9.98 























Lin et al.123 2007 NR 283 NR 2,880 RR: 
0.8 












Lin et al.123 2007 NR 283 NR 2,880 RR: 
1.2 










Lin et al.123 2007 NR 283 NR 2,880 RR: 
0.05 


































































































































No Psychiatric inpatient 
veterans 
Healthcare-





2006 7% 270 4% 3,987 RR: 
1.83 
(1.18 to 2.84)† 






1990 8% 12 7.5% 1,454 1.07 
















2008 13.5 mean 40 13.4 
mean 





No Psychiatric inpatient 
veterans 
Enrolled in 
2 year college 
Hwang et 
al.124 
2006 48% 274 33% 4,054 RR: 
1.81 
(1.44 to 2.27)†; 
OR: 
1.64 
(1.13 to 2.40)‡ 





















































































































Homeless Tabibian et 
al.121 




No Psychiatric inpatient 
veterans 
Independent or 
live with family 
(vs. homeless, 
institutional-
ized, or other) 
Butterfield et 
al.125 
2004 NR 80 NR 276 0.82 



















2004 NR 80 NR 276 1.67 





No Psychiatric inpatient 
veterans 
* Odds ratios as reported in publication, unless otherwise specified 
** As reported in publication, unless otherwise specified 
† Univariate, unadjusted 
‡ Multivariate, adjusted for other factors 
¶ Calculated by ECRI Institute 
231 













































































































 ALT reactive Orton et al.
104 2004 20% 65 <1% 225 47 
(6.7 to 2,004)† 
<0.001  Proportion in 
HCV+ vs. 
HCV- 






Jaundice Nguyen et 
al.113 
2005 20.3% 225 5.4% 204 Not reported 
(NR) 
<0.001  Proportion 
HCV+ vs. 
HCV- 







levels <40 U/L 
Armstrong et 
al.30 
2006 49% 220 92% 12,900 NR Not 
significant
(NS)† 
0-39 U/L No General 
population 




levels 40-79 U/L 
Armstrong et 
al.30 
2006 35% 220 7% 12,900 NR <0.005† 0-39 U/L Yes General 
population 




levels 80-119 U/L 
Armstrong et 
al.30 
2006 7% 220 1% 12,900 NR >0.05† 0-39 U/L Yes General 
population 













































































































levels ≥120 U/L 
Armstrong et 
al.30 
2006 8% 220 4% 12,900 NR >0.05†  0-39 U/L Yes  General 
population 






2000 27% 11 6% 1,369 NR <0.05† Proportion in 
HCV+ vs. 
HCV- 
Yes Adults comprising 
individuals at risk 
for HCV and 
healthcareworker










2000 NR 11 NR 1,369 13.9 
(2.7 to 72.1)† 
0.002 Proportion in 
HCV+ vs. 
HCV- 
Yes Adults comprising 
individuals at risk 
for HCV and 
healthcareworker
s enrolled in 
HMO 
Co-Morbidity 







 Blood transfusion 
recipient or donor 
Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS Proportion in 
HCV+ vs. 
HCV- 
No Potential tissue 
donors, as 
reported by 





















































































































History of transplant Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, 
as reported by 





2006 NR 18 NR 56 NR NS  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, 
as reported by 
next of kin 
Surgeries Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, 
as reported by 
next of kin 
HIV testing Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, 
as reported by 





Liver disease Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, 
as reported by 
next of kin 
Chest pain Sanchez et 
al.103 
2006 NR 18 NR 56 2.66 
(0.96 to 7.38)† 
0.054  Proportion in 
HCV+ vs. 
HCV 
Yes Potential tissue 
donors, 
as reported by 









































































































Cardiac medications Sanchez et 
al.103 
2006 NR 18 NR 56 2.84 
(1.0 to 8.07)† 
0.043  Proportion in 
HCV+ vs. 
HCV 
Yes Potential tissue 
donors, 
as reported by 
next of kin 
Kidney stones Sanchez et 
al.103 
2006 NR 18 NR 56 5.48 
(1.38 to 21.80)† 
0.008  Proportion in 
HCV+ vs. 
HCV 
Yes Potential tissue 
donors, as 
reported by next 
of kin 
Lung disease Sanchez et 
al.103 
2006 NR 18 NR 56 3.20 
(0.98 to 10.41)† 
0.044  Proportion in 
HCV+ vs. 
HCV 
Yes Potential tissue 
donors, as 




last 2 years 
Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 






2006 NR 18 NR 56 NR NS† Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 






2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 










































































































Medical illnesses Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by next 
of kin 
 
Medications Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS† Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by 
next of kin 
Toxic exposure Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by 
next of kin 




2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by 






2006 NR 18 NR 56 NR NS† Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by 
next of kin 
Rabies exposure Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by 









































































































Heart disease Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS† Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by 
next of kin 
 
Hypertension Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by 
next of kin 
Kidney disease Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by 





2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by 
next of kin 
Cancer history Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by 
next of kin 
Diabetes history Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by 









































































































Pulmonary disease Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by 






2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by 





2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by 





2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by 
next of kin 
Neurologic disease Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by 
next of kin 
Ocular disease Sanchez et 
al.103 
2006 NR 18 NR 56 NR NS†  Proportion in 
HCV+ vs. 
HCV 
No Potential tissue 
donors, as 
reported by 














































































































n HBV Surface 
Antigen Positive 
Gasink et al.102 2006 0.4% 261 0.03% 10,654 NR 0.003† Proportion in 
HCV+ vs. 
HCV- 






Diabetes mellitus Gasink et al.102 2006 1.6% 261 1.7% 10,654 NR 0.86† Proportion in 
HCV+ vs. 
HCV 




Gasink et al.102 2006 0 261 0.68% 10,654 NR 0.18† Proportion in 
HCV+ vs. 
HCV 
No Heart transplant 
donors 
Hypertension Gasink et al.102 2006 15.2% 261 11.3% 10,654 NR 0.05† Proportion in 
HCV+ vs. 
HCV 




Gasink et al.102 2006 12.3% 261 13.4% 10,654 NR 0.60† Proportion in 
HCV+ vs. 
HCV 





















































































































1996 27% 248 8% 131 4.68 
(3.44 to 6.36)†¶ 
<0.001‡ Proportion in 
HCV+ vs. 
HCV- 









2000 23% 758 6% 1,039 Non-IDU: 
10.9 
(6.5 to 18.2)†; 
IDU: 
0.9 























1996 13% 3,126 5.9% 859,272 2.8 
(2.5 to 3.1)‡ 
SS Proportion in 
HCV+ vs. 
HCV- 

















1996 4% 248 2% 131 NR >0.05† Proportion in 
HCV+ vs. 
HCV- 
No Blood donors 
initially positive 
on EIA 
Bloody needle stick 




2000 11% 758 4% 1,039 3.2 
(1.9 to 2.6)‡ 



















































































































2000 11% 758 4% 1,039 2.1 
(1.1 to 4.1)‡ 







Yes Blood donors 
Had same-day 
surgery in the 
6 months 
before donation 
Orton et al.104 2004 9.2% 65 6.3% 225 1.5 
(0.5 to 4.5)† 
0.41 Proportion in 
HCV+ vs. 
HCV- 
No Blood donors 
Had a medical 
and/or surgical 
procedure in the 
6 months 
before donation 
Orton et al.104 2004 21.5% 65 14.3% 225 1.6 
(0.8 to 3.3)† 
0.16 Proportion in 
HCV+ vs. 
HCV- 
No Blood donors 
Had surgery Murphy et 
al.105 
2000 74% 758 64% 1,039 1.7 
(1.2 to 2.4)‡ 





Yes Blood donors 
Had sutures Murphy et 
al.105 
2000 77% 758 65% 1,039 1.7 
(1.2 to 2.4)‡ 















































































































Was hospitalized in 
the 6 months 
before donation 
Orton et al.104 2004 7.7% 65 2.2% 225 3.7 
(0.8 to 16)† 
0.05 Proportion in 
HCV+ vs. 
HCV- 






1996 4% 248 1% 131 NR >0.05† Proportion in 
HCV+ vs. 
HCV- 
No Blood donors 
initially positive 
on EIA 
Acupuncture Murphy et 
al.105 
2000 9% 758 5% 1,039 1.4 
(0.8 to 2.4)‡ 





No Blood donors 
Had dental work in 
the 6 months 
before donation 
Orton et al.104 2004 35.4% 65 38.8% 225 0.9 
(0.5 to 1.5)†  
0.61 Proportion in 
HCV+ vs. 
HCV- 
No Blood donors 




2000 57% 758 46% 1,039 0.7 
(0.3 to 1.4)‡ 






















































































































2000 23% 758 33% 1,039 0.5 
(0.2 to 1.0)‡ 













2000 11% 758 12% 1,039 0.6 
(0.2 to 1.3)‡ 








No Blood donors 
Tooth extraction Murphy et 
al.105 
2000 73% 758 68% 1,039 1.3 
(0.9 to 1.8)‡ 





No Blood donors 
In a fight with 
blood exposure 
last 6 months 
Orton et al.104 2004 7.7% 65 2.2% 225 3.7 
(0.8 to 16† 
0.05 Proportion in 
HCV+ vs. 
HCV- 
Yes Blood donors 
 
By a bite with 
blood exposure 
last 6 months 




0.01 Proportion in 
HCV+ vs. 
HCV- 









































































































During a haircut 
with blood exposure 
last 6 months 
Orton et al.104 2004 23.1% 65 13.8% 225 1.9 (0.9 to 3.9)† 0.11 Proportion in 
HCV+ vs. 
HCV- 
No Blood donors 
During a manicure 
with blood exposure 
last 6 months 
(women only) 
Orton et al.104 2004 20.0% 30 3.8% 105 5.2 
(1.1 to 27) † 
0.02 Proportion in 
HCV+ vs. 
HCV- 
Yes Blood donors 
At accident site with 
blood exposure 
last 6 months 
Orton et al.104 2004 6.2% 65 1.3% 225 4.9 
(0.8 to 34) † 
0.05 Proportion in 
HCV+ vs. 
HCV- 
Yes Blood donors 




2000 16% 758 6% 1,039 1.4 
(0.9 to 1.5)‡ 










2000 12% 758 8% 1,039 0.9 
(0.6 to 1.5)‡ 











2000 12% 758 7% 1,039 1.5 
(1.0 to 2.3)‡ 























































































































Had a sexually 
transmitted disease 
(STD) in 
last 6 months 
before donation 
Orton et al.104 2004 6.2% 65 0% 225 Undefined 
(because zero 
in control group 
had factor) 
0.002† Proportion in 
HCV+ vs. 
HCV- 
Yes Blood donors 
History of STD Conry-
Cantilena et 
al.106 
1996 28% 248 10% 131 NR <0.001† Proportion in 
HCV+ vs. 
HCV- 
Yes Blood donors 
initially positive 
on EIA 
STD Murphy et 
al.105 
2000 33% 758 15% 1,039 2.5 
(1.8 to 3.5)‡ 














<0.001† Proportion in 
HCV+ vs. 
HCV- 
Yes Blood donors 
Seropositive for 
other infectious 
diseases (HTLV I 




1996 NR 3,126 NR 859,272 10.4 
(9.6 to 11.4)‡ 
SS Proportion in 
HCV+ vs. 
HCV- 














































































































Hepatitis B Vaccine 
in last 6 months 
Orton et al.104 2004 32.3% 65 24.6% 225 1.5 
(0.8 to 2.7)† 
0.21  Proportion in 
HCV+ vs. 
HCV- 





2000 22% 758 16% 1,039 1.6 
(1.0 to 2.6)‡ 







Yes Blood donors 
History of hepatitis Orton et al.104 2004 1.5% 65 1.8% 225 0.9 
(0.02 to 10) † 
1.00 Proportion in 
HCV+ vs. 
HCV- 
No Blood donors 





1996 31% 248 5% 131 NR <0.001† Proportion in 
HCV+ vs. 
HCV- 



















































































































Blood transfusion Nguyen et 
al.113 
2005 43.2% 225 13.7% 204 8.62 
(4.71 to 15.80)†  





Blood transfusion(s) Hand and 
Vasquez112 
2005 25% 320 19% 307 NR†;  
3.2 






Yes Adults tested for 




Blood transfusion Kaur et al.116 1996 14.6% 559 7.1% 6,170 4.09 
(2.97 to 5.62)‡ 
NR Proportion in 
HCV+ vs. 
HCV- 







2006 14% 128 5% 5,665 2.6 
(0.9 to 7.3)‡ 












2000 55% 11 25% 1,369 4.61 
(3.42 to 6.21)†¶ 
<0.001 Proportion in 
HCV+ vs. 
HCV- 
Yes Adults comprising 
individuals at risk 
for HCV and 
healthcareworker
















































































































2000 0% 11 <1% 1,369 NR NS† Proportion in 
HCV+ vs. 
HCV- 
No Adults comprising 
individuals at risk 
for HCV and 
healthcareworker














Needlestick injury Kaur et al.116 1996 6.4% 543 8.9% 5,982 0.70 
(0.55 to 0.89)† 









population – Note 
this population 
had a large 
proportion of 
healthcare 
workers who had 
a lower infection 
prevalence  
Contact with blood Hand and 
Vasquez112 
2005 5% 320 4% 307 NR 0.798† Proportion in 
HCV+ vs. 
HCV- 
No Adults tested for 




Surgery, any Fischer et 
al.114 
2000 91% 11 78% 1,369 NR NS† Proportion in 
HCV+ vs. 
HCV- 
No Adults comprising 
individuals at risk 
for HCV and 
healthcareworker










































































































Surgery Kaur et al.116 1996 8.3% 565 8.6% 6,147 0.96 
(0.80 to 1.16)† 
NS Proportion in 
HCV+ vs. 
HCV- 
No Volunteers from 
general 
population 
Surgery, exploratory Fischer et 
al.114 
2000 55% 11 41% 1,369 NR NS† Proportion in 
HCV+ vs. 
HCV- 
No Adults comprising 
individuals at risk 
for HCV and 
healthcareworker








2005 88.3% 225 79.4% 204 NR 0.02†  Proportion 
HCV+ vs. 
HCV- 





Hospitalization Nguyen et 
al.113 
2005 87.8% 225 76.5% 204 NR 0.003†  Proportion 
HCV+ vs. 
HCV- 





Kidney dialysis  Nguyen et 
al.113 
2005 5.4% 225 0.5% 204 11.36 
(1.15 to 86.5)†¶ 
0.003†  Proportion 
HCV+ vs. 
HCV- 













































































































Hemodialysis Hand and 
Vasquez112 
2005 1% 320 3% 307 NR 0.068† Proportion in 
HCV+ vs. 
HCV- 
No Adults tested for 




Hemodialysis Kaur et al.116 1996 42.3% 544 8.1% 6,033 10.95 
(3.85 to 31.13)‡ 
NR Proportion in 
HCV+ vs. 
HCV- 




Acupuncture Hand and 
Vasquez112 
2005 2% 320 0.7% 307 NR 0.106† Proportion in 
HCV+ vs. 
HCV- 
No Adults tested for 









2000 9% 11 6% 1,369 NR NS† Proportion in 
HCV+ vs. 
HCV- 
No Adults comprising 
individuals at risk 
for HCV and 
healthcareworker
s enrolled in 
HMO 
At least one family 
member with HCV 
Nguyen et 
al.113 
2005 21.2% 225 6.9% 204 NR <0.001† Proportion 
HCV+ vs. 
HCV- 

















































































































2005 78.8% 225 24.5% 204 NR <0.001†  Proportion 
HCV+ vs. 
HCV- 














HIV positive Nguyen et 
al.113 
2005 1.8% 225 1.5% 204 NR >0.99†  Proportion 
HCV+ vs. 
HCV- 






HIV positive Armstrong et 
al.30 









Adults in general 
population aged 
18 to 49 years 
HIV positive Hand and 
Vasquez112 
2005 10% 320 8% 307 NR 0.351† Proportion in 
HCV+ vs. 
HCV- 
No Adults tested for 








2005 21.2% 225 2.5% 204 4.71 



























































































































18 to 49 years 
 




2005 24.8% 225 18.1% 204 NR 0.10†  Proportion 
HCV+ vs. 
HCV- 









Blood donor Nguyen et 
al.113 
















2005 28.4% 225 16.2% 204 2.57 
(1.49 to 4.43)† 
0.002  Proportion 
HCV+ vs. 
HCV 







Kaur et al.116 1996 2.8% 528 10% 5,737 0.37 
(0.22 to 0.62)‡ 






















































































































2005 20.7% 225 3.9% 204 2.75 









Hepatitis diagnosis Fischer et 
al.114 
2000 36% 11 4% 1,369 NR <0.001† Proportion in 
HCV+ vs. 
HCV- 
Yes Adults comprising 
individuals at risk 
for HCV and 
healthcareworker







2005 15.3% 225 5.4% 204 NR <0.001†  Proportion 
HCV+ vs. 
HCV- 





Diabetes mellitus Nguyen et 
al.113 
2005 14.4% 225 9.8% 204 NR 0.18†  Proportion 
HCV+ vs. 
HCV- 





Heart disease Nguyen et 
al.113 
2005 5.4% 225 6.9% 204 NR 0.55†  Proportion 
HCV+ vs. 
HCV- 













































































































“Blood problems” Nguyen et 
al.113 
2005 18.5% 225 5.4% 204 NR <0.001† Proportion 
HCV+ vs. 
HCV- 









2000 18% 11 10% 1,369 NR NS† Proportion in 
HCV+ vs. 
HCV- 
No Adults comprising 
individuals at risk 
for HCV and 
healthcareworker








2005 22% 320 27% 307 NR 0.164† Proportion in 
HCV+ vs. 
HCV- 
No Adults tested for 





Potential Organ Donors 
S
ex





Age, median and 
interquartile range 



























































































































Ethnicity: White Gasink et al.102 2006 87.7% 261 85.5% 10,654 NR 0.55  Proportions in 
HCV+ vs. 
HCV- 
No Heart transplant 
donors 
Ethnicity: Black Gasink et al.102 2006 10.7% 261 12.3% 1,304 NR 





Male Sex Orton et al.104 2004 54% 65 54% 225 1.0 
(0.6 to 1.8)† 
0.97 Proportion in 
HCV+ vs. 
HCV- 
No Blood donors 
Male Sex Murphy et 
al.107 
1996 66% 3,126 53% 859,272 1.9 
(1.8 to 2.1)‡  
SS Proportion in 
HCV+ vs. 
HCV- 




1996 44% 248 37% 131 NR 0.17† Proportion in 
HCV+ vs. 
HCV- 












225 NR <0.001 Mean in 
HCV+ vs. 
HCV- 










131 NR <0.001† Proportion in 
HCV+ vs. 
HCV- 



















































































































 White non-Hispanic Orton et al.104 2004 84% 65 89% 225 1.6 
(0.7 to 3.5)† 
0.26 HCV+ race 
“other” 




1996 19% 248 7% 131 NR 0.002†  Proportion in 
HCV+ vs. 
HCV- 




Black race Murphy et 
al.107 
1996 17% 3,126 7% 859,272 1.7 
(1.6 to 1.9)‡ 





Yes Blood donors 
Asian Murphy et 
al.107 
1996 1.8% 3,126 3% 859,272 0.4 
(0.3 to 0.6)‡ 










Hispanic Orton et al.104 2004 5% 65 7% 225 0.6 
(0.1 to 2.1)† 
0.58 Proportion in 
HCV+ vs. 
HCV- 
No Blood donors 
Hispanic Murphy et 
al.107 
1996 8.4% 3,126 6% 859,272 1.3 
(1.1 to 1.5)‡ 











 Foreign (not U.S.) Orton et al.
104 2004 1.5% 65 7.6% 225 0.2 
(0.0 to 1.3)† 
0.09 Proportion in 
HCV+ vs. 
HCV- 









































































































Foreign (not U.S.) Murphy et 
al.107 
1996 6% 3,126 6% 859,272 2.8 
(2.5 to 3.1)‡ 
SS Proportion in 
HCV+ vs. 
HCV-  












2000 24% 758 17% 1,039 1.7 




Yes Blood donors 
Medical or dental 
job (frequent blood 
contact) 
Orton et al.104 2004 9.2% 65 3.6% 225 2.8 
(0.8 to 9.4)† 
0.09 Proportion in 
HCV+ vs. 
HCV- 
No Blood donors 
Public safety job 
(frequent blood 
contact) 
Orton et al.104 2004 3.1% 65 3.6% 225 1.0 
(0.1 to 5.4)† 
1.00 Proportion in 
HCV+ vs. 
HCV- 








GED or less 















Orton et al.104 2004 40% 65 40% 225 2.8 
At least Bachelor’s 
degree 






1996 54% 248 16% 131 NR <0.001 Proportion in 
HCV+ vs. 
HCV- 



















































































































Married Murphy et 
al.105 
2000 60% 758 71% 1,039 0.61 
(0.50 to 0.75)†¶ 












Male Nguyen et 
al.113 
2005 55.0% 225 28.1% 204 NR <0.001†  Proportion 
HCV+ vs. 
HCV- 





Male McGinn et 
al.108 
2009 40% 83 25% 917 NR 0.02†  Proportion in 
HCV+ vs. 
HCV- 
Yes In adult primary 
care clinic 
Male Armstrong et 
al.30 





Male Fischer et 
al.114 
2000 36% 11 43% 1,369 NR NS † Proportion 
with HCV+ 
vs. HCV- 
No Adults comprising 
individuals at risk 
for HCV and 
healthcareworker
s enrolled in 
HMO 
Male Kaur et al.116 1996 13.4% 544 4.7% 6,275 3.60 
(2.66 to 4.87)‡ 
NR Proportion in 
HCV+ vs. 
HCV- 


























































































































917 NR 0.01† Mean in 
HCV+ vs. 
HCV- 
Yes In adult primary 
care clinic 




2005 0% 225 0.5% 204 NR <0.001† Proportion 
HCV+ vs. 
HCV- 









2005 0.9% 225 5.4% 204 




2005 7.7% 225 7.8% 204 




2005 24.9% 225 14.7% 204 




2005 51.4% 225 22.5% 204 




2005 13.1% 225 24.0% 204 




2005 2.3% 225 22.5% 204 














































































































Age <50 years Fischer et 
al.114 
2000 55% 11 26% 1,369 NR NS † Proportion in 
HCV+ vs. 
HCV- 
No Adults comprising 
individuals at risk 
for HCV and 
healthcareworker
s enrolled in 
HMO 
Age <60 years Kaur et al.116 1996 12% 520 19% 5,853 0.53 
(0.40 to 0.71)† 






















Ethnicity: White Nguyen et 
al.113 
2005 67.1% 225 57.9% 204 NR 0.15†  Proportion 
HCV+ vs. 
HCV- 





Ethnicity: Black Nguyen et 
al.113 
2005 23.9% 225 30.2% 204 NR 
Ethnicity: Asian Nguyen et 
al.113 
2005 2.3% 225 5.9% 204 NR 
Ethnicity: Latino Nguyen et 
al.113 
2005 3.6% 225 3.0% 204 NR 
Ethnicity: Other Nguyen et 
al.113 









































































































Ethnicity: White McGinn et 
al.108 
2008 11% 83 10% 917 NR 0.38† Proportion in 
HCV+ vs. 
HCV- 
No In adult primary 
care clinic 
Ethnicity: Black McGinn et 
al.108 
2008 31% 83 32% 917 NR 
Ethnicity: Other McGinn et 
al.108 
2008 0% 83 5% 917 NR 
Ethnicity: Latino McGinn et 
al.108 





2006 42% 252 26% 13,691 1.9 














2006 23% 252 32% 13,691 2.6 








aged 20 to 
59 years 
White/Hispanic Kaur et al.116 1996 7.9% 507 9.2% 5,764 0.57 

























































































































U.S. Citizen Nguyen et 
al.113 
2005 97.7% 225 97.5% 204 NR >0.99† Proportion 
HCV+ vs. 
HCV- 





Born outside of U.S. Armstrong et 
al.30 
2006 6% 233 20% 14,787 0.2 
(0.08-0.7)‡ 




aged 20 to 
59 years 
Born in Southeast 
Asia/Africa 
Kaur et al.116 1996 7.7% 559 8.5% 6,069 0.90 
(0.50 to 1.64)† 
NS Proportion in 
HCV+ vs. 
HCV- 











2008 89% 83 79% 917 NR 0.03†  Proportion in 
HCV+ vs. 
HCV- 


















2000 27% 11 20% 1,369 NR NS† Proportion in 
HCV+ vs. 
HCV-  
No Adults comprising 
individuals at risk 
for HCV and 
healthcareworker
s enrolled in 
HMO 
Healthcare worker Kaur et al.116 1996 2.9% 568 10.3% 6, 185 0.26 
(0.19 to 0.35)† 

















































































































Armed forces Fischer et 
al.114 
2000 36% 11 27% 1,369 NR NS† Proportion in 
HCV+ vs. 
HCV- 
No Adults comprising 
individuals at risk 
for HCV and 
healthcareworker
s enrolled in 
HMO 
Services in 
U.S. armed forces 
Armstrong et 
al.30 
2006 32% 114 31% 4,063 NR NS  Prevalence 
HCV+ vs. 
HCV- 
No Men aged at 
least 20 years in 
general 
population 
Job at prison Nguyen et 
al.113 
2005 7.7% 225 1.5% 204  NR 0.002†  Proportion 
HCV+ vs. 
HCV- 












less than 12 years 
Armstrong et 
al.30 















































































































Education –  
6th grade or less 
McGinn et 
al.108 
2008 10% 83 11% 917 NR 0.62† Proportion 
with level in 
HCV+ vs. 
HCV- 

















2008 19% 83 19% 917 
Education –  




2008 7% 83 13% 917 
Education – 
High school or less 
Nguyen et 
al.113 
2005 46.4% 225 22.7% 204 NR 0.15† Proportion 
HCV+ vs. 
HCV- 









2005 30.6% 225 25.1% 204 
Education –  























































































































Homeless, ever Nguyen et 
al.113 
2005 9.2% 225 1.0% 204 NR <0.001†  Proportion 
HCV+ vs. 
HCV- 









2005 13.1% 225 10.2% 204 NR 0.90†  Proportion 
HCV+ vs. 
HCV- 





























2005 13.6% 225 14.8% 204 
 
Family income 
































































































































Community – Rural Nguyen et 
al.113 
2005 12.8% 225 10.9% 204 NR <0.001†  Proportion 
HCV+ vs. 
HCV- 









2005 52.6% 225 30.6% 204 
Community – Urban Nguyen et 
al.113 



























































































































Insurance – Private McGinn et 
al.108 





2008 1% 83 1% 917 




2008 76% 83 78% 917 NR 0.86†  Proportion 
with type in 
HCV+ vs. 
HCV- 
No In adult primary 
care clinic 




2008 17% 83 16% 917 




2008 7% 83 6% 917 
































Asian Luban et al.118 2007 0% 42 1.5% 2,474 0.7 
















































































































Caucasian Luban et al.118 2007 57% 42 48% 2,474 1.4 








Hispanic Luban et al.118 2007 0% 42 3.4% 2,474 0.3 








* Odds ratios as reported in publication, unless otherwise specified 
** As reported in publication, unless otherwise specified 
† Univariate, unadjusted 
‡ Multivariate, adjusted for other factors 
¶ Calculated by ECRI Institute 
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HIV+ vs. HIV- 
No Potential tissue donors, 

















2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 





2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 
as reported by next of kin 
Surgeries Sanchez et 
al.103 
2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 







last 2 years 
Sanchez et 
al.103 
2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 
as reported by next of kin 
Liver disease Sanchez et 
al.103 
2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 





2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 





2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 




































































































2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 
as reported by next of kin 
Medications Sanchez et 
al.103 
2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 
as reported by next of kin 
Toxic exposure Sanchez et 
al.103 
2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 






2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 







2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 





2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 
as reported by next of kin 
Heart disease Sanchez et 
al.103 
2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 
as reported by next of kin 
Hypertension Sanchez et 
al.103 
2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 
as reported by next of kin 
Kidney disease Sanchez et 
al.103 
2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 





2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 
































































































Cancer history Sanchez et 
al.103 
2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 





2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 





2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 





2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 





2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 





2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 





2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 
as reported by next of kin 
HIV testing Sanchez et 
al.103 
2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 
as reported by next of kin 
Ocular disease Sanchez et 
al.103 
2006 NR 10 NR 56 NR NS Proportion in 
HIV+ vs. HIV- 
No Potential tissue donors, 












































































































2008 25% 229  NR 16,467 1.56 
(1.15 to 2.11)† 
NR No STD, 
HIV+ 







2006 81% 31 20% 5,570 17.1 
(6.9 to 41.9)†¶ 
<0.001 Proportion in 
HCV+ vs. 
HCV- 





2008 71.2% 21 26.9% 1,589 6.46 




Negative Yes General population of 





1996 NR 35 NR 840 NR‡ SS Proportion in 
HCV+ vs. 
HCV- 




related to HIV 
Alpert et 
al.115 
1996 NR 35 NR 840 NR‡ SS Proportion in 
HCV+ vs. 
HCV- 







Male  Mehta et 
al.109 
2008 63% 229 NR 16,467 1.30 
(0.98 to 1.71)† 
NR Female HIV+ No Hospital inpatients and 
outpatients 
Male  Zetola et 
al.111 
2008 NR 15 NR 1,632 7.68 
(0.98 to 60.26)‡ 
0.053  Female HIV+ No Public hospital 
emergency room patients 
Male  Nguyen et 
al.110 
2008 57.1 21 42.4 1,602 2.01 
(0.91 to 4.40)† 
NS Female HIV+ No General population of 


































































































Age 18-30 Zetola et 
al.111 
2008 NR 15 NR 1,632 3.15 
(1.03 to 9.61)‡ 
0.044 Proportion 
HIV+ vs. HIV- 
>46 years 
Yes Public hospital 
emergency room patients 
Age 31-45 Zetola et 
al.111 
2008 NR 15 NR 1,632 0.76 





HIV+ vs. HIV- 
>46 years 
No Public hospital 
emergency room patients 
Age 25-39 Mehta et 
al.109 
2008 48% 229 NR 16,467 3.22 
(1.84 to 5.64)†  
NR Age 15-24, 
HIV+ 
Yes Hospital inpatients and 
outpatients 
Age 40-54 Mehta et 
al.109 
2008 42% 229 NR 16,467 3.39 
(2.24 to 6.91)† 
NR Age 15-24 
HIV+ 
Yes Hospital inpatients and 
outpatients 
Age 55+ Mehta et 
al.109 
2008 4% 229 NR 16,467 1.19 
(0.50 to 2.85)† 
NR Age 15-24 
HIV+ 
No Hospital inpatients and 
outpatients 




1996 NR 35 NR 840 NR‡ SS  Proportion in 
HCV+ vs. 
HCV- 











Ethnicity, Black Mehta et 
al.109 
2008 44% 229 NR 16,467 2.51 




Yes Hospital inpatients and 
outpatients 
Black Zetola et 
al.111 
2008 NR 15 NR 1,632 1.01 





HIV+ vs. HIV- 
vs. White 
No Public hospital 





2008 55.0 20 20.9 1,578 5.53 




Yes General population of 
































































































Ethnicity, Asian Mehta et 
al.109 
2008 0.4% 229 NR 16,467 0.50 
(0.07 to 3.68)†  
NR Proportion 
HIV+ vs. HIV- 






2008 5.0 20 13.0 1,578 1.12 




No General population of 





2008 4% 229 NR 16,467 3.40 
(1.16 to 7.15)†  
NR Proportion 
HIV+ vs. HIV- 






2008 13% 229 NR 16,467 3.84 
(2.24 to 6.60)†  
NR Proportion 
HIV+ vs. HIV 







2008 11% 229 NR 16,467 3.43 
(1.96 to 6.02)† 
NR Proportion 
HIV+ vs. HIV 
Yes Hospital inpatients and 
outpatients 
Hispanic Zetola et 
al.111 
2008 NR 15 NR 1,632 2.07 







No Public hospital 





2008 30.0 20 36.0 1,578 2.07 




No General population of 










2008 NR 15 NR 1,632 0.58 







No Public hospital 








































































































2006 39% 31 32% 5,889 1.4 
(0.66 to 2.8)†¶ 
0.41 Proportion in 
HIV+ vs. HIV- 





2008 30% 229 NR 16,467 1.41 
(0.96 to 2.07)† 
NR At least 
high school/ 
GED, HIV+ 













Homeless Zetola et 
al.111 
2008 NR 15 NR 1,632 3.89 




Yes Public hospital 





2006 41% 27 33% 5,371 1.41 
(0.65 to 3.0)†¶ 
0.38 Proportion 
HIV+ vs. HIV- 









2008 21% 212 NR 16,467 1.66 
(1.19 to 2.32)† 






2008 NR 15 NR 1,632 1.09 




Insured HIV+ No Public hospital 











2006 24% 29 53% 5,631 0.28 
(0.12 to 0.60)†¶ 
0.003¶ Proportion 







































































































Children and Adolescents 
S
ex
 Male  D’Angelo et 
al.119 
1991 15% 13 33% 3,507 NR <0.05† Proportion 








 Age >15 years D’Angelo et 
al.119 
1991 NR 13 NR 3,507 NR <0.05† Proportion 
HIV+ vs. 
Age <15 
Yes Adolescents attending 
urban hospital 
* Odds ratios as reported in publication, unless otherwise specified 
** As reported in publication, unless otherwise specified 
† Univariate, unadjusted 
‡ Multivariate, adjusted for other factors 
¶ Calculated by ECRI Institute 
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HBV 1 OBS127 One study of embalmers who had a needle stick 
injury during embalming did not find an association 
between needlestick injuries with known or 
suspected HBV positive blood and HBV infection.127 
Low 0 -1 -1 -1 0 0 0 0 Very Low 
HCV No studies - - - - - - - - - - Not 
Applicable 
(NA) 











HBV No studies - - - - - - - - - - NA 
HCV 1 OBS113 Jaundice: Associated in one study113 Low 0 -1 0 0 0 1 0 0 Low 
1 OBS104 ALT Reactivity: Associated in one study.104 Low 0 -1 0 0 0 1 0 0 Low 
1 OBS30 ALT >40 U/L: Associated in one study30 Low 0 -1 0 0 0 1 0 0 Low 
1 OBS114 Elevated liver enzyme: Associated in one study114 Low 0 -1 0 0 0 0 0 0 Very Low 














































































































HBV 3 OBS116,124,126 Blood transfusion was associated with HBV infection 
in a general population,116 as was blood transfusion 
before 1991 in a special population.124 Blood 
transfusion was not associated with HBV in another 
special population study.126 
Low 0 0 -1 0 0 0 0 0 Very Low 
HCV 8 OBS30,105-107,112-
114,116 
All 8 studies associated having had a blood 
transfusion with HCV, and in eight of them the effect 
size was large. It was independently associated with 
HCV with large effect sizes in three blood donor 
studies105-107 and two general population 
studies.112,116 Two additional general population study 
performed univariate analyses only and found large 
effect sizes.113,114 The remaining general population 
study found an independent association between 
having a blood transfusion before 1992 and HCV, 
but the effect size was not large.30 
Low 0 0 0 0 0 1 0 0 Moderate 





















































































































HBV 2 OBS103,116 According to data collected from a low-quality next-
of-kin, accidental needle sticks were not associated 
with HBV among potential tissue donors.103 A general 
population study found a lower prevalence of HBV 
among people who reported a needlestick.116  
Low 0 0 0 -1 0 0 0 0 Very Low 
HCV 4 OBS103,105,106,116 According to data collected from a low-quality next-
of-kin, accidental needle sticks were not associated 
with HCV among potential tissue donors103 A general 
population study found a lower prevalence of HCV 
among people who reported a needlestick.116 Among 
blood donors who work in a healthcare setting, 
needlestick injuries were not associated with HCV in 
one study,106 but “bloody” needlestick injuries were in 
another.105 
Low 0 -1 0 0 0 0 0 0 Very Low 
HIV 1 OBS103 According to data collected from a low-quality next-
of-kin, accidental needle sticks were not associated 
with HIV among potential tissue donors103 








HBV 2 OBS116,124 Hemodialysis was associated with HBV in one 
general population study116 and one special 
population study.124 Both analyses were univariate, 
and the special population study had a large effect 
size. 
Low 0 0 0 0 0 1 0 0 Moderate 
HCV 3 OBS112,113,116 In general population studies, “kidney dialysis” was 
associated with HCV in a univariate analysis in one 
study,113 and hemodialysis was associated with HCV 
with a large effect size in multivariate analysis in a 
second study.116 A third study did not find an 
association between hemodialysis and HCV.112 





































































































HBV 3 OBS103,116,117 The tissue donor study did not associate having had 
surgery with HBV.103 One general population study 
found a lower prevalence of HBV among people who 
had surgery,116 and another found no relationship.117 
Low 0 -1 0 0 0 0 0 0 Very Low 
HCV 5 OBS103-105,114,116 The tissue donor study did not associate having had 
surgery with HCV.103 One blood donor study did not 
find any association with recent surgery104 and one 
general population study did not find any association 
with history of surgery.114 However, one blood donor 
study did find an independent association between 
HCV and lifetime history of surgery (or sutures).105 A 
general population study found no association.116 
Low 0 -1 0 0 0 0 0 0 Very Low 
HIV 1 OBS103 The tissue donor study did not associate having had 
surgery with HIV.103 
















HBV 2 OBS103,121 HBV was not associated with having an organ 
transplant in one very low-quality study103 or 
a special population study.121 
Low 0 0 0 -1 0 0 0 0 Very Low 
HCV 1 OBS103 HCV was not associated with having an organ 
transplant in one very low-quality study.103 
Low -1 -1 0 -1 0 0 0 0 Very Low 
HIV 1 OBS103 HCV was not associated with having an organ 
transplant in one very low-quality study.103 






































































































HBV 2 OBS117,121 Neither the general population study117 nor the 
special population study121 found an association 
between HBV and acupuncture. 
Low 0 0 0 0 0 0 0 0 Low 
HCV 3 OBS106,107,112 Acupuncture was not associated with HCV infection 
in two studies of blood donors106,107 or one study of a 
general population.112 
Low 0 0 0 0 0 0 0 0 Low 







HBV 1 OBS117 Dental work within the last six months was not 
associated with acute HBV in one general population 
study.117 
Low 0 0 0 -1 0 0 0 0 Very Low 
HCV 2 OBS104,105 Dental work was not associated with HCV among 
blood donors in one study105; nor was having dental 
work in the six months before donation in another.104  
Low 0 0 0 0 0 0 0 0 Low 








HBV 1 OBS103 The tissue donor study did not find an association 
between HIV testing and HBV, based upon next-of-
kin interviews.103 
Low -1 -1 0 -1 0 0 0 0 Very Low 
HCV 2 OBS103,113 The low-quality tissue donor study did not find an 
association between HIV testing and HCV, based 
upon next of-kin interviews.103 One general 
population study did find an association between 
having had a blood test for HBV and having an HCV 
infection.113 The same study also found that being a 
blood donor was associated with reduced risk of 
HCV.113  































































































 HIV 1 OBS103 The tissue donor study did not find an association 
between HIV testing and HIV, based upon next of-kin 
interviews.103 











HBV 5 OBS117,122-124,126 Having household contact with someone with 
hepatitis was associated with HBV in a special 
population study124, as was a family history of HBV in 
another special population study.123 However, having 
a household member with hepatitis was not 
associated with HBV in a third special population 
study;126 nor was being the wife of a man with HBV in 
a fourth special population study.122 Sharing a razor 
or toothbrush with a household member was not 
associated with HBV in a general population study 
either.117 
Low 0 -1 -1 0 0 0 0 0 Very Low 
HCV 3 OBS105,113,114 In one blood donor study, living with someone with 
hepatitis or having a relative with hepatitis was not 
associated with HCV , but living with a transfusion 
recipient and sharing a toothbrush or razor with 
person(s) unspecified was.105 In general population 
studies, having at least one family member treated 
for viral hepatitis was not associated with an 
increased risk of HCV in one study,114 but having at 
least one family member with HCV in another study 
was.113  
Low 0 -1 0 0 0 0 0 0 Very Low 








































































































HBV 2 OBS102,124 HBV surface antigen positivity was associated with 
HCV infection among heart donors in one study.102 
HBV infection was associated with having had a 
sexually transmitted disease (STD) in a special 
population study.124 
Low 0 0 0 0 0 0 0 0 Low 
HCV 6 OBS 
30,104,106,107,112,113 
HCV was significantly associated with history of STD 
in two blood donor studies106,107 but not a general 
population study.113 HCV was associated with having 
a STD within six months of donating in another blood 
donor study.104 Herpes infection was associated with 
HCV in a general population study30 In addition, HCV 
was associated with seropositivity for other reactive 
infectious diseases in two blood donor studies.104,107 
HIV infection was not associated with HCV infection 
upon univariate analysis of a general population 
study.112  
Low 0 -1 0 0 0 0 0 0 Very Low 
HIV 4 OBS101,109,110,115 In general population studies, HIV infection was 
associated with diagnosis of STD in one study,109 
HSV-2 in two studies,101,110 and syphilis or other 
infection not apparently related to HIV in another 
study,115 


































































































HBV 6 OBS 
116,118,120,121,123,124 
In one general population study116 and 2 special 
population studies121,123 males had higher prevalence 
of HBV. Two additional special populations studies 
found no difference120 or a lower prevalence.124 
A study of children found no difference.118 
Low 0 -1 -1 0 0 0 0 0 Very Low 
HCV 9 OBS30,102,104,106-
108,113,114,116 
One organ donor study found an increased 
prevalence of HCV in males.102 Among blood donors 
it was in one study107 but not in two others.104,106 
Four general population studies found an increased 
risk among males.30,108,113,116 but one other did not.114 
Low 0 -1 0 0 0 0 0 0 Very Low 
HIV 3 OBS109-111 None of three general population studies associated 
male sex with an increased prevalence of HIV.109-111 




HBV 8 OBS116,120-125,127 Every study tested the association of HBV and age in 
different ways, and the results are inconsistent and 
difficult to compare. 
One general population study found an increased risk 
of HBV when >60 years.116 The rest of the studies 
were special population studies. One found an 
association with mean age (with older people having 
greater prevalence of HBV)124 while another did 
not.121 Increased prevalence was associated with 
age younger than 20 years,122 age over 35 years,127 
and age over 50 years.125 In another study lower 
prevalence was found in people under 49 years.120 
The remaining study did not find any association 
between age and HBV.123 
































































































HCV 7 OBS 
102,104,106,108,113,114,1
16 
Every study tested the association of HCV and age in 
different ways, and the results are inconsistent and 
difficult to compare. The organ donor study found 
that HCV infection was associated with older median 
age.102 One of the blood donor studies associated 
HCV with older mean age,104 the other did not.106 
In general population studies, HCV was associated 
with increased mean age108 and decade of birth 
(with people born between 1940 and 1959 having the 
highest prevalence),113 but not age less than 
50 years114 or age less than 60 years.116 
Low 0 -1 0 0 0 0 0 0 Very Low 
 HIV 3 OBS109,111,115 The HIV studies also measured age in different ways, 
complicating comparison. In general these studies 
found young adults to be at the highest risk. One 
study found younger adults (aged 18 to 30) had 
increased prevalence of HIV,111 another found adults 
aged 25 to 40 had higher prevalence of HIV than 
younger people aged 15 to 24 years,109 and the third 
found increased prevalence among adults aged 35 to 
44 years.115 









































































































HBV 2 OBS116,121 White or Hispanic race was associated with lower 
HBV prevalence in a general population study in a 
multivariate analysis116 but not in a special population 
study.121 
Low 0 -1 0 -1 0 0 0 0 Very Low 
 4 OBS29,121,124,125 Non-Hispanic Black race was associated with a 
higher prevalence of HBV in a general population 
study multivariate analysis29 and two special 
population studies124,125 but not another special 
population study.121 
Low 0 0 -1 0 0 0 0 0 Very Low 
 3 OBS29,121,124 Being Mexican-American was not associated with a 
different prevalence of HBV than non-Hispanic White 
race in a multivariate analysis of a general population 
study.29 In special population studies, Hispanic 
ethnicity121 and Hispanic or Latino ethnicity124 were 
not associated with HBV infection. 
Low 0 0 -1 0 0 0 0 0 Very Low 
 1 OBS124 A special population study found an increased 
prevalence of HBV among Asian Americans 
compared with non-Hispanic White Americans.124 
Low 0 -1 -1 0 0 0 0 0 Very Low 
  1 OBS117 Among African American, Caucasian, Asian, and 
Hispanic children who received blood transfusions, 
the prevalence was not significantly different. 


































































































Because about half of the studies combined races in 
analyses (their results presented first), the different 
analyses are reported together here. The different 
analysis methods complicate side-by-side 
comparison, but the evidence rating would always be 
‘very low’ for these studies. (These results are all 
presented in the same row because of overlap within 
the studies.) 
In organ donors, no relation between race and HCV 
infection was detected.102 Three general population 
studies did not find any relation either.30,108,113 
White race was not associated with a difference in 
rate of HCV compared with other races.104 
Black race was associated with increased rates of 
HCV compared to Whites in two studies.106,107 
Being Asian was associated with having a lower 
prevalence of HCV compared to Whites among 
blood donors.107 
Among blood donors, one study found that Hispanics 
had a higher risk of HCV than Whites,107 but another 
did not.104 
Low 0 -1 0 0 0 0 0 0 Very Low 
 HIV 3 OBS109-111 In univariate analyses, two general population 
studies found increased prevalence of HIV among 
people of Black race109,110 but a third did not. 111  
Low 0 -1 0 0 0 0 0 0 Very Low 
  2 OBS109,110 In univariate analyses, neither of two general 
population studies found a difference in HIV 
prevalence in Whites and Asians.109,110 












































































































HBV 5 OBS 
29,116,117,122,123 
National origin and birthplace were reported 
differently among studies and most factors cannot be 
considered side-by-side. However, since the rating 
for any factor in this group will be ‘very low’ and there 
is some overlap among studies, we present the 
findings together. 
In multivariate analysis of general populations, HCV 
was associated with being born in Southeast Asia or 
Africa in one study.116 A special population study 
found children born in Korea had higher prevalence 
of HBV than children born in the U.S.122 Other special 
population studies did not find significantly different 
rates of Asian Americans born in East Asia 
(excluding China) or Southeast Asia or Pacific 
Islands compared to Asian Americans born in 
China.123 
Birth in an area with a high endemic rate or 
household exposure to someone born in a high 
endemic rate was not in another general population 
study.117 
In multivariate analyses, a general population study29 
and a special population study123 found that being 
born in the U.S. was associated was lower 
prevalence of HBV. 
































































































HCV 5 OBS 
30,104,107,113,116 
One blood donor study did not associate foreign birth 
with HCV,104 but another did in a multivariate 
analysis.107 A general population study found people 
born outside of the U.S. had a lower prevalence of 
HCV.30 Birth in Southeast Asia or Africa was not 
associated with an increased prevalence of HCV in 
another general population study.116 A general 
population study found no association between HCV 
and U.S. citizenship.113  
Low 0 -1 0 0 0 0 0 0 Very Low 










e HBV No studies - - - - - - - - - - NA 
HCV 1 OBS108 One general population study found an association 
between preference of English or Spanish and 
HCV.108 
Low 0 -1 0 0 0 0 0 0 Very Low 
HIV 1 OBS111 One general population study found no difference in 
prevalence of HIV among Spanish speakers.111 






































































































HBV 6 OBS 
29,116,117,121,124,126 
Occupation as a health care worker was protective 
against HBV in one general population study116 and 
not associated with HBV in another general 
population study29 or a special population study.121 
However, having a healthcare-related job with 
frequent blood exposure was associated with HBV in 
one special population study.124  
Another general population study did not associate 
healthcare employment or household contact with 
someone who is a health care worker with HBV,117 
and a special population study did not associate 
being a health care worker or the spouse of one with 
HBV.126 
Low 0 0 0 0 0 0 0 0 Low 
 1 OBS29 Ever being in the military was not associated with 
HBV in a general population study.29 
Low 0 0 0 -1 0 0 0 0 Very Low 
HCV 2 OBS105,114 In any occupation, occupational blood exposure was 
associated with HCV among blood donors in one 
study,105 but work contact with blood was not 
associated with HCV in a general population study.114 
Low 0 -1 0 -1 0 0 0 0 Very Low 
 2 OBS104,116 Medical or dental job with frequent blood contact was 
not associated with HCV in one blood donor study104 
and was associated with lower prevalence of HCV in 
a general population study.116 
Low 0 -1 0 -1 0 0 0 0 Very Low 
 2 OBS30,114 Neither of two general population studies associated 
ever having served in the armed forces with 
HCV.30,114 
































































































 2 OBS104,113 Public safety job with frequent blood contact was not 
associated with HCV in one blood donor study.104 
Another study did associate having a job at a prison 
with having HCV.113 
Low 0 -1 0 0 0 0 0 0 Very Low 







HBV 3 OBS29,121,124 Having less than a high school education was 
associated with HBV in one general population study, 
compared with some college.29 In special population 
studies, one found a higher prevalence of HBV 
among students in 2-year colleges compared to 
those in 4-year colleges,124 and the other study found 
no relationship between years of education and 
HBV.121 
Low 0 -1 -1 0 0 0 0 0 Very Low 
HCV 5 
OBS30,104,106,108,113 
One blood donor study associated less education 
with HCV,104 and another associated having no 
college education with having HCV.106 One general 
population study associated having fewer than 
12 years of education with having HCV,30 but two 
others found no association between educational 
attainment and HCV.108,113 
Low 0 -1 0 0 0 0 0 0 Very Low 
HIV 2 OBS101,109 Neither of two general population studies found an 
association between having less than a high school 
education and having HIV.101,109 









































































































HBV 2 OBS121,125 One special population study did not associate 
homelessness with HBV.121 Another special 
population study did not associate homelessness, 
institutionalization, or other non-independent living 
arrangement with HBV.125 
Low 0 0 -1 -1 0 0 0 0 Very Low 
HCV 2 OBS30,113 In a general population, ever having been homeless 
was associated with an increased risk of HCV.113 
In the same study, annual income was not 
associated with HCV.  
Another general population study did not find any 
association with family poverty level and HCV.30 
Low 0 -1 0 -1 0 0 0 0 Very Low 
HIV 2 OBS101,111 Being homeless was associated with an increased 
prevalence of HIV in one general population study.111 
In another general population study, having a poverty 
index of less than one was not associated with 
HIV.101 










HBV No studies - - - - - - - - - - NA 
HCV 1 OBS108 One general population study associated insurance 
with HCV infection, with people on Medicaid having 
the highest prevalence.108 
Low 0 -1 0 0 0 0 0 0 Very Low 
HIV 2 OBS109,111 One general population study found a higher 
prevalence of HIV among people with no insurance109 
but a second did not.111 






































































































HBV 2 OBS29,125 Being divorced or separated was associated with a 
higher prevalence of HBV than any other status in 
one general population study.29 Being currently 
married was not associated with any difference in 
HBV prevalence than any other status in one special 
population study.125 
Low 0 0 0 0 0 0 0 0 Low 
HCV 1 OBS105 Being married was associated with a lower risk of 
HCV in one blood donor study.105 
Low 0 0 0 0 0 0 0 0 Low 
HIV 1 OBS101 Being married or cohabitating was associated with a 
lower risk of HIV in one general population study.101 
Low 0 0 0 0 0 0 0 0 Low 
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Table 43. Prevalence of Nonbehavioral Risk Factors among Potential Organ Donors 







>40 U/L Armstrong et al.
30
 2006 9% 13,113 General population, nationwide 






 2006 6% 5,733 General population, nationwide 
 Blood transfusion 
before 1992 
(participants aged 
at least 60 years) 
Armstrong et al.
30
 2006 16% 2,916 General population, nationwide 
 Blood transfusion Kaur et al.
116










 2006 19% 5,610 General population, nationwide 




 2008 28% 1,613 General population in N.Y.C. 
STDs STD diagnosis Mehta et al.
109
 2008 18% 16,696 Patients in urban medical care center 
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Table 44. GRADE for Question 4: Prevalence of Nonbehavioral Risk Factors 
Factor 
Quantity and Type 



































































































1 OBS*30 In one general population study, 
9% of participants had ALA 
>40 U/L.30 
High 0 -1 -1 0 0 0 0 0 Low 
Blood 
transfusion 
2 OBS30,116 In one general population study, 
the prevalence of ever having 
received a blood transfusion was 
20%.116 
In another, 6% of participants 
aged 20-59 years had received a 
blood transfusion before 1992, and 
16% of participants aged at least 
60 had.30 
High 0 -1 -1 0 0 0 0 0 Low 
Other infection: 
HSV-2 
2 OBS30,110 Two studies assessed the 
prevalence of herpes simplex virus-
2 (HSV-2) in general populations. 
In one, 19% of people aged 18-49 
tested positive.30 In the other, 
28% of adults did.110 
High 0 0 -1 0 0 0 0 0 Moderate 
Other infection: 
Other STD 
1 OBS109 Another study found that 18% of 
adults had had a STD diagnosis.109 
High 0 -1 -1 0 0 0 0 0 Low 
* Observational study 
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Question 5. What are the test characteristics of the screening methods 
available to detect HIV, HBV, and HCV in potential solid organ donors? 
Do test characteristics differ in particular populations and with donor 
clinical status (i.e., heart beating vs. non-heart beating donors OR adult 
vs. pediatric donors)? 
The purpose of this question is to summarize information and evidence on 35 diagnostic tests of interest, 
as designated by CDC. A list of these tests of interest is presented in Table 4 of the introductory section. 
Tests of interest include immunoassay tests and nucleic acid tests (NAT) currently used in the U.S. by 
Organ Procurement Organizations (OPOs), as well as, fourth-generation HIV and HCV antibody/antigen 
tests currently in use outside of the U.S. The p24 antigen test for HIV was not included because it is no 
longer used by OPOs. Additionally, an HCV antigen assay used in Europe was not included because the 
assay was licensed after the literature search was conducted. In this question, the following information is 
addressed: 
 U.S. FDA approval 
 Test format: type of test 
 Specimen collection: In particular, whether approved for use in non-heart-beating donors, which 
is primarily a consideration for testing tissue donors. Heart-beating potential organ donors are not 
deceased donors for the purposes of using these tests. 
 Window period: The duration of time between infection and when the test can detect infection 
 Turnaround time: The duration of time required for the test to be performed 
 Diagnostic performance characteristics: In particular, sensitivity and specificity. Measures of 
diagnostic performance are described in greater detail under Analysis Methods.  
To address this question, information will be provided in the following order: literature search methods 
and results; list of included peer-reviewed studies and gray literature; samples and study methods of peer-
reviewed publications; analysis methods used in this question; study assessment; methods of risk of bias 
and GRADE assessment of peer-reviewed publications; results summary, followed by data extraction 
tables and GRADE tables. 
Peer-reviewed publications and other types of information, as appropriate (see next paragraph), were only 
included if they presented information specific to the tests of interest as listed in Table 4. Information 
regarding any other tests was excluded unless the other test was used in reference to a test of interest. 
Information must have been reported for each test individually, not as part of a multiple-test algorithm, 
because the focus of this question is on the performance of individual tests. Highly selected data sets 
(such as seroconversion panels, or HIV-2 genetic diversity panels) were not included for the assessment 
of diagnostic performance due to both spectrum bias and lack of relevance to performance of the test in 
the U.S. in potential organ donors. Because they are influenced by disease prevalence, predictive values 
and likelihood ratios were only to be collected from studies that calculated them from data from 
reasonably relevant populations to the U.S. (such as clinical applications in a general population, or on 
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blood donors, not serial dilutions or other laboratory sets, or samples selected for being unusual or 
representative of an endemic area). 
Initial searches of bibliographic databases were for diagnostic instruments for HBV, HCV, or HIV. Once 
the list of included tests was generated, additional searches were performed specifically by each test’s 
name. The focus of these searches was to identify clinical literature regarding window period, turnaround 
time, and diagnostic performance characteristics. Because this strategy did not identify information for all 
of the listed tests, we also searched gray literature sources including FDA product labeling information, 
package inserts, manufacturer’s Web sites, and additional sources including the World Health 
Organization (WHO). FDA approval information was searched for all tests as well. We used these 
sources for information on turnaround time and window period but not other diagnostic characteristics 
(e.g., sensitivity and specificity), because these sources of information generally do not report sufficient 
information to enable assessment of the study design, quality, and other factors that impact the outcomes 
and the strength of the evidence. This is a particular concern given the potential for inaccuracy in these 
various sources of literature. Where data from sources other than clinical literature were used for the other 
characteristics, the source is clearly noted in the extraction tables. 
Three hundred and forty-eight potentially relevant articles were identified by the bibliographic searches. 
Most were excluded for not reporting on a test on the list of interest (including earlier generations of tests 
of interest). Most of the rest were excluded for not addressing an outcome of interest. Ultimately, 45 peer-
reviewed publications, each presenting at least one outcome for at least one data set, were included. 
Included publications, including data sets from those publications, and the outcomes they address are 
listed alphabetically by author in Table 45. This table also includes information on what test(s) of interest 
the publications investigated and which data sets were included. Ninety nine pieces of gray literature were 
reviewed for potentially useful data. These included literature from manufacturers’ Web sites (40), the 
internet (6), the Food and Drug Administration (FDA) (23), agencies in the United Kingdom (14), 
agencies from Australia (13), and items from the World Health Organization (3). Data from 26 pieces of 
gray literature reporting window period or turnaround time were included. These sources of information 
are listed in Table 46. Basic information on test format and approved uses were extracted from FDA 
approval documents and, for tests not approved in the U.S., manufacturers’ Web sites. 
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Table 45. Included Data Sets from Peer-reviewed Publications 
Citation Year 
Test 
Category Index Test(s) Data Set(s) 
Outcomes Included 
Reason Sample Set 
Excluded 

















































Blood donations and diagnostic 
test samples (clinical HIV 
submissions, antenatal syphilis 
submissions) combined 
(Tanzania) 
      




Blood donations (Cameroon)       
Anderson et al.132 1995 HCV EIA Abbott HCV 
EIA 2.0 
Blood donations (U.S.)       
Bamaga et al.133 2006 HCV NAT COBAS 
AmpliScreen 
HCV 2.0 
Blood donations (Saudi Arabia)       
Additional Information       
HIV NAT COBAS 
AmpliScreen 
HIV 1.5 
Blood donations (Saudi Arabia)        
Additional Information       











     
False-reactive EIA results      Over-selected 




     
Seroconversion samples 
(Commercial) 




Category Index Test(s) Data Set(s) 
Outcomes Included 
Reason Sample Set 
Excluded 












































Barrera et al.135 1995 HCV EIA, 
3rd 
generation 
Ortho HCV v3 
ELISA 
Seroconversion samples (U.S.)       




Diagnostic samples (France)       
Seroconversion panels 
(commercial) 
      
VIDAS DUO 
ULTRA 
Diagnostic samples (France)       
Seroconversion panels 
(commercial) 
      
Busch et al.137 2005 HIV NAT COBAS 
AmpliScreen 
HIV-1 v. 1.5 
Seroconversion samples (U.S.)       
HCV NAT COBAS 
AmpliScreen 
HCV v.2.0 









Category Index Test(s) Data Set(s) 
Outcomes Included 
Reason Sample Set 
Excluded 
















































Blood donors (U.K.)      No reference standard 
    Known positive samples with 
various subtypes 
     Overly selected/ specificity 
not appropriately reported 
(above) 
    Additional information       
    Seroconversion panels 
(commercial) 
      
Denoyel et al.139 2004 HCV EIA Advia Centaur 
HCV Assay 
Blood donors and hospitalized 
patients (France, Germany) 
 
Specificity 
     




     
Seroconversion panels 
(Commercial) 
      
Interference samples      Overly selected 
Diepersloot et 
al.140 
2000 HBsAg AxSYM HBsAg Clinical submissions (U.S.)       
Galel et al.141 2002 HCV EIA Abbott HCV 
EIA 2.0 
Blood donations (U.S.)       
Ortho HCV EIA 
3.0 




Category Index Test(s) Data Set(s) 
Outcomes Included 
Reason Sample Set 
Excluded 












































Huzly et al.142 2008 anti-HBs Advia Centaur 
anti-HBsAg 
Patients and healthcare workers 
(Germany) 
      
Additional Information       





Diagnostic samples (India)       
Commercial known-status 
samples 
      
Seroconversion panel (in-house)      Window period not 
reported 




High risk individuals (U.S.)       
Katsoulidou et 
al.145 




HCV and HIV patients (Greek)      Analytic sensitivity only 
Seronegative blood donors 
(Greek) 
     Sensitivity not reported; 
study must report both 
sensitivity and specificity to 
be included 
Seroconversion panels (Greek)       
HCV/HIV Co-infection (Greek)      Overly selected 




Category Index Test(s) Data Set(s) 
Outcomes Included 
Reason Sample Set 
Excluded 












































Kita et al.146 2009 HCV EIA Ortho EIA 3.0 Diagnostic samples (Japan)       
Seroconversion panel 
(Commercial) 
      
Advia Centaur 
HCV 
Diagnostic samples (Japan)       
Seroconversion panels 
(Commercial) 
      
Kleinman et al.147 2005 NAT HBV COBAS 
AmpliScreen 
HBV test 
Blood donations (U.S.)       






      





Diagnostic samples with known 
status (Korea) 
      
    p24 antigen subtype panel and 
p24 antigen sensitivity panel 
(Commercial) 
     Overly selected 
    Seroconversion panels 
(Commercial) 
      
    Low titer antibody panel 
(Commercial) 




Category Index Test(s) Data Set(s) 
Outcomes Included 
Reason Sample Set 
Excluded 












































    HIV antibody panel including 
various subtypes (Commercial) 
     Overly selected – 
diagnostic samples with 




Diagnostic samples with known 
status (Korea) 
      
   p24 antigen subtype panel and 
p24 antigen sensitivity panel 
(Commercial) 
     Overly selected 
   Seroconversion panels 
(Commercial) 
      
   Low titer antibody panel 
(Commercial) 
     Overly selected 
   HIV antibody panel including 
various subtypes (Commercial) 
     Overly selected – 
diagnostic samples with 
known status used 
preferentially  





HCV v. 2.0 
Seroconversion panels 
(Commercial) 
      





      




Category Index Test(s) Data Set(s) 
Outcomes Included 
Reason Sample Set 
Excluded 
















































Seroconversion samples (France)       
Laycock et al.152 1997 HCV EIA Abbott HCV v. 
2.0 
Potential cornea donors, most of 
whom positive on previous test 
(U.S.) 
      
Leon et al.153 1993 HCV EIA Abbott HCV 
EIA 2.0  
Unselected high-risk individuals 
plus known positives from archive 
(Spain) 
      




Negative samples (French)  
Specificity 
     
    Positive samples from various 
HIV endemic areas of the world, 
including mosaics and subtypes 
 
Sensitivity 
     
    Seroconversion panels 
(Commercial) 
      
   COBAS Core 
HIV Combi EIA 
Negative samples (French)  
Specificity 
     
    Positive samples from various 
HIV endemic areas of the world, 
including mosaics and subtypes 
 
Sensitivity 
     
    Seroconversion panels 
(Commercial) 




Category Index Test(s) Data Set(s) 
Outcomes Included 
Reason Sample Set 
Excluded 












































   Genscreen 
Ag/Ab HIV Ultra 
Negative samples (French)  
Specificity 
     
    Positive samples from various 
HIV endemic areas of the world, 
including mosaics and subtypes 
 
Sensitivity 
     
    Seroconversion panels 
(Commercial) 
      




     Sensitivity and specificity 
not assessed for this test 
in the publication 
   VIDAS HIV 
DUO Ultra 
Negative samples (French)  
Specificity 
     
    Positive samples from various 
HIV endemic areas of the world, 
including mosaics and subtypes 
 
Sensitivity 
     
    Seroconversion panels 
(Commercial) 
      
Ly et al.155 2006 HBV EIA Advia Centaur 
HBsAg 
Reference HBsAg panel (France) 
and HBsAg mutants (commercial) 
     No other outcomes of 
interest reported 




Positive samples from various 
HIV endemic areas of the world, 
including mosaics and subtypes 
 
Sensitivity 
     
    Negative samples  
Specificity 




Category Index Test(s) Data Set(s) 
Outcomes Included 
Reason Sample Set 
Excluded 












































    Seroconversion panel 
(Commercial) 
      
    Genscreen 
Plus Ag/Ab 
Positive samples from various 
HIV endemic areas of the world, 
including mosaics and subtypes 
 
Sensitivity 
     
    Negative samples  
Specificity 
     
    Seroconversion panel 
(Commercial) 
      
   Murex HIV 
Ag/Ab Combo 
Positive samples from various 
HIV endemic areas of the world, 
including mosaics and subtypes 
 
Sensitivity 
     
    Negative samples  
Specificity 
     
    Seroconversion panel 
(Commercial) 
      
   Vironostika Uni-
Form II Ag/Ab 
Positive samples from various 
HIV endemic areas of the world, 
including mosaics and subtypes 
 
Sensitivity 
     
    Negative samples  
Specificity 
     
    Seroconversion panel 
(Commercial) 




Category Index Test(s) Data Set(s) 
Outcomes Included 
Reason Sample Set 
Excluded 



















































      
Additional information       
HIV-1 p24 antigen panel infected 
with HIV-1 M subtype B 
(Commercial) 
     Overly selected 




Panel with various HIV subtypes, 
including group M subtypes A, B, 
C, D, CRF A/e, F, G, group O 
(Commercial) 
     Sensitivity not reported; 
study must report both 




      
Murex HIV 
Ag/Ab Combo 
Panel with various HIV subtypes, 
including group M subtypes A, B, 
C, D, CRF A/e, F, G, group O 
(Commercial) 
     Sensitivity not reported; 
study must report both 




      
VIDAS HIV 
DUO ULTRA 
Panel with various HIV subtypes, 
including group M subtypes A, B, 
C, D, CRF A/e, F, G, group O 
(Commercial) 
     Sensitivity not reported; 
study must report both 








Category Index Test(s) Data Set(s) 
Outcomes Included 
Reason Sample Set 
Excluded 

















































plus ) EIA  
Blood and plasma donors, 
including some international 
donors selected for being 
representative of non-subtype-B 
HIV-1 (78% U.S.) 
      
Seroconversion panels 
(Commercial) 




Blood and plasma donors, 
including some international 
donors selected for being 
representative of non-subtype-B 
HIV-1 (78% U.S.) 
      
Seroconversion panels 
(Commercial) 
      
HIV NAT COBAS 
AmpliScreen 
HIV-1 Test 1.5 
Blood and plasma donors, 
including some international 
donors selected for being 
representative of non-subtype-B 
HIV-1 (78% U.S.) 
     Seroconversion not 
reported for this test 
Romano et al.160 2005 HBV NAT COBAS 
AmpliScreen 
HBV v. 2.0 
Blood donors (Probably Italian, 
unclear in publication) 
     No reference standard 
    Blood donors with previous 
negative test results elevated 
ALT, chronic HCV 




Category Index Test(s) Data Set(s) 
Outcomes Included 
Reason Sample Set 
Excluded 












































    HBV DNA nucleic acid panel 
(Commercial) 
     Overly selected 
    Seroconversion panels 
(Commercial) 
      




Mixed set comprised of U.S. 
blood donors (35%), U.S. clinical 
samples (18%), high-incidence 
population in Trinidad (40%), 
STD clinic attendees in 
Bahamas (3%), confirmed HIV-1 
group 0 from Cameroon (0.4%), 
confirmed HIV-2 samples from 
Cote d’Ivoire (0.4%), p24 antigen-
only (0.3%) 
Diagnostic performance reported 
for all samples together, and 
sample groups separately 
     For U.S. sample, PPV & 
NPV only reported for 
patients seeking HIV tests 
(population may have 
different prevalence than 
potential organ donors). 
Seroconversion panel       





Blood donors (Ethiopia)       




Blood donors  
Specificity 
     
    Hospital patients  
Specificity 




Category Index Test(s) Data Set(s) 
Outcomes Included 
Reason Sample Set 
Excluded 












































    Commercial panels tested 
together: Infected with HIV-2 
group M subtypes; Non-staged 
individuals infected with unknown 
HIV-1 subtypes; Individuals with 
HIV-2 living in endemic areas; 




      
    Seroconversion panels       
Sun et al.164 1999 HCV NAT AmpliScreen 
HCV 2.0 
Blood donors      No outcomes of interest 
reported 
Known positive, genotypes 1a, 
1b, 2, 2b, 3a, 5a, 6a, from 
archives 




      
Van Binsbergen et 
al.165 





HIV-1 sub-typed samples with 
A through F, and group O 
(Yaounde and Cameroon) 
     Overly selected (sub-types 
only) 
Samples with human anti-mouse 
antibody 








Category Index Test(s) Data Set(s) 
Outcomes Included 
Reason Sample Set 
Excluded 












































Van Binsbergen et 
al.166 





Worldwide HIV-1 Performance 
Panel, including various 
subgroups (group M subtypes A 
through F, and group O) 
(Commercial) 
     Specificity not reported; 
study must report both 




      








     




     
Co-infected HIV-1/HCV samples  
Sensitivity 
     
Negative samples   
Specificity 
     
Seroconversion panels 
(Commercial) 
      
Vrielink et al.167 1995 HCV EIA Ortho 3.0 HCV 
EIA 
Volunteer random blood donors 
(Dutch) 
      
Vrielink et al.168 1995 HCV EIA Ortho 3.0 HCV 
EIA 
Blood donor samples submitted 
for characterization because of 
initial positive result, patients with 








Category Index Test(s) Data Set(s) 
Outcomes Included 
Reason Sample Set 
Excluded 












































    Positive blood donors’ serial 
dilutions 
     No outcomes of interest 
    First-time blood donors  
Specificity 
     




Seroconversion panels       
Dilutions of cell culture 
supernatants with different HIV-1 
subtypes (incl. B, E, F, G, H, O) 
     Overly selected, not 
clinical samples 
Interference panel      Overly selected 
Additional Information       
Weber et al.170 2002 HIV 4th 
generation 
COBAS Core 
HIV Combo EIA 
Seroconversion panels       
    Acute infection panels      Overly selected 
    Known positive samples from 
patients in different stages of 
HIV-1 and HIV-2 
     Overly selected 
    Sub typed samples from different 
geographical locations 
     Overly selected 
    Dilutions of cell culture 
supernatants from cells infected 
with different HIV-1 subtypes 




Category Index Test(s) Data Set(s) 
Outcomes Included 
Reason Sample Set 
Excluded 












































    Performance panels, low-titer or 
mixed titer (Commercial) 
     Overly selected 




     




     
    Interference panel      Overly selected 
Willoughby et al.171 1989 HIV 4th 
generation 
Coulter HIV-1 
p24 Ag Assay 
Blood donors, known seropositive 
samples, spinal cord fluid, 
interference samples 
     No other outcomes 
reported 
Additional Information       
Yang et al.172 2001 HIV NAT COBAS 
AmpliScreen 
HIV-1 v.1.5 
Known negative blood donors       Specificity not reported; 
study must report both 
sensitivity and specificity to 
be included 
Seroconversion panel       
Group M subtype panel      Overly selected 




Category Index Test(s) Data Set(s) 
Outcomes Included 
Reason Sample Set 
Excluded 












































Yang et al.173 1999 HIV NAT AmpliScreen 
HIV-1 v.1.5 
Genotype panel      Overly selected 
Blood donors, seronegative      Sensitivity not reported; 
study must report both 
sensitivity and specificity to 
be included 
Interference panels      Overly selected 
Seroconversion panels       
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Table 46. Included Data Sets from Gray Literature 














ARCHITECT HIV Ag/Ab Combo  (None)   Manufacturer Web site 
product information 
(Seroconversion also 
reported but only for 
selected 3 or 31 panels, 



















2008 4th generation 
HIV EIA 
ARCHITECT HIV Ag/Ab Combo 
Assay 
AxSYM HIV Ag/Ab Combo 
GENSCREEN Ultra HIV Ag/Ab 
Murex HIV Ag/Ab Combination 
Vironostika HIV Uni-Form II 
Ag/Ab 
20 seroconversion panels, with 
comparative data for 18 of them 
  Independent public health 
laboratory evaluation 
Burgess et al.178 2001 4th generation 
HIV EIA 
AxSYM HCV version 3.0  22 seroconversion panels   Independent public health 
laboratory evaluation 
Cooray et al.179 2003 4th generation 
HIV EIA 
AxSYM HIV Ag/Ab Combo 
Murex HIV Ag/Ab Combination 
Genscreen PLUS HIV Ag/Ab 
Vironostika HIV Uni-Form 
Ag/Ab 
35 seroconversion panels   Independent public health 
laboratory evaluation 
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Coulter HIV-1 p24 Antigen 
Assay 
5 seroconversion panels   Manufacturer Web site 
product information 
Curtis et al.181 2006 4th generation 
HIV EIA 
Genscreen ULTRA HIV Ag/Ab 
Murex HIV Ag/Ab Combo 
Vironostika HIV Uni-Form 
Ag/Ab 
21 seroconversion panels   Independent public health 
laboratory evaluation 
Dean et al.182 2006 HCV 
4th generation 
MONOLISA HCV Ag/Ab ULTRA 19 seroconversion panels   Independent public health 
laboratory evaluation 
Delieu et al.183 2001 4th generation 
HIV EIA 
Murex HIV Ag/AB Combination 
EIA 








HCV NAT COBAS AmpliScreen HCV Test 9 seroconversion panels   FDA documentation 







HBV NAT COBAS AmpliScreen HBV Test 
Ortho HBsAg 
40 seroconversion panels   FDA documentation 







HBV HBc ADVIA Centaur HBc 7 seroconversion panels   FDA documentation 







HBV Core PRISM HBcore None reported   FDA documentation 
including package insert 
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HCV assay ADVIA Centaur HCV Assay 
Ortho HCV v. 3 
23 seroconversion panels   FDA documentation 







HBV HBsAg ADVIA Centaur HBsAg 6 seroconversion panels   FDA documentation 









HIVAB HIV-1/HIV-2 (rDNA) EIA 9 seroconversion panels   FDA documentation 







HIV/HCV NAT ProCleix HIV-1/HCV Assay 10 HIV seroconversion panels 
10 HCV seroconversion panels 
  FDA documentation 








HIV NAT COBAS AmpliScreen HIV-1 
Test 
Coulter HVI-1 p24 Ag test 
41 seroconversion panels   FDA documentation 







HBsAg EIA Genetic Systems HBsAg EIA 
3.0 
21 seroconversion panels   FDA documentation 







HBsAg Assay AxSYM HBsAg Assay 15 seroconversion panels   FDA documentation 
including package insert 
317 
















Genetic Systems HIV-1/HIV-2 
Plus O EIA 
50 seroconversion panels   FDA documentation 





Innotest HCV Ab IV 
Ortho HCV 3.0 






HBV HBsAg  Genetic Systems HBsAg EIA 
3.0 








2004 4th generation 
EIA 
Enzygnost HIV Integral II 
Genscreen Plus HIV Ag/Ab 
Murex HIV Ag/Ab Combination 
Vironostika HIV Uni-Form II 
Ag/Ab 





Samples and Study Methods in Peer-reviewed Publications 
Table 47 shows a summary of the general study and sample characteristics for each of the included peer-
reviewed publications. We sometimes refer to the tested blood sets as samples because not all came from 
clinical populations (most were purchased from laboratory supply companies). Publications were first 
categorized by whether or not the test(s) of interest are currently in use by U.S. O.P.Os. Tests were further 
categorized as immunoassays (e.g., EIA) or nucleic acid tests (NAT). All were further subdivided by 
which virus(es) they are intended to detect. (Where studies addressed tests of interest from more than one 
category, the study information is repeated for each category. The test pertinent to the category is bolded.)  
For each of the publications, information regarding the national origin of the samples, the sources(s) of 
the samples, how the samples were selected, references standard(s) employed, and source(s) funding 
(if reported) is listed. Many of these studies were conducted internationally, and some conducted 
domestically used international samples. Although most of the commercial samples were purchased from 
U.S. companies, many of those U.S.-purchased panels had samples from all over the world. None of the 
sources of samples were potential organ donors. Publications used samples from a variety of sources (and 
often, multiple sources within the same publication), including clinical samples from routine screening or 
diagnosis, blood donor samples, and commercially purchased or archived known-status samples and 
seroconversion panels. Correspondingly, the prevalence of infection ranged widely, from a very small 
fraction of 1% to over 60% (not including seroconversion panels or all known-positive sets). Some 
sample sets were unselected (i.e., part of a consecutive or randomly selected sample), while others were 
selected for known characteristics (e.g., known infection or known non-infection, known seroconversion). 
All samples appear to have been drawn from living individuals, with the exception of one publication. 
None appear to have specifically studied pediatric populations. Everything from previous-generation EIA 
to NAT to exhaustive algorithms were employed as reference standards. Well-defined commercially 
purchased samples did not always have the reference standard explicitly described in the study, but those 
that did typically used multiple confirmatory analyses and quantitative analyses to determine the sample 
status. Some studies report funding from the manufacturer and some appear to have been publicly funded 
through federal health organizations, but for most the funding source was not reported. 
In gray literature, window periods were always determined relative to other tests using seroconversion 
panels. Methods used to determine turnaround time were not reported. 
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Table 47. General Study and Sample Characteristics of Peer-reviewed Studies 
Virus/ Test 












Clearly Stated Funding Source 










1994 France Obstetric samples 
(n = 1,546) (for 
specificity) 
Prevalence 0.05% 
HIV positive samples 
(n = 7) (for sensitivity) 
Seroconversion 
samples (8 samples) 
Unselected 
prenatal screening 













test with Western 
blot (WB) 
confirmation 











HIV-1 Test 1.5 
Owen et 
al.159  








U.S. blood donors 
(n = 997), 
international donors 
(n = 97). 
samples from 
Cameroon (n = 114) 
HIV-2 specimens from 
Ivory Coast (n = 32) 
and commercial HIV-2 
specimens (n = 2) 
Prevalence 56% (53% 
HIV-1, 2% HIV-2) 
Seroconversion 
panels (15 panels, 
183 specimens) 
For defined 
properties (at left); 
all commercially 
purchased 





































2000 U.S. Clinical submissions 
for HBV tests 
(n = 200) 
Prevalence: 6% 

















2008 Germany Patients and 
healthcare workers 
(n = 200) 
Prevalence of surface 
antigen (including 
vaccinated individuals 
73%); Core antigen 
12% 












No None reported 
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Virus/ Test 












Clearly Stated Funding Source 




1995 U.S. Blood donors 
(n = 21,431) 
Prevalence 0.6% 







No None reported 
 Laycock et 
al.152 
1997 U.S. Potential cornea 




apparently not for 
any particular 
characteristics 







 Leon et al.153 1993 Spain High-risk individuals 
(n = 398) 
Prevalence 2% 
Known positive blood 
donations from 










 Blood donors 
who were known 
to have tested 





11 methods,  
Negatives by 
consensus 
Those reactive in 
at least one also 
tested with 
supplemental 
assays to confirm 
positives 
No Not reported, but 


















Clearly Stated Funding Source 






2002 U.S. Blood donors 

























panels (20 panels) 
For specificity, blood 
donors (n = 5,015) 

















Blood donors and 
hospitalized 
patients: Abbott 





No  None reported 
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Virus/ Test 












Clearly Stated Funding Source 
 Advia 
Centaur HCV 
Ortho 3.0 EIA 







for HCV tests 
















other tests to 
define negativity 
(Ortho Quick 
Chaser HCV Ab, 
VITROS HCV, 
Ortho HCV Ab PA 










(RIBA III, or 
RNA PCR) 
No None reported 








(n = 21) 
For 
seroconversion 
Known status No None reported, 



















Clearly Stated Funding Source 
  Vrielink et 
al.167  
1995 The Netherlands Blood bank archives 





Ortho 2.0 HCV 
EIA 
For sensitivity, 
Ortho 2.0 HCV 
EIA, PCR, RIBA-2 
No None reported 
  Vrielink et 
al.168 
1995 The Netherlands Tested together: 
Repeatedly positive 
blood donors (403 
samples), non-A non-








For properties at 
left 
PCR, RIBA-2 No None reported 
Tests currently in use in U.S. Organ Procurement Organizations (OPO): NAT 








2006 Saudi Arabia Blood donors 







No None reported 
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Virus/ Test 
































available at least 


























HIV-1 Test 1.5 
Owen et 
al.159  








U.S. blood donors 
(n = 997), 
international donors 
(n = 97). 
samples from 
Cameroon (n = 114) 
HIV-2 specimens from 
Ivory Coast (n = 32) 
and commercial HIV-2 
specimens (n = 2) 
Prevalence 56% 






properties (at left); 
all commercially 
purchased 


























panels (10 panels) 
For 
seroconversion 
Known status  No None reported, 


















Clearly Stated Funding Source 





panels (10 panels)  
For 
seroconversion 
Known status No None reported, 




HCV NAT COBAS 
AmpliScreen 






2006 Saudi Arabia Blood donors 



























available at least 











No Funded in part by 
National Heart, 
























No Not reported, 




























Known status No None reported, 









2005 U.S. Blood donors 



















NAT, and DNA 
quantification. 
No Roche Molecular 
Systems 
  Romano et 
al.160 
2005 Commercial Seroconversion 




Known status No None reported 
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Virus/ Test 



































available at least 































  Jackson et 
al.144 
2002 U.S. High-risk individuals’ 
archived samples 
(n = 539) 
Prevalence:  
2.2% HIV only, 
48% HCV only, 
2% co-infected 
At high risk for 
HIV and HCV 
“Standard” 
serological test, 




No Not reported, but 
3 co-authors 
employed at 
Gen-Probe Inc.  
  Katsoulidou 
et al.145 
2004 Greece Seroconversion 
panels from dialysis 
patients (25 panels) 
For 
seroconversion 
Known status No None reported, 
but Chiron Corp. 
provided 
reagents. 
  Kolk et al.148 2002 Commercial Commercial 
seroconversion panels 
(26 panels HIV, 
24 panels HCV) 
For 
seroconversion 





















Clearly Stated Funding Source 
  Vargo et 
al.128 
2002 U.S.  
Commercial 
Blood donors 




(n = 2,015:  
1,040 HIV infected, 
1,015 HCV infected)) 
for sensitivity 
Seroconversion 
panels (10 panels 
HIV-1 and 10 HCV) 
Blood donors 







nce and/or p24 
Ag test for HIV 
and RIBA for 























Korean samples in 






















No None reported 
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Virus/ Test 
























Ly et al.154 2007 France 
Commercial 
Lab archives:  
For specificity: 





endemic areas (669) 
Seroconversion 













negative if all 
samples run were 
negative 













submitted to university 
hospital microbiology 
department 
(n = 1,443) 
Prevalence: 0.8%  
Commercial panel: 
Seroconversion 
panels (14 panels, 













Western blot or 
HIV-1 antigen 
assay or 




tests of interest 
negative. 
No None reported 
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Virus/ Test 












Clearly Stated Funding Source 




















































tested together for 
sensitivity:  
HIV-1+ (n = 453), 
HIV-2 from endemic 
area (n = 108), 
HIV+ not staged or 
genotyped (n = 107) 
HIV-1 group O 
(n = 19) 
HIV-1 with p24 Ag 
(n = 50) 
Blood donors 

















Monitor RNA test, 
Lav Blot I or 
Lav Blot II for 
confirmation 


















Clearly Stated Funding Source 


















(94 panels, 709 sera) 
Assessed together for 
specificity: blood 
donor samples 
(n = 7,579), daily 
routine samples 




samples (n = 1,222) 
Assessed together for 
sensitivity: acute 
positives (n = 32), 
HIV-1 positive 
(n = 620), HIV-1 
subtyped (n = 462), 
HIV-2 positive 
(n = 462), HIV p24 
Ag/Ab positive 
(n = 120), commercial 
performance panel 
(n = 102) 














or negative WB, 
or WB 
indeterminate and 
p24 Ag negative 
Positives 







for testing WB 
and confirmation 
assays 
 Coulter HIV-1 
p24 Ag Assay 
Willoughby 
et al.171 
1989 U.S. Seropositive samples 
(from 34 individuals) 
For 
seroconversion 
Known status No National Institutes 
of Health  
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Virus/ Test 


















2004 Cameroon Blood donors 


















8 other tests: 











HIV Blot 2.2  
No National French 
















Clearly Stated Funding Source 
  Saville et 
al.161 




Mixed set comprised 
of U.S. diagnostic 
samples (n = 503) 
U.S. blood donors 
(n = 1,010)  
High-incidence 
population in Trinidad 
(n = 1,141)  
STD clinic attendees 
in Bahamas (N = 83) 
Confirmed HIV-1 
group 0 from 
Cameroon (n = 10)  
Confirmed HIV-2 
(n = 16) 
Commercial panels: 
1 panel HIV-1 group 
M antigen reactive 





(10 panels with 
n = 74) 
Mostly unselected 






Known status (for 
panel and known 
samples) 
Genetic Systems 
HIV-1 and HIV-2 
ELISA, or rDNA 
EIA and HIV AG-
1 monoclonal p24 








Yes Funded by 
bioMerieux 











Known status No Roche 
Diagnostics 

















Clearly Stated Funding Source 








Ly et al.158 2001 Commercial 
panels 
Seroconversion 
panels (19 panels) 
For 
seroconversion 










2006 Tanzania Submitted for 
diagnostic HIV testing 
(n = 361) or antenatal 
testing (n = 511) in 
hospital lab, or 
by blood donors 
(n = 508) 
Prevalence: 
22% overall confirmed 
Not reported, 






anti-HIV 1/2 Plus 
Vironostika HIV 






antibody assay.  
For 
discrepancies, 
Innotest p24 Ag 
assay. 









provided by tests 
manufacturers 
 Iqbal et al.143 2005 India  Clinical samples from 
AIDS counseling 






















Clearly Stated Funding Source 














 Seyoum et 
al.162 
2005 Ethiopia 
(n = 408) 
Blood donors 
Prevalence: 3.4% 
Unselected Amplicor DNA 
PCR 
ExaVir Load Test 
for HIV reverse 
transcriptase (v.2) 
Amplicor HIV-1 




No Collaboration of 
several public 
health services, 















Known status No None reported. 






  Van 
Binsbergen 
et al.166 
1999 Commercial Seroconversion 
panels (10 panels) 
For 
seroconversion 






























2005 France Blood donors (n = 12), 
Hemodialysis patients 






(Based upon tests 
and follow-up) 
No Not reported. 
All authors 
appear to be 
affiliated with 




















Known status No Not reported, 







The characteristics of interest for this question are turnaround time, window period, and diagnostic 
performance. The methods used to assess each of these outcomes differ. The following paragraphs define 
those characteristics and explain the procedures used to collect information regarding them. In data 
extraction tables, data are presented separately for each test because results may vary by test, even within 
the same generation. 
Turnaround Time 
Turnaround time is the duration of time required for a sample to be fully assessed. As this information 
was sparsely reported in clinical literature, we also extracted relevant data from other sources, particularly 
review articles and grey literature including primary technology assessments and package insert 
information. Where no other data were available we also extracted similar information such as “run time.” 
Note that “run time” is only the analytic component of turnaround time and does not include time needed 
for specimen preparation and ost-analytic reporting time. These instances are clearly noted in the data 
tables.  
Window Period 
Window period refers to the duration of time between infection and test positivity. The information 
regarding window periods comes from using the test of interest on seroconversion panels. Seroconversion 
panels are series of blood draws from patients who eventually become seropositive. They are typically 
collected from people at high risk for infection. Although a few investigators studied their own in-house 
seroconversion panels, most such panels were purchased from laboratory supply companies. These tests 
enable estimation of time to positive test result from first blood collection. However, the first day of blood 
collection may not coincide with the day of infection. Also, these samples are typically collected at 
irregular intervals, not daily. These limitations cloud the estimation of the period of time between 
infection and when the test detects infection. Studies generally reported the difference in window period 
between two tests (e.g., Test 2 detected infection an average of 5 days later than Test 1). This type of 
information comprises the information in the results section on window period. No information was 
identified that captured absolute window periods using actual samples. 
Diagnostic Performance 
The most commonly used study design to evaluate the accuracy of a diagnostic test is the diagnostic 
cohort study, in which all enrolled patients are examined with both the diagnostic test of interest and the 
accepted reference standard test. “Accuracy” is defined as the proportion of times the test of interest 
correctly categorizes an individual as having disease or not. The accepted reference standard test 
accurately categorizes the patient as having infection or not. (A reference standard capable of determining 
the true infection status of the patient is sometimes referred to as the “gold standard.”) The accuracy of 
the test of interest is determined with reference to the infection status of the patient, as determined by the 
reference standard, as shown in Table 48. The information in this table can be used to calculate sensitivity 
and specificity of the test of interest, and where the prevalence of disease in the tested data set is similar 
to the prevalence in the target population, can be used to determine predictive values and likelihood ratios 
(these terms are defined in the text following the table). 
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Table 48. Determining Diagnostic Performance 
  True Status (Reference Standard) 
  Infected Not Infected 
Test of interest Positive True Positive False Positive 
Negative False Negative True Negative 
 
However, because there are no perfect tests for the diagnosis of HBV, HCV, or HIV, no true single gold 
standard test currently exists. True disease state would be most accurately determined using information 
from more than one source (e.g., confirmatory tests, clinical assessment), possibly with repeat testing at a 
follow-up time to confirm negatives (after a window period has passed). However, for the purposes of 
identifying as much information as possible for inclusion in this report, data were collected without regard 
to the accuracy of the reference standard (although studies that employ poor reference standards will be 
downgraded for study design and quality). It is important to bear this in mind when assessing the 
extracted data because the reference standard influences diagnostic performance data. This is particularly 
true when a more sensitive test is compared to a less sensitive test. For instance, if the test of interest is 
more sensitive than the reference standard and no additional discriminatory tests are performed, positives 
that the test of interest catches but the reference standard misses will be misclassified as false positives 
and specificity will be underestimated. (For this reason we refer to these outcomes as measures of 
“Diagnostic Performance” rather than “Diagnostic Accuracy.”) In the data extraction tables, the reference 
standard used is always presented alongside the diagnostic performance data. Where more than one set of 
information is reported for a particular test of interest, greatest heed should be paid to the statistic 
determined using the most accurate reference standard(s). 
Commonly used diagnostic performance measures are calculated from the type of information provided in 
Table 48 and include sensitivity and specificity, predictive values, and likelihood ratios. Sensitivity is the 
proportion of people with the infection (as determined by the reference standard) that the test of interest 
correctly recognizes as positive. A test with high sensitivity will rarely misclassify people with the disease 
as not having the disease (the test has a low rate of false-negatives). Specificity is the proportion of people 
without infection (as determined by the reference standard) that the test of interest correctly recognizes as 
negative. A test with high specificity will rarely misclassify people without the disease as diseased (it has 
a low rate of false-positives). Sensitivity and specificity are both expressed on a scale of 0% to 100%, 
with greater values showing more agreement between the test of interest and the reference standard, and a 
value of 50% being correct as frequently as random guessing. However, knowing the sensitivity and 
specificity of a test does not tell you whether a particular patient with a positive or negative test is 
infected or not. 
Other measures of diagnostic performance are more clinically applicable. The positive predictive value 
(PPV) of a test is the probability of a patient having the disease following a positive test result. The 
negative predictive value (NPV) is the probability of a patient not having the disease following a negative 
test result. Likelihood ratios indicate how much more likely patients with the disease are to have that 
particular result than patients without the disease. Positive likelihood ratios (PLR) indicate how much 
more likely people with infection are to have a positive test result, and negative likelihood ratios (NLR) 
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indicate how much more people with infection are to have a negative result. Values of greater than one 
suggest infection, and values of less than one suggest not having infection. Unlike sensitivity and 
specificity, predictive values and likelihood ratios are influenced by the prevalence of the disease in the 
population of patients being tested. For this reason, we did not report (or calculate) predictive values or 
likelihood ratios from data not applicable to potential organ donors. 
Diagnostic performance measures typically involve a trade-off between counterpart metrics. For instance, 
increasing sensitivity (catching more of the true positives) may be at the expense of decreasing specificity 
(more false positives too). Acceptable thresholds for diagnostic performance and trade-off between 
sensitivity and specificity will vary by intended use of the test. 
Assessment of Peer-reviewed Studies 
We assessed the design and risk of bias (quality) of the peer-reviewed studies and rated the strength of the 
evidence using guidelines proposed by the GRADE working group (Schunemann et al. (2008)
2
; also 
available online through links found at the GRADE Web site.) We assessed studies reporting diagnostic 
characteristics using these protocols. It is likely that there is an interaction between study design and 
study limitations/risk of bias, with the lower-rated studies providing less reliable results. Where multiple 
studies report data on the same test, the study or studies with the fewest detractions on quality should be 
considered more reliable.  
We did not assess turnaround time because most of that information was not evidence-based. We did not 
assess window period in this manner either, because much of the information came from sources other 
than peer-reviewed publications and insufficient information was reported to assess them in full, and 
because there was no information directly pertinent to absolute window period. 
Study Design 
According to the GRADE diagnostics rating guidance, study design should initially be considered “high” 
quality if the study assesses patients with diagnostic uncertainty (e.g., unknown infection status) and 
comparison of results of test of interest with an appropriate reference standard.
2
 The following paragraphs 
describe the standards we used to determine appropriateness of reference standard and diagnostic 
uncertainty. Studies that fulfilled both of these criteria were initially rated as “high.” Studies that fulfilled 
only one were initially rated as “moderate.” For evidence bases comprised of more than one study, we 
used the median number of items to determine the overall initial GRADE rating. Individual study design 
factors are itemized in Table 49. 
Reference Standard 
As described in the Methods section, the correctness of the reference standard in deeming whether or not 
the sample is infected influences the diagnostic characteristics reported in that study, because all 
characteristics are calculated with reference to that standard. When a reference standard mis-categorizes 
the true status of samples, correct identification of samples by the test of interest will be considered 
wrong. An example of a test that is not reasonable could be an earlier generation of the test of interest. 
Because a first-generation EIA should be less sensitive than a third generation test, it is an inappropriate 
reference standard and will lead to positive samples identified by the more sensitive 3
rd
 generation that 
were not recognized by the older test being misclassified as false positives rather than true positives. If the 
older test has more frequent false positives, the sensitivity of the newer test will be underestimated. 
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Although another EIA may be an appropriate reference standard for specificity (to confirm negatives), a 
NAT or Western blot (WB) would have been more appropriate reference standards for sensitivity (to 
confirm positives) or to resolve discrepancies between the EIAs. However, because no single test is 
always correct, the most accurate way to determine the true status of the sample is to use multiple testing 
methods, including using additional tests to resolve discrepant findings between the test of interest and 
the reference test, and to confirm positives. Clinical information could also contribute to the definitive 
status. In addition, to determine whether either the reference test or the test of interest may have both 
misclassified an infected sample as negative, samples should be drawn again after completion of a 
window period. Such practices could provide a very convincing and definitive reference standard by 
which to judge the characteristics of the test of interest. Well-characterized commercially purchased 
samples (such as from a laboratory supply company) should also provide a very accurate reference 
standards. Commercial samples are typically characterized using a variety of tests, including confirmatory 
tests and quantitative tests for positive samples. 
Diagnostic Uncertainty 
Diagnostic uncertainty pertains to whether the infection status of a sample is known before study 
enrollment. Selecting individuals based upon their infection status is likely to cause spectrum bias. 
Spectrum bias is mostly an issue of external validity; however, it may also bias diagnostic performance 
characteristics. If only patients who are either infected or uninfected are selected for inclusion, the study 
results generally suggest the test is more accurate than it really is. Spectrum bias would be best controlled 
for by enrolling an unselected (preferably consecutive or random) group of potential organ donors. Other 
unselected populations, such as general populations or blood donors, may provide reasonable substitutes, 
although these populations may differ in unknown way from potential organ donors (the characteristics of 
whom have been poorly described), including prevalence of infection and severity of disease. When test 
performance is measured within a cohort of individuals with unknown disease status representative of the 
target population, the study is assessing “clinical” performance. Such studies minimize the potential 
influence of spectrum bias and provide the best approximation of real-world use. 
Studies that only assessed sensitivity or specificity (or only positive or negative likelihood ratios or 
predictive values) were excluded from the evidence base. We included studies that reported both 
sensitivity and specificity with the intent of assessing both counterpart statistics derived from testing the 
same set of samples, to assess “clinical” diagnostic performance. However, some studies assessed 
sensitivity in known infected samples only and specificity in known uninfected samples only. 
Characterized infected and uninfected samples were purchased from laboratory supply companies or 
retrieved from laboratory archives. This type of a study is assessing “analytic” performance. Such studies 
may not accurately represent the performance of the test in real-world use (typically, overestimation can 
be expected) and are ripe for spectrum bias. They may also be susceptible to further potential bias if no 
blinding occurs, especially if investigators have a vested interest in any particular test(s). Because the true 




Table 49. Study Design Items for Diagnostic Performance 
Virus/ Test 
Type 
















Genetics System (GS) HIV-1/HIV-2 Plus 0 EIA Bio-Rad 
Laboratories 
Owen et al. 
2008159 
 - Moderate Moderate 
HIVAB HIV-1/HIV-2 (rDNA) EIA Abbott Laboratories Barbe et al. 
1994134 
 - Moderate  Moderate 
Owen et al. 
2008159 




Abbott AxSYM HBsAg Assay Abbott Laboratories Diepersloot et al. 
2000140 
  High High 
Abbott PRISM HBsAg Abbott Laboratories No studies - - - - 
ADVIA Centaur HBsAg Assay Siemens Healthcare 
Diagnostics 
Huzly et al. 
2008142 
 - Moderate Moderate 
Genetic Systems (GS) HBsAg EIA 3.0 Bio-Rad 
Laboratories 





Ortho Antibody to HBsAg ELISA Test System 3 Ortho Clinical 
Diagnostics 





Abbott PRISM HBcore Abbott Laboratories No studies - - - - 
 ADVIA Centaur HBc Total Assay Siemens Healthcare 
Diagnostics 
















 AxSYM Core 2.0 Abbott Laboratories No studies - - - - 
 CORZYME Abbott Laboratories No studies - - - - 
 Ortho HBc ELISA Test System Ortho Clinical 
Diagnostics 
No studies - - - - 
HCV Abbott HCV EIA 2.0 Abbott Laboratories Anderson et al. 
1995132 
-  Moderate High 
Laycock et al. 
1997152 
  High 
Leon et al. 
1993153 
  High 
ADVIA Centaur HCV assay Siemens Healthcare 
Diagnostics 
Denoyel et al. 
2004139 
 - Moderate High 
Kita et al.  
2009146 
  High 
AxSYM Anti-HCV Abbott Laboratories No studies - - - - 
Ortho HCV Version 3.0 ELISA Test System Ortho Clinical 
Diagnostics 
Kita et al.  
2009146 
  High High 
Vrielink et al. 
1995167 
  High 
Vrielink et al. 
1995168 
















Tests currently in use in U.S. Organ Procurement Organization (OPO): NAT 
HIV NAT COBAS AmpliScreen HIV-1 Test v. 1.5 Roche Diagnostics Bamaga et al. 
2006133 
-  Moderate Moderate 
Owen et al. 
2008159 
 - Moderate 
HCV NAT COBAS AmpliScreen HCV Test version. 2.0 Roche Diagnostics Bamaga et al. 
2006133 
-  Moderate Moderate 
HBV NAT COBAS AmpliScreen HBV Test Roche Diagnostics Kleinman et al. 
2005147 
  High High 
HCV and HIV-1 
NAT 
ProCleix HIV-1/HCV Assay Gen-Probe 
Incorporated 
Jackson et al. 
2002144 – HIV 
  High Moderate 
Vargo et al. 
2002128 – HIV  
 - Moderate 
Jackson et al. 
2002144 – HCV 
  High 
Vargo et al. 
2002128 – HCV 
 - Moderate 
Vargo et al. 
2002128 – 
Co-infected 
















Tests not in use in U.S. Organ Procurement Organization (OPO): 4th generation Ag/Ab Immunoassays 
HIV 
4th generation 
ARCHITECT HIV Combo Abbott Laboratories Kwon et al. 
2006149 
 - Moderate Moderate 
 Ly et al.  
2007154 
 - Moderate 
 AxSYM HIV Ag/Ab Combo Abbott Laboratories Bourlet et al. 
2005136 
  High Moderate 
 Kwon et al. 
2006149 
 - Moderate 
 Ly et al. 2007156  - Moderate 
 Sickinger et al. 
2007163 
 - Moderate 
 COBAS Core HIV Combi Roche Diagnostics Ly et al.  
2007154 
 - Moderate Moderate 
 Weber et al. 
2002170 
 - Moderate 
 Coulter HIV-1 p24 Antigen Assay Coulter Corporation No studies - - - - 
 Enzygnost HIV Integral II Siemens Healthcare 
Diagnostics 
No studies - - - - 
 Genscreen Plus HIV Ag/Ab Combo Bio-Rad 
Laboratories 
Aghokeng et al. 
2004131 
  High High 
 Ly et al.  
2007156 
 - Moderate 
 Genscreen HIV Ultra Ag-Ab Assay Bio-Rad 
Laboratories 
Ly et al.  
2007154 
















 Modular HIV Combi Roche Diagnostics No studies - - - - 
 Murex HIV Ag/Ab Combo Abbott Laboratories Ly et al.  
2007156 
 - Moderate Moderate 
 VIDAS DUO QUICK bioMerieux Clinical 
Diagnostics 
No studies - - - - 
 VIDAS DUO ULTRA bioMerieux Clinical 
Diagnostics 
Bourlet et al. 
2005136 
  High High 
 Ly et al.  
2007154 
 - Moderate 
 Saville et al. 
2001161 
  High 
 Vironostika HIV Uni-Form II Ag/Ab bioMerieux Clinical 
Diagnostics 
Aboud et al. 
2006130 
  High High 
 Iqbal et al. 
2005143* 
  High 
 Ly et al.  
2007156 
 - Moderate 
 Seyoum et al. 
2005162 
  High 
HCV 
4th generation 
INNOTEST HCV Ab IV Innogenetics NV No studies - - - - 
Monolisa HCV Ag/Ab Ultra  Bio-Rad 
Laboratories 
No studies - - - - 
Murex 4.0 Abbott Laboratories No studies - - - - 
* Iqbal et al. reported outcomes for two data sets, which are both shown in Table 56. However, for the purposes of assessment of the evidence base (to eliminate double-influence of one study on the overall 
rating), the diagnostic data set is represented here. 
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Limitations (Risk of Bias/Quality) 
In addition to study design, we assessed the limitations of each study using three more items. To assess 
the limitations of the included studies that report diagnostic performance outcomes, we asked the 
following three questions: 
 Enrollment: Was there enrollment of consecutive/all, or random sample, of eligible patients? 
 Data loss: Is data loss minimal? 
 Blinding: Was blinding performed for both the test of interest and the reference standard? 
Failure to apply a reference standard to all samples was basis for exclusion (e.g., if all negatives were 
assumed to be true negatives), so we did not assess that factor. 
The following paragraphs describe the criteria used to determine whether a particular study had a 
limitation. Itemized limitation assessment for all included studies is provided in Table 50. Studies with 
one or more limitations are detracted one point in GRADE. If the majority of studies in a multiple-study 
evidence base have one or more limitations, the strength is likewise detracted one point in GRADE. 
Following these paragraphs, itemized assessment for each study is provided in Table 50. 
Enrollment 
Enrollment of all eligible patients, a consecutive series of patients, or a random selection of patients or 
blood samples minimizes the threat of sampling bias. Samples that are “unselected” with unknown status 
also satisfy this criterion. Selecting panels for a particular characteristic (i.e., known infected or known 
uninfected) does not satisfy this item regardless of the method used to select them because such sample 
sets are highly selected and prone to selection bias. 
Data Loss 
Although there may be no attrition in diagnostic cohort studies, data may be excluded from the evidence 
base when the true status of the sample is inconclusive. Ideally, researchers would deal with conflicting or 
inconclusive test results by performing additional tests on the sample. Samples that remain inconclusive 
may have low antibody titers or amounts of nucleic acid and were possibly collected during a window 
period. Re-testing at a later date (to allow for a window period to pass) could help to establish definitive 
status. Rather than perform these additional tests to reconcile conflicting results with true status, some 
studies simply exclude the inconclusive samples from the data set. Data may also be excluded if there are 
errors in collecting the samples or performing the test. If enough data sets are excluded to impact the 
outcome statistics, diagnostic performance is likely to be overestimated. We considered this criterion not 
satisfied if more than 5% of data are lost due to any cause. 
Blinding 
Blinding is a commonly recognized way to protect against diagnostic bias when interpreting results. 
Although qualitative assessment of a sample should require little interpretation, lack of blinding could 
lead to miscategorization. Knowing the sample status could lead to misclassification of incorrect results 
as inconclusive (possibly resulting in the exclusion of that sample), especially if the result is close to the 
threshold or if it leads the researcher to recognize an error was made. This could be a particular problem 
if the investigator has a potential conflict of interest with the study findings.
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Table 50. Quality Assessment of Question 5: Diagnostic Characteristics 
Virus/ Test 
Type 












Genetics System (GS) 
HIV-1/HIV-2 Plus 0 EIA 
Bio-Rad 
Laboratories 
Owen et al. 
2008159 
  - 2 -1 




Barbe et al.  
1994134 
  - 2 
-1 
Owen et al. 
2008159 








Diepersloot et al. 
2000140 
  - 2 -1 
Abbott PRISM HBsAg  Abbott 
Laboratories 
No studies - - - - - 





Huzly et al. 
2008142 
  - 2 -1 
Genetic Systems (GS) 
HBsAg EIA 3.0 
Bio-Rad 
Laboratories 
No studies - - - - - 
HBV (anti-HBs; 
antibodies to the 
surface antigen) 
Ortho Antibody to HBsAg 
ELISA Test System 3 
Ortho Clinical 
Diagnostics 
No studies - - - - - 
HBV (anti-HBc; 
antibodies to the 
core antigen) 
Abbott PRISM HBcore Abbott 
Laboratories 
No studies - - - - - 

















 AxSYM Core 2.0 Abbott 
Laboratories 
No studies - - - - - 
 CORZYME Abbott 
Laboratories 
No studies - - - - - 




No studies - - - - - 
HCV Abbott HCV EIA 2.0 Abbott 
Laboratories 
Anderson et al. 
1995132 
  - 2 
-1 
Laycock et al. 
1997152 
  - 2 
Leon et al.  
1993153 
  - 2 
ADVIA Centaur HCV assay  Siemens 
Healthcare 
Diagnostics 
Denoyel et al. 
2004139 
-  - 1 
-1 
Kita et al.  
2009146 
  - 2 
AxSYM Anti-HCV Abbott 
Laboratories 
No studies - - - - - 
Ortho HCV Version 3.0 
ELISA Test System 
Ortho Clinical 
Diagnostics 
Kita et al.  
2009146 
  - 2 
-1 
Vrielink et al. 
1995167 
  - 2 
Vrielink et al. 
1995168 












Tests currently in use in U.S. Organ Procurement Organization (OPO): NAT 
HIV NAT COBAS AmpliScreen HIV-1 
Test v. 1.5 
Roche 
Diagnostics 
Bamaga et al. 
2006133 
  - 2 
-1 
Owen et al. 
2008159 
  - 2 
HCV NAT COBAS AmpliScreen HCV 
Test version. 2.0 
Roche 
Diagnostics 
Bamaga et al. 
2006133 
  - 2 -1 




Kleinman et al. 
2005147 
  - 2 -1 
HCV and HIV-1 
NAT 
ProCleix HIV-1/HCV Assay Gen-Probe 
Incorporated 
Jackson et al. 
2002144 – HIV 
  - 2 
0 
Vargo et al. 
2002128 – HIV  
   3 
Jackson et al. 
2002144 – HCV 
  - 2 
Vargo et al. 
2002128 – HCV 
   3 
Vargo et al. 
2002128 – 
Co-infected 












Tests not in use in U.S. Organ Procurement Organization (OPO): 4th generation Ag/Ab Immunoassays 
HIV 
4th generation 
ARCHITECT HIV Combo Abbott 
Laboratories 
Kwon et al. 
2006149 
-  - 1 
-1 
 Ly et al.  
2007154 
-  - 1 
 AxSYM HIV Ag/Ab Combo Abbott 
Laboratories 
Bourlet et al. 
2005136 
  - 2 -1 
 Kwon et al. 
2006149 
-  - 1 
 Ly et al.  
2007156 
-  - 1 
 Sickinger et al. 
2007163 
-  - 1 
 COBAS Core HIV Combi Roche 
Diagnostics 
Ly et al.  
2007154 
-  - 1 -1 
 Weber et al. 
2002170 
-  - 1 




No studies - - - - - 
 Enzygnost HIV Integral II Siemens 
Healthcare 
Diagnostics 
















Aghokeng et al. 
2004131 
  - 2 -1 
 Ly et al.  
2007156 
-  - 1 




Ly et al.  
2007154 
-  - 1 -1 
 Modular HIV Combi Roche 
Diagnostics 
No studies - - - - - 
 Murex HIV Ag/Ab Combo Abbott 
Laboratories 
Ly et al.  
2007156 
-  - 1 -1 
 VIDAS DUO QUICK bioMerieux 
Clinical 
Diagnostics 
No studies - - - - - 
 VIDAS DUO ULTRA bioMerieux 
Clinical 
Diagnostics 
Bourlet et al. 
2005136 
  - 2 -1 
 Ly et al.  
2007154 
-  - 1 
 Saville et al. 
2001161 
   3 





Aboud et al. 
2006130 
  - 2 -1 
   Iqbal et al. 
2005143* 
  - 2 
   Ly et al.  
2007156 












   Seyoum et al. 
2005162 
  - 2 
HCV 
4th generation 
INNOTEST HCV Ab IV Innogenetics NV No studies - - - - - 
Monolisa HCV Ag/Ab Ultra  Bio-Rad 
Laboratories 
No studies - - - - - 
Murex 4.0 Abbott 
Laboratories 
No studies - - - - - 
* Iqbal et al. reported outcomes for two data sets, which are both shown in Table 55. However, for the purposes of assessment of the evidence base (to eliminate double-influence of one study on the overall rating), 





Although in some instances several studies addressed the same test of interest, different reference 
standards and samples were used. Differences in these two fundamental study design factors can be 
expected to lead to differences in outcomes and to dictate generalizability. In this respect, each study 
should probably best be considered in isolation. For this reason we did not downgrade for inconsistency, 
although we do summarize multiple studies to provide an overall picture of the tests’ performances. 
Directness 
In the assessment of diagnostic technologies, GRADE assessment of directness pertains to whether direct 
measures of diagnostic performance (e.g., patient-oriented clinical outcome) or indirect measures of 
diagnostic performance (e.g., intermediate or surrogate outcomes such as sensitivity and specificity) are 
reported. In this assessment, all data were indirect. However, the purpose of the question was to assess 
“test characteristics,” specifically including sensitivity and specificity. Detracting points because the 
study addresses the question of interest is inappropriate; therefore, we did not. 
Precision 
Lack of precision is typically measured by 95% confidence intervals (CI) of outcome statistics. Because 
not all studies reported CI or data necessary to calculate CI, we considered the factor that influences 
precision instead, number of samples assessed. As most of the sample sets assessed were large (only four 
had 200 or fewer samples) and the smaller evidence bases had an over-representation of infection 
compared with real-world prevalence, we did not detract for precision. 
Publication Bias 
Because traditional methods of publication bias assessment are not useful for small evidence bases and 
evidence bases for which quantitative assessment is inappropriate, such as those addressing each test of 
interest, we assessed the potential for publication bias by considering whether at least half of the studies 
for a particular test were funded by the test’s manufacturer. If studies with significant findings are more 
likely to be published, and if only manufacturers funded the published studies, it is possible that 
independently funded studies with non-significant findings were never published. The main limitation of 
this method is that most of the studies did not report a funding source.  
Full GRADE assessments are shown in Table 56, after the Results section and tables. 
Results 
Although a large number of peer-reviewed publications and pieces of gray literature were included, little 
(or no) data addressed each of the individual studies of interest. Only one study may have collected 
samples from deceased individuals (corneal donors). None of the studies appear to have focused on 
pediatric use. Due to this, it was not possible to determine differential test performance among 
populations or by donor clinical status. 




Information on the time required to fully administer diagnostic tests was sparse. For most of the test 
categories, no data were identified, despite consulting multiple sources for data. Available turnaround 
times are summarized by test type in Table 51. Full data extraction on turnaround time on a per-test basis 
is shown in Table 4. 
Table 51. Summary of Turnaround Times 
Test Category Turnaround Time 
Tests currently in use in U.S. Organ Procurement Organizations (OPO): Immunoassays 
HIV, 3rd generation EIA No data 
HBsAg EIA 29 minutes for Advia Centaur (not reported for any of the others) 
Anti-HBs EIA No data 
Anti-HBc EIA No data 
HCV, 2nd or 3rd generation EIA No data 
Tests currently in use in U.S. Organ Procurement Organizations (OPO): NAT 
HIV NAT 2 hours 
HCV NAT 2 hours 
HBV NAT No data 
HCV and HIV-1 NAT Combined 6 hours 
Tests not in use by U.S. Organ Procurement Organizations (OPO): 4th generation Ag/Ab Immunoassays 
HIV 4th generation Ag/Ab EIA 26 minutes to 4 hours, depending on test brand 




Due to the limitations of using seroconversion panels to attempt to determine absolute window periods 
(previously defined as the duration between being infected and testing positive), we summarized the 
window periods relative to other tests. We report mean differences in time to detection among tests, and 
where reported, the range of time to detection. “Mean range” refers to the range of means when more than 
one study reported this data. These data were extracted from peer-reviewed publications and gray 
literature including independent laboratory assessments and product labeling information. 
This information is presented in Table 52. Full data extraction on window periods and additional related 
information on a per-test basis is shown in Table 4. 
Table 52. Summary of Window Periods and Related Data 
Test Category Window Period 
Tests currently in use in U.S. Organ Procurement Organizations (OPO): Immunoassays 
HIV, 3rd generation EIA Positive mean 12-14 days before Western blot, but in one panel at the same time 
as Western blot 
HBsAg EIA Positive range of 0-7 days before other unnamed licensed test 
Anti-HBs EIA Positive range of 14-18 days after NAT 
Positive later than HBsAg EIA on some samples 
Anti-HBc EIA Positive 1-4 weeks after HBsAg, coincident with symptom onset 
HCV, 2nd or 3rd generation EIA Positive mean of 30-35 days after RNA test, and overall range of time to detect 
infection 4-118 days  
Tests currently in use in U.S. Organ Procurement Organizations (OPO): NAT 
HIV NAT* Positive range of 2-15 days before Ab test 
Positive range 7-10 days before p24 Ag test 
Positive range of 0-28 days before Ag test alone 
HCV NAT* Positive mean range of 25-85 days (and where reported absolute range 5-186 
days) before confirmed 3rd generation Ab test (and a mean of 113 days before 
2nd generation Ab test) 
Positive mean 5 days (range: 0-24 days) before 4th generation test  
 
HBV NAT Positive mean range 10 to 15 days (overall range where reported 4-18 days) 
before HBsAg (single-sample procedure) 
Tests not in use by U.S. Organ Procurement Organizations (OPO): 4th generation Ag/Ab Immunoassays 
HIV 4th generation Ag/Ab EIA Positive means of 1.4 to 2 days after PCR 
Positive means of 1.5 to several days before 3rd generation 
HCV 4th generation Ag/Ab EIA Positive mean of 5 days (range: 0-24 days) after NAT, a mean of 4.8 days 
(range: 0-32 days) after PCR, and a mean of 30 days after RNA assay 
Positive mean of 26 days (range: 0-72 days) before 3rd generation 
*Includes data from combined HIV/HCV NAT 
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Diagnostic Performance 
All of the extracted diagnostic performance data were sensitivity and specificity, drawn from clinical and 
analytic performance studies. Predictive values and likelihood ratios from potentially generalizable 
populations were not reported. We did not calculate these values because the prevalence of infection 
among potential solid organ donors has not been clearly defined. A summary of sensitivity and specificity 
data by test category are shown in Table 53. The summarized data are point estimates. Where multiple 
estimates were reported, the lowest and highest (range of) values are reported. Full data extraction per test 
by name is shown in Table 55.  
The last column of Table 53 shows the median GRADE assessment for the evidence base for the test 
category; full GRADE assessments for each test are shown in Table 56. In brief, reasons for GRADE 
detraction most commonly included lack of blinding and lack of diagnostic uncertainty. Inappropriate 
reference standard was encountered less frequently, but could have strong effects on the outcomes (see 
HIV NAT and HCV NAT summary statistics in the table below). No studies had substantial data loss. 
Table 56 also notes whether each statistic was calculated from an analytic study or a clinical study. 
Table 53. Summary of Sensitivity and Specificity Data (Range of Reported Point 
Estimates) 
Test Category Sensitivity Specificity GRADE (Table 56) 
Tests currently in use in U.S. Organ Procurement Organizations (OPO): Immunoassays 
HIV, 3rd generation EIA 99.4% to 100% 97.7% to 99.7% Low 
HBsAg EIA 100% 97.9% to 99.4% Low to Moderate 
Anti-HBs EIA No data No data - 
Anti-HBc EIA No data  No data - 
HCV, 2nd or 3rd generation EIA 73.2% to 100% 92.7% to 99.9% Moderate 
Tests currently in use in U.S. Organ Procurement Organizations (OPO): NAT* 
HIV NAT** 92.6% to 100% 96.9% to 100% Low  
HCV NAT** 99.3% to 99.6% 97.4% to 99.6% Low 
HBV NAT 84.8% 100% Very Low 
Tests not in use by U.S. Organ Procurement Organizations (OPO): 4th generation Ag/Ab Immunoassays 
HIV 4th generation Ag/Ab EIA 100% (all) 82.5% to 100% (Most >99%) Low to Moderate 
HCV 4th generation Ag/Ab EIA No data No data - 
*Includes data from combined HIV/HCV test 
**Summary table does not include data from Bamaga et al. due to lack of sufficiently accurate reference standard for determining sensitivity 
and specificity. Data from that study are shown in the evidence tables. 
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Collection Window Period 
Turnaround 
Time 







Plus 0 EIA 
Bio-Rad 
Laboratories 






From 15 seroconversion panels, at least half of the results were 
positive about 14 days before Western blot.159 
In the package labeling in the FDA approval document, data are 
reported on use in 50 seroconversion panels, compared with FDA 
licensed HIV-1/HIV-2 EIAs and a licensed HIV-1 Western blot. 
Compared with (unnamed) kit 1, it detected infection sooner 74% of 
the time and at the same time in the remainder. Compared with 
(unnamed) kit 2 (in only 46 of the panels), it detected HIV sooner 
18% of the time, at the same time 70% of the time, and later 12% of 
the time. Compared with the Western blot it became positive sooner 













In 7 of 8 seroconversion panels, positive responses were obtained 
4 to >9 days sooner than Western blot, and at the same time in the 
eighth.134 
From 15 seroconversion panels, at least half of the test results were 
positive about 12 days before Western blot.159 
In the package insert, on 9 seroconversion panels this test detected 
antibody at the same time or sooner than the Abbott HIVAB HIV-1 
EIA (three times positive when Abbott was inconclusive, and one 
time inconclusive when Abbott was negative). In one of the panels it 



























In its FDA Summary of Safety and Effectiveness Data and Product 
Label, AxSYM HBsAg detected infection 3 to 7 days earlier than a 
(unnamed) FDA-licensed reference in 5 out of 15 seroconversion 








































In the product label, in 6 seroconversion panels this test was positive 
at the same time as the (unnamed) reference assay in 5 serials, and 















 As reported on its package insert, on 21 seroconversion panels, the 
GS HBsAg EIA 3.0 detected infection at the same time or earlier 














4/23/2003 EIA Serum, 
plasma 
In the FDA product label for Cobas AmpliScreen HBV test, on 
40 seroconversion panels Ortho HBsAg System 3 detected HBV 
a median of 14 to 18 days later than the NAT, depending on 
preparation method.185 
In company marketing materials for Genetic Systems HBsAg EIA, 
the window period for the GS test and this Ortho test was the same 
for 10 of 21 commercial seroconversion panels. For the remaining 










































10/13/2005 ChLIA Living 
(serum, 
plasma) 
The product label states, “Anti-HBc appears in the serum of patients 
infected with HBV one to four weeks after the appearance of HBsAg, 








12/22/2004 ChLIA Living 
(serum, 
plasma) 
The product labeling reports that, in a study of 7 seroconversion 
panels, the Advia Centaur detected infection at the same time as the 

















4/18/1991 EIA Living 
(serum, 
plasma) 
In a U.K. Health Protection Agency-sponsored evaluation of the 
ORTHO HBc ELISA Test System, the test was evaluated in four 
seroconversion panels. All evaluated HBc tests detected the same 



































In an independent laboratory evaluation sponsored by the U.K. 
Medical Devices Agency, AxSYM HCV v.3 and six other HCV tests 
were evaluated. On 22 seroconversion panels and 2 performance 
panels AxSYM detected HCV a mean of 1.6 days after the most 
sensitive assay for a given panel (ranking #2 out of all the tests), 
compared with 1.1 for Vitros ECi anti-HCV (which ranked first).178 
In an evaluation sponsored by the U.K. Health Protection Agency on 
19 seroconversion panels, the Monolisa HCV Ab/Ab Ultra detected 
infection a mean of 4.8 days after PCR at a 0.5 threshold, and 
7.5 days after PCR at a 1.0 threshold. For either threshold the range 
of days to detection was 0-32. By comparison, AxSYM HCV v. 3.0 
detected HCV a mean of 19.7 days (range: 0-38) after PCR.182 
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Of 19 blood donors who were RNA-positive but initially EIA-2 
antibody negative, EIA-2 was positive at follow-up  a median of 63 
days later, but 4 of the samples were still not EIA-2 reactive on the 
last follow-up sample available (at 23 days, 93 days, 317 days, and 
190 days, respectively). For comparison, 8 of the donors were EIA-3 
positive at initial test, 9 more were reactive at first follow-up, and all 
were reactive by second follow-up. So, by the last follow-up time 
EIA-3 was positive for all donors, but for 4 of them EIA-2 was never 
reactive within the duration of the study. Intervals between blood 
































Advia detected infection a mean of 34.6 days (range: 6 to 182 days) 
from the initial draw date on 20 panels.139 
In a study with two panels, Advia detected infection on bleed day 11 
on one and day 28 on the other.146 
In its FDA submission of Summary of Safety and Effectiveness data, 
on 23 seroconversion panels, Advia Centaur was “at least as 
sensitive in the detection of seroconversion for HCV as commercially 
available assays,” compared with published data. 
In the same document, on 20 seroconversion panels Centaur 
detected HCV on the same day as Ortho HCV v. 3.0 in 14 series, 
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8 of 19 blood donors who were RNA-positive but initially EIA-2 
antibody negative were EIA-3 reactive. 17 of the 19 were reactive 
when recalled for additional testing a median of 34 (range: 5 to 70) 
days later, and all were reactive by the next follow-up. This includes 
4 who were EIA-2 negative for the entire duration of the study, with 
blood last tested at 23 days, 93 days, 190 days, and 317 days, 
respectively.. Intervals between blood draws were long, the authors 
noted.141 
The mean time to detect infection in transfusion recipients was 
74 days post-transfusion(range: 26 to 118 days).  
15/21 cases were detected in the same bleed by Ortho 3.0 and the 
second generation version. In the other 5, this test detected infection 
a mean of 26 days (range: 20 to 34 days) earlier than the second 
generation version.135 
In a study with two panels, this test detected infection on bleed 
day 11 day on one and day 14 on the other.146 
In the FDA product label for COBAS AmpliScreen HCV Test 2.0, on 
9 seroconversion panels it detected HCV a mean of 32 days before 
seroconversion, defined as positive results on both Ortho 3.0 EIA 
and Chiron RIBA 3.0.184 
In its FDA submission of Summary of Safety and Effectiveness data 
and product label, on 20 seroconversion panels Centaur detected 
HCV on the same day as Ortho HCV v. 3.0 in 14 series, three days 
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Tests Currently in Use by U.S. Organ Procurement Organizations (OPOs): Nucleic Acid Tests (NAT) 
HIV NAT COBAS 
AmpliScreen 























Based upon modeling, the window period was about 12 hours 
(95% CI: 5 to 19 hours) less than the Gen-Probe TMA HIV-NAT 
test.137 
In 10 seroconversion panels, this test was positive 2 to 14 days 
(range) days before antibody seroconversion and 0 to 28 days 
(range) before p24 antigen test.172 
In 10 seroconversion panels, this test was positive 7 to 17 days 
before antibody seroconversion tested with anti-HIV-1 Ortho Anti-
HIV1/2 Test.173 
According to its FDA product label, AmpliScreen HIV Test v.1.5 
detected HIV a mean of 12 days before Abbott HIV-1-2 antibody test 
on 41 seroconversion panels, 6.8 days before the Abbott p24 
antigen test on 40 panels, and 4.4 days before the Coulter p24 
antigen test on 38 panels, using the multiprep procedure.  
As reported in its FDA product label, this test detected HIV a mean 
of 14.2 days before Abbott HIV-1-2 antibody test on 41 panels, 
8.3 days before the Abbott p24 antigen test on 40 panels, and 
5.8 days before the Coulter p24 antigen test on 38 panels using the 
standard processing procedures.192 
Also reported in its FDA product label, COBAS HIV-1 Test v. 1.5 was 
evaluated on 10 plasma seroconversion panels. COBAS v.1.5 
recognized HIV a mean of 12 days before Abbott HIV-1/2, 7.5 days 
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Based upon modeling, the window period was about 14 hours 
(95% CI: 10 to 9 hours) less than the Gen-Probe TMA HCV-NAT 
test.137 
In 4 of 5 seroconversion panels, the AmpliScreen test returned 
positive results 23 to 32 days before seroconversion panels. In the 
other panel, it detected infection later164 
On 44 blood donor samples in the window period, this test returned 
positive results a mean of 5.1 days (range: 0 to 24 days) before 
Monolisa HCV Ag-Ab testing.150 
In the FDA product label for COBAS AmpliScreen HCV Test 2.0, on 
9 seroconversion panels it detected HCV a mean of 32 days before 
seroconversion, defined as positive results on both Ortho 3.0 EIA 




as two hours.133 




















Using 5 seroconversion panels this test was positive a mean of 
10 days (range: 4 to 18 days) before HBsAg in single-sample 
procedure; mean 3.7 days (0 to 11) with minipool.160 
In the FDA product label, in 40 seroconversion panels this test had a 
window period of 15 (SD: 17) days fewer than Ortho 3 for HBsAg 
using multiprep procedure and 20 (SD: 17) days fewer using the 































Based upon modeled data and compared with AmpliScreen, the 
window period with ProCleix for HIV is an estimated 12 hours 
(95% CI: 5 to 19 hours) less, and for HCV it was an estimated 
14 hours (95% CI: 5 to 19 hours).137 
HIV: 
In two seroconversion panels, ProCleix was positive 7 to 10 days 
before p24 antigen and 12 to 14 days before an antibody test for 
HIV.138 
In 26 seroconversion panels, ProCleix was positive for HIV at a 
mean of 10.2 bleed days (range: 0 to 61), compared with 12.3 
(range: 1 to 61) for PCR, 16.9 (range: 1 to 67) for HIV-1 antigen, and 
24.5 (range: 9 to 74) for HIV-1 antibody. The window period was 
reduced by a mean of 14.6 (SD: 6.2) days compared with antibody 
testing and a mean of 6.6 (SD: 4.4) days compared with antigen 
testing.148 
In 10 HIV seroconversion panels, ProCleix tested neat was positive 
a median of 12 days (neat) or 10 days (diluted 1:16) before antibody 
test (HIV 1/2 antibody assay by Abbott). It was positive a median of 
7 days (neat) or 3 days (diluted) before p24 antigen test (Abbott or 
Coulter). The discriminatory assay was positive a median of 12 days 
before the antibody test and 6 days before the antigen test.128  
In its product label, on 10 HIV seroconversion panels ProCleix 
detected infection a median of 10 days before Abbott HIV-1/2 and 
3 days before the Abbott or Coulter p24 antigen test in a 1:16 
dilution. The discriminatory assay tested neat detected infection a 
median of 12 days before the antibody test and 6 days before the 
antigen tests. ProCleix recognized HIV before the comparators in 





6 hours to 
perform two 
HIV/HCV tests, 
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      HCV: 
In 2 seroconversion panels, one of the HCV panels had “similar” 
findings; the other had an 85 day difference between detection of 
HCV RNA and confirmed 3rd generation antibody test.138 
In 25 seroconversion panels, ProCleix detected HCV a mean of 
113.2 (Standard Deviation [SD]: 98.7) days before a 2nd generation 
anti-HCV assay and 80.5 (SD: 55.9) days before a 3rd-generation 
assay.145 (The window period for HIV was not reported in the article.) 
In 24 seroconversion panels, ProCleix detected HCV at a mean of 
12 days (range: 0 to 140) compared with 13.35 for PCR (of the 
20 panels tested, range: 0 to 140) and 37.9 (range: 5 to 186) for 
antibody test. Compared with an antibody test, this test had a 
mean reduction of 25.8 (SD: 15.5) day reduction in detection.148 
In 10 HCV seroconversion panels, ProCleix (including the 
discriminatory assay) was positive a median of 25 days before the 
antibody test (Ortho 3.0).128 
In its product label, on 10 HCV seroconversion panels, 
ProCleix detected HCV sooner than the Ortho HCV 3.0 ELISA or the 
Abbott Anti-HCV 2.0 for every series, and a median of 25 earlier 
whether diluted or not.191 
 















In 24 seroconversion panels, ARCHITECT HIV Combo was positive 
at mean of 13.1 days (range: 1 to 37).154 
In 3 panels, it was positive on day 8 in two and day 23 on the 
third.149 
In an evaluation funded by the U.K. Health Protection Agency on 
18 seroconversion panels, the mean delay (range) in days of the 
Architect HIV Ag/Ab Combo was 0.9 (0-6) compared with the most 
sensitive assay. (For AxSYM HIV Ag/Ab Combo this was 0.6 (0-7); 
Genscreen Ultra HIV Ag-Ab 1.5 (0-7); Murex HIV Ag/Ab Combo 4.8 
(0-53); Vironostika HIV Uni-Form II Ag/Ab 8.6 (0-57)).177 
Run time 
26 minutes154 
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In 24 seroconversion panels, AxSYM HIV Ag/Ab Combo was 
positive at mean of 14.8 days (range: 1 to 37).156  
In 19 seroconversion panels, it was positive at a mean of 13.2 days 
(range: 1 to 35).158 
In 14 seroconversion panels it detected HIV at a mean of 24.6 days 
(range: 7 to 50).136 
In 3 seroconversion panels it detected HIV at 15, 23, and 34 days.149 
In 25 seroconversion panels, it detected HIV a mean of 0.44 days 
(range: 0-5 days) after the first assay (which varied by panel).156 
This was 2-3 days before the 3rd-generation assays. 
In 22 panels, compared with a 3rd generation test (AxSYM gO), 
the window period was reduced by a mean of 6.15 days.163 It was 
positive first by 1 to 2 bleeds in 18 of the panels, and equal in the 
other 4. 
In an evaluation funded by the U.K. Health Protection Agency on 
18 seroconversion panels, the mean delay (range) in days of the 
Architect HIV Ag/Ab Combo was 0.9 (0-6) compared with the most 
sensitive assay. (For AxSYM HIV Ag/Ab Combo this was 0.6 (0-7); 
Genscreen Ultra HIV Ag-Ab 1.5 (0-7); Murex HIV Ag/Ab Combo 4.8 
(0-53); Vironostika HIV Uni-Form II Ag/Ab 8.6 (0-57)).177  
In an evaluation by the U.K. Medicines and Healthcare products 
Regulation Agency of 35 seroconversion panels, AxSYM Ag/Ab 
combo was always the first positive test out of the other tested 
4th and 3rd generation assays. By comparison, the mean (range) of 
days longer for positivity by Murex HIV Ag/Ab Combination were 
2.4 (0-53), Genscreen PLUS HIV Ag-Ab were 3.6 (0-53), and 
Vironostika HIV Uni-Form II Ag/Ab 5.9 (0-57).179 
In an evaluation of the Genscreen ULTRA HIV Ag-Ab funded by the 
U.K. Health Protection Agency, in 21 seroconversion panels, this 
test detected HIV a mean of 1 day (range: 0-6) after AxSYM (the 
earliest test). By comparison, Murex HIV Ag/Ab Combination 
detected HIV a mean of 3.8 days (range: 0-53) days later, and 
Vironostika HIV Uni-Form II Ag/Ab detected HIV a mean of 7.3 





2 hours for 
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EIA  Of 24 seroconversion panels, COBAS Core Combi only recognized 
HIV in 23 of the sample sets. Of those 23, the mean time to positive 
test result was 16.8 days (overall range 1 to never within panel 
set).154 
In 94 seroconversion panels, compared with 3rd generation tests the 
window period was reduced by 3.6 to 5.7 days.170 


















In the package insert, on 5 seroconversion panels the Coulter test 
detected HIV antigen prior to antibodies (tested by Abbott HIVAB 
HIV-1 antibody EIA test) on 4 tests, by 21 days, 23 days, 42 days, 
and 28 days. In the other panel, antigen was not detected.180 
The package insert also reported on findings on 31 seroconversion 
panels by “independent investigators.” Window period was 
compared with Abbott HIVAB HIV-1/HIV-2 (rDNA) EIA and 
GS HIV-1/HIV-2 EIA, and several investigational tests. The Coulter 
test detected antigen prior to seroconversion in 80.6% of panels, and 
at the same time in 9.7%. Of the three remaining panels, one was 
not RNA-positive either. The Coulter test reportedly detect antigen at 
the same time as the investigational tests detected RNA in the 
rest.180 
As reported in its FDA product label, this test detected HIV a mean 
of 14.2 days before Abbott HIV-1-2 antibody test on 41 panels, 
8.3 days before the Abbott p24 antigen test on 40 panels, and 
5.8 days before the Coulter p24 antigen test on 38 panels using the 
standard processing procedures.192 
Also reported in its FDA product label, COBAS HIV-1 Test v. 1.5 was 
evaluated on 10 plasma seroconversion panels. COBAS v.1.5 
recognized HIV a mean of 12 days before Abbott HIV-1/2, 7.5 days 
before Abbott HIV-1 p24 Antigen, and 4.3 days before Coulter HIV-1 
Antigen test.192 






















In a WHO/UNAIDS evaluation, Enzygnost HIV Integral II detected 
HIV a mean of 1 day (range: 0 to 2) earlier than Enzygnost HIV 1/2 
Plus, using 8 seroconversion series. By comparison, means were 
0.9 for Genscreen Plus HIV Ag/Ab, - 0.9 for Murex HIV Ag/Ab 
Combination, and -0.7 for Vironostika HIV Uni-Form II Ag/Ab.199 
Total time 2 hours 















In an evaluation by the U.K. Health Protection Agency on 
18 seroconversion panels, the mean delay (range) in days of the 
Architect HIV Ag/Ab Combo was 0.9 (0-6) compared with the most 
sensitive assay. (For AxSYM HIV Ag/Ab Combo this was 0.6 (0-7); 
Genscreen Ultra HIV Ag-Ab 1.5 (0-7); Murex HIV Ag/Ab Combo 
4.8 (0-53); Vironostika HIV Uni-Form II Ag/Ab 8.6 (0-57)).177 
In an evaluation funded by the U.K. Medical Devices Agency of 
38 seroconversion panels, the Murex Combo test detected HIV a 
mean of 3.9 days (range: 0 to 20) before the most sensitive antibody 
test. By comparison, the mean (range) was 2.76 (0 to 20) for 
Genscreen PLUS HIV Ag-Ab and 0.34 (-9 to 20) for Vironostika Uni-
Form II Ag/Ab.183 
In an evaluation funded by the U.K. Medicines and Healthcare 
products Regulation Agency of 35 seroconversion panels, AxSYM 
Ag/Ab combo was always the first positive test out of the other 
tested 4th and 3rd generation assays. By comparison, the mean 
(range) of days longer for positivity by Murex HIV Ag/Ab 
Combination were 2.4 (0-53), Genscreen PLUS HIV Ag-Ab were 
3.6 (0-53), and Vironostika HIV Uni-Form II Ag/Ab 5.9 (0-57).179 
In a WHO/UNAIDS evaluation on 8 seroconversion panels, 
Genscreen Plus HIV Ag/Ab was positive a mean of 0.9 days 
(range: -0.1 to 1.75 days) earlier than the reference assay, 
Enzygnost HIV1/2 Plus. By comparison, means were 
-1 for Enzygnost HIV Integral II, -0.9 for Genscreen Plus,  
-0.9 for Murex HIV Ag/Ab Combination, and -0.7 for Vironostika HIV 
Uni-Form II Ag/Ab.199 
Total time 3 hours 

























EIA  In 24 seroconversion panels, Genscreen HIV Ultra Ag-Ab was 
positive at mean of 18.3 days (range: 1 to 37).154 
In an evaluation of the Genscreen ULTRA HIV Ag-Ab funded by the 
U.K. Health Protection Agency, in 21 seroconversion panels, this 
test detected HIV a mean of 1 day (range: 0-6) after AxSYM (the 
earliest test). By comparison, Murex HIV Ag/Ab Combination 
detected HIV a mean of 3.8 days (range: 0-53) days later, and 
Vironostika HIV Uni-Form II Ag/Ab detected HIV a mean of 7.3 














EIA  Of 24 seroconversion panels, Modular Combi only recognized HIV in 
23 of the sample sets. Of those 23, the mean time to positive test 
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Of 24 seroconversion panels, Murex Combo only recognized HIV in 
23 of the sample sets. Of those 23, the mean time to positive test 
result was 14.6 days (overall range 1 to never within panel set).154 
In 19 seroconversion panels, it recognized HIV in 16 of the sample 
sets. Of those 16, the mean time to positive test was 15 days 
(overall range 1 to never within panel set).158 
In 25 seroconversion panels it recognized HIV a mean of 0.92 days 
(range: 0-15 days) after the first assay (which varied by panel).156 
This was about 1.5 days before the 3rd generation assays. 
In an evaluation funded by the U.K. Health Protection Agency on 
18 seroconversion panels, the mean delay (range) in days of the 
Architect HIV Ag/Ab Combo was 0.9 (0-6) compared with the most 
sensitive assay. (For AxSYM HIV Ag/Ab Combo this was 0.6 (0-7); 
Genscreen Ultra HIV Ag-Ab 1.5 (0-7); Murex HIV Ag/Ab Combo 
4.8 (0-53); Vironostika HIV Uni-Form II Ag/Ab 8.6 (0-57)).177 
In an evaluation by the U.K. Medical Devices Agency of 
38 seroconversion panels, the Murex Combo test detected HIV a 
mean of 3.9 days (range: 0 to 20) before the most sensitive antibody 
test. By comparison, the mean (range) was 2.76 (0 to 20) for 
Genscreen PLUS HIV Ag-Ab and 0.34 (-9 to 20) for Vironostika Uni-
Form II Ag/Ab.183 
In an evaluation funded by the U.K. Medicines and Healthcare 
products Regulation Agency of 35 seroconversion panels, AxSYM 
Ag/Ab combo was always the first positive test out of the other 
tested 4th and 3rd generation assays. By comparison, the mean 
(range) of days longer for positivity by Murex HIV Ag/Ab 
Combination were 2.4 (0-53), Genscreen PLUS HIV Ag-Ab were 
3.6 (0-53), and Vironostika HIV Uni-Form II Ag/Ab 5.9 (0-57).179 
In an evaluation of the Genscreen ULTRA HIV Ag-Ab funded by the 
U.K. Health Protection Agency, in 21 seroconversion panels, this 
test detected HIV a mean of 1 day (range: 0-6) after AxSYM (the 
earliest test). By comparison, Murex HIV Ag/Ab Combination 
detected HIV a mean of 3.8 days (range: 0-53) days later, and 
Vironostika HIV Uni-Form II Ag/Ab detected HIV a mean of 7.3 
(range: 0-57) days later. By comparison, means were -1 for 
Enzygnost HIV Integral II, -0.9 for Genscreen Plus HIV Ag/Ab, 
-0.7 for Vironostika HIV Uni-Form II Ag/Ab.181 
Total time to run 









140 minutes, as 
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EIA  In 24 seroconversion panels, VIDAS DUO QUICK was positive 
at mean of 13.2 bleeding days (range: 1 to 37).154 
On the manufacturer Web site, on 25 seroconversion panels there 











EIA  In 14 seroconversion panels, VIDAS DUO ULTRA was positive at a 
mean of 23.5 days (range: 2 to 47)136 
In 24 seroconversion panels, it was positive at mean of 13.5 days 
(range: 1 to 30).154 
In 19 seroconversion panels, it was positive a mean of 16.2 days 
(range: 1 to 35).158 
In 16 seroconversion panels, it was positive at a mean of 2.31 days 
(range: 0 to 20) after RT-PCR.169 
Compared with the most sensitive antibody test in the test’s 
information enclosure, on 10 seroconversion panels it detected HIV 
one bleed earlier in 2 cases, 2 bleeds earlier in 3, 3 bleeds earlier in 
4, and 5 bleeds earlier in 1.161 
On the same panels compared with the most sensitive antigen test, 
it tested infection at the same time in 7 panels, 4 bleeds earlier in 1, 
1 bleed earlier in 1, and 1 bleed later in the other.161 
On the company Web site, in 16 seroconversion panels this test 
detected infection at a mean of 2.13 bleeding days (range: 0-20) 














Of 24 seroconversion panels, Vironostika Uni-Form II Ag/Ab only 
recognized infection in 21. Of those 21, the mean time to positivity 
was 19.3 days (range 1 to never within panel set).156  
Of 19 seroconversion panels, it only recognized HIV in 16. Of those 
16, the mean time to positivity was 15.6 days (overall range 1 to 
never within panel set).158 
Of 7 seroconversion panels, it was positive on day bleed 7, 15, 47, 
26, 9, 18, and 27, respectively. It was always positive before 
Western blot and was positive from 0 to 37 days before the 
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3rd generation Vironostika test.165 
In 10 seroconversion panels this test was found to have a window 
period shortened by 6.2 days compared with the 3rd generation 
Vironostika test. This is 2.2 days longer than a HIV-1 p24 antigen 
assay.166 
Modeling from the same study suggests a total window period of 
18 days.166 
In 30 seroconversion panels, it missed 3 positives. Of the rest, it 
detected HIV at a mean of 17.1 days (overall range 0 to never).157 
On the same panels three 3rd generation tests all missed either 3 or 
4 positives, and had means detection at 17.6 days, 20.3 days, and 
23.3 days. 
In 25 seroconversion panels, it detected HIV a mean of 2.6 days 
(range: 0 to 19 days) after the most sensitive assay (which varied by 
panel).156 This was about the same as one 3rd generation assay and 
a day sooner than another 3rd generation assay. 
In an evaluation by the U.K. Health Protection Agency on 
18 seroconversion panels, the mean delay (range) in days of the 
Architect HIV Ag/Ab Combo was 0.9 (0-6) compared with the most 
sensitive assay. (For AxSYM HIV Ag/Ab Combo this was 0.6 (0-7); 
Genscreen Ultra HIV Ag-Ab 1.5 (0-7); Murex HIV Ag/Ab Combo 
4.8 (0-53); Vironostika HIV Uni-Form II Ag/Ab 8.6 (0-57)).177 
In an evaluation funded by the U.K. Medical Devices Agency of 
38 seroconversion panels, the Murex Combo test detected HIV a 
mean of 3.9 days (range: 0 to 20) before the most sensitive antibody 
test. By comparison, the mean (range) was 2.76 (0 to 20) for 
Genscreen PLUS HIV Ag-Ab and 0.34 (-9 to 20) for Vironostika Uni-
Form II Ag/Ab.183 
In an evaluation by the U.K. Medicines and Healthcare products 
Regulation Agency of 35 seroconversion panels, AxSYM Ag/Ab 
combo was always the first positive test out of the other tested 4th 
and 3rd generation assays. By comparison, the mean (range) of days 
longer for positivity by Murex HIV Ag/Ab Combination were 2.4 (0-
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Vironostika HIV Uni-Form II Ag/Ab 5.9 (0-57).179 
In an evaluation of the Genscreen ULTRA HIV Ag-Ab by the U.K. 
Health Protection Agency, in 21 seroconversion panels, this test 
detected HIV a mean of 1 day (range: 0-6) after AxSYM (the earliest 
test). By comparison, Murex HIV Ag/Ab Combination detected HIV a 
mean of 3.8 days (range: 0-53) days later, and Vironostika HIV Uni-
Form II Ag/Ab detected HIV a mean of 7.3 (range: 0-57) days 
later.181 
In a WHO/UNAIDS evaluation on 8 seroconversion panels, 
Vironostika HIV Uni-Form II Ag/Ab was positive a mean of 0.6 days 
(range: -0.2 to 1.5 days) earlier than the reference assay, Enzygnost 
HIV1/2 Plus. By comparison, means were -1 for Enzygnost HIV 
Integral II, -0.9 for Genscreen Plus HIV Ag/Ab, - 0.9 for Murex HIV 
Ag/Ab Combination.199 
HCV INNOTEST 







In company marketing materials, on 30 seroconversion panels the 
Innotest HCV Ab IV had a total delay of 22 days for the detection of 




















EIA  In 10 seroconversion panels, there was a mean delay in positivity 
between the Monolisa HCV Ag/Ab Ultra and MP-NAT of 5.1 days 
(range: 0 to 24 days).150  
Compared with Prism HCV EIA (Abbott) (3rd generation EIA), this 
was a reduction of 26.8 days (range: 0 to 72 days).150 
In non-commercial conversion panels of 23 hemodialysis patients, 
there Monolisa Ultra detected HCV a mean of 21.6 days before the 
most sensitive antibody test (which varied by panel).151  
The mean delay of the Monolisa after RNA assay was 30.3 days. 
The mean delay after the trak-C antigen assay was 27.9 days 
compared with the HCV core Ag quantification assay and 16.3 days 
compared with the HCV Ag blood screening assay.151 
In an evaluation funded by the U.K. Health Protection Agency on 
19 seroconversion panels, the Monolisa HCV Ab/Ab Ultra detected 
infection a mean of 4.8 days after PCR at a 0.5 threshold, and 
7.5 days after PCR at a 1.0 threshold. For either threshold the range 
of days to detection was 0-32. By comparison, AxSYM HCV v. 3.0 




as reported by 








EIA  - - 
* ChLIA: Chemiluminescent immunoassay; EIA: Enzyme Immunoassay; PCR: Polymerase chain reaction; TMA: Transcription-mediated amplification 
† No FDA approval documentation found 
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Table 55. Diagnostic Characteristics 
Virus/ Type Test Trade 
Name 
Manufacturer Cite Study Type Sensitivity Specificity Data Loss Comments 
Samples Reference Sensitivity Samples Reference Specificity 












































99.74% None  
Owen et 
al. 2008159 
























t et al. 
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99.4% None  






- - - - - - - - - 
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Virus/ Type Test Trade 
Name 
Manufacturer Cite Study Type Sensitivity Specificity Data Loss Comments 







Huzly et al. 
2008142 
Analytic 139 Consensus 







by >6 of 
9 assays  
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Virus/ Type Test Trade 
Name 
Manufacturer Cite Study Type Sensitivity Specificity Data Loss Comments 
Samples Reference Sensitivity Samples Reference Specificity 


























the 2.0 EIA 
reported 
 Laycock et 
al. 1997152 
Clinical 101 Matrix HCV 
RIBA 
100% 101 Matrix HCV 
RIBA 
92.7% None  
 Leon et al. 
1993153 
Clinical 496 Consensus 






















































 Kita et al. 
2009146 
























Virus/ Type Test Trade 
Name 
Manufacturer Cite Study Type Sensitivity Specificity Data Loss Comments 





No studies - - - - - - - - - 






Kita et al. 
2009146 




















RIBA here to 
avoid data 
loss 
 Vrielink et 
al. 1995167 
Clinical 2,153 Ortho 2.0, 
PCR, and 
RIBA-2 
100%  2,153 Ortho 2.0  99.7% 
(99.4% to 
99.9%) 
No data loss 
(because 






 Vrielink et 
al. 1995168 














99.9% No data loss 
(because 






Tests currently in use in U.S. Organ Procurement Organization (OPO): NAT 
HIV NAT COBAS 
AmpliScreen 






Clinical 3,288 Enzygnost 
HCV (EIA) 
7.7% (0% to 
52.8%) 
(Note: 








None 0.5 was 
















96.9% None  
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Virus/ Type Test Trade 
Name 
Manufacturer Cite Study Type Sensitivity Specificity Data Loss Comments 
Samples Reference Sensitivity Samples Reference Specificity 













EIA used as 
reference 
standard) 
































































   Vargo et 
al. 2002128 





























   Jackson et 
al. 2002144 
– HCV 

























Virus/ Type Test Trade 
Name 
Manufacturer Cite Study Type Sensitivity Specificity Data Loss Comments 
Samples Reference Sensitivity Samples Reference Specificity 



































for HIV and 
HCV 
separately) 

















Kwon et al. 
2006149 






99.6% None  
 Ly et al. 
2007154 






























Clinical 1,443 2 other 
assays plus 
confirmation 
100% 1,443 2 other 
assays 
99.65% None  
 Kwon et al. 
2006149 






98.0% None  
383 
Virus/ Type Test Trade 
Name 
Manufacturer Cite Study Type Sensitivity Specificity Data Loss Comments 
Samples Reference Sensitivity Samples Reference Specificity 
   Ly et al. 
2007156 









































99.87% None  




Ly et al. 
2007154 

























































- - - - - - - - -  
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Virus/ Type Test Trade 
Name 
Manufacturer Cite Study Type Sensitivity Specificity Data Loss Comments 
Samples Reference Sensitivity Samples Reference Specificity 
 Enzygnost 













Clinical 503 Another EIA, 
1 discrimina-






503 Another EIA, 
1 discrimina-




















 Ly et al. 
2007156 

























Ly et al. 
2007154 


























- - - - - - - - -  




Ly et al. 
2007156 























Virus/ Type Test Trade 
Name 
Manufacturer Cite Study Type Sensitivity Specificity Data Loss Comments 
Samples Reference Sensitivity Samples Reference Specificity 





- - - - - - - - -  











100% 1,443 2 other 
assays 
99.86% None  
 Ly et al. 
2007154 




















 Saville et 
al. 2001161 



































   Iqbal et al. 
2005143 
Clinical 264 WB 100% (100% 
to 100%) 









   Iqbal et al. 
2005143 
Analytic 104 infected WB 100% 100 un-
infected 









Virus/ Type Test Trade 
Name 
Manufacturer Cite Study Type Sensitivity Specificity Data Loss Comments 
Samples Reference Sensitivity Samples Reference Specificity 
   Ly et al. 
2007156 






















   Seyoum et 
al. 2005162 
Clinical 408 NAT and 
ExaVir Load 
test 
100% 408 NAT and 
ExaVir Load 
test 





HCV Ab IV 
Innogenetics 
NV 
- - - - - - - - -  
Monolisa HCV 
Ag/Ab Ultra  
Bio-Rad 
Laboratories 
- - - - - - - - -  
Murex 4.0 Abbott 
Laboratories 
- - - - - - - - -  
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Table 56. GRADE Table for Question 5: Diagnostic Performance (Sensitivity/Specificity) 






























































Plus 0 EIA 
Bio-Rad 
Laboratories 
1 A*159 Sensitivity: 99.8%A** 
Specificity: 99.4%A 
Main limitations: lack of 
diagnostic uncertainty, 
no blinding 





2 A134,159 Sensitivity: 99.4%A159 and 
100%A134 
Specificity: 97.7%A159 and 
99.74%A134 
Main limitations: lack of 
diagnostic uncertainty, no 
blinding. 
Study design and quality 
assessment equal for the 
two studies. 








1 CDx†140 Sensitivity: 100%C‡ 
Specificity: 99.4%C 
Main limitation: no blinding 
High -1 0 0 0 0 Moderate 




No studies - - - - - - - - 
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1 A142 Sensitivity: 100%A 
Specificity: 97.9%A 
Main limitations: lack of 
diagnostic uncertainty, 
no blinding  
Moderate -1 0 0 0 0 Low 
 Genetic Systems 
(GS) HBsAg EIA 3.0 
Bio-Rad 
Laboratories 






Ortho Antibody to 














No studies - - - - - - - - 





No studies - - - - - - - - 
AxSYM Core 2.0 Abbott 
Laboratories 
No studies - - - - - - - - 
CORZYME Abbott 
Laboratories 
No studies - - - - - - - - 
Ortho HBc ELISA 
Test System  
Ortho Clinical 
Diagnostics 
No studies - - - - - - - - 
389 
























































HCV Abbott HCV EIA 2.0 Abbott 
Laboratories 




Main limitations: one study 
less appropriate reference 
standard, no blinding in 
any. 
Anderson et al.132 used a 
less reliable reference 
standard. All other factors 
in study design and 
limitations assessment the 
same for all three studies. 
High -1 0 0 0 0 Moderate 





1 A139  
1 DxC146 
Sensitivity: Both 100% 
Specificity: 94.4%C146, 
99.9%A139 
Main limitations: one study 
suboptimal enrollment 
methods, no blinding in 
either. 
Denoyel et al.139 did not 
report appropriate 
enrollment methods. 
All other study design and 
limitations assessments 
were the same. 
High -1 0 0 0 0 Moderate 
 AxSYM Anti-HCV Abbott 
Laboratories 
No studies - - - - - - - - 
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 Ortho HCV 






Sensitivity: All three 100%C 
Specificity: 95.5%C146, 
99.7%C167, 99.9%A168 
Main limitations: one study 
lack of diagnostic 
uncertainty, one study 
suboptimal enrollment 
methods, no blinding. 
Vrielink et al.168 did not use 
samples with diagnostic 
uncertainty or report 
adequate enrollment 
methods. The rest of the 
study design and limitations 
assessment factors were 
the same for all three 
studies. 
High -1 0 0 0 0 Moderate 
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Tests currently in use in U.S. Organ Procurement Organization (OPO): NAT 
HIV NAT COBAS AmpliScreen 
HIV-1 Test v. 1.5 
Roche 
Diagnostics 
1 DxC133  
1 A159 
Sensitivity: 7.7%C133 and 
92.6%A159 
Specificity: 96.9%A159 and 
100%C133 
Main limitations: one study 
inappropriate reference 
standard, other lack of 
diagnostic uncertainty, 
neither blinded 
The main difference in 
findings appears to be due 
to the use of a reference 
standard inappropriate to 
calculate sensitivity in 
Bamaga et al.133 
Moderate -1 0 0 0 0 Low 
HCV NAT COBAS AmpliScreen 








standards, no blinding 
Moderate -1 0 0 0 0 Low 




1 CDx147 Sensitivity: 84.8%C 
Specificity: 100%C 
Main limitations: 
no blinding, potential for 
publication bias 
Moderate -1 0 0 0 -1 Very Low 
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1 CDx144  
1 A128 
HIV 
Sensitivity: 99.9%A128 and 
100%C144 
Specificity: 99.67%A128 and 
100%C144 
HCV 
Sensitivity: 99.3%C144 and 
99.6%A128 
Specificity: 97.4%C144 and 
99.6%A128 
Main limitations: one study 
lack of diagnostic 
uncertainty, one study 
no blinding, potential for 
publication bias. 
Vargo et al.128 did not have 
diagnostic uncertainty, and 
Jackson et al. did not have 
blinding. The studies were 
on the same for the rest of 
the study design and 
limitations assessment 
factors. 
Moderate 0 0 0 0 -1 Low 
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2 A149,154 Sensitivity: Both 100%A 
Specificity: 99.6%A149 and 
100%A154 
Main limitations: lack of 
diagnostic uncertainty, 
suboptimal enrollment 
methods, no blinding. 
The study design and 
limitations assessments 
were the same for both 
studies. 
Moderate -1 0 0 0 0 Low 
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1 CDx136  
3 A149,156,163 
Sensitivity: All 100% 
Specificity: 98%A,149 
99.65%C,136 99.8%A,156 
99.9%/99.87%A163 (last two 
from same study, different 
data sets) 
Main limitations: two 
studies lack of diagnostic 
uncertainty and/or 
suboptimal enrollment 
methods, all studies no 
blinding. 
Bourlet et al.136 had 
diagnostic uncertainty and 
appropriate enrollment 
methods while the rest did 
not. The studies were the 
same on all other study 
design and limitations 
assessment factors. 
Moderate -1 0 0 0 0 Low 
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2 A154,170 Sensitivity: Both 100%A  
Specificity: 99.3%A154 and 
99.73%A170 
Main limitations: lack of 
diagnostic uncertainty, 
one study suboptimal 
enrollment methods, 
both no blinding. 
The two studies were the 
same for study design and 
limitations assessment. 
Moderate -1 0 0 0 0 Low 




No studies - - - - - - - - 





No studies - - - - - - - - 
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1 DxC131  
1A156 
Sensitivity: Both 100% 
Specificity: 82.5%C,131 
99.9%A156 
Main limitations: One study 
lack of diagnostic 
uncertainty, one suboptimal 
enrollment methods, 
neither blinded. 
Ly et al.156 did not have 
diagnostic uncertainty or 
report appropriate 
enrollment methods. 
All other study design and 
limitation assessment 
factors were the same. 
High -1 0 0 0 0 Moderate 




1 A154 Sensitivity:100%A 
Specificity: 99.8%A 
Main limitations: lack of 
diagnostic uncertainty, 
suboptimal enrollment 
methods, blinding  
Moderate -1 0 0 0 0 Low 
 Modular HIV Combi Roche 
Diagnostics 
No studies - - - - - - - - 
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1 A154 Sensitivity: 100%A 
Specificity: 99.6%A 




Moderate -1 0 0 0 0 Low 
 VIDAS DUO QUICK bioMerieux 
Clinical 
Diagnostics 
No studies - - - - - - - - 





Sensitivity: All 100%  
Specificity:99.5%C,154 
99.5%A,161 99.86%C136 
Main limitations: one study 
lack of diagnostic 
uncertainty, one study 
suboptimal enrollment 
methods, two studies lack 
of blinding 
Ly et al.154 did not have 
diagnostic uncertainty or 
report appropriate 
enrollment methods. None 
of the studies besides 
Saville et al.161 used 
blinding. All other study 
design and limitation 
assessment factors were 
the same. 
High -1 0 0 0 0 Moderate 
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 Vironostika HIV 










Main limitations: one study 
lack of diagnostic 
uncertainty, no blinding 
Ly et al.156 did not have 
diagnostic uncertainty or 
report appropriate 
enrollment methods. 
All other study design and 
limitation assessment 
factors were the same. 
High -1 0 0 0 0 Moderate 
HCV 
4th generation 




No studies - - - - - - - - 




No studies - - - - - - - - 
Murex 4.0 Abbott 
Laboratories 
No studies - - - - - - - - 
* A: Analytic study 
** A: Analytic sensitivity/specificity 
† CDx: Clinical diagnostic cohort 
‡ C: Clinical sensitivity/specificity 
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Evidence Reviews: III. Donor interventions to decrease 
transmission of HIV, HBV,or HCV from infected donors 
Question 6. Which donor interventions reduce the probability of 
pathogen transmission from an organ donor infected with HIV, HBV, or 
HCV to a previously uninfected recipient? 
Two publications of the same study of virus inactivation in organs met the inclusion criteria.
200,201
 
The study described kidney perfusion techniques that may potentially inactivate hepatitis C. The study 
methods and results are shown in Table 57 and Table 58, respectively. The study procured kidneys from 
HCV positive deceased donors, and investigated the virus-reducing capacity of four inactivation 
protocols: 
 The first (called “standard” by the authors) involved initial flushing with 1.0L of University of 
Wisconsin (U/W) solution, 20 hours of pulsatile perfusion, and another U/W flushing. 
U/W solution is “a normokalemic, intracellular colloid injected into vital organs during 
harvesting to preserve function before transplantation”.
202
 
 The second (called “enhanced”) involved a second pulsatile perfusion and additional flushings.  
 The third involved 24 hours of pulsatile perfusion at a lower flow rate 
 The fourth (“ultrafiltered”) involved the filtration of used perfusate during the perfusion process.  
The results (Table 58) showed that all four methods substantially reduced the viral load. The best results 
were found with the enhanced pulsatile perfusion, for which 99.7% of the HCV viral particles had been 
removed within 15 minutes after the start of the second perfusion. 
Regarding study quality (Table 59), there was no control group that did not receive inactivation; no 
“patients” were actually enrolled. Applying the GRADE system (Table 60) resulted in a grade of Low. 
This was based on the fact that it was only a single study, and there was no non-inactivated control group, 
but it did find a large magnitude of effect as well as a dose response association. 
400 
Table 57. Inactivation Methods in Zucker et al. (1994) 
Kidney Donor 
Inactivation 
Procedure Procedural Steps 




1) Flushed with 1.0 L of U/W solution 
2) 20 hours of perfusion on a Waters MOX-9 pulsatile 
perfusion apparatus using 1.0 L of silica gel-treated 
plasma at between 4-6 degrees Celsius at a flow 
rate of approximately 400mL/minute  
3) Again flushed with 1.0 L of U/W solution 




Steps 1-2 of the standard procedure, and then: 
3) Three additional flushes with 1.0 L of U/W solution 
4) Another 20 hours of perfusion using 1.0 L of silica 
gel-treated plasma at between 4-6 degrees Celsius 
at a flow rate of approximately 400mL/minute  
5) Again flushed with 1.0 L of U/W solution 






1) Flushed with 1.0 L of U/W solution 
2) 24 hours of perfusion on a Waters MOX-9 pulsatile 
perfusion apparatus using 1.0 L of silica gel-treated 
plasma at between 6 degrees Celsius at a flow rate 
of 200mL/minute 




with ultrafiltration of 
perfusate 
1) Flushed with 1.0 L of U/W solution 
2) 24 hours of perfusion on a Waters MOX-9 pulsatile 
perfusion apparatus using 1.0 L of silica gel-treated 
plasma at between 6 degrees Celsius at a flow rate 
of 200mL/minute, with ultrafiltration of perfusate 
using a high-flow hollow-fiber filter with a molecular 
weight cut-off of 300k daltons 
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that had been 
Removed 
Standard Pulsatile Renal Preservation Procedure 
4.78 x 10
5
 After the first 4 hours of pulsatile perfusion 1.28 x 10
5
 73% 
Enhanced Pulsatile Renal Preservation Procedure 
247 x 10
5





 After the 3 additional U/W flushes and 15 minutes 




Pulsatile Renal Preservation Procedure, without Ultrafiltration of Perfusate 
160 x 10
5





 After the full 24 hours of pulsatile perfusion 50 x 10
5
 69% 
Pulsatile Renal Preservation Procedure, with Ultrafiltration of Perfusate 
160 x 10
5











Table 59. Question 6: Quality Assessment 
Study 6a 6b 6c 6d 6e 6f 6g 6h 
Zucker et al. (1994)
200,201
         
A checkmark () means that the study met the quality criterion for this Question; the lack of a checkmark means that 
the study either did not meet the criterion, or it was unclear whether the study met the criterion. The criteria specific to 
this Question were:  
6a. Were the patients randomly assigned to treatments? 
6b. Was the study planned prospectively (i.e., before any data were collected) 
6c. Were all consecutive patients enrolled (or a random sample of eligible patients)? 
6d. Were the two groups comparable at baseline? (age, sex, comorbidities, indication for transplant, 
previous duration on waitlist) 
6e. If not, were statistical adjustments performed to control for baseline differences?  
6f. Were the two groups treated concurrently? 
6g. Did at least 85% of the study enrollees provide data? 
6h. Was the between-group difference in study completion rates less than 15%? 
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to 99.7%  
Low -1 -1 0 0 0 +1 +1 0 Low 
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Evidence Reviews: IV. Potential risks and benefits of 
transplanting, or not transplanting, solid organs from donors 
positive for HIV, HBV, or HCV 
Question 7. How do the clinical outcomes of recipients of organs from 
donors infected with HIV, HBV, or HCV compare to those who remain on 
the transplant list? 
This question involves whether the long-term health of a recipient will be better if 1) an organ from a 
known infected donor is transplanted, or 2) the patient remains on the waiting list for an organ from an 
uninfected donor. Transplanting an organ from an infected donor incurs the chance of a new infection, in 
addition to the usual risks of organ transplantation (e.g., graft failure, graft-vs. host disease). However, 
remaining on the waiting list also entails risks, primarily the risk of death before an organ becomes 
available. Even if an organ from an uninfected donor become available, transplantation procedural risks 
will still apply, and these risks would be slightly higher at that time because the recipient would be older. 
This question should not be confused with Question 8, which considers clinical outcomes after the 
transplantation of organs from at-risk donors with unknown infection status. 
Our original inclusion criteria for this question (Table 2) required a waitlist control group; only one study 
met those original criteria: Abbott et al. (2004).
82
 This study involved the transplantation of kidneys from 
deceased donors known to have been infected with HCV; its methods and results are detailed in the next 
section. Due to the paucity of evidence, we relaxed the initial inclusion criteria to include: 
 Studies of recipients who were negative before transplant that compared the clinical outcomes 
after receiving an organ from a positive donor vs. receiving an organ from a negative donor 
 Studies of recipients who were positive before transplant that compared clinical outcomes after 
receiving an organ from a positive donor vs. receiving an organ from a negative donor 
This expansion yielded 7 and 22 additional publications, respectively; they are listed in Table 64. 
Although these comparisons do not involve the waitlist, they are still relevant. When a potential organ 
recipient does not receive an organ because it is from a known positive donor, the recipient remains on 
the waitlist for an organ from a negative donor. This hoped-for organ may or may not become available 
before the patient dies. The comparison group “receiving an organ from a negative donor” represents the 
realization of this hope, so it estimates a relatively good waitlist outcome. 
The use of organs from infected donors may be more acceptable for recipients who are already positive 
before transplant, because disease transmission is less important (although dual infection with a different 
genotpye is possible). Their outcomes may be quite different from the outcomes of recipients who were 
negative before transplant, which is why we considered the two types of recipients separately. 
Some centers may reserve organs from infected donors only for the most ill recipients. For example, 
Haji et al. (2004)
77
 stated that “at our institution, an HCV-seropositive donor was used when, in the 
judgment of the transplant team, the recipient was critically ill and not a candidate for mechanical 
404 
ventricular assist device or had a significant complication while on the ventricular assist device.”
77
 
(page 278) Based on this practice, a simple comparison of survival times between those who received 
organs from infected donors and those who received organs from uninfected donors would be biased 
against the former group. Thus, a better analysis would attempt to control for pre-transplant differences so 
that the comparison is more balanced. 
Organs from Positive Donors Compared to Remaining on the Waitlist 
Abbott et al. (2004)
82
 considered the clinical scenario of a patient with end-stage renal disease (ESRD) on 
dialysis, and a kidney from a deceased HCV+ donor becomes available to this patient. Authors used 
retrospective data on Medicare beneficiaries in the United States Renal Data System who had been on the 
kidney transplant waiting list between 4/1/1995 and 7/31/2000. Of the 38,270 potential recipients: 
 389 patients (1%) were transplanted with kidneys from deceased HCV+ donors (abbreviated 
DHCV+). Of these 389 recipients, 201 of them (52%) were HCV+ before the transplant. 
 16,106 patients (42%) were transplanted with kidneys from deceased HCV- donors. Of these 
recipients, 508 of them (3%) were HCV+ before the transplant. 
 17,044 patients (45%) were not transplanted during the study period. The pre-transplant HCV 
status of these recipients was not reported. 
 4,731 patients (12%) were transplanted prior to dialysis, or transplanted with an organ other than 
a kidney, or transplanted with any kidney from a living donor (neither separate counts not 
outcome data were reported for these patients). The pre-transplant HCV status of these recipients 
was not reported. 
A critical question is whether these groups of patients were similar before the transplantations occurred. 
If they were not, then pre-transplant factors (e.g., age, or amount of time already on waitlist) could 
explain subsequent differences in mortality rates. In this study, there were some differences between 
the 389 patients who received kidneys from DHCV+ and the full group of patients (all reported 
characteristics are listed in Table 61 below). The only characteristic with a particularly large difference 
at baseline involved race: 58% of recipients of organs from DHCV+ donors were African-American, 
as compared to only 30.4% of the full group of enrolled patients. Several of the other differences were 
statistically significant (due to the extremely large number of enrolled patients), but the actual size of the 
baseline differences were not generally large.  
The authors performed adjusted analyses to control for pre-transplant differences. Any variable that was 
statistically significantly associated with mortality (defined as p <0.10) was adjusted for: recipient age, 
recipient race, cause of end-stage renal disease (ESRD), year of first dialysis, presence of congestive heart 
failure, ischemic heart disease, peripheral vascular disease, serum albumin level, Medicare claims for 
access-related complications, and Medicare HCV claims at the time of listing.  
The mortality analyses contained an important limitation: if an organ from any donor other than a 
deceased HCV+ donor was transplanted, all subsequent survival times were excluded from the analysis. 
Therefore, the mortality from remaining on the waitlist was only up to the point of receiving an alternate 
kidney. A more comprehensive approach would have included post-transplant survival times for those 
who did eventually receive kidneys from alternate donors. 
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Authors compared the adjusted mortality rates of kidney recipients from a DHCV+ donor to waitlist 
patients. The reported results are shown in Figure 11. The adjusted hazard ratio of 0.76 (95% confidence 
interval 0.60 to 0.96) indicated reduced mortality after receiving a kidney from a deceased HCV+ donor 
as compared to being on the waitlist.  
Authors did not directly compare the mortality rates of recipients of kidneys from HCV+ donors to 
recipients of kidneys from HCV- donors. However, they did report a comparison between receiving a 
kidney from any deceased donor (regardless of donor HCV status) and being on the waitlist. This 
comparison favored transplantation substantially (adjusted hazard ratio of 0.47; 95% CI: 0.43 to 0.50). 
Thus, the mortality advantage of receiving a kidney more than doubled when recipients of HCV- donor 
kidneys were included in the analysis (i.e., the 24% mortality advantage in the primary analysis increased 
to a 53% advantage). 
The GRADE evidence profile appears in Table 63. The grade was Very Low, which was due to three 
factors: 1) the study did not randomly assign recipients to groups; 2) the study excluded survival data 
after the transplantation of any kidney that was not a kidney from a deceased HCV+ donor; and 




Table 61. Baseline Characteristics in the Abbott et al. (2004) Study 
Characteristic 
DHCV+ 
(N = 389) 
Full Group of 
Enrolled Patients 
(N = 38,270) 
Between-group Difference in 
Percentage Points (p.p.), or Hedges’ g 
% male 75.3% 61.3% 14 p.p. 
% African-American 58.4% 30.4% 28 p.p.; Large difference at baseline 
% with diabetes as the cause of end-
stage renal disease 
29.8% 35.3% 5 p.p. 
% with hypertension 77% 73.9% 4 p.p. 
% with congestive heart failure 15.9% 13.8% 2 p.p. 
% ischemic heart disease 9.7% 8.9% 1 p.p. 
% with smoking history 8.4% 5.3% 3 p.p. 
% with hemodialysis (not peritoneal) 86.1% 80.5% 6 p.p. 
% with peripheral vascular disease 4.4% 5.3% 1 p.p. 
% with Medicare claims for HCV at the 
time of listing 
5.4% 0.5% 5 p.p. 
% with positive HCV serology by UNOS 51.7% Not reported Not calculable 
% with Medicare claims for access 17.7% 14.2% 3.5 p.p. 
Mean Age 51.2 (SD: 11.3) 47.6 (SD: 13.8) g = 0.26 
Mean Body Mass Index 26.0 (SD: 5.5) 26.7 (SD: 6.2) g = 0.11 
Mean Serum albumin (gm/dL) 3.2 (SD: 0.7) 3.4 (SD: 0.7) g = 0.29 
Mean Hematocrit 28.2 (SD: 5.8) 27.9 (SD: 5.7) g = 0.05 
Note: Shaded cells represent baseline characteristics that differed by 15+ percentage points, or differed by 0.4+ on the scale of Hedges’ g.  
Hedges’ g is the difference between means divided by the pooled standard deviation. The difference in percentage points, and values for Hedges’ g, were 
calculated by ECRI Institute 
SD – Standard deviation 
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Figure 11. Adjusted Mortality Results of Transplanting Kidneys from DHCV+ Donors Compared to the Waitlist 




Note: The horizontal bars represent the reported 95% confidence interval around the adjusted hazard ratio. The fact that the confidence intervals was fully below 1.0 
indicates that the adjusted hazard ratio was statistically significantly in favor of receiving a kidney from a DHCV+ donor over being on the waitlist. 
* Variables adjusted for included recipient age, recipient race, cause of end-stage renal disease, year of first dialysis, presence of congestive heart failure, 
ischemic heart disease, peripheral vascular disease, serum albumin level, and Medicare claims for access-related complications and Medicare claims for access-
related complications HCV 
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Organs from Positive Donors Compared to Organs from Negative Donors When the 
Recipients were Negative Before Transplant 
We included seven publications (five unique studies) that made this comparison. One study involved HBV, 
and four involved HCV. General study characteristics are listed in the upper portion of Table 64, and details 
of methods appear in the upper portion of Table 65. 
Regarding quality (the upper portion of Table 67), none of the studies were randomized or prospective, but 
all five treated the groups concurrently, and three studies enrolled patients consecutively. Two studies 
reported data on at least 85% of the enrolled patients and also had less than a 15% difference in completion 
rates between groups. For baseline comparability of groups (upper portion of Table 66), only two of the five 
studies reported any specific characteristics to enable a comparison (the Fong et al. [2002]
55
 study of HBV, 
and the Haji et al. [2004]
77,79
 study of HCV). Our analyses of between-group comparability identified three 
large differences at baseline (identified as gray cells in the upper portions of Table 66). For Fong et al. 
(2002)
55
, the rate of donor death due to stroke was substantially higher in the D+ group (51% than the D- 
group (36%). For Haji et al. (2004)
77,79
, the percentage of donors who were male was greater in the D+ group 
(74%) than in the D- group (57%), and also the mean recipient age was greater in the D+ group (age 57) than 
in the D- group (age 52).  
One way to address the problem of differing pre-transplant characteristics is to perform statistical 
adjustments of the results. Only one of the five studies (Abbott et al. 2003)
83,84
 clearly performed such 
adjustments. The methods section of the Haji et al. (2004)
77,79
 study reported some use of Cox regression 
“to adjust for significant covariates”, but authors did not report whether the reported hazard ratio of 2.8 was 
adjusted or unadjusted. 
All study results appear in the upper portion of Table 68, and pertinent plots are in Figure 12. The points 
appear without confidence intervals because studies did not report enough information to permit such 
calculation, which is also why no meta-analyses of these results were possible. Note that in the figure, the 
data generally fall below the 45 degree line, suggesting shorter survival among those who received D+ 
organs than those who received D- organs. However, the lack of demonstrated group comparability, and the 
possibility that in some studies the pre-transplant prognosis was poorer for recipients of D+ organs, make it 
difficult to interpret these raw results. The one study that controlled for baseline differences (Abbott et al. 
2003)
83,84
) found a significantly shorter survival of those who received D+ organs (adjusted hazard ratio of 
2.25; see footnote to the figure). The Haji et al. (2004)
77,79
 study, which may have controlled for baseline 
differences, also reported shorter survival for recipients of D+ organs (see Table 68). 
Regarding different genotypes of HBV and HCV, none of the five studies reported donors' genotypes, or 
stated whether recipient survival was different by donor genotype.  
The GRADE evidence profiles appear in Table 63. We graded the evidence as Very Low for all of these 
evidence bases, except for the comparison of recipient survival of HCV+ and HCV- organs, which we 
graded as Low. None of these studies had randomized recipients to groups, and several had pre-transplant 
differences between groups that were not statistically adjusted for. The single “Low” GRADE (for recipient 
survival comparing HCV+ and HCV- donors) was due to the large effect magnitudes found in those three 
studies. 
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Figure 12. Clinical Outcomes of Negative Recipients: Positive vs. Negative Donors, 


















Graft survival of HBV- recipients after kidney transplant
Graft survival of HCV- recipients after liver transplant
Patient survival of HBV- recipients after kidney transplant
Patient survival of HCV- recipients after liver transplant





Note: The diagonal line represents no difference in survival between those who received an organ from a positive donor 
and those who received an organ from a negative donor. Points above the diagonal line favor recipients of organs 
from positive donors, whereas points below the diagonal line favor recipients of organs from negative donors. 
This figure only includes studies that reported graft or survival data as percentages, and it only includes the 
longest followup timepoint from each study. The full data are provided in Table 68. None of the plotted studies 
reported confidence intervals. Studies with a lower case ‘s’ next to the point reported that the comparison of full 
survival curves was statistically significant; all other studies either did not report whether the difference was 
statistically significant, or reported that the difference was not statistically significant. One of the studies did not 
report results on a percentage scale, and so its results do not appear in the plot. This was the Abbott et al. 
(2003)
83,84
 study, which found an adjusted hazard ratio of death of 2.25 (95% CI: 1.56 to 3.24) in favor of 
recipients of organs from HCV- donors. 
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Organs from Positive Donors Compared to Organs from Negative Donors When the 
Recipients were Positive Before Transplant 
We included 22 publications (17 unique studies) that made this comparison. Three studies involved HBV 
only, 13 studies involved HCV only, and one study provided separate data on both HBV and HCV. General 
study characteristics are listed in the lower portion of Table 64, and details of methods appears in the lower 
portion of Table 65. 
Regarding quality (the lower portion of Table 67), none of the studies were randomized or prospective, but 
all 17 treated the groups concurrently, and 13 studies enrolled patients consecutively. Ten studies reported 
data on at least 85% of the enrolled patients and also had less than a 15% difference in completion rates 
between groups.  
For baseline comparability of groups, 10 of the 17 studies (two of HBV and eight of HCV) reported specific 
characteristics to enable a comparison. These 10 studies reported 128 characteristics that could be compared 
(listed in the lower portions of Table 66), and we classified 27 of these 128 were as large differences 
(reproduced below in Table 62). In the HBV studies, the differences involved rates of donor HCV 
(HBV+ donors were more likely to also be HCV+), donor and recipient age (both were higher in D+ groups), 
and race (D+ donors were more likely to be African-American and less likely to be Caucasian-American). 
In the HCV studies, we noticed two types of consistent differences: donor/recipient ages (which were higher 
in D+ groups) and the recipient’s amount of time on the waitlist (which was much shorter in the D+ groups: 
9.9 months vs. 17.7 months in Woodside et al. (2003)
85




Table 62. Large Pre-transplant Differences between Recipients of D+ and D- Organs in 
Studies of Pre-transplant Positive Recipients 
Study Characteristic 













Recipients Infected Before Transplant; Comparison of Clinical Outcomes after HBV+ Donor vs. HBV- Donor 


















g = 0.43 













g = 0.47 
Recipients Infected Before Transplant; Comparison of Clinical Outcomes after HCV+ Donor vs. HCV- Donor 








































g = 0.66 
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Study Characteristic 




































g = 1.08 




g = 0.68 




g = 0.84 




g = 0.45 




g = 0.51 




g = 1.71 



























g = 0.45 








g = 0.49 









Note: This table only includes pre-transplant differences that met our criteria for “large”, which was a Hedges’ g of 0.4 or 
more for continuous data, or a difference in percentage points of 15 or more. These differences were calculated 
by ECRI Institute. The full list of reported baseline characteristics is in Table 66. 
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One way to address the problem of differing pre-transplant characteristics is to perform statistical 
adjustments of the results. Only four of the 17 studies did this (Fong et al. [2002]
55
, Madayag et al. [1997]
56
, 
Abbott et al. [2003]
83,84
, and Marroquin et al. [2001]).
90
 
All study results appear in the lower portion of Table 68, and pertinent plots are in Figure 13, Figure 14, and 
Figure 15. The points appear without confidence intervals because studies did not report enough information 
to permit such calculation; this also explains why no meta-analyses of these results were possible. The HBV 
plot (Figure 13) shows no consistent trend: two data points favored the D+ group, three data points favored 
the D- group, and four data points suggested equivalence. Restricting the analysis to the two HBV studies 
that used statistical adjustments to control for baseline prognosis, one study (Madayag et al. [1997]
56
) found 
poorer graft survival in the D+ group, and the other study (Fong et al. [2002]
55
) found no large differences in 
either graft survival or patient survival.  
The two HCV plots (Figure 14 for kidney transplants, and Figure 15 for liver transplants) each suggest a 
small but consistently better survival for recipients of D+ organs than recipients of D- organs; one cannot 
determine the statistical significance of this effect due to insufficient reporting. Restricting the analysis to the 
two HCV studies that used statistical adjustments to control for baseline prognosis, they found conflicting 
results. Whereas Abbott et al. (2003)
83,84
 found shorter survival in the D+ group (adjusted hazard ratio 2.04), 
Marroquin et al. (2001)
90
 found longer survival in the D+ group (adjusted odds of patient survival at two 
years was 0.51) (results of these two studies are not plotted because the results were not reported as 
percentages; see the footnote to the figure). 
Regarding different genotypes of HBV, none of the four studies reported donors' genotypes, or stated 
whether recipient survival different by donor genotype. For HCV genotypes, two studies
88,91
 attempted to 
investigate the impact of genotype, but they did not draw conclusions due to the paucity of data. A third 
study
92
 provided pre-tranpslant genotypes for all donors and recipients, as well which which genotype 
predominated for each donor-recipient pair. Recipient survival was unaffected by whether the predominant 
genotype was from the donor or was already present in the recipient. None of the other studies attempted 
analyses by HCV genotype. 
GRADE Assessment of Clinical Outcomes After Receiving Organs from Infected Donors 
The GRADE evidence profiles (HBV graft survival; HBV patient survival; HCV graft survival; and HCV 
patient survival) appear in Table 63. We graded the evidence as Very Low for all four pathogen/outcome 
combinations, due to the lack of randomization to groups and the pre-transplant differences between groups. 
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Figure 13. Clinical Outcomes of Positive Recipients: Positive vs. Negative Donors, 


















Graft survival of HBV+ recipients after kidney transplant
Graft survival of HBV+ recipients after liver transplant
Patient survival of HBV+ recipients after kidney transplant




Note: The diagonal line represents no difference in survival between those who received an organ from a positive donor 
and those who received an organ from a negative donor. Points above the diagonal line favor recipients of organs 
from positive donors, whereas points below the diagonal line favor recipients of organs from negative donors. 
This figure only includes studies that reported graft or survival data as percentages, and it only includes the 
longest followup timepoint from each study. The full data are provided in Table 68. None of the plotted studies 
reported confidence intervals. Studies with a lower case ‘s’ next to the point reported that the comparison of full 
survival curves was statistically significant; all other studies either did not report whether the difference was 























Graft survival of HCV+ recipients after kidney transplant
Patient survival of HCV+ recipients after kidney transplant
 
Note: The diagonal line represents no difference in survival between those who received an organ from a positive donor 
and those who received an organ from a negative donor. Points above the diagonal line favor recipients of organs 
from positive donors, whereas points below the diagonal line favor recipients of organs from negative donors. 
This figure only includes studies that reported graft or survival data as percentages, and it only includes the 
longest followup timepoint from each study. The full data are provided in Table 68. None of the plotted studies 
reported confidence intervals. Studies with a lower case ‘s’ next to the point reported that the comparison of full 
survival curves was statistically significant; all other studies either did not report whether the difference was 
statistically significant, or reported that the difference was not statistically significant. One of the studies did not 
report results on a percentage scale, and so its results do not appear in the plot. This was the Abbott et al. 
(2003)
83,84
 study, which found an adjusted hazard ratio of death of 2.04 (95% CI: 1.20 to 3.45) in favor of 
recipients of negative organs. 
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Graft survival of HCV+ recipients after liver transplant
Patient survival of HCV+ recipients after liver transplant
s
 
Note: The diagonal line represents no difference in survival between those who received an organ from a positive donor 
and those who received an organ from a negative donor. Points above the diagonal line favor recipients of organs 
from positive donors, whereas points below the diagonal line favor recipients of organs from negative donors. 
This figure only includes studies that reported graft or survival data as percentages, and it only includes the 
longest followup timepoint from each study. The full data are provided in Table 68. None of the plotted studies 
reported confidence intervals around the data. Studies with a lower case ‘s’ next to the point reported that the 
comparison of full survival curves was statistically significant; all other studies either did not report whether the 
difference was statistically significant, or reported that the difference was not statistically significant. One of the 
studies did not report results on a percentage scale, and so its results do not appear in the plot. These was the 
Marroquin et al. (2001)
90
 study, which found an adjusted two-year odds of graft failure of 0.88, in favor of 




Table 63. GRADE Table for Question 7 (Clinical Outcomes of Known Positive Organs vs. Waitlist or 












































































































Receiving an HCV+ organ 
compared to remaining 






Adjusted hazard ratio 0.76 
(95% CI: 0.6 to 0.96) 
(in favor of transplantation 
over the waitlist) 
Low -1 -1 0 0 0 0 0 0 Very Low Very Low 
Receiving an HBV+ organ 
compared to receiving a 
negative organ for 








Results favored receiving 
an organ from a negative 
donor: 
1 year: D+ 87%, D- 88% 
2 yrs.: D+ 78%, D- 83% 
3 yrs: D+ 72%, D- 77% 







Results favored receiving 
an organ from a negative 
donor: 
1 year: D+ 94%, D- 94% 
2 yrs.: D+ 90%, D- 92% 
3 yrs: D+ 86%, D- 90% 













































































































Receiving a HCV+ organ 
compared to receiving a 
negative organ for 









No statistically significant 
difference was reported by 
any of the three studies. 







Two of the three studies 
reported results in favor of 
receiving an organ from a 
negative donor. The third 
study found a statistically 
nonsignificant result. 













































































































Receiving an HBV+ organ 
compared to receiving a 
negative organ for 









Only one of the four studies 
reported any statistically 
significant difference. This 
study found that if the 
kidney donor was living, 
results slightly favored 
receiving an organ from an 
HBsAg+ donor, whereas if 
the kidney donor was 
deceased, results favored 
receiving an organ from an 
HBsAg- donor. 








Only one of the three 
studies reported any 
statistically significant 
difference. This study found 
that if the kidney donor was 
living, there was no 
statistically significant 
difference, whereas if the 
kidney donor was 
deceased, results favored 
receiving an organ from an 
HBsAg- donor. 













































































































Receiving a HCV+ organ 
compared to receiving a 
negative organ for 









No statistically significant 
difference was reported by 
any of the 13 studies. 








Only 2 of the 11 studies 
found any statistically 
significant difference. 
One of the two favored 
recipients of organs of 
positive donors, and the 
other favored recipients of 
organs of negative donors. 
Low -1 0 0 0 0 0 0 0 Very Low 
Note: The shaded rows denote recipient survival, which was considered a “critical” outcome. Graft survival is unshaded because it was not considered “critical” for the purpose of evidence grading. 
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Additional Evidence Tables for Question 7 
Table 64. Question 7: General Information about Included Studies 





Recipients Negative Before Transplant; Comparison of Clinical Outcomes After HBV+ Donor vs. HBV- Donor 
Fong et al. (2002)
55
 USA UNOS Scientific Renal Transplant 
Registry 
Kidney UNOS 1994 to 1999 NR 
Recipients Negative Before Transplant; Comparison of Clinical Outcomes After HCV+ Donor vs. HCV- Donor 
Abbott et al. (2003)
83,84
 USA United States Renal Data System 
(USRDS) 
Kidney USRDS Jan-96 to May-01 NR 
Velidedeoglu et al. (2002)
93,94
 USA University of Pennsylvania (Penn), 
Philadelphia, PA, and UNOS 
Liver 1 Jan-95 to Dec-99 NR 
Shah et al. (1993)
12,16
 USA University of Pittsburgh 
School of Medicine, Pittsburgh, PA 
Liver 1 Mar-86 to Mar-90 NR 
Haji et al. (2004)
77,79
 USA Cleveland Clinic, Cleveland, OH Heart 1 Jul-93 to Dec-98 NR 
Recipients Positive Before Transplant; Comparison of Clinical Outcomes After HBV+ Donor vs. HBV- Donor 
Fong et al. (2002)
55
 USA UNOS Scientific Renal Transplant 
Registry 
Kidney UNOS 1994 to 1999 NR 
Madayag et al. (1997)
56
 USA University of Maryland, Baltimore, MD Kidney 1 Jan-92 to Jul-96 NR 
Lai et al. (1996)
95-97
 Taiwan National Taiwan University, 
Taipei, Taiwan 
Kidney NR Jul-81 to Jan-94 NR 
Saab et al. (2003)
91
 USA Dumont-UCLA Liver Transplant 
Center, Los Angeles, CA 
Liver 1 Jan-90 to Apr-01 NR 
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Recipients Positive Before Transplant; Comparison of Clinical Outcomes After HCV+ Donor vs. HCV- Donor 
Kasprzyk et al. (2007)
98
 Poland Medical University of Wroclas, 
Wroclas, Poland 
Kidney NR Jul-94 to Jul-06 NR 
Abbott et al. (2003)
83,84
 USA USRDS Kidney USRDS Jan-96 to May-01 NR 
Woodside et al. (2003)
85
 USA University of Texas Medical Branch, 
Galveston, TX 
Kidney 1 Jul-92 to Jul-00 NR 
Mandal et al. (2000)
86
 USA Johns Hopkins Hospital, 
Baltimore, MD 
Kidney 1 Jan-97 to Jun-99 NR 
Ali et al. (1998)
99
 USA Washington Hospital Center, 
Washington, DC 
Kidney 1 Feb-91 to Sep-96 NR 
Morales et al. (1995)
87
 Spain Hospital 12 de Octubre, Madrid, and 
Hospital Clinic, Barcelona 
Kidney 2 Mar-90 to Dec-92 Partially 
supported by FIS 
grant No. 94/1002 
Saab et al. (2003)
91
 USA Dumont-UCLA Liver Transplant 
Center, Los Angeles, CA 
Liver 1 Jan-90 to Apr-01 NR 
Velidedeoglu et al. (2002)
93,94
 USA University of Pennsylvania, 
Philadelphia, PA, and UNOS 




Jan-95 to Dec-99 NR 
Marroquin et al. (2001)
90
 USA UNOS Scientific Renal Transplant 
Registry 
Liver UNOS Apr-94 to Jun-97 NR 
Salizzoni et al. (2001)
88
 Italy S. Giovanni Battista Hospital, Torino, 
Italy 
Liver 1 Jul-98 to Dec-99 NR 
Vargas et al. (1999)
92
 USA Thomas E. Starzl Transplantation 
Institute, Pittsburgh, PA 
Liver 1 Feb-92 to May-05 NR 
Testa et al. (1998)
89
 USA Baylor University Medical Center, 
Dallas, Texas 
Liver 1 Jul-85 to Jul-95 NR 
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Shah et al. (1993)
12,16
 USA University of Pittsburgh 
School of Medicine, Pittsburgh, PA 
Liver 1 Mar-86 to Mar-90 NR 
NR – Not reported 
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Recipients Negative Before Transplant; Comparison of Clinical Outcomes after HBV+ Donor vs. HBV- Donor 
Fong et al. (2002)
55
 No Yes NR 763 24,661 anti-HBc+ NR 
Recipients Negative Before Transplant; Comparison of Clinical Outcomes after HCV+ Donor vs. HCV- Donor 
Abbott et al. (2003)
83,84
 No Yes Mean: 33 (SD: 20) 280 34,151 anti-HCV “Presumably 
ELISA” 
Velidedeoglu et al. (2002)
93,94
 No Yes For Pennsylvania data, the 
mean followup was 23.4 months. 
For UNOS data, the 
mean followup was 22.4 months. 
29 7,811 “HCV+” NR 
Shah et al. (1993)
12,16
 No No NR 25 375 anti-HCV ELISA2 
Haji et al. (2004)
77,79
 No No Mean: 50 months (SD: 23) 34 183 anti-HCV ELISA2 
Recipients Positive Before Transplant; Comparison of Clinical Outcomes after HBV+ Donor vs. HBV- Donor 
Fong et al. (2002)
55
 No Yes NR 140 2,093 anti-HBc+ NR 
Madayag et al. (1997)
56
 No Yes Mean: 24 (Range: 2-64) 45 45 Donor anti-HBc+ and 
HBsAg-; Recipient had 
prior HBV infection or 
had been vaccinated 
Abbott tests 
Lai et al. (1996)
95-97




















































Saab et al. (2003)
91
 No NR For HBV+ recipients, 
mean follow-up for patient 
survival data was 2.3 years 
(Range: 0-8.7), and for graft 
survival data was 2.0 years 
(Range: 0-8.7). 
For HCV+ recipients, 
mean follow-up for patient 
survival data was 2.6 years 
(Range: 0-5.8), and for graft 
survival data was 1.8 years 
(Range: 0-5.8). 
74 42 anti-HBc+ NR 
Recipients Positive Before Transplant; Comparison of Clinical Outcomes after HCV+ Donor vs. HCV- Donor 
Kasprzyk et al. (2007)
98
 No Yes Range: 12-156 60 199 anti-HCV NR 
Abbott et al. (2003)
83,84
 No Yes Mean: 33 (SD: 20) 593 1,932 anti-HCV “Presumably 
ELISA” 
Woodside et al. (2003)
85
 No Yes Mean: 26 months  
(Range: 0.4-119) for those who 
received a positive organ, and  
34 months (Range: 0.2-66) for 
those who received a negative 
organ 
20 20 “seropositive” NR 
Mandal et al. (2000)
86
 No Yes Median: 16,  
Mean: 15 (standard error of the 
mean: 2),  
Range: 3-33 
18 10 anti-HCV and 
HCV-RNA+ 
HCV RNA 
measured by PCR 
Ali et al. (1998)
99
 No Yes Mean: 36,  
Range: 12-60 



















































Morales et al. (1995)
87
 NR Yes Mean: 26 months (SD: 8) for 
those who received a positive 
organ, and 30 months (SD: 10) 
for those who received a 
negative organ 
24 40 anti-HCV ELISA2 (Ortho) 
and RIBA (Chiron) 
Saab et al. (2003)
91
 No NR For HBV+ recipients, 
mean follow-up for 
patient survival data was 
2.3 years (Range: 0-8.7), and  
for graft survival data was 
2.0 years (Range: 0-8.7). 
For HCV+ recipients, 
mean follow-up for 
patient survival data was 
2.6 years (Range: 0-5.8), and 
for graft survival data was 
1.8 years (Range: 0-5.8) 
27 212 anti-HCV NR 
Velidedeoglu et al. (2002)
93,94
 No Yes For Penn data, the 
mean followup was 23.4 months. 
For UNOS data, the 









Penn: “HCV+”;  
 
UNOS: Donors were 
anti-HCV+, and of 
recipients, 96% were 
anti-HCV+ and 
4% were RIBA+ and/or 
HCV-RNA+ 
NR 
Marroquin et al. (2001)
90
 No Yes Median was 34 months for those 
who received a positive organ, 
and 37 months for those who 
received a negative organ 



















































Salizzoni et al. (2001)
88
 No NR Mean: 12,  
Range: 1-25 
12 103 anti-HCV NR 
Vargas et al. (1999)
92
 No Yes NR 23 169 anti-HCV ELISA3 (Abbott) 
Testa et al. (1998)
89
 No Yes Mean:  
40 months (Range: 12-58) for 
those who received a 
positive organ, and  
36 months (Range: 17-135) for 
those who received a 
negative organ 
22 115 anti-HCV ELISA1 until 1990, 
then ELISA2 
Shah et al. (1993)
12,16
 No No NR 5 111 anti-HCV ELISA2 
NR – Not reported 
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Table 66. Question 7: Pre-transplant Patient Characteristics 
Study Characteristic 
Mean (SD) 











or Hedges’ g Comments 
Recipients Negative Before Transplant; Comparison of Clinical Outcomes After HBV+ Donor vs. HBV- Donor 
Fong et al. (2002)
55




7 p.p.  




15 p.p. Large difference 
at baseline. 




9 p.p.  




1 p.p.  




9 p.p.  




2 p.p.  




6 p.p.  




2 p.p.  




1 p.p.  




g = 0.18  



















or Hedges’ g Comments 




g = 0.17  




g = 0.16  




g = 0.04  




g = 0.03  
Recipients Negative Before Transplant; Comparison of Clinical Outcomes After HCV+ Donor vs. HCV- Donor 
Abbott et al. (2003)
83,84
, 
Velidedeoglu et al. (2002)
93,94
 
These studies did not report pre-transplant characteristics comparing those who received organs from infected donors vs. 
those who received organs from uninfected donors 
Shah et al. (1993)
12,16
 Study only reported that “No statistical difference in disease indication for OLTx was evident between the 4 study groups” 
Haji et al. (2004)
77,79




2 p.p.  




6 p.p.  




4 p.p.  




17 p.p. Large difference 
at baseline. 




3 p.p.  



















or Hedges’ g Comments 




g = 0.46 Large difference 
at baseline. 




g = 0.3  
 Mean number of recipient episodes of acute 





g = 0.06  
Recipients Positive Before Transplant; Comparison of Clinical Outcomes After HBV+ Donor vs. HBV- Donor 
Lai et al. (1996)
95-97
, 
Saab et al. (2003)
91
 
These studies did not report pre-transplant characteristics comparing those who received organs from infected donors vs. 
those who received organs from uninfected donors 
Fong et al. (2002)
55




13 p.p.  




10 p.p.  




17 p.p. Large difference 
at baseline. 




8 p.p.  




17 p.p. Large difference 
at baseline. 




6 p.p.  




2 p.p.  



















or Hedges’ g Comments 




9 p.p.  




g = 0.01  




g = 0.43 Large difference 
at baseline. 




g = 0.36  




g = 0.23  




g = 0.05  






g = 0  
Madayag et al. (1997)
56




11 p.p.  




11 p.p.  




7 p.p.  




11 p.p.  




23 p.p. Large difference 
at baseline. 



















or Hedges’ g Comments 




0 p.p.  




5 p.p.  




6 p.p.  






4 p.p.  




6 p.p.  






0 p.p.  




13 p.p.  




g = 0.47 Large difference 
at baseline. 
Dispersion reported 
as “+/-” but authors 
did not specify what 
this was; ECRI 
Institute estimated 
the SD for each 
group to be 11.8 
based on the 
reported p = 0.03 for 
ANOVA 
 Recipient date of transplant The study intentionally matched 
















or Hedges’ g Comments 
 Recipient Pre-transplant HBV serology The study intentionally matched 
patients on this characteristic 
  
 Type of organ transplanted The study intentionally matched 
patients on this characteristic 
  
Recipients Positive Before Transplant; Comparison of Clinical Outcomes After HCV+ Donor vs. HCV- Donor 
Kasprzyk et al. (2007)
98
, 
Abbott et al. (2003)
83,84
, 
Ali et al. (1998)
99
, 
Saab et al. (2003)
91
 
These studies did not report pre-transplant characteristics comparing those who received organs from infected donors vs. 
those who received organs from uninfected donors 
Woodside et al. (2003)
85




10 p.p.   




0 p.p.   




15 p.p. Large difference 
at baseline. 






10 p.p.   






0 p.p.   






5 p.p.   




0 p.p.   



















or Hedges’ g Comments 




15 p.p. Large difference 
at baseline. 




5 p.p.  




10 p.p.   




20 p.p. Large difference 
at baseline. 




30 p.p. Large difference 
at baseline. 




0 p.p.   




15 p.p. Large difference 
at baseline. 




0 p.p.   




5 p.p.   




0 p.p.   




5 p.p.   




















or Hedges’ g Comments 




g = 0.39 ECRI Institute 
estimated the SDs 
using the reported 
SEMs and Ns 




g = 0.03 ECRI Institute 
estimated the SDs 
using the reported 
SEMs and Ns 




g = 0.66 Large difference 
at baseline. 
ECRI Institute 
estimated the SDs 
using the reported 
SEMs and Ns 
Mandal et al. (2000)
86




37 p.p. Large difference 
at baseline. 




5 p.p.   
 Donor % prior cocaine snorting or selling of 
drugs 
NR NR NC   




6 p.p.   




13 p.p.   




14 p.p.   




















or Hedges’ g Comments 




7 p.p.   




32 p.p. Large difference 
at baseline. 




g = 1.08 Large difference 
at baseline. 
ECRI Institute 
estimated the SDs 
using the reported 
SEMs and Ns 




g = 0.68 Large difference 
at baseline. 
ECRI Institute 
estimated the SDs 
using the reported 
SEMs and Ns 




g = 0.84 Large difference 
at baseline. 
ECRI Institute 
estimated the SDs 
using the reported 
SEMs and Ns 




g = 0.45 Large difference 
at baseline. 
ECRI Institute 
estimated the SDs 
using the reported 















or Hedges’ g Comments 




g = 0.51 Large difference 
at baseline. 
ECRI Institute 
estimated the SDs 
using the reported 
SEMs and Ns 




g = 0.07 ECRI Institute 
estimated the SDs 
using the reported 
SEMs and Ns 




g = 0 ECRI Institute 
estimated the SDs 
using the reported 
SEMs and Ns. One 
of the reported SDs 
was 0, which is not 
reasonable, 
therefore we used 
the SD from the 
other group 




g = 1.71 Large difference 
at baseline. 
ECRI Institute 
estimated the SDs 
using the reported 
SEMs and Ns 
Morales et al. (1995)
87




19 p.p. Large difference 
at baseline. 




















or Hedges’ g Comments 




10 p.p.  




1 p.p.  




9 p.p.  




4 p.p.  




5 p.p.  




5 p.p.  




0 p.p.  




0 p.p.  




7 p.p.  




5 p.p.  




8 p.p.  






1 p.p.  






















or Hedges’ g Comments 
 Recipient % renal disease: 





4 p.p.  




5 p.p.  




12 p.p.  




0 p.p.  




12 p.p.  




g = 0.23  




g = 0.06  






g = 0.45 Large difference 
at baseline. 
Velidedeoglu et al. (2002)
93,94




7.7 p.p. Only reported 
comparative 
characteristics for 
the Penn data, not 
for the UNOS data 




8.8 p.p. Only reported 
comparative 
characteristics for 
the Penn data, not 















or Hedges’ g Comments 




1.1 p.p.  




g = 0 ECRI Institute 
estimated the SDs 
using the reported 




the Penn data, not 
for the UNOS data 




g = 0.03 ECRI Institute 
estimated the SDs 
using the reported 




the Penn data, not 
for the UNOS data 




g = 0.3 ECRI Institute 
estimated the SDs 
using the reported 




the Penn data, not 















or Hedges’ g Comments 




g = 0.01 ECRI Institute 
estimated the SDs 
using the reported 
SEMs and Ns. One 
of the reported SDs 
was 0, which is not 
reasonable, 
therefore we used 
the SD from the 




the Penn data, not 
for the UNOS data 
Marroquin et al. (2001)
90




2.9 p.p.  






2.2 p.p.  






7.1 p.p.  




4.8 p.p.  




0.1 p.p.  




5.5 p.p.  



















or Hedges’ g Comments 




0.9 p.p.  




1.7 p.p.  




6 p.p.  
 Recipient % year of transplant 1997 (the last 





6 p.p.  




g = 0.07 Dispersion not 
reported, but 
p >0.05 reported. 
ECRI Institute 
estimated 
Hedges’ g using an 
estimated SD of 8.2 
for both groups, 
which was based on 
pooling on other 
studies’ reported 
















or Hedges’ g Comments 




g = 0.15 Dispersion not 
reported, but 
p >0.05 reported. 
ECRI Institute 
estimated 
Hedges’ g using an 
estimated SD of 18 
for both groups, 
which was based on 
pooling on other 
studies’ reported 
SDs for this 
characteristic. 




g = 0.06 Dispersion not 
reported, but 
p >0.05 reported. 
ECRI Institute 
estimated 
Hedges’ g using an 
estimated SD of 
14.1 for both 
groups, which was 
based on pooling on 
other studies’ 
reported SDs for 
this characteristic. 




NC Dispersion not 
reported, but 
p >0.05 reported 




NC Dispersion not 
reported, but 















or Hedges’ g Comments 




NC Dispersion not 
reported, but 
p >0.05 reported 




NC Dispersion not 
reported, but 
p >0.05 reported 




NC Dispersion not 
reported, but 
p >0.05 reported 
Salizzoni et al. (2001)
88




g = 0.49 Large difference 




authors stated there 




Hedges’ g using an 
estimated SD of 18 
for both groups, 
which was based on 
pooling on other 
studies’ reported 
















or Hedges’ g Comments 




NC These are medians. 
Dispersion not 
reported, but 
authors stated there 
was “no significant 
difference” 




NC These are medians. 
Dispersion not 
reported, but 
authors stated there 
was “no significant 
difference” 




NC These are medians. 
Dispersion not 
reported, but 
authors stated there 
was “no significant 
difference” 






NC These are medians. 
Dispersion not 
reported, but 
authors stated there 
was “no significant 
difference” 




NC Dispersion not 
reported, but 
authors stated there 
















or Hedges’ g Comments 




NC These are medians. 
Dispersion not 
reported, but 
authors stated there 
was “no significant 
difference” 
Vargas et al. (1999)
92




11 p.p.  




g = 0.14 SD of the age of 
recipients of 
infected organs was 
calculated by 
ECRI Institute 
based on Table 1 of 
the article. SD of the 
age of recipients of 
uninfected organs 
was calculated by 
ECRI Institute using 
the reported SEM of 
0.9 and the N for 
















or Hedges’ g Comments 
Testa et al. (1998)
89




23 p.p. Large difference 
at baseline. 




g = 0.08 Neither SD nor SEM 
were reported, and 




Hedges’ g using an 
estimated SD of 
14.1 for both 
groups, which was 
based on pooling on 
other studies’ 
reported SDs for 
this characteristic. 
Shah et al. (1993)
12,16
 Study only reported that “No statistical difference in disease indication for OLTx was evident between the 4 study groups” 
Note: Shaded cells denote comparisons for which the groups differed at baseline by 15 or more percentage points (dichotomous outcomes) or for which the groups 
differed at baseline by Hedges’ g of 0.4 or more (continuous measures). Hedges’ g is the difference between means divided by the pooled standard deviation. 
This was calculated by ECRI Institute. 
NC – Not calculable 
NR – Not reported 
p.p. – Percentage points 
SD – Standard deviation 
SEM – Standard error of the mean 
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Table 67. Question 7: Quality Assessment 
Study 7a 7b 7c 7d 7e 7f 7g 7h 
Recipients Negative Before Transplant; Comparison of Clinical Outcomes After HBV+ Donor vs. HBV- Donor 
Fong et al. (2002)55         
Recipients Negative Before Transplant; Comparison of Clinical Outcomes After HCV+ Donor vs. HCV- Donor 
Abbott et al. (2003)83,84         
Velidedeoglu et al. (2002)93,94         
Shah et al. (1993)12,16         
Haji et al. (2004)77,79         
Recipients Positive Before Transplant; Comparison of Clinical Outcomes After HBV+ Donor vs. HBV- Donor 
Fong et al. (2002)55         
Madayag et al. (1997)56         
Lai et al. (1996)95-97         
Saab et al. (2003)91         
Recipients Positive Before Transplant; Comparison of Clinical Outcomes After HCV+ Donor vs. HCV- Donor 
Kasprzyk et al. (2007)98         
Abbott et al. (2003)83,84         
Woodside et al. (2003)85         
Mandal et al. (2000)86         
Ali et al. (1998)99         
Morales et al. (1995)87         
Saab et al. (2003)91         
Velidedeoglu et al. (2002)93,94         
Marroquin et al. (2001)90         
Salizzoni et al. (2001)88         
Vargas et al. (1999)92         
Testa et al. (1998)89         
Shah et al. (1993)12,16         
A checkmark () means that the study met the quality criterion for this Question; the lack of a checkmark means that the study either did not 
meet the criterion, or it was unclear whether the study met the criterion. The criteria specific to this Question were:  
7a. Were the patients randomly assigned to treatments? 
7b. Was the study planned prospectively (i.e., before any data were collected) 
7c. Were all consecutive patients enrolled (or a random sample of eligible patients)? 
7d. Were the two groups comparable at baseline? (age, sex, comorbidities, indication for transplant, previous duration on waitlist) 
7e. If not, were statistical adjustments performed to control for baseline differences?  
7f. Were the two groups treated concurrently? 
7g. Did at least 85% of the study enrollees provide data? 
7h. Was the between-group difference in study completion rates less than 15%? 
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Table 68. Question 7: Reported Data 





Recipients Negative Before Transplant; Comparison of Clinical Outcomes After HBV+ Donor vs. HBV- Donor 





(N = Not 
reported [NR]) 
88% 
(N = NR) 
None Overall graft 
survival curve: 
p = 0.009 for 
D+R- vs. D-R-; 
p = 0.06 for  
D-R+ vs. D-R-; 
p = 0.69 for  










(N = NR) 
83% 
(N = NR) 
None Overall graft 
survival curve: 
p = 0.009 for 
D+R- vs. D-R-; 
p = 0.06 for  
D-R+ vs. D-R-; 
p = 0.69 for  










(N = NR) 
77% 
(N = NR) 
None Overall graft 
survival curve: 
p = 0.009 for 
D+R- vs. D-R-; 
p = 0.06 for  
D-R+ vs. D-R-; 











(N = NR) 
94% 
(N = NR) 
None Overall patient 
survival curve: 
p = 0.01 for  





from Figure 2 in the 
article 
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(N = NR) 
92% 
(N = NR) 
None Overall patient 
survival curve: 
p = 0.01 for  










(N = NR) 
90% 
(N = NR) 
None Overall patient 
survival curve: 
p = 0.01 for  





from Figure 2 in the 
article 
Recipients Negative Before Transplant; Comparison of Clinical Outcomes After HCV+ Donor vs. HCV- Donor 




NA Relative risk was 0.97 (95% CI: 
0.6 to 1.56) (very slightly in 
favor of recipients of positive 
organs) 






NA Unadjusted hazard ratio of 
death was 2.30 (95% CI: 1.75 to 
3.26) in favor of recipients of 
negative organs. 






NA Adjusted hazard ratio of death 
was 2.25 (95% CI: 1.56 to 3.24) 
in favor of recipients of negative 
organs. 
Donor age, recipient 
age, HLA mismatch, 
elevated creatinine 
at 1 year post-
transplantation, 


















(N = 29) 
82.3% 
(N = 7,811) 




(N = NR) 
76% 
(N = NR) 




(N = NR) 
70.1% 
(N = NR) 
None NR  





(N = NR) 
69% 
(N = NR) 




(N = NR) 
75% 
(N = NR) 
None n.s.  
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(N = NR) 
96% 
(N = NR) 
Not reported. The 
methods section 
reported the use of 
Cox regression 
“to adjust for significant 
covariates”, but authors 
did not report whether 
the hazard ratio of 2.8 
was adjusted or 
unadjusted. They did 
report that “By univariate 
Cox regression, recipient 
and donor age, 
ischemia time, 
cumulative episodes of 
rejection, standard 






infection were not 
significant (All p-values 
>0.1) in determining 
mortality in our patient 
population.” (page 280) 
Overall p-value 
for the survival 
curves was 
reported as 
p = 0.004 in favor 
of D- recipients 
Confounding by 
indication: “At our 
institution, an 
HCV-seropositive 
donor was used 
when, in the 
judgment of the 
transplant team, 
the recipient was 
critically ill and 








inclusion in the 
analysis was that 










from Figure 1 in the 
article 
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(N = NR) 
92% 
(N = NR) 
Not reported. The 
methods section 
reported the use of 
Cox regression “to 
adjust for significant 
covariates”, but authors 
did not report whether 
the hazard ratio of 2.8 
was adjusted or 
unadjusted. They did 
report that “By univariate 
Cox regression, recipient 
and donor age, ischemia 
time, cumulative 
episodes of rejection, 
standard biopsy score, 





infection were not 
significant (All p-values 
>0.1) in determining 
mortality in our patient 
population.” (page 280) 
Overall p-value 
for the survival 
curves was 
reported as 
p = 0.004 in favor 





from Figure 1 in the 
article 
454 








(N = NR) 
88% 
(N = NR) 
Not reported. The 
methods section 
reported the use of 
Cox regression “to 
adjust for significant 
covariates”, but authors 
did not report whether 
the hazard ratio of 2.8 
was adjusted or 
unadjusted. They did 
report that “By univariate 
Cox regression, recipient 
and donor age, 
ischemia time, 
cumulative episodes of 
rejection, standard 






infection were not 
significant (All p-values 
>0.1) in determining 
mortality in our patient 
population.”(page 280) 
Overall p-value 
for the survival 
curves was 
reported as 
p = 0.004 in favor 

















None Relative risk or 
mortality: 
2.8 
(95% CI: 1.3-5.7; 
p = 0.006) in favor 
of D- recipients 
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Recipients Positive Before Transplant; Comparison of Clinical Outcomes After HBV+ Donor vs. HBV- Donor 





(N = NR) 
86% 
(N = NR) 
Adjusted for previous 
transplant, recipient age, 
recipient race, peak 
panel reactive antibody, 
recipient HCV, duration 
of dialysis, donor age, 
cold ischemia time, 
donor race, cause of 
donor death, ABDRMM 
(definition of this 









(N = NR) 
83% 
(N = NR) 
Adjusted for previous 
transplant, recipient age, 
recipient race, peak 
panel reactive antibody, 
recipient HCV, duration 
of dialysis, donor age, 
cold ischemia time, 
donor race, cause of 
donor death, ABDRMM 
(definition of this 









(N = NR) 
75% 
(N = NR) 
Adjusted for previous 
transplant, recipient age, 
recipient race, peak 
panel reactive antibody, 
recipient HCV, duration 
of dialysis, donor age, 
cold ischemia time, 
donor race, cause of 
donor death, ABDRMM 
(definition of this 




from Figure 1 in the 
publication 
456 








(N = NR) 
94% 
(N = NR) 
Adjusted for previous 
transplant, recipient age, 
recipient race, peak 
panel reactive antibody, 
recipient HCV, duration 
of dialysis, donor age, 
cold ischemia time, 
donor race, cause of 
donor death, ABDRMM 
(definition of this 









(N = NR) 
91% 
(N = NR) 
Adjusted for previous 
transplant, recipient age, 
recipient race, peak 
panel reactive antibody, 
recipient HCV, duration 
of dialysis, donor age, 
cold ischemia time, 
donor race, cause of 
donor death, ABDRMM 
(definition of this 









(N = NR) 
88% 
(N = NR) 
Adjusted for previous 
transplant, recipient age, 
recipient race, peak 
panel reactive antibody, 
recipient HCV, duration 
of dialysis, donor age, 
cold ischemia time, 
donor race, cause of 
donor death, ABDRMM 
(definition of this 




from Figure 1 in the 
publication 
457 










(N = 32) 
100% 
(N = 37) 




organ type, and date of 
transplant 
n.s. Recipients of 
positive organs 
were significantly 
older (Mean: 49 vs. 




(N = 8) 
100% 
(N = 11) 




organ type, and date of 
transplant 
n.s. Recipients of 
positive organs 
were significantly 
older (Mean: 49 vs. 

















organ type, and date of 
transplant 
n.s.; Relative risk 
was 5.7 in favor 
(but not 
statistically 
significant) of the 
recipients of 
negative organs 





older (Mean: 49 vs. 
44; p = 0.03). 






(N = NR) 
91.7% 
(N = NR) 




D+ vs. D- when 








(N = NR) 
100% 
(N = NR) 




D+ vs. D- when 













(N = NR) 
72.4% 
(N = NR) 
None p = 0.334 for the 
comparison of 
patient survival 
curves for  
D+ vs. D- when 








(N = NR) 
96.6% 
(N = NR) 
None p = 0.063 for the 
comparison of 
patient survival 
curves for  
D+ vs. D- when 







(N = NR) 
91.6% 
(N = NR) 
None p = 0.0013 for the 
comparison of 
graft survival 
curves for  
D+ vs. D- when 








(N = NR) 
100% 
(N = NR) 
None p = 0.0035 for the 
comparison of 
graft survival 
curves for  
D+ vs. D- when 







(N = NR) 
53.9% 
(N = NR) 
None p = 0.0013 for the 
comparison of 
graft survival 
curves for  
D+ vs. D- when 














(N = NR) 
92.4% 
(N = NR) 
None p = 0.0035 for the 
comparison of 
graft survival 
curves for  
D+ vs. D- when 
the donor was 
deceased 
 





(N = NR) 
91% 
(N = NR) 







(N = NR) 
81% 
(N = NR) 







(N = NR) 
81% 
(N = NR) 







(N = NR) 
84% 
(N = NR) 







(N = NR) 
75% 
(N = NR) 







(N = NR) 
75% 
(N = NR) 










Recipients Positive Before Transplant; Comparison of Clinical Outcomes After HCV+ Donor vs. HCV- Donor 


















themselves in this 
table are 
restricted to those 



















themselves in this 
table are 
restricted to those 















Unadjusted hazard ratio of 
death was 1.43 (95% CI: 1.02 to 
2.02) in favor of recipients of 
negative organs. 
None Significant This comparison 
was restricted to 
the ~90% of 
patients who 
survived at least 
2 years after 
transplant, 
because of the 




was no difference 
between groups up 






Adjusted hazard ratio of death 
was 2.04 (95% CI: 1.20 to 3.45) 




HLA mismatch, elevated 
creatinine at 1 year 
post-transplantation, 
years of dialysis before 
transplantation, and 
albumin level. 
Significant This comparison 
was restricted to 
the ~90% of 
patients who 
survived at least 
2 years after 
transplant, 
because of the 




was no difference 
between groups up 








None NR Denominator for D- 
calculated by 
ECRI Institute 
based on reported 
percentage and 
number of events 
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(N = 19) 
89% 
(N = 19) 




(N = 17) 
89% 
(N = 17) 
None NR  















None NR In the D+ group, 
there were 
19 operations in 
the 18 patients. 
Diabetes was 





D+ recipients were 
significantly older 
(46 vs. 35). 
D+ recipients rate 
of antiCMV was 
higher (87% vs. 
50%). 
Mismatching of 
HLA-A and HLA-B 
was higher in the 
D+ recipients 
(3.2 vs. 2.3). 
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error of the 







None NR In the D+ group, 
there were 
19 operations in 
the 18 patients. 
Diabetes was more 
common in D+ 
recipients (5/18) 
than D- recipients 
(1/10). 
D+ recipients were 
significantly older 
(46 vs. 35). 
D+ recipients rate 
of antiCMV was 
higher (87% vs. 
50%). 
Mismatching of 
HLA-A and HLA-B 
was higher in the 
D+ recipients (3.2 
vs. 2.3). 











None p-value was 
reported as 
p >0.3. However 
the chi-squared 
test yields 
p = 0.23. 
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None n.s. Number of blood 
transfusions less in 
D+ recipients 




















None n.s. Number of blood 
transfusions less in 
D+ recipients 
(7 vs. 21); p <0.05. 





(N = NR) 
87% 
(N = NR) 







(N = NR) 
79% 
(N = NR) 







(N = NR) 
69% 
(N = NR) 













(N = NR) 
78% 
(N = NR) 







(N = NR) 
70% 
(N = NR) 







(N = NR) 
59% 
(N = NR) 




Velidedeoglu et al. 
(2002)
93,94




(N = 13) 
79.6% 




was p = 0.6778 
These data refer to 





(N = NR) 
71.6% 




was p = 0.6778 
These data refer to 





(N = NR) 
61.2% 




was p = 0.6778 
These data refer to 








None NR These data refer to 
patients seen at 
Penn 
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Velidedeoglu et al. 
(2002)
93,94




(N = 190) 
80.6% 




was p = 0.965 






(N = NR) 
69.1% 




was p = 0.965 






(N = NR) 
62.2% 




was p = 0.965 
These data refer to 
patients from 
UNOS 





(N = NR) 
85% 
(N = NR) 






were more likely to 
have liver cancer 
(8.3% vs. 3.1%; 
p = 0.01), 
more likely to have 
ABO incompatibility 
(4.2% vs. 1.3%; 
p = 0.04), and they 
had poorer waitlist 
status (see Table 5 




(N = NR) 
82% 
(N = NR) 






were more likely to 
have liver cancer 
(8.3% vs. 3.1%; 
p = 0.01), 
more likely to have 
ABO incompatibility 
(4.2% vs. 1.3%; 
p = 0.04), and they 
had poorer waitlist 
status (see Table 5 
in the publication). 
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(N = NR) 
79% 
(N = NR) 






were more likely to 
have liver cancer 
(8.3% vs. 3.1%; 
p = 0.01), more 
likely to have ABO 
incompatibility 
(4.2% vs. 1.3%; 
p = 0.04), and they 
had poorer waitlist 
status (see Table 5 




(N = NR) 
77% 
(N = NR) 






were more likely to 
have liver cancer 
(8.3% vs. 3.1%; 
p = 0.01), more 
likely to have ABO 
incompatibility 
(4.2% vs. 1.3%; 
p = 0.04), and they 
had poorer waitlist 
status (see Table 5 
in the publication). 
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None NR Recipients of 
positive organs 
were more likely to 
have liver cancer 
(8.3% vs. 3.1%; 
p = 0.01), more 
likely to have ABO 
incompatibility 
(4.2% vs. 1.3%; 
p = 0.04), and they 
had poorer waitlist 
status (see Table 5 




(N = NR) 
81% 
(N = NR) 
None NR Data estimated by 
ECRI Institute from 




were more likely to 
have liver cancer 
(8.3% vs. 3.1%; 
p = 0.01), more 
likely to have ABO 
incompatibility 
(4.2% vs. 1.3%; 
p = 0.04), and they 
had poorer waitlist 
status (see Table 5 
in the publication). 
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(N = NR) 
76% 
(N = NR) 
None NR Data estimated by 
ECRI Institute from 




were more likely to 
have liver cancer 
(8.3% vs. 3.1%; 
p = 0.01), more 
likely to have ABO 
incompatibility 
(4.2% vs. 1.3%; 
p = 0.04), and they 
had poorer waitlist 
status (see Table 5 




(N = NR) 
72% 
(N = NR) 
None NR Data estimated by 
ECRI Institute from 




were more likely to 
have liver cancer 
(8.3% vs. 3.1%; 
p = 0.01), more 
likely to have ABO 
incompatibility 
(4.2% vs. 1.3%; 
p = 0.04), and they 
had poorer waitlist 
status (see Table 5 
in the publication). 
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(N = NR) 
70% 
(N = NR) 
None NR Data estimated by 
ECRI Institute from 




were more likely to 
have liver cancer 
(8.3% vs. 3.1%; 
p = 0.01), more 
likely to have ABO 
incompatibility 
(4.2% vs. 1.3%; 
p = 0.04), and they 
had poorer waitlist 
status (see Table 5 









both donor and recipient, 
ABO incompatibility, 
coexisting diseases, 
change in liver function 
tests, 
immunosuppressive 
regimens, causes of 
graft failure, 
UNOS status at time of 
transplant, ICU length of 













6 0.66 See previous 
column 
Adjusted for 
sex/age/weight of both 
donor and recipient, 
ABO incompatibility, 
coexisting diseases, 
change in liver function 
tests, 
immunosuppressive 
regimens, causes of 
graft failure, UNOS 
status at time of 
transplant, ICU length of 











both donor and recipient, 
ABO incompatibility, 
coexisting diseases, 
change in liver function 
tests, immuno-
suppressive regimens, 
causes of graft failure, 
UNOS status at time of 
transplant, ICU length of 











both donor and recipient, 
ABO incompatibility, 
coexisting diseases, 
change in liver function 
tests, immuno-
suppressive regimens, 
causes of graft failure, 
UNOS status at time of 
transplant, ICU length of 

















both donor and recipient, 
ABO incompatibility, 
coexisting diseases, 
change in liver function 
tests, immuno-
suppressive regimens, 
causes of graft failure, 
UNOS status at time of 
transplant, ICU length of 











both donor and recipient, 
ABO incompatibility, 
coexisting diseases, 
change in liver function 
tests, immuno-
suppressive regimens, 
causes of graft failure, 
UNOS status at time of 
transplant, ICU length of 











both donor and recipient, 
ABO incompatibility, 
coexisting diseases, 
change in liver function 
tests, immuno-
suppressive regimens, 
causes of graft failure, 
UNOS status at time of 
transplant, ICU length of 

















both donor and recipient, 
ABO incompatibility, 
coexisting diseases, 
change in liver function 
tests, immuno-
suppressive regimens, 
causes of graft failure, 
UNOS status at time of 
transplant, ICU length of 
stay, hospital length of 
stay 
n.s.  





(N = NR) 
82.4% 
(N = NR) 




(N = NR) 
79.8% 
(N = NR) 
None n.s.  












(N = NR) 
88% 
(N = NR) 




(N = NR) 
73% 
(N = NR) 
None n.s.  





(N = NR) 
76.2% 
(N = NR) 




(N = NR) 
79.1% 
(N = NR) 
None n.s.  
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None n.s.  







(N = NR) 




(N = NR) 
80% 
(N = NR) 
None n.s.  
NR – Not reported 
n.s. – Not statistically significant 
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Evidence Reviews: V. Potential risks and benefits of 
transplanting, or not transplanting, solid organs from donors 
with risk factors for HIV, HBV, or HCV 
Question 8. How do the clinical outcomes of transplant recipients who 
receive organs from donors with behavioral or nonbehavioral risk 
factors compare to those who remain on the transplant list? 
This question is similar to Question 7, however, Question 7 involved the use of an organ known to be 
infected, whereas Question 8 involves an organ from a donor at increased risk of infection. Some 
individuals may test negative for HIV/HBV/HCV and yet have the virus (possibly due to the window 
period for virus detection, or because of test insensitivity).  
Two studies met the inclusion criteria (Schweitzer et al. [2007]
203
 and Freeman and Cohen [2009]
204
). 
Both performed simulations on the key dilemma of whether to use organs from serologically negative 
donors who have behavioral risks of infection. The two studies, however, made different comparisons, 
and so they were considered separately. Schweitzer et al. (2007)
203
 estimated mortality after transplanting 
the kidneys vs. keeping patients on the waitlist. Freeman and Cohen (2009)
204
 estimated waitlist mortality 
rates, however they did not estimate mortality of all who received organs from at-risk donors. Instead, 
they reported the overall prevalence of infection among recipients of organs from at-risk donors (which 
was exceedingly low), and then estimated mortality just for infected recipients. Both studies are described 
in more detail in the sections below. 
Due to the small amount of evidence, we also looked for studies comparing the clinical outcomes of two 
types of recipients: recipients of organs from at-risk donors, and recipients of organs from not-at-risk 
donors (these donors may or may not have been infected). We defined “at risk” for this question as having 
a potential behavioral risk factor, or having a clinical symptom/physical finding associated with infection, 
or having a medical comorbidity associated with infection. No such comparative studies were identified. 
Schweitzer et al. (2007)
203
 
This simulation addressed the question: Should the kidneys of negative-serology donors who are at 
increased risk of infection based on 1994 CDC criteria be transplanted or discarded? Authors constructed 
a complicated Markov model of these two alternatives. They considered four types of increased-risk 
donors (IRDs): intravenous drug users (IDU), men who have sex with men (MSM), commercial sex 
workers (CSW), and prison inmates. The authors’ methods, our quality assessment, and study results are 
detailed in the text below, as well as in Table 69 through Table 75. 
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The model considered a 20-year interval, with one-year cycles. During each year, each simulated patient 





1) On the waitlist HIV- HCV- 
2) Received a kidney HIV- HCV- 
3) On the waitlist HIV+ HCV- 
4) On the waitlist HIV- HCV + 
5) On the waitlist HIV + HCV + 
6) Received a kidney HIV + HCV- 
7) Received a kidney HIV- HCV + 
8) Received a kidney HIV + HCV + 
9) Dead 
 
Each of the first eight health states was associated with a different death rate, a different quality-of-life, 
and a different cost of care. For simplicity, authors assumed that all recipients were immune to acute 
HBV infection, which explains why none of the nine states involve HBV status. Transition probabilities 
between states were based on various assumptions using the published literature (see Table 69 through 
Table 71 below). 
The epidemiology assumptions listed in Table 70 and Table 71 can be compared informally with the 
corresponding estimates in Question 1 of this evidence review. For HIV, the incidence estimates matched 
closely (Schweitzer assumed 0.02 per 100 person-years, and the estimate in Question 1 was 0.019 per 
100 person years). However, the prevalence of HIV was about one-third of the estimate from Question 1 
(0.128% vs 0.37%). Also, for HCV, the incidence rates were very different (Schweitzer assumed 
0.11 cases per 100 person-years but in Question 1 the estimate was 0.057 per 100 person-years). For HCV 
prevalence, the assumed 1.8% was within the range of estimates from Question 1 (1.3% to 1.9%). 
The base case simulation assumed that the CDC-IRD donors were all seronegative injection drug users, 
and the results appear in Table 72. The transplant strategy resulted in lower mortality, more quality-
adjusted life-years (QALYs), and also lower cost. There were more HIV infections using the transplant 
strategy, but the number of them was too small (and the resulting health problems not severe enough) to 
overcome the advantages of transplantation. Interestingly, with HCV, there were actually more infections 
with the discard strategy. This was because the discard strategy led to more time on hemodialysis than the 
transplant strategy; the assumed incidence of HCV when on hemodialysis (0.34 per 100 patient-years) 
was 30 times higher than the assumed incidence of HCV after kidney transplant (0.011 per 100 patient-
years; see the bottom two rows of Table 71). 
Authors performed separate analyses for three other types of increased-risk donors (MSM, CSW, and 
inmates); results were very similar to the base case for outcomes such as the number of transplants, 
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survival, QALYs, and costs. There were some differences, however, regarding HIV and HCV infections 
(Table 73). Infection counts due to the use of kidneys from MSM or inmates were low for both HIV and 
HCV. The counts for CSW were somewhat higher, but even for this subgroup the total number of 
infections using the transplant strategy (13.7, comprised of 3.4 HIV and 9.3 HCV) was still lower than the 
total number of infections using the discard strategy (14.8, comprised of 1.9 HIV and 12.9 HCV). 
Authors conducted numerous one-way sensitivity analyses (in which a single assumption is altered and 
all others left unchanged), and they stated that in most cases the conclusions of the base case “were not 
substantially changed”. They did note that the number of HCV infections was strongly influenced by 
assumptions about incidence rates, but concluded that “the ‘Discard’ policy would yield fewer HCV 
infections only in a setting where a recipient’s risk of infection on dialysis is very low, while the 
probability of CDC-IRD infection in a donor is high”.
203
 
Authors also conducted a “worse-case scenario” analysis that used the following alternate assumptions: 
- That CDC-IRD donors have much higher HIV incidence (25 per 100 person-years) and HIV 
prevalence (50%) than assumed in the base case analysis (2 per 100 person-years, and 18%, 
respectively) 
- That CDC-IRD donors have higher HCV incidence (25 per 100 person-years) and HCV prevalence 
(50%) than assumed in the base case analysis (21 per 100 person-years, and 38%, respectively) 
- While on the waitlist, the risk of HCV is much lower (0.1 infections per 100 person-years instead of 
the 0.34 assumed in the base case) 
- Lower chance of an individual receiving an offer of a CDC-IRD kidney because of increased number 
of eligible individuals for those kidneys (30% instead of the base case 5%) 
- Lower percentage of CDC-IRD kidneys (2% of donors instead of 5%) 
- Higher cost associated with HIV or HCV infection ($30,000/year instead of $21,000) 
- Lower utility associated with HIV or HCV infection (0.45 instead of 0.78 for HIV and 0.82 for HCV) 
Interestingly, even though these assumptions were slanted against the Transplant strategy, it still was 
preferable to the discard strategy, resulting in more transplants, less time on the waitlist, more time with a 
functioning transplant, lower mortality, more QALYs, and lower cost. 
Finally, because NAT testing may not be widely available, authors also modeled a scenario where only 
antibody testing was available, lengthening the window period for HIV to 22 days from 11; lengthening 
the window period for HCV to 70 days from 10). Results still favored the transplant strategy for all 
outcomes except the number of infections, which rose to 2.6 HIV infections per 1,000 patients and 
27.7 HCV infections per 1000 patients. These additional infections were not sufficient to overcome the 
overall advantages of the transplant strategy. 
The GRADE evidence profile appears in Table 76. The evidence was rated as Very Low, because this 
was a simulation and not an empirical study. The GRADE system does not consider simulations as 
informative as empirical studies. 
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Table 69. Assumptions in the Schweitzer et al. (2007) Model 
Key Assumptions about Donors 
 Deceased donors only 
 All donors tested negative on antibody and nucleic amplification tests (NAT) for both HIV and HCV. NAT has a relatively short window 
period (i.e., the duration when it cannot detect the virus), so it would be relatively unlikely to miss a virus for this reason. 
 5% of donors are classified as “CDC-IRD” (IRD = increased risk donor; sensitivity analyses ranging 2%-8%), defined as being in one of the 
seven categories in the 1994 CDC guideline on HIV.  
Key Assumptions about Recipients 
 50-year old hemodialysis patients (sensitivity analyses ranging from 18-65) 
 All recipients were willing to accept kidneys from CDC-IRDs. 
 All recipients were immune to “acute HBV infection”. Thus if any donor were HBV+, this had no impact on the analysis. 
 In any given year, a recipient could acquire either HIV or HCV, but not both. They could acquire the other one in subsequent years. 
 5% of patients on waitlist would be candidates for CDC-IRD kidney (sensitivity analyses ranging from 1%-30%) 
 Number of patients on the waitlist at the end of 2002 was 50,535 
 Annual number of standard deceased donor kidney transplants in 2002 was 8,288 
 Median time to transplant for new waiting list registrants was 3.5 years 
 Annual standard donor kidney transplant rate was 20% (sensitivity analyses ranging 2%-53% 
 Median waiting time for CDC-IRD kidney transplants was 3.5 years 
Key Assumptions about Death Rates 
 Annual death rate among all patients on the U.S. kidney waitlist was 3.7% for those 18-34; 5.4% for those aged 35-49; 9.2% for those 
aged 50-64; and 12.9% for those aged 65+ 
 Annual death rate in the first year after kidney transplant was 2.3% for those 18-34; 3.9% for those aged 35-49; 8.0% for those aged 50-64; 
and 11.6% for those aged 65+ 
 Annual death rate in all subsequent years after kidney transplant was 2.1% for those 18-34; 2.3% for those aged 35-49; 4.0% for those 
aged 50-64; and 7.2% for those aged 65+ 
 Relative risk of death due to HIV infection was 1.5 
 Relative risk of death due to HCV infection was 1.7 
479 
Key Assumptions about Costs and Quality-Adjusted-Life-Years (QALYs) 
 Costs in 2002 dollars, adjusted using the medical care component of the consumer price index 
 Cost of “Stat HIV” and HCV nucleic acid testing (NAT) were estimated at $500/donor or $250/kidney was added to the cost when the donor 
was CDC-IRD 
 Cost of hemodialysis $61,000/year (sensitivity analyses ranging from) (sensitivity analyses ranging from $49,000-$71,000) 
 Cost of care of kidney recipient in the first year after transplant $97,000/year (sensitivity analyses ranging from $76,000-$177,000) 
 Cost of care kidney recipient in all subsequent years $21,000/year (sensitivity analyses ranging from $17,000-$38,000) 
 Cost of care for HIV infection was $21,000/year (sensitivity analyses ranging from $19,000-$23,000) 
 Cost of care for HCV infection was $2,000/year (sensitivity analyses ranging from $1,000-$30,000) 
 Utility of being on hemodialysis was 0.57 (0 denotes death, 1 denotes perfect) (sensitivity analyses ranging from 0.41-0.64) 
 Utility of post-transplant quality-of-life was 0.70 (0 denotes death, 1 denotes perfect) (sensitivity analyses ranging from 0.62-0.82) 
 Utility of HIV was 0.82 (0 denotes death, 1 denotes perfect) (sensitivity analyses ranging from 0.45-1.00) 
 Utility of HCV was 0.78 (0 denotes death, 1 denotes perfect) (sensitivity analyses ranging from 0.60-0.86) 
 Discounting of both costs and QALYs at 3% 
Other Assumptions 
 Overall risk of graft failure after kidney transplant was 6% in the first year (sensitivity analyses ranging from 4%-7%), and 4% in 
subsequent years (sensitivity analyses ranging from 2%-6%). After graft failure, the patient returned to one of the waitlist health states. 
 Relative risk of graft failure specifically due to HIV infection was 1.0 (sensitivity analyses ranging from 1.0 to 1.3) 
 Relative risk of graft failure specifically due to HCV infection was 1.6 (sensitivity analyses ranging from 1.4 to 1.8) 
 The window period for HIV antibody testing alone was 22 days; for HIV antibody plus NAT was 11 days; for HCV antibody alone was 
70 days; for HCV antibody plus NAT was 10 days 
 The false-negative rate for pre-transplant serological testing of CDC-IRDs donors was 5%. Together with the window period, this 








Population Base Case 
Sensitivity 
Range Base Case 
Sensitivity 
Range 
General population 0.02 N.A. 0.128% N.A. 
Potential Donors 
Intravenous drug users 2 1-3 18% 1-49 
Men who have sex with men 3 1-12 25% 0-40 
Commercial sex workers 10 3-30 24% 0-60 
Inmates 0.2 0-0.4 2% 1-17 
Potential Recipients 
Hemodialysis patients 0.02 N.A. N.E. N.E. 
Kidney transplant patients 0.02 N.A. N.E. N.E. 
a
 Incidence is the number of new cases per 100 patient-years. 
N.A. – Not applicable because no sensitivity analysis of this parameter was performed. 
N.E. – Not estimated, because the model did not require estimates of the prevalence of HIV or HCV among recipients. 




Population Base Case 
Sensitivity 
Range Base Case 
Sensitivity 
Range 
General population 0.011 N.A. 1.8% N.A. 
Potential Donors 
Intravenous drug users 21 10-45 38% 10-90 
Men who have sex with men 0.2 0-1 4% 2-18 
Commercial sex workers 10 5-23 12% 6-45 
Inmates 1 0.3-6 23% 16-41 
Potential Recipients 
Hemodialysis patients 0.34 0.1-3 N.E. N.E. 
Kidney transplant patients 0.011 N.A. N.E. N.E. 
a
 Incidence is the number of new cases per 100 patient-years. 
N.A. – Not applicable because no sensitivity analysis of this parameter was performed. 
N.E. – Not estimated, because the model did not require estimates of the prevalence of HIV or HCV among recipients. 
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Table 72. Base Case Results of the Schweitzer et al. (2007) Model 
Outcome Transplant Discard 
Number of kidney transplants 
per 1,000 patients 
Total: 990 
Standard donors: 495 
CDC-IRD donors: 495 
Total: 740, all standard donors 








Quality-adjusted life-years 5.6 5.1 
Cost of care over 20 years for 
a typical patient 
$338,000 $363,000 
HIV infections per 
1,000 patients over 20 years 
2.3, comprising 1.9 infections 
when on the waitlist or 
community acquired, and 
0.3 from window-period 
CDC-IRD donations (these 
do not add to 2.3 due to 
rounding) 
1.9, all while on the waitlist or 
community-acquired  
HCV infections per 
1,000 patients over 20 years 
10.8*, comprising 7.9 infections 
when on the waitlist or 
community acquired, and 
2.9 from window-period 
CDC-IRD donations 
12.9*, all while on the waitlist or 
community-acquired 
CDC-IRD – CDC increased-risk donor 
* The reason that there were actually more HCV infections using the discard strategy is that the discard strategy led to 
more time on hemodialysis than the transplant strategy; the assumed incidence of HCV when on hemodialysis (0.34 
per 100 patient-years) was 30 times higher than the assumed incidence of HCV after kidney transplant (0.011; 
see the bottom two rows of Table 71). 
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Injection drug users 
(base case) 
2.3* 1.9 0.3 10.8 7.9 2.9 
Men who have sex 
with men 
2.4 1.9 0.5 8.0 7.9 0.1 
Commercial sex 
workers 
3.4 1.9 1.5 9.3 7.9 1.4 
Prison inmates 2.0 1.9 0.1 8.1 7.9 0.2 
* All numbers are the number of infections per 1,000 patients, all in the Transplant group willing to receive kidneys 
from CDC increased-risk donors. Due to rounding, numbers in the two columns “Waitlist or community acquired” and 
“Transplant-acquired” may not add up exactly to the numbers in the Total column. 
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Freeman and Cohen (2009)
204
 
This study was a comprehensive risk analysis of numerous considerations pertaining to solid organ 
donation. Authors emphasized that the risk of transmitting an infection to a recipient is only one among a 
set of competing risks, including the risk of dying while on the waitlist, the risk of dying after the 
transplant (regardless of the donor’s status), and risks of dying from medications, employment, 
transportation, and recreation. Taking this broad perspective, the authors provided real-world context to 
critical decisions about organ donation. 
Most of the data reported in the article did not address this particular research question. These include 
data on the transmission of other pathogens or conditions (e.g., CMV), mortality risks after receiving an 
organ from an extended-criteria kidney or a standard criteria kidney, and everyday mortality risks. This 
question specifically involves the comparison of the clinical outcomes (e.g., mortality rates) of two types 
of potential recipients: 1) those who remained on the waitlist, and 2) those who received organs from at-
risk donors. For at-risk donors, the study only addressed mortality after HIV (see Table 3 of the article; 
a row for “High risk donors” appears in the HIV section). 
The waitlist mortality estimates are reproduced in Table 74 below. These were based on the authors’ 
Markov model that utilized 90-day waitlist mortality and transplantation probabilities from the 
OPTN/SRTR 2007 Annual Report. Authors reported rates separately for 12 different types of recipients 
(see table). Three-year estimates were also provided for kidney recipients. For confirmation, ECRI 
Institute replicated the reported results using the reported probabilities using TreeAge Pro (TreeAge 
Software Inc., Williamstown, MA). 
The GRADE evidence profile appears in Table 76; the evidence was rated as Very Low, because it was a 
simulation; the GRADE rating system provides higher ratings to empirical studies. 
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Table 74. Waitlist Mortality Estimates by Freeman and Cohen (2009) 





Kidney recipient, age 18-34 2.7% 9.8% 
Kidney recipient, age 35-49 4.6% 17.2% 
Kidney recipient, age 50-64 7.5% 28.0% 
Kidney recipient, age 65+ 10.5% 40.3% 
   
Liver recipient, Model for End-Stage Liver Disease (MELD) 
score 10 or less 
4.1% NR 
Liver recipient, MELD score 11-14 7.1% NR 
Liver recipient, MELD score 15-20 11.4% NR 
Liver recipient, MELD score 21-30 18.5% NR 
Liver recipient, MELD score 31+ 37.1% NR 
   
Heart recipient, status 2 5.9% NR 
Heart recipient, status 1B 13.6% NR 
Heart recipient, status 1A 21.8% NR 
NR – Not reported. 
Note: These data are from Table 3 of the Freeman and Cohen article.
204
 Other data in that table (such as one-year 
mortality after receiving an immediate extended-criteria kidney, and one-year mortality after receiving an 
immediate standard-criteria kidney, liver or heart) do not address Question 8 of this evidence review, and 
therefore are not included in this table. 
For consideration of at-risk donors, authors stated that “The 2,189 CDC ‘high-risk’ donors since 2004 
have resulted in 1 HIV positive donor, corresponding to an infection risk of 46 per 100,000.”(footnote b 
of Table 3 of the article)
204
 In a conservative analysis, they assumed that HIV is 100% fatal, and therefore 
estimated that the HIV-related mortality per 100,000 recipients of organs from at-risk donors was 46 in 
100,000. This corresponds to 0.046%, which is much lower than all of the waitlist mortality rates in 
Table 74 (the lowest in the entire table is 2.7%, which is 59 times higher than HIV-related mortality after 
receiving organs from at-risk donors). The authors concluded that the waitlist mortality risk far outweighs 
the risk of HIV-related mortality associated with receiving an organ from a serologically negative donor 
with a behavioral risk factor. They did not attempt to make mortality estimates for either HBV or HCV 
due to insufficient documentation in the literature regarding the mortality rate for infected recipients. 
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Schweitzer et al. (2007)
203
 Simulation 
Freeman and Cohen (2009)
204
         
The Schweitzer et al. (2007)
203
 article was not assessed with these items because it was a simulation rather than a study 
enrolling patients. Extensive details about this simulation appear in the text for Question 8. A checkmark () means that 
the study met the quality criterion for this Question; the lack of a checkmark means that the study either did not meet the 
criterion, or it was unclear whether the study met the criterion. The criteria specific to this Question were:  
8a. Were the patients randomly assigned to treatments? 
8b. Was the study planned prospectively (i.e., before any data were collected) 
8c. Were all consecutive patients enrolled (or a random sample of eligible patients)? 
8d. Were the two groups comparable at baseline? (age, sex, comorbidities, indication for transplant, previous 
duration on waitlist) 
8e. If not, were statistical adjustments performed to control for baseline differences?  
8f. Were the two groups treated concurrently? 
8g. Did at least 85% of the study enrollees provide data? 
8h. Was the between-group difference in study completion rates less than 15%? 
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91% survival in 
both groups at 
one year. 
At five years, 
survival was 68% 
for the transplant 
group and 65% for 
the discard group. 
At 10 years, 
survival was 49% 
for the transplant 
group and 45% for 
the discard group. 
At 20 years, 
survival was 23% 
for the transplant 
group and 20% for 
the discard group. 
Very 
Low 








5.6 QALYs for the 
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kidneys was 3% to 
11% (increasing 
with age); for livers 
it was 4% to 37% 
(increasing with 
MELD score); for 





provided for all 
those who received 
at-risk organs. Of 
2,189 ‘high-risk’ 
donors, there was 
only one confirmed 








Question 9. What is the impact of excluding potential solid organ donors 
with behavioral or nonbehavioral risk factors on the organ donor pool? 
The exclusion of any potential donors, if employed, would reduce the size of the organ donor pool. This 
question is intended to quantify the size of that potential reduction if exclusion were based on the 
presense of a risk factor for HIV, HBV, or HCV. One study was included for this question (Schweitzer et 
al. (2007).
203
 This simulation study was described in great detail under Question 8. 
Over a 20-year period, the simulation estimated that if at-risk kidneys were excluded from transplantation, 
there would only be 740 transplanted kidneys per 1,000 patients, instead of 990 if at-risk donors were 
included in the pool. Thus 250 fewer kidneys would have been transplanted. This is a reduction of 25.3% 
(250/990). Note that the study only considered four types of behavioral exclusions (IDU, MSM, CSW, 
and prison inmates), and furthermore the study considered only HIV and HCV. Exclusions for other 
reasons (e.g., HBV risk, or nonbehavioral risk factors for HIV or HCV) would mean a larger reduction in 
the organ donor pool. 
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Question 10. What is the impact of false positive tests on the organ donor 
pool? 
No studies were identified that met the inclusion criteria.  
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Gaps in the Current Literature 
This systematic review uncovered numerous gaps in the literature about the possible transmission of HIV, 
HBV, or HCV through solid organ transplantation. This section describes the most prominent gaps. 
In Question 1, we sought to identify literature on the prevalence and incidence of HIV, HBV, and HCV 
among people whose organs are being considered for donation. Only four small studies of this population 
were identified, and two involved living relatives wishing to donate solid organs to children, which 
comprise only a small proportion of potential organ donors. None of the studies reported incidence, and 
only two of the four studies reported rates of HIV.  
In Question 2, the major gap was the lack of studies of the rate of HIV transmission. This is likely 
because federal regulations prohibit the use of organs from donors testing positive for HIV for transplant..  
Several important gaps affect the usefulness of the current evidence for Questions 3 and 4. Very little 
literature on potential organ donors exists, and the applicability of data from other populations is unclear. 
In addition, almost no information on children was found, and there is very little information on HBV. 
Nearly all of the studies focused on risk factors for prevalent infection; little information on factors for 
incident infection, including signs and symptoms, has been published. Differentiating dependent from 
independent risk factors was inconsistent. Most of the information on identification of factors came from 
self-report, and the reliability of next-of-kin interviews on highly private and personal behavioral factors 
is brought into question by the sole study of potential tissue donors. 
Data on performance of diagnostic tests in potential organ donors is lacking for Question 5. For some of 
the tests, there is no data at all. For many tests, some or most of the data is from analytic validation 
studies and may not be applicable to real-world use. Study of the test in relevant clinical applications, or 
at least reasonably similar applications or populations, is needed to draw strong conclusions regarding the 
‘real-world’ use of these tests in this context. This is also needed to enable the calculation of useful 
statistics including predictive values, likelihood ratios, and post-test probabilities of diseases.  
Question 6, on inactivation, only yielded a single uncontrolled study that had been published in 1994; no 
additional studies of the inactivation of solid organs have appeared since then. The last three questions (8 
through 10) all contained low amounts of evidence, and are all potential targets for future research.  
In Question 7, only one included study had a waitlist control group. Numerous studies used a control 
group of recipients who received organs from negative donors, however, those studies had various quality 
problems (e.g., differing pre-transplant characteristics, without statistical adjustment) that limit the 
interpretability of their results. More comprehensive analyses of competing risks (of both transplanting 
and discarding organs from infected donors) would help inform critical decision making. 
Question 8 included only two studies, both of which estimated survival on the waitlist using Markov 
models. One of them also provided data for Question 9 on the size of reduction in the organ donor pool, 
and no studies addressed Question 10. 
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Details of Literature Search 
Electronic Database Searches 
The following databases have been searched for relevant information: 
Table 77. Electronic Databases Searched 
Database Date Limits Platform/Provider 
The Cochrane Central 
Register of Controlled Trials 
(CENTRAL) 
Through 2009, Issue 3 www.thecochranelibrary.com  
The Cochrane Database of 
Methodology Reviews 
(Methodology Reviews) 
Through 2009, Issue 3 www.thecochranelibrary.com  
The Cochrane Database of 
Systematic Reviews 
(Cochrane Reviews) 
Through 2009, Issue 3 www.thecochranelibrary.com  
Database of Abstracts of 
Reviews of Effects (DARE) 
Through 2009, Issue 3 www.thecochranelibrary.com  
EMBASE (Excerpta Medica) 1990 – July 13, 2009 OVID 
Health Technology 
Assessment Database (HTA) 
Through 2009, Issue 3 www.thecochranelibrary.com  
Healthcare Standards Searched February 10, 2009 ECRI Institute 
MEDLINE 1990 – July 13, 2009 
Searches for some key questions 
not limited by date 
OVID 
PreMEDLINE Searched July 13, 2009 OVID 
U.K. National Health Service 
Economic Evaluation 
Database (NHS EED) 
Through 2009, Issue 3 www.thecochranelibrary.com  
U.S. National Guideline 
Clearinghouse™ (NGC) 
Searched February 10, 2009 www.ngc.gov  
 
Hand Searches of Journal and Nonjournal Literature 
Journals and supplements maintained in ECRI’s collections were routinely reviewed. Nonjournal 
publications and conference proceedings from professional organizations, private agencies, and 
government agencies were also screened. Other mechanisms used to retrieve additional relevant 
information included review of bibliographies/reference lists from peer-reviewed and gray literature. 
(Gray literature consists of reports, studies, articles, and monographs produced by federal and local 
government agencies, private organizations, educational facilities, consulting firms, and corporations. 
These documents do not appear in the peer-reviewed journal literature.) 
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Grey Literature Searches 
The following resources have been searched for information relevant to specific diagnostic tests: 
Resource Date Limits Platform/Provider 
Google 
(“CE Mark” OR “CE marked” 
OR registered) (test name) 
Searched August 8, 2009 www.google.com  




Searched August 7, 2009 www.hpa-midas.org.uk  
HealthCanada Searched August 8, 2009  http://www.hc-sc.gc.ca/dhp-
mps/index-eng.php  















National Serology Reference 
Laboratory 
Searched August 7, 2009 www.nrl.gov.au  
U.S. Food and Drug 
Administration (FDA) 
Web site 
Searched August 6, 2009 www.fda.gov  
World Health Organization 
Web site 




The search strategies employed combinations of free text keywords as well as controlled vocabulary 
terms including (but not limited to) the following concepts. The strategy below is presented in OVID 
syntax; the search was simultaneously conducted across EMBASE, MEDLINE, and PsycINFO. 
A parallel strategy was used to search the databases comprising the Cochrane Library. 
Medical Subject Headings (MeSH), EMTREE and Keywords 
Conventions: 
OVID 
$ = truncation character (wildcard)  
exp = “explodes” controlled vocabulary term (e.g., expands search to all more specific related terms 
in the vocabulary’s hierarchy) 
/ = limit controlled vocabulary heading 
.fs. = floating subheading 
.hw. = limit to heading word 
.md. = type of methodology (PsycINFO) 
.mp. = combined search fields (default if no fields are specified) 
.pt. = publication type 
.ti. = limit to title  
.tw. = limit to title and abstract fields 
Dialog  
? = truncation character (wildcard) 
! = “explodes” controlled vocabulary term (e.g., expands search to all more specific related terms 
in the vocabulary’s hierarchy) 
/de = limit controlled vocabulary heading 
pt = publication type 
/ti = limit to title 
/ti,ab = limit to title and abstract fields 
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Topic-specific Search Terms 
Concept Controlled Vocabulary Keywords 
Analytic validity Accuracy 
Diagnostic accuracy 
Exp diagnostic error/ 




Exp Prediction and forecasting/ 
Predictive value of tests 
Receiver operating characteristic 
ROC curve 
Sensitivity and specificity 
Accurate 
Accuracy  






























Diagnosis Exp diagnosis/ 
di.fs. (diagnosis) 
Diagnos$ 
Disease transmission Disease transmission/pc 




Concept Controlled Vocabulary Keywords 








Exp Tissue donors/ 
Exp Tissue and organ procurement/ 
Exp Transplantation  
 
Classification.fs. 
Supply & distribution.fs. 
Donor$ 
Donat$ 
Epidemiology eh.fs. (ethnology) 
ep.fs. (epidemiology) 
prevalence 







Risk Exp Anamnesis/ 
Behavioral risk factor surveillance 
system 
High risk behavior 
High risk patient 
High risk population 
Exp Medical history taking/ 
Medical record review  
Medical records 




Risk reduction behavior 
Risk-taking 
Sexual behavior 
















Multiple adj2 partner$ 




Risk (in the title) 
Sex  




Concept Controlled Vocabulary Keywords 
Solid organ & 
tissue transplantation 
Allotransplantation  




























Exp hepatitis b antigen/ 
Exp hepatitis b antigens/ 
Exp hepatitis c antigens/ 
Exp HIV Infections/ 
HTLV-1 infections  
Exp human immunodeficiency virus 
Human immunodeficiency virus 
antigen 












Concept Controlled Vocabulary Keywords 
Testing DNA microarray 
Exp gene amplification/ 
Exp hybridization/ 
Exp in situ hybridization/ 
Microarray analysis 
Exp Microarray analysis/ 
Molecular diagnostic techniques 
Exp molecular probe/ 
Exp molecular probe techniques/ 
Exp nucleic acid amplification 
techniques/ 



















































Concept Controlled Vocabulary Keywords 




Organ perfusion  
Organ preservation 
exp Organ preservation/ 
Perfusion  








Unless otherwise specified, all searches were limited to human population and by date range 1990 – 2009. 
Donor   1966 – 2009 
Set 
Number Concept Search Statement 
1 Transplantation exp organ transplantation/ 
2  (((transplantation, homologous or allotransplantation).de. or 
tr.fs.) and (solid organ or heart or lung$ or kidney$ or liver or 
intestin$ or bowel$ or pancreas or face or hand$ or (composite 
adj vascular) or ovar$ or testes or testicl$))  
3  Exp tissue transplantation/ 
4 Combine sets or/1-3 
5 Donors exp tissue donors/ or exp tissue/ or living donors/ or donor/ or 
kidney donor/ or living donor/ or organ donor/ or cadaver donor/ 
or cadaver/ 
6  donor$.ti.  
7  6 and (solid organ or heart or lung$ or kidney$ or liver or 
intestin$ or bowel$ or pancreas or face or hand$ or (composite 
adj vascular) or ovar$ or testes or testicl$) 
8 Combine sets or/5-7  
9 Combine sets 
(tissue donors) 
4 and 8 
10 Specific infections exp HIV infections/ or exp human immunodeficiency virus 
infections/ or exp hepatitis b antigens/ or exp hepatitis c 
antigens/ or exp hepatitis b antigen/ or (hepatitis b or hepatitis c 
or hepatitis c antigen).de. or (hepatitis adj (b or c) or HIV$) 
11 Combine sets 
(Infections and tissue 
transplantation) 
9 and 10 
13 Limit by publication 
type 
12 not (letter/ or editorial/ or news/ or comment/ or note/ or 
conference paper/ or (letter or editorial or news or comment).pt.) 
14 Eliminate overlap Remove duplicates from 13 
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Epidemiology (Q1) (2004-2009) 
Set 
Number Concept Search Statement 
1 Specific infections exp HIV infections/ or exp human immunodeficiency virus 
infections/ or exp hepatitis b antigens/ or exp hepatitis c 
antigens/ or exp hepatitis b antigen/ or (hepatitis b or hepatitis c 
or hepatitis c antigen).de. or (hepatitis adj (b or c)) 
2 Epidemiology 1 and ep.fs. 
3  1 and eh.fs. 
4  1 and prevalence.de. 
5  1 and (prevalen$ or incidence or epidemiol$).ti. 
6 Combine sets or/2-5 
7 Reviews 6 and review$.ti,de,pt. 
8 RCTs 
Narrow filter 
6 and (random$.ti. or randomized controlled trial.pt.) 
9 Limit by publication 
type 
6 not (letter/ or editorial/ or news/ or comment/ or note/ or 
conference paper/ or case reports/ or (letter or editorial or news 
or comment or case reports).pt.)) 
10 Systematic reviews 
Broad filter 
9 and ((research synthesis or pooled).mp. or review.ti,pt. or 
(systematic review or meta analysis or meta-analysis).de. or 
((evidence base$ or methodol$ or systematic or quantitative$ or 
studies).mp. and (review.de. or review.pt.))) 
11 Eliminate overlap Remove duplicates from 10 
  The retrieval was still too large so we used another approach 
12  5 and 11 
13 Limit by region 12 and (exp United States/ or United States.tw. or us.ti. or 
usa.ti.) 
14 HIV infections as major 
topic 
Exp *HIV infections/ep,eh 
15  Exp *human immunodeficiency virus infection/ep 
16 Hepatitis infection as 
major topic 
*hepatitis b/ep or *hepatitis c/ep 
17 Combine sets or/15-17 
18 Systematic reviews 
Broad filter 
17 and ((research synthesis or pooled).mp. or review.ti,pt. or 
(systematic review or meta analysis or meta-analysis).de. or 
((evidence base$ or methodol$ or systematic or quantitative$ or 
studies).mp. and (review.de. or review.pt.))) 




Number Concept Search Statement 
20 Limit by concept 18 and prevalence.ti. 
  One more another approach 
21 Limit by concept 17 and prevalence.ti. 
22  21 and (hepatitis or HIV$ or HBV$ or HCV$).ti. 
23 Limit by publication 
type 
22 not ((letter or editorial or news or comment or case reports or 
note or conference paper).de. or (letter or editorial or news or 
comment or case reports).pt.) 
24 Limit by region 23 and (exp United States/ or United States.tw. or us.ti. or 
usa.tw.) 
25 Limit by publication 23 and mmwr morbidity & mortality weekly report.jn. 
25  Author search (Armstrong$ and Wasley$ and Simard$).au. 
26 Related articles search Find articles related to The prevalence of hepatitis C virus 
infection in the United States, 1999 through 2002 
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Inactivation (Q6) – includes animal population 
Set 
Number Concept Search Statement 
1 Transplantation exp organ transplantation/ 
2  (((transplantation, homologous or allotransplantation).de. or 
tr.fs.) and (solid organ or heart or lung$ or kidney$ or liver or 
intestin$ or bowel$ or pancreas or face or hand$ or (composite 
adj vascular) or ovar$ or testes or testicl$)) 
3  Exp tissue transplantation/ 
4  (((transplantation, homologous or allotransplantation).de. or 
tr.fs.) and (tissue$ or bone$ or allograft$ or homograft$)) 
5 Combine sets or/1-4 
6 Organ donors ((exp tissue donors/ or exp tissue/) and organ procurement/) or 
(living donors or donor or kidney donor or living donor or organ 
donor).de. 
7  donor$.ti. 
8  7 and (solid organ or heart or lung$ or kidney$ or liver or 
intestin$ or bowel$ or pancreas or face or hand$ or (composite 
adj vascular) or ovar$ or testes or testicl$ or tissue or bone or 
allograft$ or homograft$) 
9 Combine sets 6 or 8 
10  Combine sets 5 or 9 
11 Specific infections exp HIV infections/ or exp human immunodeficiency virus 
infections/ or exp hepatitis b antigens/ or exp hepatitis c 
antigens/ or exp hepatitis b antigen/ or (hepatitis b or hepatitis c 
or hepatitis c antigen).de. or (hepatitis adj (b or c)) or HIV$ 
12 Infections and 
transplantation 
Combine sets 
10 and 11 
13 Limit by publication 
type 
12 not ((letter or editorial or news or comment or case reports or 
note or conference paper).de. or (letter or editorial or news or 
comment or case reports).pt.) 
14 Virus inactivation 13 and (Virus inactivation.de. or (inactivat$ or deactivat$).tw.) 
15  13 and (Exp *antiviral agents/ or exp *antivirus agent/) 
16   13 and irrigat$ 
17  Combine sets or/14-16 
18 Eliminate overlap Remove duplicates from 
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Hepatitis B (1966 – 2009) 
Set 
Number Concept Search Statement 
1 Hepatitis B Exp hepatitis b antigens/ or exp hepatitis b antigen/ or hepatitis 
b/ or hepatitis b or HBV 
2 Diagnosis 1 and (exp diagnosis/ or di.fs. or receiver operating 
characteristic/ or ROC curve/ or sensitivity and specificity/ or 
accuracy/ or diagnostic accuracy/ or precision or exp prediction 
and forecasting/ or likelihood or ((false or true) adj (positive or 
negative)) or predictive value of tests/) 
3 Molecular testing 
(EMTREE) 
2 and (exp molecular probe/ or exp hybridization/ or exp 
molecular probe/ or exp gene amplification/ or Microarray 
analysis/ or DNA microarray/) 
4 Molecular testing 
(MeSH) 
2 and (molecular diagnostic techniques/ or exp molecular probe 
techniques/ or exp nucleic acid amplification techniques/ or exp 
nucleic acid hybridization/ or exp in situ hybridization/ or exp 
microarray analysis/) 
5 Specific tests ((HBsAg adj2 (Elecsys or AxSYM or Architect or Centaur or 
Enzygnost or Vitros)) or AMRAD or NucliSens-AmpliScreen or 
VERSANT HCV PRISM HCV or anti-p22 antibody test or NAT or 
nucleic acid amplification technology or Cobas Amplicor or 
Qiagen QIAamp or Virus BioRobot or PCR or TaqMan or 
MATRIX HCV or western blot or corecell haemagglutination 
assay).mp,df, dm. 
6 Combine sets or/3-5 
7 Eliminate overlap Remove duplicates from 6 
8 Limit by publication 
type 
12 not ((letter or editorial or news or comment or case reports or 
note or conference paper).de. or (letter or editorial or news or 
comment or case reports).pt.) 
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Risk (Q3 and Q4) 7/2/09 
Set 
Number Concept Search Statement 
1 Specific infections exp HIV infections/ or exp human immunodeficiency virus 
infections/ or exp hepatitis b antigens/ or exp hepatitis c 
antigens/ or exp hepatitis b antigen/ or (hepatitis b or hepatitis c 
or hepatitis c antigen).de. or (hepatitis adj (b or c) or HIV) 
2 Donors ((exp tissue donors/ or exp tissue/) and organ procurement/) or 
(living donors or donor or kidney donor or living donor or organ 
donor or cadaver donor or cadaver).de. or donor$ or donat$ 
3 Risk (risk-taking or risk reduction behavior or behavioral risk factor 
surveillance system or risk factors or population characteristics 
or sexual behavior or unsafe sex or substance abuse, 
intravenous).de. 
4  (high risk behavior or risk factor or high risk population or high 
risk patient).de. 
5  (high adj2 risk$).ti. or (multiple adj2 partner$) or ((intravenous or 
iv or injectable) adj drug$) or (needle adj shar$) or hemophilia$ 
or haemophilia$ or incarcerat$ or prison$ or gaol or jail$ or 
inmate$ or MSM.tw.  
6 Donor history (exp Medical history taking/ or exp Physical examination/ or exp 
Anamnesis/ or exp Physical examination/ or (medical records or 
medical record review).de. or ((Medical or patient) adj history) or 
chart review) 
7 Combine sets or/3-6 
8 Combine sets 1 and 2 and 6 
9 Eliminate overlap Remove duplicates from 7 
10 Limit by publication 
type 
8 not ((letter or editorial or news or comment or case reports or 
note or conference paper).de. or (letter or editorial or news or 
comment or case reports).pt.) 
11 Limit by major concept 10 and (*risk factor/ or *risk factors/ or *risk-taking/ or *high risk 
behavior/) 
12 Limit by concept 10 and risk$.ti. 
14 Limit by concept 10 and (behavio?r$ or sex$) 
15 Combine sets 6 and 10 





Number Concept Search Statement 
1 Specific infections exp HIV infections/ or exp human immunodeficiency virus 
infections/ or exp hepatitis b antigens/ or exp hepatitis c 
antigens/ or exp hepatitis b antigen/ or (hepatitis b or hepatitis c 
or hepatitis c antigen).de. or (hepatitis adj (b or c)) 
2 Screening 1 and (screen$.ti. or exp screening/ or exp mass screening/)  
3 Limit by publication 
type 
2 not ((letter or editorial or news or comment or note or 
conference paper).de. or (letter or editorial or news or 
comment).pt.) 
6 Eliminate overlap Remove duplicates from 5 
7 Analytic validity of 
tests 
6 and (Analytic adj2 valid$) 
8  Exp “prediction and forecasting”/ 
9  6 and 8 
10  6 and ((predictive value of tests or receiver operating 
characteristic or ROC curve or sensitivity and specificity or 
accuracy or diagnostic accuracy or precision or likelihood).de. or 
((false or true) adj (positive or negative))) 
11  6 and Valid$.ti,ab. 
12  6 and ((intraobserver or intra-observer or interobserver or inter-
observer or interpret$ or kappa or observer bias or observer 
variability or reader$ or reader concordance or reliab$ or 
repeatab$ or replicat$).tw. or observer variation.de.) 
13 Combine sets  or/7,9-12 
14 Donors  13 and ((Living donor or cadaver donor).de. or exp Tissue 
donors/ or exp transplantation/ or donor$ or donat$) 
15  exp “Tissue and organ procurement”/  
16 Combine sets 13 and 15 
17 Combine sets 14 or 16 
18 Combine sets 13 not 17 
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Specific Tests (Q5) 
Set 
Number Concept Search Statement 
1 Genetics System (GS) 
HIV 1-1/HIV-2 Plus 0 
EIA 
((genetic$ adj system$) and ((HIV$ or HBV$ or HCV$ or HbsAg 
or anti-HB$ or anti-HC$ or HBc$) or Bio-Rad or Biorad).mp.) or 
(genetic$ adj system$).dv. 
2 HIVAB HIV-1/HIV-2 
(rDNA) EIA 
HIVAB$.mp,dv. 
3 AxSYM  (AxSYM and (core$ or HIV$ or HBV$ or HCV$ or HbsAg or anti-
HB$ or anti-HC$ or HBc$)).mp,dv. 
4 ADVIA Centaur (ADVIA Centaur and (core$ or HIV$ or HBV$ or HCV$ or HbsAg 
or anti-HB$ or anti-HC$ or HBc$)).mp,dv. 
5 PRISM (PRISM and (core$ or HIV$ or HBV$ or HCV$ or HbsAg or anti-
HB$ or anti-HC$ or HBc$)).mp,dv. 
6 CORZYME (CORZYME and (core$ or HIV$ or HBV$ or HCV$ or HbsAg or 
anti-HB$ or anti-HC$ or HBc$)).mp,dv. 
7 COBAS AmpliScreen ((COBAS and (core or AmpliScreen)) and (core$ or HIV$ or 
HBV$ or HCV$ or HbsAg or anti-HB$ or anti-HC$ or 
HBc$)).mp,dv. 
8 ProCleix HIV-1/HCV  (ProCleix and (core$ or HIV$ or HBV$ or HCV$ or HbsAg or 
anti-HB$ or anti-HC$ or HBc$)).mp,dv. 
9 VIDAS DUO ((VIDAS and DUO) and (core$ or HIV$ or HBV$ or HCV$ or 
HbsAg or anti-HB$ or anti-HC$ or HBc$)).mp,dv. 
10 ARCHITECT (ARCHITECT and (core$ or HIV$ or HBV$ or HCV$ or HbsAg 
or anti-HB$ or anti-HC$ or HBc$)).mp,dv. 
11 Genscreen (Genscreen and (core$ or HIV$ or HBV$ or HCV$ or HbsAg or 
anti-HB$ or anti-HC$ or HBc$)).mp,dv. 
12 Murex (Murex and (core$ or HIV$ or HBV$ or HCV$ or HbsAg or anti-
HB$ or anti-HC$ or HBc$)).mp,dv. 
13 Enzygnost (Enzygnost and (core$ or HIV$ or HBV$ or HCV$ or HbsAg or 
anti-HB$ or anti-HC$ or HBc$)).mp,dv. 
14 Vironostika ((Vironostika or Uni-Form) and (core$ or HIV$ or HBV$ or HCV$ 
or HbsAg or anti-HB$ or anti-HC$ or HBc$)).mp,dv. 
15 INNOTEST (INNOTEST and (core$ or HIV$ or HBV$ or HCV$ or HbsAg or 
anti-HB$ or anti-HC$ or HBc$)).mp,dv. 
16 Monolisa (Monolisa and (core$ or HIV$ or HBV$ or HCV$ or HbsAg or 
anti-HB$ or anti-HC$ or HBc$)).mp,dv. 
17 Ortho ELISA v 3 (Ortho and ELISA and (core$ or HIV$ or HBV$ or HCV$ or 
HbsAg or anti-HB$ or anti-HC$ or HBc$)).mp,dv. 
18 Coulter HIV-1 p24 
Antigen Assay 
(Coulter and (antigen$ or p24) and (core$ or HIV$ or HBV$ or 
HCV$ or HbsAg or anti-HB$ or anti-HC$ or HBc$)).mp,dv. 
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Set 
Number Concept Search Statement 
19 Modular HIV Combo (Roche and (modular or combo) and (core$ or HIV$ or HBV$ or 
HCV$ or HbsAg or anti-HB$ or anti-HC$ or HBc$)).mp,dv. 
20 HCV EIA 2.0 (Abbot and EIA and 2$ and (core$ or HIV$ or HBV$ or HCV$ or 
HbsAg or anti-HB$ or anti-HC$ or HBc$)).mp,dv. 
21 Combine sets or/1-20 
22 Eliminate overlap Remove duplicates from 21 
23 Limit by publication 
type 
22 not ((letter or editorial or news or comment or case reports or 
note or conference paper).de. or (letter or editorial or news or 
comment or case reports).pt.) 
24 Limit to diagnosis & 
screening 
23 and (screen$ or diagnos$.tw. or exp diagnosis/ or di.fs. or 
receiver operating characteristic.de. or ROC curve.de. or 
sensitivity and specificity/ or accuracy.de. or diagnostic 
accuracy.de. or precision or exp prediction and forecasting/ or 
exp diagnostic errors/ or exp diagnostic error/ or likelihood or 
((false or true) adj (positive or negative)) or predictive value of 
tests.de.) 
25 Window 23 and (window$ or WPRT$).tw.  
26 Combine sets 24 or 25 
27  23 and borderline$  
28 Combine sets 26 or 27 
29  23 and occult$ 
30 Combine sets 28 or 29 
 
 
